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Mechanisms of Longevity Regulation and Extension in Yeast and Mechanisms 
Underlying the Anti-Tumor Effect of Lithocholic Acid in Human Neuroblastoma Cells 
 
Alexander A. Goldberg, Ph.D. 
 
            Aging of multicellular and unicellular eukaryotic organisms is a multifactorial 
biological phenomenon that has various causes and affects a plethora of cellular 
activities. I employ the yeast Saccharomyces cerevisiae as a model to study the basic 
biology and molecular mechanisms of cellular aging in multicellular eukaryotes. The use 
of this budding yeast as an advantageous model organism in aging research greatly 
contributed to the current understanding of the molecular and cellular mechanisms 
underlying longevity regulation in evolutionarily distant eukaryotic organisms, thereby 
convincingly demonstrating that longevity signaling pathways and mechanisms of their 
modulation by dietary and pharmacological interventions are conserved across phyla.  
            To address the inherent complexity of aging from a systems perspective and to 
build an integrative spatiotemporal model of aging process, I investigated the effect of 
caloric restriction (CR), a low-calorie dietary regimen, on the metabolic history of 
chronologically aging yeast. CR has been shown not only to exhibit a robust longevity-
extending effect in evolutionarily distant organisms ranging from yeast to rhesus 
monkeys, but also to improve health by attenuating age-related pathologies and delaying 
the onset of age-related diseases across phyla. I examined how CR influences the age-
related dynamics of changes in the intracellular levels of numerous proteins and 
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metabolites, carbohydrate metabolism, interorganellar metabolic flow, concentration of 
reactive oxygen species (ROS), mitochondrial morphology, essential oxidation-reduction 
processes in mitochondria, mitochondrial proteome, frequency of mitochondrial DNA 
mutations, dynamics of mitochondrial nucleoid, susceptibility to mitochondria-controlled 
apoptosis, and stress resistance.  
            Based on my comparison of the metabolic histories of long-lived CR yeast and 
short-lived non-CR yeast, I concluded that yeast define their long-term viability by 
designing a diet-specific pattern of metabolism and organelle dynamics prior to 
reproductive maturation. My data imply that longevity in chronologically aging yeast is 
programmed by the level of metabolic capacity and organelle organization they 
developed, in a diet-specific fashion, prior to entry into a non-proliferative state. 
Therefore, chronological aging in yeast is the final step of a developmental program 
progressing through a series of checkpoints. 
            I designed a chemical genetic screen for small molecules that increase the 
chronological life span (CLS) of yeast under CR by targeting lipid metabolism and 
modulating housekeeping longevity pathways that regulate longevity irrespective of the 
number of available calories. My screen identifies lithocholic acid (LCA) as one of such 
molecules. My evaluation of the life-extending efficacy of LCA in wild-type (WT) strain 
on a high- or low-calorie diet revealed that this compound extends yeast CLS irrespective 
of the number of available calories. I found that the extent to which LCA extends 
longevity is highest under CR conditions, when the pro-aging processes modulated by the 
adaptable target of rapamycin (TOR) and cAMP/protein kinase A (cAMP/PKA) signaling 
pathways are suppressed and the anti-aging processes are activated. Furthermore, the life-
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extending efficacy of LCA in CR yeast significantly exceeded that in yeast on a high-
calorie diet, in which the adaptable TOR and cAMP/PKA pathways greatly activate the 
pro-aging processes and suppress the anti-aging processes. Altogether, my findings 
suggest that, consistent with its sought-after effect on a longevity signaling network, LCA 
mostly targets certain housekeeping longevity assurance pathways that do not overlap (or 
only partially overlap) with the adaptable TOR and cAMP/PKA pathways modulated by 
calorie availability.  
            Consistent with my assumption that LCA extends longevity not by modulating the 
adaptable TOR pathway, I found that lack of Tor1p does not impair the life-extending 
efficacy of LCA under CR. I also revealed that, LCA extends longevity of the tor1 
mutant strain to a very similar degree under CR and non-CR conditions. Thus, by 
eliminating a master regulator of this key adaptable pathway that shortens the CLS of 
yeast on a high-calorie diet, the tor1 mutation abolished the dependence of the anti-
aging efficacy of LCA on the number of available calories.  
            My findings revealed two mechanisms underlying the life-extending effect of 
LCA in chronologically aging yeast. One mechanism operates in a calorie availability-
independent fashion and involves the LCA-governed modulation of housekeeping 
longevity assurance pathways that do not overlap with the adaptable TOR and 
cAMP/PKA pathways. The other mechanism extends yeast longevity under non-CR 
conditions and consists in LCA-driven unmasking of the previously unknown anti-aging 
potential of PKA. I provide evidence that LCA modulates housekeeping longevity 
assurance pathways by 1) attenuating mitochondrial fragmentation, a hallmark event of 
age-related cell death; 2) altering oxidation-reduction processes in mitochondria, 
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including oxygen consumption, the maintenance of membrane potential, and reactive 
oxygen species production; 3) enhancing resistance to oxidative and thermal stresses; 4) 
suppressing mitochondria-controlled apoptosis; and 5) enhancing stability of nuclear and 
mitochondrial DNA. 
            Yeast do not synthesize LCA or any other bile acids produced by mammals. 
Therefore, I propose that bile acids released into the environment by mammals may act as 
interspecies chemical signals providing longevity benefits to yeast and, perhaps, other 
species within an ecosystem. I hypothesize that, because bile acids are known to be 
mildly toxic compounds, they may create selective pressure for the evolution of yeast 
species that can respond to the bile acids-induced mild cellular damage by developing the 
most efficient stress protective mechanisms. It is likely that such mechanisms may 
provide effective protection of yeast against molecular and cellular damage accumulated 
with age. Thus, I propose that yeast species that have been selected for the most effective 
mechanisms providing protection against bile acids may evolve the most effective anti-
aging mechanisms that are sensitive to regulation by bile acids. I extend my hypothesis 
on longevity regulation by bile acids by suggesting a hypothesis of the xenohormetic, 
hormetic and cytostatic selective forces driving the evolution of longevity regulation 
mechanisms at the ecosystemic level.  
            To verify my hypothesis empirically, I carried out the LCA-driven multistep 
selection of long-lived yeast species under laboratory conditions. I found that a lasting 
exposure of wild-type yeast to LCA results in selection of yeast species that live longer in 
the absence of this bile acid than their ancestor. My data enabled to rank different 
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concentrations of LCA with respect to the efficiency with which they cause the 
appearance of long-lived yeast species.  
            Aging is one of the major risk factors in the onset and incidence of cancer, and 
cancer is considered as one of the numerous age-associated diseases whose onset can be 
delayed and incidence reduced by anti-aging interventions. The interplay between aging 
and cancer is intricate as these two complex and dynamic biological phenomena have 
both convergent and divergent underlying mechanisms. One of the major objectives of 
my thesis was to examine if LCA, a novel anti-aging compound that I identified in a 
high-throughput chemical genetic screen, also exhibits an anti-tumor effect in cultured 
human cancer cells by activating certain anti-cancer processes that may (or may not) play 
an essential role in cellular aging. As a model system for addressing this important 
question (and if LCA indeed displays an anti-tumor effect, for establishing the 
mechanism underlying such effect), I choose several cell lines of the human 
neuroblastoma (NB) tumor.  
            My findings provide strong evidence that LCA exhibits a potent anti-tumor effect 
in cultured human NB cells by: 1) activating both intrinsic (mitochondrial) and extrinsic 
(death receptor) pathways of apoptotic death in these cells; 2) sensitizing them to 
hydrogen peroxide-induced apoptotic death; and 3) preventing growth and proliferation 
of their neighbouring NB cells in the culture. Importantly, my findings also imply that 
LCA does not display any of these deleterious effects in human neurons and, therefore, is 
a selective anti-tumor compound. Moreover, my mass spectrometry-based measurement 
of intracellular and extracellular levels of exogenously added LCA revealed that this bile 
acid does not enter cultured NB cells. Thus, LCA prevents proliferation of human NB 
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cells and selectively kills these cancer cells by binding to their surface and then initiating 
intracellular signaling cascades that not only impair their growth and division, but also 
cause their apoptotic death. The demonstrated inability of LCA to enter cultured human 
NB cells suggests that this potent and selective anti-cancer compound is unlikely to 
display undesirable side effects in non-cancerous human neurons. My findings suggest a 



















            I am grateful to my supervisor, Dr. Vladimir Titorenko, for his guidance and 
support during the years I spent in his laboratory. I would like to thank the members of 
my committee, Dr. Patrick Gulick and Dr. Reginald Storms, for their valuable 
suggestions during the course of my graduate research and studies. 
            Many thanks to all of my current and former lab-mates Adam Beach, Tatiana 
Boukh-Viner, Simon Bourque, Michelle Tali Burstein, Subrata Chowdhury, Asya 
Glebov, Tong Guo, Christopher Gregg, Tatiana Iouk, Olivia Koupaki, Pavlo Kyryakov, 
Oleh Petriv, Vincent Richard, Bahador Abadi, Daniel Aguirre, Zineea Ahmed, Riad 
Akkari, Alex Alexandrian, Samira Ansary, Sadaf Anwar, Mohammad Sharif Askari, 
Zeinab Aziz, Kabongo Balufu, Alpana Bangur, Farhana Banu, Quesny Jean Baptiste, 
Carmen Bayly, Gabriella Bazdikian, Guillaume Beaudoin, Matthieu Bedard, Moria 
Belanger, Adrian Buensuceso, Stephanie Bramwell, Aman Brar, Andre Cerracchio, 
Andrew Chang, Steve Chausse, Eileen Colella, Thaisa Cotton, David Cyr, Julie Cyr, 
Mark Dass, Rosa De Fenza, Gabrielle Depres, Cassandra Di Tomasso, Ozlem Doygun, 
Supria Mohan Dubey, Lucia Farisello, Fernando Fiscina, Victor Germanov, Colin 
Goldfinch, Alejandra Gomez Perez, Alexandra Greco, Sandra Haile, Karen Hung Yeung 
San, Saeeda Hasan, Ahmed Hossain, Mara Inniss, Chidiebere Michael Iro, Mylène 
Juneau, Wael Kalaji, Narges Kalantari, Simin Kargari, Mulanda Kayembe, Sukhdeep 
Kenth, Hyun Young Kim, Petko Komsalov, Shogher Kouyoumjian, Karine Lalonde, 
Melanie Larche, Clemence Larroche, Jeffrey MacKenzie Lee, Sabrina Lo, Michael A. 
London, Samira Lorne, Lawrence Ma, Gayane Machkalyan, Lydia Makoroka, Naveed 
Malik, Cynthia Mancinelli, Patrick Marcoux, Haider Mashhedi, Dale Mc Naught, 
x 
 
Hannah Meltzer, Svetlana Milijevic, Gianni Montanaro, Janine Morcos, Ramandeep 
Mudhar, Rasesh Nagar, Andrew Naimi, Parisa Namitabar, Florentina Negoita, Phuong 
Nguyen, Yves Nimbona, Mehdi Noei, Reza Noei, Jordan O’Byrne, Derek O’Flaherty, 
Aloysius Oluoha, David Papadopoli, Christian Parent-Robitaille, Bhavini Patel, Mital 
Patel, Sabrina Piccioni, Premala Premanathan, Peter Quashie, Nishant Ramlal, Sonia 
Rampersad, Savitri Rampersad, Parvin Ranjbar, Joel Richard, Stephanie Russo, Tarek 
Sabri, Abdelhak Saddiki, Mohammad Hassan Salah, Karen Hung Yeung San, Eric 
Scazzosi, Sandra Scharaw, Christine Schäfers, Elyse Schmidt, Nadia Sheikh, Arash B. 
Shokouhi, Cristina Sison, Jerani Sivayogan, Rhoda Sollazzo, Jonathan Solomon, Saamala 
Subramaniam, Nader Toban, Victor Uscatescu, Andrew Victor, Lisiana Vigliotti, Laura 
Whelton and Vivianne Wong for their friendship and support. 


















Table of Contents 
List of Figures and Tables 
List of Abbreviations 
 
1 Introduction                                                                                                          1 
1.1 Biological aging: A “passive” lifelong accumulation of unrepaired  
cellular and molecular damage or an “active” process progressing  
through a series of checkpoints and governed by a limited number  
of “master” regulators?                                                                                          1 
1.2 A signaling network regulates longevity by integrating three signaling  
pathways that govern numerous longevity-defining cellular processes                2 
1.3 Some dietary regimens can extend longevity and improve health by  
attenuating age-related pathologies                                                                        8 
1.4 Certain pharmacological interventions can delay aging by beneficially  
influencing age-related pathologies                                                                       11 
1.5 Yeast as a valuable model system for unveiling mechanisms of cellular  
aging in multicellular eukaryotes                                                                           22 
1.6 Cancer as an age-associated disease whose onset can be delayed and  
incidence reduced by anti-aging interventions: The complex interplay  
between aging and cancer through convergent and divergent mechanisms          24 
1.7 Thesis outline and contributions of colleagues                                                      31 
 
2 Aging is the final step of a developmental program: The longevity of 
chronologically aging yeast is programmed by the level of metabolic  
capacity and organelle organization they developed, in a diet-specific  
fashion, prior to entry into a non-proliferative state                                        40 
2.1 Abstract                                                                                                                  40                                                                                                                  
2.2 Introduction                                                                                                            41                                                                                                           
2.3 Materials and methods                                                                                           44                                                                                            
2.4 Results                                                                                                                    56                                                                                                                 
2.4.1 My rationale for choosing a nutrient-rich growth medium for  
xii 
 
studying yeast chronological aging                                                                        56 
2.4.2 CR extends the chronological life span of yeast                                        57 
2.4.3 CR remodels the metabolism of trehalose and glycogen                           61 
2.4.4 Life-span extension by CR relies in part on the ability of yeast to  
maintain trehalose concentration at optimal level                                     63 
2.4.5 Proper balance between the biosynthesis and degradation of  
glycogen is obligatory for life-span extension by CR                               65 
2.4.6 CR alters the abundance of many mitochondrial proteins, modulates 
oxidation-reduction processes in mitochondria and changes the  
age-related dynamics of mitochondrially produced ROS                          68 
2.4.7 CR influences the frequency of mitochondrial DNA (mtDNA)  
mutations and modulates the abundance and mtDNA-binding  
activity of mitochondrial nucleoid-associated proteins                           103 
2.4.8 CR alters mitochondrial morphology and delays  
mitochondria-controlled apoptosis                                                           106 
2.4.9 CR increases the resistance of aging yeast to chronic thermal and 
oxidative stresses                                                                                     109 
2.5  Discussion                                                                                                            109                                                                                                              
2.6  Conclusions                                                                                                          119                                                                                                            
 
3 Chemical genetic screen identifies lithocholic acid as an anti-aging  
compound that extends yeast chronological life span in a TOR- 
independent manner, by modulating housekeeping longevity  
assurance processes                                                                                           122  
3.1 Abstract                                                                                                                122                                                                                                                  
3.2 Introduction                                                                                                          124                                                                                                             
3.3 Materials and methods                                                                                         129                                                                                        
3.4 Results                                                                                                                  144                                                                                                                   
3.4.1 My rationale for choosing a mutant strain and growth conditions  
xiii 
 
to screen compound libraries for anti-aging small molecules                 144 
3.4.2 A chemical genetic screen for small molecules that extend the  
CLS of yeast under CR conditions                                                           153 
3.4.3 Pharmacophore modeling of the anti-aging potential of bile acids         157 
3.4.4 LCA extends the CLS of WT yeast under both CR and non-CR  
conditions, although to a different extent                                                160 
3.4.5 LCA extends the CLS of WT yeast under CR by modulating several 
longevity-related processes                                                                      163 
3.4.6 LCA extends yeast CLS independent of TOR, by  
modulating housekeeping longevity assurance pathways                        165 
3.5  Discussion                                                                                                            173                                                                                                             
3.6  Conclusions                                                                                                          179                                                                                                          
 
4  Xenohormetic, hormetic, and cytostatic forces may drive the  
evolution of longevity regulation mechanisms within  
ecosystems: A hypothesis and its empirical verification                                181 
4.1 Abstract                                                                                                                181                                                                                                                 
4.2 Introduction                                                                                                          183                                                                                                           
4.3 Materials and Methods                                                                                         186                                                                                          
4.4 Results                                                                                                                  187 
4.4.1 Bile acids may function as interspecies chemical signals extending  
yeast longevity within ecosystems                                                           187 
4.4.2 Natural variations of bile acid levels within ecosystems may modulate 
both housekeeping and adaptable longevity pathways in yeast               188 
4.4.3 Rapamycin may also act as an interspecies chemical signal  
modulating longevity at the ecosystemic level                                        189 
4.4.4 The “xenohormesis” hypothesis: a case of xenohormetic  
phytochemicals                                                                                        191 
4.4.5 The “anti-aging side effect” hypothesis: delaying aging by  
attenuating the growth-promoting TOR signaling pathway                    193 
4.4.6 The xenohormetic, hormetic and cytostatic selective forces may drive  
xiv 
 
the evolution of longevity regulation mechanisms within ecosystems    195 
4.4.7 The empirical verification of my hypothesis of the xenohormetic,  
hormetic and cytostatic selective forces driving the evolution of  
longevity regulation mechanisms at the ecosystemic level                     197 
4.5 Discussion                                                                                                            203                                                                                                             
4.6 Conclusions                                                                                                          207 
 
5  Lithocholic acid exhibits a potent and selective anti-tumor effect in  
cultured human neuroblastoma cells by activating both intrinsic and 
extrinsic pathways of their apoptotic death, sensitizing them to  
hydrogen peroxide-induced apoptotic death, and preventing  
growth and proliferation of their neighbouring neuroblastoma cells in  
the culture                                                                                                           209 
5.1 Abstract                                                                                                                209                                                                                                                
5.2 Introduction                                                                                                          210                                                                                                          
5.3 Materials and Methods                                                                                         212                                                                                         
5.4 Results                                                                                                                  218 
5.4.1 LCA selectively kills cultured human NB cells by causing their  
apoptotic death if used at concentrations that are not cytotoxic to  
primary cultures of human neurons                                                         218 
5.4.2 LCA sensitizes cultured human NB cells to hydrogen peroxide- 
induced apoptotic cell death                                                                     226 
5.4.3 In two NB cell lines, LCA causes the efflux of cytochrome c from 
mitochondria, activation of the initiator caspase-9, mitochondrial 
fragmentation and loss of mitochondrial transmembrane potential –  
all characteristic of the intrinsic (mitochondrial) apoptotic  
death pathway                                                                                          229 
5.4.4 In two NB cell lines, LCA triggers a proteolytic cascade of events  
leading to activation of two executioner caspases, caspase-3 and  
caspase-6                                                                                                  235 
5.4.5 In two NB cell lines, LCA increases the activity of caspase-8, an  
xv 
 
initiator caspase that functions in the extrinsic (death receptor)  
apoptotic death pathway but can also cause MOMP and trigger the 
intrinsic (mitochondrial) pathway of apoptosis                                       241 
5.4.6 In two NB cell lines, LCA reduces the activity of caspase-1, an 
inflammatory caspase that drives the processing and secretion of the 
cytokines interleukin-1β and interleukin-18                                            243 
5.4.7 LCA does not enter cultured NB cells                                                     245  
5.5 Discussion                                                                                                            249                                                                                                            
5.6 Conclusions                                                                                                          253 
                                                                                                          
6 Conclusions and suggestions for future work                                                 254 
6.1 General conclusions                                                                                             254                                                                                             
6.1.1 Chronological aging in yeast is the final step of a developmental  
program progressing through a series of checkpoints                              254 
6.1.2 My chemical genetic screen identifies lithocholic acid as an  
anti-aging compound that extends yeast chronological life span in  
a TOR-independent manner, by modulating housekeeping  
longevity assurance process                                                                     255 
6.1.3 A hypothesis on xenohormetic, hormetic and cytostatic forces  
driving the evolution of longevity regulation mechanisms  
within ecosystems and its empirical verification                                     257 
6.1.4 The molecular mechanism underlying a potent and selective  
anti-tumor effect of LCA in cultured human neuroblastoma cells          258   
6.2 Suggestions for future work                                                                                 260                                                                                  
 
7 References                                                                                                           264                                                                                                           
 




List of Figures and Tables  
Figure 1.1 The functional states of numerous longevity-defining processes and  
their spatiotemporal organization are modulated by only a few nutrient- 
and energy-sensing signaling pathways                                                     4 
Table 1.1 Caloric restriction and dietary restriction exhibit a robust  
longevity-extending effect in evolutionarily distant organisms  
ranging from yeast to rhesus monkeys and improve health by  
attenuating age-related pathologies and delaying the onset of  
age-related diseases across phyla                                                               9 
Table 1.2 Known anti-aging compounds, their abilities to increase life  
span in different organisms (under caloric or dietary restriction,  
on a standard diet or fed a high-calorie diet), and the mechanisms  
of their anti-aging action                                                                            12 
Figure 1.3  Two different paradigms of yeast aging                                                    23 
Figure 1.4 A longevity-defining signaling network that is centered at the  
mTORC1 complex of the pro-aging and pro-cancer AMPK/TOR 
pathway in mammalian cells                                                                      27 
Figure 2.1 CR extends the chronological life span of yeast                                        59 
Figure 2.2 Survival of the chronologically aging wild-type strain BY4742  
and the mean chronological life spans of different cultures of  
BY4742 grown in YP medium initially containing 0.02%,  
0.05%, 0.1%, 0.2% or 0.5% glucose                                                          60 
Figure 2.3 CR remodels trehalose and glycogen metabolism                                     62 
Figure 2.4 CR extends life span in part by maintaining a proper balance  
between the biosynthesis and degradation of trehalose and glycogen       66 
Figure 2.5 CR alters the abundance of a distinct set of proteins in  
mitochondria of chronologically aging yeast                                             69 
Table 2.1 List of proteins recovered in mitochondria purified from  
wild-type cells grown in YP media initially containing 0.2%,  
0.5%, 1% or 2% glucose                                                                            71 
Table 2.2 Relative levels of proteins recovered in mitochondria purified  
xvii 
 
from wild-type cells grown in YP media initially containing  
0.2%, 0.5%, 1% or 2% glucose                                                                96 
Figure 2.6 CR influences oxidation-reduction processes in mitochondria  
and modulates the level of mitochondrially produced ROS                    102 
Figure 2.7 CR modulates the frequency of mtDNA mutations and  
influences the efficiency of aconitase binding to mtDNA                       104 
Figure 2.8 CR influences mitochondrial morphology and delays age-related  
apoptosis                                                                                                  108 
Figure 2.9 CR enhances the resistance of aging yeast to chronic  
thermal and oxidative stress                                                                     110 
Figure 2.10 CR and non-CR yeast that enter ST phase have different  
patterns of metabolism, interorganellar communications and  
mitochondrial morphology                                                                       113 
Figure 3.1 The pex5Δ mutation shortens chronological life span                             146 
Figure 3.2 The pex5Δ mutation alters mitochondrial morphology and  
functions in CR yeast                                                                               148 
Figure 3.3 The pex5Δ mutation reduces the resistance of CR yeast to  
stresses, sensitizes them to exogenously induced apoptosis and  
elevates the frequencies of mutations in their mitochondrial  
and nuclear DNA                                                                                     149 
Figure 3.4 The pex5Δ mutation alters the abundance of many proteins  
recovered in total cell lysates, purified ER and mitochondria  
of CR yeast                                                                                               150 
Figure 3.5 For many proteins, the fold increase or decrease in the level of  
a protein enriched or depleted in pex5Δ yeast under CR correlates  
with the fold increase or decrease (respectively) in the mean  
CLS of a mutant strain lacking it                                                             152 
Figure 3.6 A high-throughput screen of compound libraries for small  
molecules that extend the CLS of yeast under CR conditions                 154 
Figure 3.7 The life-extending potential of a bile acid correlates with  
its hydrophobicity                                                                                    156 
xviii 
 
Figure 3.8 LCA and some other bile acids extend the CLS of WT strain  
under CR conditions                                                                                158 
Figure 3.9 In chronologically aging WT yeast, the life-extending efficacy  
of LCA under CR exceeds that under non-CR conditions                       161 
Figure 3.10 LCA does not cause significant changes in growth pattern  
of wild-type strain at any tested concentration of glucose in medium    162 
Figure 3.11 In reproductively mature WT yeast that entered the  
non-proliferative stationary phase under CR, LCA  
modulates mitochondrial morphology and functions,  
enhances stress resistance, attenuates mitochondria-controlled  
apoptosis, and increases stability of nuclear and mitochondrial DNA    164 
Figure 3.12 LCA increases the CLS of WT strain to the highest extent  
under CR conditions                                                                                166 
Figure 3.13 Chronological survival data for WT strain cultured in medium  
initially containing 0.2%, 0.5%, 1% or 2% glucose in the presence  
of LCA or in its absence                                                                          168 
Figure 3.14 Lack of Tor1p does not impair the life-extending effect of  
LCA and abolishes the dependence of the anti-aging efficacy of  
LCA on the number of available calories                                                169 
Figure 3.15 Chronological survival data for tor1 strain cultured in medium  
initially containing 0.2%, 0.5%, 1% or 2% glucose in the presence  
of LCA or in its absence                                                                          171 
Figure 3.16 Outline of pro- and anti-aging processes that are controlled by  
the TOR and/or cAMP/PKA signaling pathways and are  
modulated by LCA or rapamycin (RAP) in chronologically  
aging yeast                                                                                               172 
Figure 4.1 Lithocholic acid extends longevity of chronologically aging yeast  
through two different mechanisms                                                           183 
Figure 4.2 Bile acids are beneficial to health and longevity in animals                    185 
Figure 4.3 The xenohormetic, hormetic and cytostatic selective forces may  
drive the evolution of longevity regulation mechanisms  
xix 
 
within an ecosystem                                                                                 196 
Figure 4.4 A 3-step process of the LCA-driven experimental evolution of  
longevity regulation mechanisms by conducting selection of  
long-lived yeast species through a lasting exposure to LCA                   199 
Figure 4.5 A 3-step process of the LCA-driven experimental evolution of  
longevity regulation mechanisms by conducting selection of  
long-lived yeast species through a lasting exposure to LCA                   200 
Figure 4.6 A 3-step process of the LCA-driven experimental evolution of  
longevity regulation mechanisms by conducting selection of  
long-lived yeast species through a lasting exposure to LCA                   201 
Figure 4.7 A 3-step process of the LCA-driven experimental evolution of  
longevity regulation mechanisms by conducting selection of  
long-lived yeast species through a lasting exposure to LCA                   202 
Figure 4.8 The fraction of long-lived mutants in a population of yeast is  
increased by the end of each of the 3 steps of the LCA-  
driven experimental evolution of longevity regulation mechanisms       203 
Table 4.1 The fraction of long-lived mutants in a population of yeast is  
increased by the end of each of the 3 steps of the LCA- 
driven experimental evolution of longevity regulation mechanisms       204 
Figure 4.9 A spot-assay of cell survival for the 1
st
 step of the LCA- 
driven experimental evolution of longevity regulation mechanism        205 
Figure 4.10 A spot-assay of cell survival for the 2
nd
 step of the LCA- 
driven experimental evolution of longevity regulation mechanism        206 
Figure 4.11 A spot-assay of cell survival for the 3
rd
 step of the LCA- 
driven experimental evolution of longevity regulation mechanism        207 
Figure 5.1 LCA kills cultured human NB cell lines BE(2)-m17, Lan-1,  
SK-n-SH and SK-n-MCIXC if used at concentrations that  
are not cytotoxic or only mildly cytotoxic (as in case of  
Lan-1 cells) to primary cultures of human neurons                                 219 
Figure 5.2 The NB cell line SK-n-MCIXC is the most sensitive (as compared  
to other NB cell lines tested and especially as compared to primary  
xx 
 
cultures of human neurons) to the cytotoxic effect of LCA                    220         
Figure 5.3 The NB cell lines BE(2)-m17 and SK-n-SH exhibit much  
higher sensitivity to LCA than primary cultures of human neurons  
(or than the NB cell line Lan-1)                                                               221 
Figure 5.4 Although the NB cell line Lan-1 is less sensitive to the cytotoxic  
effect of LCA than the three other NB cell lines tested, it is  
significantly more sensitive to LCA than primary cultures of  
human neurons                                                                                         222 
Figure 5.5 If used at concentrations that are not cytotoxic to primary  
cultures of human neurons, LCA selectively kills the NB cell  
lines BE(2)-m17, SK-n-SH and SK-n-MCIXC by causing their  
apoptotic death                                                                                         224 
Figure 5.6 The NB cell line SK-n-MCIXC is the most sensitive (as compared  
to other NB cell lines tested and especially as compared to  
primary cultures of human neurons) to LCA-induced apoptotic death   225 
Figure 5.7 LCA protects primary cultures of human neurons – but not  
cultured human NB cell lines BE(2)-m17 or SK-n-MCIXC –  
against mitochondria-controlled apoptosis induced in response  
to exogenously added 0.1 mM hydrogen peroxide                                  227 
Figure 5.8 While 75 μM LCA causes apoptotic death of all or most of the  
cells of cultured human NB cell lines BE(2)-m17 and  
SK-n-MCIXC exposed to 0.1 mM hydrogen peroxide,  
in this concentration LCA greatly increases the resistance of  
primary cultures of human neurons to the hydrogen peroxide- 
induced form of  mitochondria-controlled  apoptotic  cell   
death in the absence of hydrogen peroxide do not compromise  
their viability                                                                                            228 
Figure 5.9 In cultured human NB cell line SK-n-MCIXC, LCA triggers the  
release of cytochrome c from the mitochondrial intermembrane  
space into the cytosol                                                                               230 
Figure 5.10 LCA significantly increases the activity of the initiator  
xxi 
 
caspase-9 in cultured human NB cell lines BE(2)-m17 and  
SK-n-MCIXC                                                                                           232 
Figure 5.11 LCA causes mitochondrial fragmentation in cultured human NB  
cell lines BE(2)-m17 and SK-n-MCIXC                                                 233 
Figure 5.12 LCA triggers the dissipation of the electrochemical potential  
across the inner mitochondrial membrane in cultured human NB  
cell lines BE(2)-m17 and SK-n-MCIXC                                                 234 
Figure 5.13 LCA increases the activity of caspase-3 in cultured human NB  
cell lines BE(2)-m17 and SK-n-MCIXC by promoting a  
proteolytic conversion of a zymogen pro-caspase-3 form  
of this executioner caspase into its enzymatically active 17 kDa form   236 
Figure 5.14 z-DEVD-fmk, a potent and specific inhibitor of caspase-3,  
completely inhibits the LCA-induced activity of this caspase in  
cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC                 237 
Figure 5.15 z-DEVD-fmk, a potent and specific inhibitor of caspase-3, weakens  
the anti-tumor effect of LCA in cultured human NB cell lines  
BE(2)-m17 and SK-n-MCIXC                                                                 238 
Figure 5.16 LCA increases the activity of caspase-6 in cultured human NB  
cell lines BE(2)-m17 and SK-n-MCIXC by promoting a  
proteolytic conversion of a 32-kDa zymogen pro-caspase-6 form  
of this executioner caspase into its enzymatically active 10 kDa form   239 
Figure 5.17 LCA significantly increases the activity of the initiator  
caspase-8 in cultured human NB cell lines BE(2)-m17 and  
SK-n-MCIXC                                                                                           242 
Figure 5.18 LCA significantly reduces the activity of the inflammatory  
caspase-1 in cultured human NB cell lines BE(2)-m17 and  
SK-n-MCIXC                                                                                           244 
Figure 5.19 Exogenously added LCA does not enter cultured human NB  
cell lines BE(2)-m17. LCA was added to cultured cells at the  
indicated final concentrations                                                                  246 
Figure 5.20 Exogenously added LCA does not enter cultured human NB cell  
xxii 
 
lines SK-n-MCIXC                                                                                  247 
Figure 5.21 Exogenously added LCA does not enter cultured human NB  
cell lines Lan-1. LCA was added to cultured cells at the indicated  
final concentrations                                                                                  248 
Figure 5.22 A model for a mechanism underlying a potent and selective  
anti-tumor effect of LCA in cultured human NB cell lines BE(2)-m17  
and SK-n-MCIXC                                                                                    251 
 
List of Abbreviations 
ACO, aconitase; AMPK/TOR, AMP-activated protein kinase/target of rapamycin; 
cAMP/PKA, cAMP/protein kinase A; C/EBP, CCAAT/enhancer-binding protein; CCO, 
cytochrome c oxidase; CFU, colony forming units; CNS, central nervous system; CL, 
cardiolipin; CLS, chronological life span; CR, caloric restriction; DAG, diacylglycerols; 
DHAP, dihydroxyacetone phosphate; DHR, dihydrorhodamine 123; DR, dietary 
restriction; EE, ergosteryl esters; ESI/MS, electrospray ionization mass spectrometry; ER, 
endoplasmic reticulum; ERG, ergosterol; FA-CoA, CoA esters of fatty acids; FFA, free 
fatty acids; FoxO, Forkhead box type O; GC/MS, gas chromatography followed by mass 
spectrometry; HPLC, high performance liquid chromatography; IGF-1, insulin/insulin-
like growth factor 1; LBs, lipid bodies; LCA, lithocholic acid; LOD, limit of detection; 
LOQ, limit of quantitation; LPA, lysophosphatidic acid; MCA, metabolic control 
analysis; NB, neuroblastoma; PA, phosphatidic acid; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PI, phosphatidylinositol; PI3K, phosphatidylinositol-3-kinase; 
PKC, protein kinase C; PMBC, peripheral blood mononuclear cells; rDNA, ribosomal 
DNA; ROS, reactive oxygen species; RLS, replicative life span; SD, standard deviation; 
SDH, succinate dehydrogenase; TAG, triacylglycerols; TLC, thin-layer chromatography; 









1.1 Biological aging: A “passive” lifelong accumulation of unrepaired cellular 
and molecular damage or an “active” process progressing through a series of 
checkpoints and governed by a limited number of “master” regulators?   
            Aging of multicellular and unicellular eukaryotic organisms is a multifactorial 
biological phenomenon that has various causes and affects a plethora of cellular activities 
[1 - 16]. At the organismal level, aging can be defined as the progressive decline in the 
ability of an organism to resist stress, repair damage and battle disease [2, 5, 10 - 14], 
whereas demographically aging manifests itself as an exponential increase in the 
mortality rate with the age of the cohort [2, 3, 7, 10, 12 - 15].  
            There are two contradictory views of biological aging. In one view, aging of 
multicellular and unicellular eukaryotic organisms is due to a “passive” lifelong build-up 
of unrepaired damage to cellular macromolecules and organelles [1 - 3, 12 - 14, 17]. 
Progressive, age-related accumulation of such damage impairs normal functioning of the 
entire organism, thereby increasing a risk of disease and death [2, 11 - 15]. Thus, in this 
view, aging is merely a result of the time-dependent, unavoidable accumulation of 
unrepaired cellular and molecular damage [1 - 3, 12, 17]. However, a growing body of 
evidence supports the view that aging is the final step of a developmental program. In this 
alternative view, aging is an “active” process, in which a limited number of “master” 
regulators orchestrate numerous cellular processes in space and time [18 - 29]. Each of 
these processes can be considered as a functional module integrated with other modules 
into a longevity network [4, 10, 24 - 29]. The synergistic action of individual modules 
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could establish the rate of aging. Furthermore, the relative impact of each module on the 
rate of aging in a particular organism or cell type could differ at various stages of its 
lifetime and could also vary in different organisms and cell types [18 - 24]. In this 
conceptual framework, the longevity network could progress through a series of 
checkpoints [19 - 21, 24]. At each of these checkpoints, a distinct set of master regulators 
senses the functional states of critical modules comprising the network. Based on this 
information and considering the input of some environmental cues (such as caloric and 
dietary intake, environmental stresses, endocrine factors etc.), master regulators modulate 
certain processes within monitored modules in order to limit the age-related accumulation 
of molecular and cellular damage [18 - 21, 24 - 29]. The resulting changes in the 
dynamics of individual modules comprising the network and in its general configuration 
are critically important for specifying the rate of aging during late adulthood [18 - 24]. 
            One of the major objectives of my thesis was to test the validity of the above 
hypothesis that aging is the final step of a developmental program, in which a limited 
number of “master” regulators orchestrate numerous longevity-defining cellular 
processes in space and time, and to define the molecular mechanisms underlying such 
program in chronologically aging yeast.   
 
1.2 A signaling network regulates longevity by integrating three signaling 
pathways that govern numerous longevity-defining cellular processes 
            The view of biological aging as the final step of a developmental program, in 
which numerous cellular processes are governed by a limited set of signaling proteins 
integrated into signaling pathways and networks, has been supported by the identification 
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of single-gene mutations that extend life span. Although these mutations target only a 
limited number of genes regulating longevity in such evolutionarily distant organisms as 
yeast, worms, flies and mice, they affect a plethora of cellular processes [4, 5, 10, 13, 25, 
26, 30 - 34]. This wide array of longevity-defining cellular processes - which across 
phyla are governed by a limited number of signaling proteins integrated into longevity 
signaling pathways and networks - includes oxidative metabolism in mitochondria, lipid 
and carbohydrate metabolism, NAD
+
 homeostasis, amino acid biosynthesis and 
degradation, ammonium and amino acid uptake, ribosome biogenesis and translation, 
proteasomal protein degradation, nuclear DNA replication, chromatin assembly and 
maintenance, actin organization, apoptosis, necrosis, autophagy, protein folding, stress 
response, signal transduction, cell cycle, and cell growth [4, 7, 8, 10, 24 - 32, 35, 36]. The 
functional states of all these numerous longevity-defining processes and their 
spatiotemporal organization are modulated by only a few nutrient- and energy-sensing 
signaling pathways that are conserved across phyla and include the AMP-activated 
protein kinase/target of rapamycin (AMPK/TOR), cAMP/protein kinase A (cAMP/PKA) 
and insulin/insulin-like growth factor 1 (IGF-1) pathways (Figure 1.1) [4, 10, 25 – 27, 30, 
35]. 
            The AMPK/TOR pathway regulates longevity in yeast, worms, fruit flies and 
mammals by acting as an intracellular sensor for the nutrient and energy status (Figure 
1.1) [37 - 42]. In response to the high AMP:ATP ratio characteristic of a low level of 
nutrients or energy within a cell, AMPK is activated to phosphorylate and inhibit TOR 
protein kinase associated with several other proteins into the TOR complex 1 (TORC1) 




Figure 1.1. The functional states of numerous longevity-defining processes and their spatiotemporal 
organization are modulated by only a few nutrient- and energy-sensing signaling pathways that are 
conserved across phyla and include the AMP-activated protein kinase/target of rapamycin (AMPK/TOR), 
cAMP/protein kinase A (cAMP/PKA) and insulin/insulin-like growth factor 1 (IGF-1) pathways (see text 
in section 1.2 for details). Reproduced from Fontana, L., Partridge, L. and Longo, V.D. (2010). Extending 
healthy life span - from yeast to humans. Science 328:321-326. 
 
by 1) slowing down the energy-consuming processes of cellular growth, ribosome 
biogenesis and protein translation; 2) initiating a pro-longevity translational program by 
causing a switch from cap-dependent to cap-independent translation; 3) activating 
nutrient- and energy-producing autophagy aimed at the removal of damaged 
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macromolecules and organelles; 4) accelerating mitochondrial translation of oxidative 
phosphorylation subunits; and 5) causing global changes in mitochondrial gene 
expression pattern [37, 43 - 45]. The life-extending inhibition of TORC1 can be also 
achieved in an AMPK-independent manner, in response to low intracellular levels of 
amino acids [39, 41, 46 - 49]. Moreover, following its phosphorylation by the LKB1 
protein kinase under low nutrient or energy conditions within a cell, AMPK extends the 
life span of worms in a TORC1-independent fashion by slowing down hydrolysis of the 
neutral lipids triacylglycerols (TAG) [50]. 
            The cAMP/PKA pathway regulates longevity in mice and yeast (Figure 1.1). In 
mice, this signaling pathway accelerates aging if activated by cAMP produced by AC5, a 
highly abundant in the heart and brain isoform of adenylate cyclase [51]. Lack of AC5 
attenuates cAMP/PKA signaling in mice, thereby reducing the inhibitory effect of PKA 
on the Raf/MEK/ERK protein kinase cascade [51]. The resulting activation of the protein 
kinase ERK extends longevity and delays age-related degenerative processes in the heart 
and bone, likely by elevating the level of the reactive oxygen species (ROS) scavenging 
enzyme manganese superoxide dismutase, increasing the resistance of mice to oxidative 
stress and attenuating apoptotic cell death [51]. The essential role for cAMP/PKA in 
regulating longevity and modulating physiological processes underlying healthy aging in 
mice has been recently confirmed by observations that lack of either a catalytic subunit of 
PKA or its regulatory subunit extends life span and improves health by attenuating age-
related pathologies [52 - 53].   
            In yeast cells, the cAMP/PKA pathway is attenuated in response to glucose 
deprivation, which inhibits such activators of adenylate cyclase Cyr1p as the G protein-
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coupled receptor Gpr1p, Gα protein Gpa2p and two small GTP-binding proteins, Ras1p 
and Ras2p (Figure 1.1) [54, 55]. The attenuation of cAMP/PKA signaling in glucose-
deprived yeast cells impairs the ability of cytosolic PKA to phosphorylate the following 
three proteins in the cytosol: 1) the protein kinase Rim15p (thereby restoring the kinase 
activity of Rim15p inhibited by PKA-dependent phosphorylation); and 2) the stress 
response transcription factors Msn2p and Msn4p (thereby enabling the import of their 
unphosphorylated forms into the nucleus) [56 - 58]. After being imported into the 
nucleus, Msn2p and Msn4p collaborate with a nuclear pool of Rim15p in activating 
transcription of numerous pro-longevity genes involved in carbohydrate metabolism, the 
tricarboxylic acid cycle, trehalose biosynthesis, proteolysis, stress protection, ROS 
detoxification and cell growth regulation [59 - 62]. The establishment of such global pro-
longevity transcriptional pattern ultimately extends both the chronological and replicative 
life spans of yeast [56, 63, 64]. It should be stressed that, akin to the Raf/MEK/ERK 
signaling cascade in mammals (see above) [51], its homologous Ste11p/Ste7p/Kss1p 
protein kinase cascade in yeast is attenuated by PKA and, if active, promotes longevity of 
chronologically aging yeast [65]. This pro-longevity effect of the Ste11p/Ste7p/Kss1p 
cascade in yeast under conditions of attenuated cAMP/PKA signaling is synergistic with 
the pro-longevity action of the nuclear forms of Msn2p, Msn4p and Rim15p not 
subjected to phosphorylation by cytosolic PKA [65]. 
            Unlike the AMPK/TOR and cAMP/PKA signaling pathways regulating longevity 
by acting as sensors of the intracellular nutrient and energy status, the insulin/IGF-1 
signaling pathway regulates longevity in worms, fruit flies and mice by responding to an 
endocrine signal that monitors the nutritional status of the whole organism (Figure 1.1) 
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[66]. In response to an insulin-like ligand, the insulin/IGF-1 pathway activates a 
phosphatidylinositol-3-kinase and a cascade of protein kinases, ultimately causing 
phosphorylation of a Forkhead box type O (FoxO) family transcription factor and its 
sequestration in the cytosol [67, 68]. In worms, fruit flies and mice, reduced signaling 
through the insulin/IGF-1 pathway extends longevity by inhibiting phosphorylation of 
their FoxO transcription factors (DAF-16, dFOXO and FoxO1, respectively), thereby 
enabling their import into the nucleus [69]. Following their nuclear import, these 
transcription factors activate or repress transcription of numerous longevity-defining 
genes involved in metabolism, detoxification, apoptosis, stress response, transcription, 
translation, signaling and development to ultimately establish a global pro-longevity 
transcriptional pattern [70, 71].   
            Because in evolutionarily distant organisms the AMPK/TOR, cAMP/PKA and 
insulin/IGF-1 signaling pathways share several protein kinases and adaptor proteins, they 
converge into a network regulating longevity in yeast, worms, fruit flies and mammals [4, 
35 - 38]. Growing evidence supports the view that this longevity regulation network also 
includes several proteins that currently are not viewed as being in any of these signaling 
pathways, including 1) Rtg2p in yeast; 2) CLK-1, ISP-1, JNK, MST-1, PHA-4, 
Rictor/TORC2/SGK-1, SIR-2.1, SKN-1 and SMK-1 in worms; 3) dSir2 and JNK in fruit 
flies; and 4) MCLK, P66
Shc
, SIRT1, SIRT6, and SIRT7 in mammals [4, 36, 72 - 74]. It 
should be stressed that this longevity regulation network responds to the age-related 
partial mitochondrial dysfunction and is modulated by mitochondrially produced ROS 
[36, 37, 73, 75]. By sensing the nutritional status of the whole organism as well as the 
intracellular nutrient and energy status, functional state of mitochondria, and 
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concentration of ROS produced in mitochondria, the longevity network regulates life 
span across species by coordinating information flow along its convergent, divergent and 
multiply branched signaling pathways. 
            One of the major objectives of my thesis was to examine if lithocholic acid, a 
novel anti-aging compound that I identified in a high-throughput chemical genetic screen, 
extends longevity of chronologically aging yeast by attenuating the pro-aging 
AMPK/TOR and/or cAMP/PKA signaling pathways. 
 
1.3 Some dietary regimens can extend longevity and improve health by 
attenuating age-related pathologies 
            Because nutrient intake modulates the organismal and intracellular nutrient and 
energy status, it plays an important role in defining both life span and health span [7, 76 - 
78]. Two dietary regimens - known as caloric restriction (CR) and dietary restriction 
(DR) - have been shown not only to exhibit a robust longevity-extending effect in 
evolutionarily distant organisms ranging from yeast to rhesus monkeys, but also to 
improve health by attenuating age-related pathologies and delaying the onset of age-
related diseases across phyla (Table 1.1) [76 - 83]. A CR dietary regimen reduces only 
calorie intake, but does not compromise the supply of amino acids, vitamins and other 
nutrients [77 - 80]. In contrast, a DR diet reduces the intake of nutrients (but not 
necessarily of calories) by limiting food supply without causing malnutrition [76, 81 - 
83].      
            A “TOR-centric” model of longevity regulation considers AMPK/TOR as the 
only signaling pathway underlying all life-extending and health-improving effects of CR  
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Table 1.1. Caloric restriction (CR) and dietary restriction (DR) exhibit a robust longevity-extending effect 
in evolutionarily distant organisms ranging from yeast to rhesus monkeys and improve health by 
attenuating age-related pathologies and delaying the onset of age-related diseases across phyla. Adapted 
from Fontana, L., Partridge, L. and Longo, V.D. (2010). Extending healthy life span - from yeast to 
humans. Science 328:321-326 with modifications. 
 
Organism Life-span increase by CR or DR Health improvement by CR or DR  
Yeast 3-fold (chronological life span) Extended reproductive period 
Worms 2- to 3-fold Resistance to misexpressed toxic 
proteins 
Fruit flies 2-fold None reported 
Mice 30-50% Protection against cancer, diabetes, 
atherosclerosis, cardiomyopathy, 
autoimmune, kidney and respiratory 
diseases; reduced neurodegeneration 
Rhesus monkeys Tend noted Prevention of obesity; protection 
against cancer, diabetes and 
cardiovascular disease 
Humans Not tested  Prevention of obesity, diabetes, 
hypertension; reduced risk factors for 
cancer and cardiovascular disease 
 
and DR [84 - 89]. According to this model, TORC1 - a core protein complex governing 
the AMPK/TOR pathway - performs three global functions, all of which are pivotal to the 
beneficial effects of CR and DR on longevity and health span. First, it integrates the flow 
of information on the organismal and intracellular nutrient and energy status from AMPK 
(a protein kinase in the AMPK/TOR pathway), PKA (a protein kinase in the cAMP/PKA 
pathway), PKB/AKT (a protein kinase in the insulin/IGF-1 pathway), ERK1/2 (a protein 





sensor of the redox status within this organelle) [84 - 86]. Second, it functions 
(independently of AMPK) as a sensor of the intracellular levels of amino acids [84 - 86]. 
Third, by gathering and processing the information on the organismal and intracellular 
nutrient, energy and redox status and amino acid availability, it operates as a control 
center that governs numerous longevity-related processes independently of sirtuins [84 - 
86]. The validity of the TOR-centric model for TORC1-orchestrated modulation of the 
life-extending effects of CR and DR has been confirmed in worms and replicatively 
aging yeast. In fact, DR is unable to extend longevity of worms with reduced TOR 
signaling [88, 89]. Furthermore, lack of key components of the TOR signaling pathway 
eliminates the beneficial effect of CR on the replicative life span of yeast [87]. 
            It seems that, although the TOR pathway alone mediates the longevity benefit 
associated with CR in replicatively aging yeast, the life-extending effect of this dietary 
regimen in chronologically aging yeast relies on a signaling network in which the protein 
kinase Rim15p operates as a nutritional integrator of the TOR and cAMP/PKA pathways 
and which also includes some other, yet to be identified signaling pathways that are not 
converged on Rim15p [35]. Furthermore, because the AMPK/TOR, cAMP/PKA and 
insulin/IGF-1 pathways in worms, fruit flies and mammals are known to converge into a 
complex network regulating their longevity (see above) [4, 7, 36 - 38], it is likely that 
these three divergent and multiply branched signaling pathways equally contribute to the 
life-extending effects of CR and DR in these organisms [4, 90 - 99]. The emerging 
concept of a signaling network (rather than the AMPK/TOR pathway alone) that 
mediates the longevity benefit associated with CR and DR by coordinating information 
flow along its convergent, divergent and multiply branched signaling pathways has been 
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recently supported by studies in worms. In fact, the life-extending efficacies of different 
DR regimens in these organisms depend on both independent and overlapping signaling 
pathways [100]. 
            One of the major objectives of my thesis was to identify small molecules that can 
extend longevity of chronologically aging yeast even under CR conditions, under which a 
pro-aging signaling network that integrates the TOR and cAMP/PKA pathways is greatly 
attenuated or even entirely inactivated. I thought that the availability of such anti-aging 
compounds would provide a potent chemical biological tool for defining what I call 
“housekeeping” longevity assurance pathways. I coined this term to emphasize that these 
pathways: 1) modulate longevity irrespective of the extracellular and intracellular nutrient 
and energy status – in contrast to TOR and cAMP/PKA, the two longevity signaling 
pathways that are “adaptable” by nature because they define yeast chronological life span 
only in response to certain changes in such status; and 2) do not overlap (or only partially 
overlap) with the adaptable TOR and cAMP/PKA pathways that in yeast are under the 
stringent control of calorie availability.  
 
1.4 Certain pharmacological interventions can delay aging by beneficially 
influencing age-related pathologies 
            CR and DR are not the only interventions known to extend longevity in 
evolutionarily distant organisms. Aging can be slowed down, health improved, age-
related pathologies attenuated and the onset of age-related diseases delayed also by 
certain small molecules, many of which exhibit the beneficial effects on longevity and 
health span in organisms across phyla (Table 1.2). Many of these longevity- and health 
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Table 1.2. Known anti-aging compounds, their abilities to increase life span in different organisms (under 
caloric or dietary restriction [CR or DR, respectively], on a standard diet or fed a high-calorie diet), and the 
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Caffeine Not tested (NT)  
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[101]  
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transcription of genes 







processes [103] known 
to be influenced by 
age-related chromatin 
reorganization [104] 
Lipoic acid, propyl 




+ (nematodes [105] 
(all); fruit flies 
[106] (lipoic acid))  
 
Antioxidants that may 

















[107]; mice [108])  
 
Type 2 diabetes 
therapeutics that - by 
activating 
LKB1/AMPK 
signaling and thereby 
inhibiting TORC1 [38, 
109] - modulate 
unspecified longevity-
related processes [107, 
108] known to be 
governed by the TOR 

















increases life span - 











A serotonin receptor 
antagonist used as an 
antidepressant in 
humans; may increase 
life span by inhibiting 
neurotransmission 
related to food 
sensing, thereby 







+ (fruit flies) [113] 
 
+ (yeast, CLS [101, 
110, 114] and RLS 
[115]; fruit flies 




cells - all RLS 
[110])  
 
By inhibiting TORC1 
(yeast and fruit flies) 
[101, 102, 113, 114] 
and mTORC1 
(mammals) [38, 102, 
116], increases life 
span by activating 
macroautophagy (yeast 
and fruit flies) [113, 
118] and inhibiting 
cap-dependent protein 
translation (fruit flies 
and mice) [113, 116] 





resistance (yeast) [110, 
115], and increasing 
neutral lipid levels 
(fruit flies) [113] 
Resveratrol 
 
- (yeast, RLS [119]; 
fruit flies [120]; 
+ (yeast, RLS [119] 
but not CLS [119]; 
Increases life span by 
modulating a number 
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mice [121])  
 
nematodes [120]; 
fruit flies [120]; 
fishes [122]; mice 







processes (e.g., by 
altering transcription 
of numerous genes 






mitochondrial number,  
reducing IGF-1 levels, 
activating AMPK and 
PGC-1α, promoting 
ER stress response, 
repressing 
transcription of PPAR-
γ, inhibiting adipocyte 
differentiation, 




autophagy [119, 121, 
123 - 131]; its life-
extending ability in 
yeast, nematodes and 
fruit flies depends on 
Sir2p - a member of 















+ (fungi, daphnias, 
fruit flies, mice) 
[132]  
 
By being specifically 
targeted to 
mitochondria, acts as 
an antioxidant that 
may increase life span 
by preventing 
oxidative damage to 







induced apoptosis and 
necrosis, and/or 
slowing down the age-
related 
phosphorylation of 







PBMC,RLS) [133]  
 
By activating 
expression of the 
human sirtuin SIRT1 
and thereby increasing 
the extent of SIRT1-
dependent histone H4 
lysine 16 
deacetylation, may 
cause the development 
of an anti-aging 
pattern of transcription 
of numerous genes 






+ (yeast, CLS; 
nematodes; fruit 
flies; human 
PBMC, RLS) [134]  
 
By inhibiting histone 
acetyltransferases and 
promoting histone H3 
deacetylation, 




genes; the resulting 
induction of autophagy 
suppresses age-related 
necrotic cell death 
[134] 







Is used as a mood 
stabilizer and an 
anticonvulsant in 
humans; may increase 
life span by promoting 
nuclear localization of 
the DAF-16 forkhead 
transcription factor, 
thereby reducing the 














An inhibitor of 
phosphatidylinositol-
3-kinase that – by 
reducing mTORC1 
signaling [37, 102] – 
modulates unspecified 
longevity-related 
processes [136] known 
to be governed by the 










An inhibitor of the 
protein kinase MEK 
that – by reducing 
mTORC1 signaling 
[37, 102] – modulates 
unspecified longevity-
related processes [136] 
known to be governed 
by the TOR pathway 
[37, 38, 102] 
 
* Mean, median and/or maximum life spans. 
** Nematodes carrying mutations that mimic DR under non-DR conditions [103, 105]. 
*** The ability of mianserin to increase nematode life span can only be seen in liquid media [112], whereas 
in solid media the compound reduces life span [137]. 
**** Increases the replicative life span of yeast grown under non-CR conditions [119] only in one out of four 
different yeast strain backgrounds [138]; one group has been unable to reproduce the life span extension by 
resveratrol in nematodes and fruit flies [139]; increases the life of mice only if fed a high-calorie diet, but 
not a standard diet [121, 124]. 
***** Although the life-extending ability of resveratrol in yeast, nematodes and fruit flies depends on Sir2p 
[119, 120, 125], it is currently debated whether this anti-aging compound binds to Sir2p (or SIRT1, a 
mammalian sirtuin) in vivo and/or activates Sir2p or SIRT1 in living cells [126, 138 - 142]; importantly, 
resveratrol has been shown to inhibit or activate many proteins other than sirtuins by interacting with them 
[143, 144].   
Abbreviations: AMPK, the AMP-activated serine/threonine protein kinase; CLS, chronological life span; 
IGF-1, insulin-like growth factor 1; LKB1, a serine/threonine protein kinase that phosphorylates and 
activates AMPK; mTORC1, the mammalian target of rapamycin complex 1; NT, not tested; PBMC, 
peripheral blood mononuclear cells; PGC-1α, peroxisome proliferator-activated receptor-γ co-activator 1α; 
RLS, replicative life span; TORC1, the yeast target of rapamycin complex 1. 
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span-extending pharmacological interventions target the AMPK/TOR signaling pathway 
known to modulate longevity in response to the intracellular nutrient and energy status. 
Metformin, a type 2 diabetes therapeutics that activates AMPK, extends longevity in 
worms and mice by reducing TORC1 signaling (Table 1.2) [107, 108]. Methionine 
sulfoximine, a glutamine synthetase inhibitor that attenuates TORC1 signaling by 
decreasing the intracellular concentration of the TORC1 activator glutamine, extends the 
chronological life span of yeast (Table 1.2) [110, 111]. LY294002 and U0126, which 
lower TORC1 signaling by inhibiting upstream TORC1 activators PI3K and MEK 
(respectively), increase the replicative life span of cultured human fibrosarcoma cells 
(Table 1.2) [136]. By acting through FKBP12 to inhibit TORC1, the macrocyclic lactone 
rapamycin extends 1) longevity in fruit flies and mice [113, 116]; 2) the replicative life 
spans of cultured rodent fibroblasts, human epithelium cells and human fibrosarcoma 
cells [117]; and 3) the replicative and chronological life spans of yeast (Table 1.2) [56, 
110, 114]. Caffeine, a xanthine alkaloid, increases the chronological life span of yeast by 
reducing the catalytic activity of Tor1p (Table 1.2) [101].  
            Some anti-aging compounds extend longevity by targeting the insulin/IGF-1 
pathway, which monitors the nutritional status of the whole organism. By modulating an 
upstream step in this signaling pathway, the serotonin receptor antagonist mianserin 
(which is used as an antidepressant in humans) increases life span in worms, likely by 
inhibiting neurotransmission related to food sensing and mimicking a DR-like 
physiological state (Table 1.2) [112]. A downstream step in this signaling pathway is a 
target of valproic acid (a mood stabilizer and an anticonvulsant in humans), which 
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extends longevity in worms by promoting the translocation of the pro-longevity FoxO 
transcriptional factor DAF-16 into the nucleus (Table 1.2) [135]. 
            Some anti-aging small molecules extend longevity, improve health and attenuate 
age-related pathologies by modulating longevity-defining processes controlled by 
proteins that are not viewed as components of the AMPK/TOR, cAMP/PKA and 
insulin/IGF-1 signaling pathways but are dynamically integrated into a longevity 
regulation network (see section 1.2 in this chapter of my thesis) they govern. One of these 
longevity-extending molecules is resveratrol, a small polyphenol produced by plants 
(Table 1.2). Although the demonstrated by in vitro studies ability of resveratrol to 
activate the protein deacetylase activities of the sirtuins Sir2p (yeast), SIR-2.1 (worms), 
dSir2 (fruit flies) and SIRT1 (mammals) [131, 145] is disputed [142, 146], it has been 
shown to modulate activities of many other longevity-related proteins by interacting with 
them [143, 144] – thereby influencing a plethora of longevity-defining processes [119, 
121, 124 - 127, 129]. It is likely that the resveratrol-driven modulation of activities of 
numerous longevity-defining proteins and processes they govern underlies the observed 
ability of this small polyphenol molecule 1) to extend the replicative (but not 
chronological) life span of yeast [119]; 2) to increase the replicative life span of cultured 
human fibroblasts [123]; and 3) to extend longevity of worms, fruit flies, fishes and mice 
[120 - 122, 124] (Table 1.2). 
            Akin to resveratrol, sodium nitroprusside exhibits a potent anti-aging effect by 
promoting sirtuin-dependent protein deacetylation. Unlike resveratrol, sodium 
nitroprusside activates expression of the gene encoding sirtuin SIRT1 [133]. The 
resulting enhancement of SIRT1-driven deacetylation of lysine 16 in histone H4 may 
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underlie the observed establishment of an anti-aging pattern of transcription and the 
concomitant replicative life span extension in cultured human peripheral blood 
mononuclear cells (PMBC) (Table 1.2) [133] 
            The reduction of the extent of histone acetylation is a longevity-extending process 
that can be promoted not only by sodium nitroprusside, but also by spermidine. This 
natural polyamine has been shown to inhibit histone acetyltransferases and promote 
histone H3 deacetylation - thereby activating transcription of numerous autophagy-
related genes, suppressing age-related necrotic cell death and ultimately extending the 
chronological life span of yeast, the replicative life span of cultured human PMBC, and 
longevity of worms and fruit flies (Table 1.2) [131, 134]. Of note, histone modification is 
also a target of another longevity-extending compound, Li
+
. The ability of this alkali 
metal ion to cause the age-related chromatin reorganization by altering transcription of 
genes involved in histone methylation, nucleosome composition and chromatin structure 
may underlie its beneficial properties as a mood stabilizer in humans and an anti-aging 
compound in worms (Table 1.2) [103].   
            Considering the essential role of mitochondria in longevity regulation across 
phyla [36, 73, 75, 147], it is not surprisingly that several anti-aging compounds extend 
longevity by influencing longevity-defining processes confined to or governed by these 
organelles. SkQ1, a plastoquinone derivate, is specifically sorted to mitochondria and 
operates as an antioxidant that attenuates oxidative damage to mitochondrial proteins and 
lipids, changes mitochondrial morphology, and impairs mitochondria-controlled forms of 
apoptotic and necrotic cell death caused by an excessive accumulation of mitochondria-
produced hydrogen peroxide (Table 1.2) [132]. By influencing these longevity-defining 
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processes confined to mitochondria, SkQ1 not only extends longevity in fungi, daphnias, 
fruit flies and mice, but also improves health and delays the onset of age-related diseases 
in mice [132]. Furthermore, longevity in worms and fruit flies can be extended by the 
thermal stress mimetics lipoic acid, propyl gallate, trolox and taxifolin, all of which may 
delay aging by detoxifying free radicals and enhancing resistance to age-related oxidative 
stress (Table 1.2) [106, 105].             
            It should be stressed that all anti-aging compounds known prior to my study are 
so-called “CR mimetics” and “DR mimetics” because they: 1) similar to CR and DR 
dietary regimens, increase life span and/or health span under non-CR or non-DR 
conditions;  2) unlike CR and DR diets, do not restrict caloric and nutrient intake; and 3) 
mimic life-extending and health-improving effects of CR and DR on metabolic pathways, 
physiological processes, stress response and gene expression (Table 1.2) [148 - 150]. 
Furthermore, as detailed in Table 1.2, almost all longevity-extending compounds known 
prior to my study target the AMPK/TOR and insulin/IGF-1 pathways and impact the 
sirtuin-governed protein deacetylation module of the longevity signaling network 
integrating these pathways. As I mentioned in sections 1.2 and 1.3, this network defines 
longevity only in response to the organismal and intracellular nutrient and energy status. 
Moreover, such CR mimetics and DR mimetics as resveratrol, metformin and mianserin 
beneficially influence life span and health span only under non-CR or non-DR 
conditions, but do not extend longevity or improve health if the supply of calories or 
nutrients is limited (Table 1.2) [107, 112, 119 - 121]. Therefore, I coined the term 
“adaptable” to define the AMPK/TOR, cAMP/PKA and insulin/IGF-1 signaling 
pathways and sirtuin-governed protein deacetylation module - because they all are 
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integrated into the longevity regulation network targeted by the currently known anti-
aging CR mimetics and DR mimetics. The term “adaptable” emphasizes the fact that all 
these pathways and the sirtuin-governed module exhibit the beneficial effects on 
longevity and attenuate age-related pathologies only in response to certain changes in the 
extracellular and intracellular nutrient and energy status of an organism. It should be 
stressed, however, that recent studies in worms and fruit flies revealed that Li
+
 and 
rapamycin (respectively) can extend life span even under DR conditions – although their 
longevity-extending efficacy under such nutrient-limited conditions is significantly lower 
than that under non-CR conditions (Table 1.2) [103, 113]. Based on these findings, I 
thought that some longevity assurance pathways could be “constitutive” or 
“housekeeping” by nature, assuming that they 1) modulate longevity irrespective of the 
extracellular and intracellular nutrient and energy status – in contrast to the adaptable 
AMPK/TOR, cAMP/PKA and insulin/IGF-1 signaling pathways and sirtuin-governed 
protein deacetylation module; and 2) do not overlap (or only partially overlap) with the 
adaptable pathways that are under the stringent control of calorie and nutrient 
availability.  
            One of the major objectives of my thesis was therefore to identify such 
housekeeping longevity pathway(s) operating in chronologically aging yeast. To attain 
this objective, I carried out a chemical genetic screen for anti-aging small molecules that 
can extend longevity even under CR conditions. I thought that, because under CR 
conditions the adaptable pro-aging pathways would be fully suppressed and the adaptable 
anti-aging pathways would be fully activated, a small molecule that can further increase 
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yeast chronological life span could target the housekeeping longevity pathway(s) that I 
was trying to identify.  
 
1.5 Yeast as a valuable model system for unveiling mechanisms of cellular aging 
in multicellular eukaryotes 
            The budding yeast Saccharomyces cerevisiae is a valuable model for studying the 
basic biology of aging and revealing longevity regulation mechanisms in multicellular 
eukaryotes [6, 34, 152]. There are two different paradigms of aging of this unicellular 
eukaryote amenable to comprehensive biochemical, genetic, cell biological, chemical 
biological and system biological analyses. In the replicative aging paradigm, yeast aging 
is defined by the maximum number of daughter cells that a mother cell can produce 
before becoming senescent (Figure 1.2) [6, 31]. Replicative aging in yeast mimics aging 
of dividing (“mitotic”) cells in a multicellular eukaryotic organism [6, 31]. In the 
chronological aging paradigm, yeast aging is defined by the length of time during which 
a cell remains viable following entry into a non-proliferative state (Figure 1.2) [6, 63, 
152]. Chronological aging in yeast is an advantageous model for studying aging of non-
dividing (“post-mitotic”) cells in a multicellular eukaryotic organism [6, 63, 152]. Yeast 
chronological aging is assessed using a simple clonogenic assay, which measures the 
percentage of yeast cells that remain viable at different time points following the entry of 
a cell population into the non-proliferative stationary phase [63]. A CR diet, which in 
yeast can be imposed by reducing the initial glucose concentration in a growth medium 
from 2% to 0.5% or lower, decelerates both replicative and chronological aging of yeast 




















Figure 1.3. Two different paradigms of yeast aging. In the replicative aging paradigm, yeast aging is 
defined by the maximum number of daughter cells that a mother cell can produce before becoming 
senescent. Replicative aging in yeast mimics aging of dividing (“mitotic”) cells in a multicellular 
eukaryotic organism. In the chronological aging paradigm, yeast aging is defined by the length of time 
during which a cell remains viable following entry into a non-proliferative state. Chronological aging in 
yeast is an advantageous model for studying aging of non-dividing (“post-mitotic”) cells in a multicellular 
eukaryotic organism. Yeast chronological aging is assessed using a simple clonogenic assay, which 
measures the percentage of yeast cells that remain viable at different time points following the entry of a 
cell population into the non-proliferative stationary phase. (See text in section 1.5 for details). Reproduced 
from [151].  
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            As I mentioned in sections 1.2, 1.3 and 1.4 of my thesis, longevity signaling 
pathways and mechanisms of their modulation by dietary and pharmacological 
interventions are conserved across phyla. It should be stressed that the use of yeast as an 
advantageous model organism in aging research greatly contributed to the current 
understanding of the molecular and cellular mechanisms underlying longevity regulation 
in evolutionarily distant eukaryotic organisms. Due to the relatively short and easily 
monitored replicative and chronological life spans of this genetically and biochemically 
manipulable unicellular eukaryote with annotated genome, it has been successfully used 
to 1) identify numerous novel longevity genes, all of which have been later implicated in 
regulating longevity of multicellular eukaryotic organisms; 2) establish the chemical 
nature of molecular damage that causes aging and accelerates the onset of age-related 
diseases across phyla; and 3) identify several longevity-extending small molecules, all of 
which have been later shown to slow down aging, improve health, attenuate age-related 
pathologies and delay the onset of age-related diseases in eukaryotic organisms across 
phyla [6, 7, 31, 79, 134, 151 - 153].  
   
1.6 Cancer as an age-associated disease whose onset can be delayed and 
incidence reduced by anti-aging interventions: The complex interplay 
between aging and cancer through convergent and divergent mechanisms 
            Because of a multi-step nature of the tumorigenesis process whose progression 
and completion requires an extended period of time, incidence rates of almost all cancers 
increase with age [154 - 156]. Therefore, aging is considered as one of the major risk 
factors in the onset and incidence of cancer, whereas cancer is believed to be one of the 
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numerous diseases associated with aging [157 - 162]. In the commonly accepted 
paradigm of the relationship between aging and cancer, due to their co-evolution these 
two complex and dynamic biological processes share common aetiology (i.e., an age-
related progressive accumulation of cellular damage) and have coalescent underlying 
mechanisms [157 - 159]. In this paradigm: 1) some genetic interventions that accelerate 
the age-related accumulation of cellular damage (or hasten some other common 
aetiologies of aging and cancer) and target some of the common mechanisms underlying 
aging and cancer are expected to exhibit both pro-aging and pro-cancer effects; and 2) 
some genetic, pharmacological and/or dietary interventions that reduce the age-related 
accumulation of cellular damage (or attenuate some other common aetiologies of aging 
and cancer) and target some of the common mechanisms underlying aging and cancer are 
expected to exhibit both anti-aging and anti-cancer effects [157 - 159]. A body of 
evidence supports the validity of this hypothesis.  
            In fact, some protein components of a longevity-defining signaling network 
centered at the mTORC1 complex of the pro-aging AMPK/TOR pathway have been 
shown to function as oncogenes (i.e., PI3K, Akt and eIF4E – two of which (PI3K and 
Akt) activate mTORC1, whereas eIF4E is activated by mTORC1 to promote protein 
synthesis and cell growth) (Figure 1.4) [39, 156 - 165]. In contrast, other proteins 
integrated into this longevity-defining signaling network are known to be tumor 
suppressors (i.e., PTEN, LKB1, TSC1 and TSC2 – all of which are mTORC1 inhibitors) 
(Figure 1.4) [39, 156 - 165]. Accordingly, inherited mutations inactivating the tumor 
suppressor protein components LKB1, TSC1 and TSC2 of this signaling network 
hyperactivate mTORC1 (Figure 1.4), thereby promoting cell growth and cell cycle 
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progression and ultimately resulting in the dominantly inherited benign cancer syndromes 
of the phakomatose group - which includes the Cowden’s syndrome, neurofibromatosis 
type 1, tuberous sclerosis complex syndrome and Peutz-Jeghers syndrome [39, 156, 161, 
163, 164]. Furthermore, somatic mutations in the gene encoding tumor suppressor protein 
LKB1 hyperactivate mTORC1, thereby promoting cell growth and cell cycle progression 
(Figure 1.4), and are common for up to 40% of all sporadic non-small cell lung cancers 
[163, 164]. Moreover, by hyperactivating mTORC1 and promoting cell growth and cell 
cycle progression (Figure 1.4), mutations in the gene for tumor suppressor protein PTEN 
cause glioblastoma and metastatic renal cell carcinoma [156, 161, 163, 164].  
            It should be stressed that by inhibiting (directly or indirectly) mTORC1 and 
thereby attenuating the pro-aging AMPK/TOR pathway, certain FDA-approved 
pharmacological interventions exhibit both anti-aging and anti-cancer effects (Figure 
1.4). By attenuating the AMPK/TOR pathway that promotes both aging and 
tumorigenesis, these pharmaceuticals: 1) slow down glycolysis, ribosome biogenesis, 
protein translation in the cytosol, mitochondrial ROS production, cell growth and cell 
cycle progression; 2) increase the efficiency of respiration, ROS detoxification and 
translation of oxidative phosphorylation subunits in mitochondria; 3) activate nutrient- 
and energy-producing autophagy aimed at the removal of damaged macromolecules and 
organelles; and 4) enhance stress response [37, 39, 43 - 45]. In fact, both the direct 
inhibition of mTORC1 by rapamycin and its analogues as well as the indirect (through 
the activation of the mTORC1 inhibitors LKB1 and AMPK) inhibition of mTORC1 by 
metformin and its analogues phenformin and Abbott A769662 (Figure 1.4) have been 




Figure 1.4. A longevity-defining signaling network that is centered at the mTORC1 complex of the pro-
aging and pro-cancer AMPK/TOR pathway in mammalian cells. By attenuating the AMPK/TOR pathway 
that promotes both aging and tumorigenesis, the tumor suppressors PTEN, LKB1, TSC1 and TSC2, as well 
as the FDA-approved pharmaceuticals rapamycin and metformin (and their analogues): 1) slow down 
glycolysis, ribosome biogenesis, protein translation in the cytosol, mitochondrial ROS production, cell 
growth and cell cycle progression; 2) increase the efficiency of respiration, ROS detoxification and 
translation of oxidative phosphorylation subunits in mitochondria; 3) activate nutrient- and energy-
producing autophagy aimed at the removal of damaged macromolecules and organelles; and 4) enhance 
stress response. The PI3K, Akt and eIF4E protein components of the pro-aging and pro-cancer signaling 
network centered at the mTORC1 complex function as oncogenes. PI3K and Akt activate mTORC1, 




mouse models; ii) delay the onset or lower incidence of tumors in transgenic and 
carcinogen-treated mouse cancer models; and even iii) cure some types of the pre-
existing human tumors in pre-clinical trials and clinical settings [160 - 164, 166 - 192].  
            Certain genetic, pharmacological and dietary interventions exhibit both anti-aging 
and anti-cancer effects by attenuating two other pro-aging signaling pathways, 
cAMP/PKA and insulin/IGF-1. Some of these interventions slow down only one of these 
two pathways, whereas others decelerate both of them or, additionally, also the pro-aging 
AMPK/TOR pathway and/or the sirtuin-governed protein deacetylation module of the 
longevity signaling network integrating all these pro-aging signaling pathways. These 
interventions include disruption of PKA in mice [193], growth hormone receptor and/or 
IGF-1 deficiencies in mice and humans [194, 195], resveratrol in mice and humans (both 
in cultured cells and in pre-clinical trials) (reviewed in [161, 162, 196 - 198]), as well as a 
CR or DR dietary regimen [10, 161, 162, 199 - 208]. 
            Noteworthy, a growing body of evidence supports the view the interplay between 
aging and cancer is more complex than only sharing common aetiology and having 
convergent underlying mechanisms (as the commonly accepted paradigm of the 
relationship between aging and cancer asserts). Indeed, in some situations aging and 
cancer have antagonistic aetiologies and divergent underlying mechanisms [157 - 159, 
209 - 223]. In these situations, the age-dependent accumulation of DNA damage and 
mutations in normal somatic cells (especially in adult stem and progenitor cells) triggers 
telomere shortening and/or a gradual rise in the expression of the INK4a/ARF locus [157 
- 159, 211, 217 - 219, 222]. (The INK4a/ARF locus is known to encode two tumor 
suppressor proteins, namely 1) the p16INK4a protein inhibitor of the cyclin D-dependent 
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protein kinases CDK4 and CDK6, both of which have been shown to target RB1 and 
other tumor suppressor members of the retinoblastoma protein family; and 2) the 
p14ARF/p19ARF protein inhibitor of Mdm2/Hdm2, which has been shown to operate as 
an oncogene destabilizing tumor suppressor protein p53 [157 - 159, 210, 217, 218]). Both 
telomere shortening and transcriptional activation of the INK4a/ARF locus in normal 
somatic cells reduce their proliferative potential, thereby promoting cellular senescence, 
causing a decline in tissue regeneration and repair, impairing tissue homeostasis, and 
ultimately accelerating cellular and organismal aging [157 - 159, 210, 217 - 219, 223]. 
Unlike their pro-aging effects in normal somatic cells, both telomere shortening and 
enhanced expression of INK4a/ARF have been shown to exhibit potent anti-cancer effects 
by reducing the proliferative potential of tumor cells, thereby causing their senescence 
and preventing their indefinite proliferation [157 - 159, 209 - 223]. Hence, a genetic, 
pharmacological or dietary anti-cancer intervention that can limit the excessive 
proliferation of tumor cells by, for instance, inhibiting telomerase or activating 
expression of INK4a/ARF has been predicted to have a pro-aging effect on the cellular 
and organismal levels [157 - 159, 210, 211, 213, 215 - 218, 221, 223]. Unlike several 
mentioned above examples of genetic, pharmacological and/or dietary interventions that 
exhibit both anti-aging and anti-cancer effects by attenuating some common aetiologies 
of aging and cancer and targeting some of their common underlying mechanisms, the 
hypothesis on the envisioned pro-aging effect of those anti-cancer interventions that 
promote cellular senescence by causing telomere shortening and/or activating expression 
of INK4a/ARF remains to be validated.     
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            One of the major objectives of my thesis was to examine if lithocholic acid, a 
novel anti-aging compound that I identified in a high-throughput chemical genetic screen, 
also exhibits an anti-tumor effect in cultured human cancer cells by activating certain 
anti-cancer processes that may (or may not) play an essential role in cellular aging. Of 
note, my studies described in this thesis revealed that lithocholic acid extends longevity 
of chronologically aging yeast not by attenuating the pro-aging AMPK/TOR and/or 
cAMP/PKA signaling pathways - both of which, as mentioned above in this section, have 
been shown to operate as pro-cancer signaling pathways in mice and humans. Therefore, 
I thought that an anti-tumor (if any) effect of this bile acid could be due to its ability to 
modulate some cellular processes whose potential essential role in the tumorigenesis 
process on the cellular level has not been appreciated so far. As a model for examining if 
lithocholic acid exhibits an anti-tumor effect in cultured human cancer cells (and if so, for 
establishing the mechanism underlying such effect), I choose several cell lines of the 
human neuroblastoma (NB) tumor. 
            NB is the most commonly diagnosed extracranial solid tumor among children, 
accounting for approximately 600 new cases diagnosed annually in the US alone [224 - 
226]. All NB originate from primordial neuroblast cells that eventually differentiate into 
the adrenal medulla and early sympathetic nervous system [225, 227 - 229]. In over 70% 
of all cases studied so far, NB metastasize to other tissues, including bone, bone marrow, 
lymph nodes, the liver as well as the leptomeningeal and parenchymal regions of the 
central nervous system (CNS) [224 - 229]. Although most patients diagnosed with non-
metastasizing NB have been reported to be cured, less than 40% of those with cancerous 
migration to other tissues survive despite rigorous chemotherapeutic and surgical 
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treatment [225]. Noteworthy, even though metastasis of NB to the CNS is rare, it usually 
coincides with recurrent high-risk cases and accounts for 1 to 16% of all patients with NB 
recurrence with an often fatal prognosis [226]. These high-risk NB cases regularly 
contain various genetic abnormalities, most notably 1) amplification of the MYCN gene 
[230 - 232], a transcription factor known for its role in growth, cell metabolism and 
division [233]; and 2) deletion of the short arm of chromosome 1p [234], which greatly 
reduces expression of numerous tumour-suppressing genes [235 - 238]. One of the main 
challenges of combating high-risk recurring NB is the use of non-toxic agents that not 
only prevent tumor metastasis, but also eliminate the primary tumor. Currently, NB is 
treated with a combination of the following seven chemotherapeutic drugs and their 
derivatives: doxorubicin, cisplatin, cyclophosphamide, topotecan, the 
epipodophyllotoxins etoposide and teniposide, and vincristine [239 - 240]. These 
chemotherapeutic compounds are known to induce DNA strand intercalation 
(doxorubicin, cisplatin, cyclophosphamide and topotecan), DNA strand breaks 
(epipodophyllotoxins) or mitotic inhibition (vincristine), all of which cause apoptotic 
death of malignant cancer cells [241 - 245]. In addition, all these anti-NB drugs have 
been shown to stimulate the release of significant amount of ROS from the major site of 
their production in mitochondria [241 - 245].   
 
1.7 Thesis outline and contributions of colleagues 
            Chapter 2 describes how I used a combination of functional genetic, cell 
biological, electron and fluorescence microscopical, proteomic, lipidomic, and 
metabolomic analyses to investigate the effect of CR, a low-calorie dietary regimen, on 
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the metabolic history of chronologically aging yeast. I examined how CR influences the 
age-related dynamics of changes in the intracellular levels of numerous proteins and 
metabolites, carbohydrate metabolism, interorganellar metabolic flow, concentration of 
ROS, mitochondrial morphology, essential oxidation-reduction processes in 
mitochondria, mitochondrial proteome, frequency of mitochondrial DNA mutations, 
dynamics of mitochondrial nucleoid, susceptibility to mitochondria-controlled apoptosis, 
and stress resistance. As my comparison of the metabolic histories of long-lived CR yeast 
and short-lived non-CR yeast revealed, yeast define their long-term viability by designing 
a diet-specific pattern of metabolism and organelle dynamics prior to reproductive 
maturation. My data imply that longevity in chronologically aging yeast is programmed 
by the level of metabolic capacity and organelle organization they developed, in a diet-
specific fashion, prior to entry into a non-proliferative state. Therefore, my conclusion is 
that chronological aging in yeast is the final step of a developmental program progressing 
through a series of checkpoints. 
            Chapter 3 describes how I designed a chemical genetic screen for small molecules 
that increase the chronological life span of yeast under CR by targeting lipid metabolism 
and modulating housekeeping longevity pathways that regulate longevity irrespective of 
the number of available calories. My screen identifies lithocholic acid (LCA) as one of 
such molecules. My evaluation of the life-extending efficacy of LCA in yeast cells on a 
high- or low-calorie diet revealed that this compound extends yeast chronological life 
span irrespective of the number of available calories. I found that the extent to which 
LCA extends longevity is highest under CR conditions, when the pro-aging processes 
modulated by the adaptable TOR and cAMP/PKA pathways are suppressed and the anti-
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aging processes are activated. Furthermore, the life-extending efficacy of LCA in CR 
yeast significantly exceeded that in yeast on a high-calorie diet, in which the adaptable 
TOR and cAMP/PKA pathways greatly activate the pro-aging processes and suppress the 
anti-aging processes. These findings imply that, consistent with its sought-after effect on 
a longevity signaling network, LCA mostly targets certain housekeeping longevity 
assurance pathways that do not overlap (or only partially overlap) with the adaptable 
TOR and cAMP/PKA pathways modulated by calorie availability. Moreover, my 
findings presented in chapter 3 revealed two mechanisms underlying the life-extending 
effect of LCA in chronologically aging yeast. One mechanism operates in a calorie 
availability-independent fashion and involves the LCA-governed modulation of 
housekeeping longevity assurance pathways. The other mechanism extends yeast 
longevity under non-CR conditions and consists in LCA-driven unmasking of the 
previously unknown anti-aging potential of PKA. 
            Chapter 4 describes how by fusing the “xenohormesis” hypothesis [119, 343, 
344], the “anti-aging side effect” hypothesis [349] and my hypothesis on longevity 
regulation by bile acids and rapamycin within ecosystems, I put forward a unified 
hypothesis of the xenohormetic, hormetic and cytostatic selective forces driving the 
evolution of longevity regulation mechanisms at the ecosystemic level. In my unified 
hypothesis, organisms from all domains of life (i.e., bacteria, fungi, plants and animals) 
within an ecosystem are able to synthesize chemical compounds that 1) are produced and  
then  released  into  the  environment  permanently  or  only in response to deteriorating 
environmental conditions, increased population density of competitors and/or predators, 
or changes in food availability and its nutrient and/or caloric content; 2) are mildly toxic 
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compounds that trigger a hormetic response in an organism that senses them or, 
alternatively, are not toxic for any organism within the ecosystem  and  do  not  cause  a  
hormetic  response;  3)  are  cytostatic  compounds  that attenuate the TOR-governed 
signaling network (e.g., rapamycin and resveratrol) or, alternatively, do not modulate this 
growth-promoting network (e.g., LCA and other bile acid); and 4) extend longevity of 
organisms that can sense these compounds, thereby increasing their chances of survival 
and creating selective force aimed at maintaining the ability of organisms composing the 
ecosystem to respond to these compounds by undergoing specific life-extending  changes  
to their physiology. My hypothesis implies that the evolution of longevity regulation 
mechanisms in each group of the organisms composing an ecosystem is driven by the 
ability of this group of organisms to undergo specific life-extending physiological 
changes in response to a compendium of “critical” chemical compounds that are 
permanently or transiently released to the ecosystem by other groups of organisms. 
Chapter 4 also describes how I verified my hypothesis empirically by carrying out the 
LCA-driven multistep selection of long-lived yeast species under laboratory conditions. I 
found that a lasting exposure of wild-type yeast to LCA results in selection of yeast 
species that live longer in the absence of this bile acid than their ancestor. My data 
enabled to rank different concentrations of LCA with respect to the efficiency with which 
they cause the appearance of long-lived yeast species. Because the lowest used 
concentration of LCA resulted in the highest frequency of long-lived species appearance, 
I believe that it is unlikely that the life-extending mutations they carry are due to 
mutagenic action of this bile acid. In chapter 4, I outlined the most critical questions 
needed to be addressed empirically in the near future to test the validity of other aspects 
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of my hypothesis on the ecosystemic evolution of longevity regulation mechanisms.       
            Chapter 5 describes how, by examining the effect of the novel anti-aging 
compound LCA in cultured human neuroblastoma (NB) cancer cells, I found that this bile 
acid exhibits a potent anti-tumor effect in NB cells by: 1) activating both intrinsic 
(mitochondrial) and extrinsic (death receptor) pathways of apoptotic death in these cells; 
2) sensitizing them to hydrogen peroxide-induced apoptotic death; and 3) preventing 
growth and proliferation of their neighbouring NB cells in the culture. Importantly, LCA 
does not display any of these deleterious effects in human neurons and, therefore, is a 
selective anti-tumor compound. My mass spectrometry-based measurement of 
intracellular and extracellular levels of exogenously added LCA revealed that this bile 
acid does not enter cultured NB cells. I therefore concluded that LCA prevents 
proliferation of human NB cells and selectively kills these cancer cells by binding to their 
surface and then initiating intracellular signaling cascades that not only impair their 
growth and division, but also cause their apoptotic death. The demonstrated inability of 
LCA to enter cultured human NB cells suggests that this potent and selective anti-cancer 
compound is unlikely to display undesirable side effects in non-cancerous human 
neurons. My findings described in chapter 5 suggest a mechanism underlying a potent 
and selective anti-tumor effect of LCA in cultured human NB cells. In this mechanism, 
LCA first binds to the G-protein-coupled receptor TGR5, the only known receptor for 
bile acids in the plasma membrane. In response to such binding, TGR5 and its associated 
protein partners: 1) transmit the signal from the plasma membrane to the mitochondrial 
surface to activate mitochondrial outer membrane permeabilization (MOMP); 2) activate, 
perhaps by a mechanism similar to the one involved in activation of the extrinsic (death 
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receptor) pathway of apoptosis through ligation of death receptors in the plasma 
membrane, the initiator caspase-8; and 3) inhibit the inflammatory caspase-1. The 
LCA/TGR5-induced MOMP results in efflux of cytochrome c from mitochondria, 
thereby causing apoptosome formation and initiator caspase-9 activation. The proteolytic 
cleavage of pro-caspase-3 by the enzymatically active caspase-9 elevates caspase-3 
activity, thereby enabling the caspase-3-driven cleavage of pro-caspase-6 and activation 
of the downstream executioner caspase-6. Together, activated caspase-3 and caspase-6 
(and perhaps other executioner caspases that are necessary for the proper execution of the 
LCA-driven, mitochondria-mediated apoptotic program) complete the demolition phase 
of the program by cleaving their respective protein substrates and producing the 
morphological features characteristic of apoptotic cell death. In LCA-exposed NB cells, 
the proteolytic cleavage of pro-caspase-3 and the resulting increase of caspase-3 activity 
(which in turn cleaves pro-caspase-6 and activates the downstream executioner caspase-
6) is also triggered by the initiator caspase-8 acting in the LCA-driven extrinsic pathway 
of apoptosis. In addition, activated in LCA-exposed NB cells caspase-8 causes MOMP 
and triggers the intrinsic (mitochondrial) pathway of apoptosis by cleaving and activating 
the BH-3 only protein BH3-interacting domain death agonist (BID). In my model, the 
LCA-driven inhibition of the inflammatory caspase-1 contributes to the anti-tumor effect 
of LCA in cultured NB cells by attenuating the processing and unconventional secretion 
of the cytokines interleukin-1β and interleukin-18 - thereby preventing growth and 
proliferation of neighbouring NB cells in culture. 
            Most of the findings described in Chapter 2 have been published in The 
Biochemical Society Transactions [Goldberg, A.A., Bourque, S.D., Kyryakov, P., Boukh-
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Viner, T., Gregg, C., Beach, A., Burstein, M.T., Machkalyan, G., Richard, V., 
Rampersad, S. and Titorenko, V.I. (2009). A novel function of lipid droplets in regulating 
longevity. Biochem. Soc. Trans. 37:1050-1055] and Experimental Gerontology 
[Goldberg, A.A., Bourque, S.D., Kyryakov, P., Gregg, C., Boukh-Viner, T., Beach, A., 
Burstein, M.T., Machkalyan, G., Richard, V., Rampersad, S., Cyr, D., Milijevic, S. and 
Titorenko, V.I. (2009). Effect of calorie restriction on the metabolic history of 
chronologically aging yeast. Exp. Gerontol. 44:555-571]. I carried out and supervised 
more than 30% of all of the work described in each of these publications and prepared the 
first draft of sections relevant to my work. I am an equally contributed first co-author on 
both these publications. Dr. V. Titorenko provided intellectual leadership of these 
projects and edited both manuscripts. Moreover, some of the findings described in 
Chapter 2 are presented in the manuscript of a paper [Kyryakov, P., Goldberg, A.A., 
Beach, A., Burstein, M.T., Richard, V.R. and Titorenko, V.I. Caloric restriction extends 
longevity of chronologically aging yeast in part by remodeling trehalose and glycogen 
metabolism] that is currently in preparation for submission to Aging. I expect this 
manuscript to be submitted for publication in late July or early August 2011. 
            Most of the findings described in Chapter 3 have been published in Aging 
[Goldberg, A.A., Richard, V.R., Kyryakov, P., Bourque, S.D., Beach, A., Burstein, M.T., 
Glebov, A., Koupaki, O., Boukh-Viner, T., Gregg, C., Juneau, M., English, A.M., 
Thomas, D.Y. and Titorenko, V.I. (2010). Chemical genetic screen identifies lithocholic 
acid as an anti-aging compound that extends yeast chronological life span in a TOR-
independent manner, by modulating housekeeping longevity assurance processes. Aging 
2:393-414]. I carried out and supervised more than 30% of the work described in this 
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publication and prepared the first draft of sections relevant to my work. I am an equally 
contributed first co-author on this publication. Dr. V. Titorenko provided intellectual 
leadership of this project and edited the manuscript. Moreover, some of the findings 
described in Chapter 3 are presented in the manuscript of a paper [Kyryakov, P., 
Goldberg, A.A., Beach, A., Burstein, M.T., Richard, V.R. and Titorenko, V.I. 
Identification of novel gerontogenes reveals a complex signaling network regulating 
longevity in the chronologically aging yeast Saccharomyces cerevisiae.] that is currently 
in preparation for submission to PLoS Genetics. I expect this manuscript to be submitted 
for publication in November or December 2011. 
            Most of the findings described in Chapter 4 have been published in Aging 
[Goldberg, A.A., Kyryakov, P., Bourque, S.D. and Titorenko, V.I. (2010). Xenohormetic, 
hormetic and cytostatic selective forces driving longevity at the ecosystemic level. Aging 
2:361-370]. I carried out and supervised more than 30% of the work described in this 
publication and prepared the first draft of sections relevant to my work. I am an equally 
contributed first co-author on this publication. Dr. V. Titorenko provided intellectual 
leadership of this project and edited the manuscript. Moreover, some of the findings 
described in Chapter 4 are presented in the manuscript of a paper [Kyryakov, P., 
Goldberg, A.A., Koupaki, o., Beach, A., Burstein, M.T., Richard, V.R. and Titorenko, 
V.I. Laboratory evolution of longevity regulation mechanisms by a lasting exposure of 
the yeast Saccharomyces cerevisiae to a bile acid] that is currently in preparation for 
submission to Current Biology. I expect this manuscript to be submitted for publication in 




            Most of the findings described in Chapter 5 are presented in the manuscript of a 
paper [Goldberg, A.A., Beach, A., Davies, G.F., Harkness, T.A.A., LeBlanc, A. and 
Titorenko, V.I. Lithocholic acid exhibits a potent and selective anti-tumor effect in 
human neuroblastoma cells by activating both intrinsic and extrinsic apoptotic death 
pathways and sensitizing these cells to hydrogen peroxide-induced death] that is currently 
in preparation for submission to Oncotarget. I expect this manuscript to be submitted for 
publication in June of 2012. 
          All abbreviations, citations, and the numbering of figures and tables that have been 
used in the published paper and in the manuscripts in preparation have been changed to 
















2 Aging is the final step of a developmental program: The longevity of 
chronologically aging yeast is programmed by the level of metabolic capacity 
and organelle organization they developed, in a diet-specific fashion, prior to 
entry into a non-proliferative state  
 
2.1 Abstract 
            Aging of multicellular and unicellular eukaryotic organisms is a multifactorial 
biological phenomenon that has various causes and affects a plethora of cellular activities 
[1 - 16]. I employ the yeast Saccharomyces cerevisiae as a model to study the basic 
biology and molecular mechanisms of cellular aging in multicellular eukaryotes [24, 246 
- 248]. The use of this budding yeast as an advantageous model organism in aging 
research greatly contributed to the current understanding of the molecular and cellular 
mechanisms underlying longevity regulation in evolutionarily distant eukaryotic 
organisms, thereby convincingly demonstrating that longevity signaling pathways and 
mechanisms of their modulation by dietary and pharmacological interventions are 
conserved across phyla [6, 7, 31, 79, 134, 151 - 153].  
            To address the inherent complexity of aging from a systems perspective and to 
build an integrative spatiotemporal model of aging process, I investigated the effect of 
caloric restriction (CR), a low-calorie dietary regimen, on the metabolic history of 
chronologically aging yeast. CR has been shown not only to exhibit a robust longevity-
extending effect in evolutionarily distant organisms ranging from yeast to rhesus 
monkeys, but also to improve health by attenuating age-related pathologies and delaying 
the onset of age-related diseases across phyla [76 - 83]. I examined how CR influences 
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the age-related dynamics of changes in the intracellular levels of numerous proteins and 
metabolites, carbohydrate metabolism, interorganellar metabolic flow, concentration of 
reactive oxygen species (ROS), mitochondrial morphology, essential oxidation-reduction 
processes in mitochondria, mitochondrial proteome, frequency of mitochondrial DNA 
mutations, dynamics of mitochondrial nucleoid, susceptibility to mitochondria-controlled 
apoptosis, and stress resistance.  
            Based on my comparison of the metabolic histories of long-lived CR yeast and 
short-lived non-CR yeast reported here, I concluded that yeast define their long-term 
viability by designing a diet-specific pattern of metabolism and organelle dynamics prior 
to reproductive maturation. My data imply that longevity in chronologically aging yeast 
is programmed by the level of metabolic capacity and organelle organization they 
developed, in a diet-specific fashion, prior to entry into a non-proliferative state. 
Therefore, my conclusion is that chronological aging in yeast is the final step of a 
developmental program progressing through a series of checkpoints. 
 
2.2 Introduction 
            Aging is a highly complex biological phenomenon, which affects numerous 
processes within cells [1 - 16]. These cellular processes include cell cycle, cell growth, 
stress response, protein folding, apoptosis, autophagy, proteasomal protein degradation, 
actin organization, signal transduction, nuclear DNA replication, chromatin assembly and 
maintenance, ribosome biogenesis and translation, lipid and carbohydrate metabolism, 
oxidative metabolism in mitochondria, NAD
+
 homeostasis, amino acid biosynthesis and 
degradation, and ammonium and amino acid uptake [5, 10, 13, 100, 31 - 34]. Some of 
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these processes damage cellular macromolecules and organelles, while the others prevent 
the collapse of cellular homeostasis by repairing the damage [1 - 3, 10, 13]. A lifelong 
accumulation of unrepaired cellular damage increases a risk of disease and death [1, 2, 
11, 13]. A challenge is to understand how the spatiotemporal organization of damage-
producing and damage-repairing processes influences longevity and how cells integrate 
and control these processes. The most important unanswered question is whether aging is 
the final step of a developmental program governed by a certain signaling network [19 - 
24] or merely a result of the lifelong accumulation of unrepaired cellular and molecular 
damage [1, 3, 12 - 18]. To identify the cellular processes that play a critical role in 
longevity regulation and to rank their relative contributions to aging, the concepts and 
methodologies of so-called metabolic control analysis (MCA) can be useful [1, 8]. It has 
been envisioned that the application of these concepts and methodologies to the analysis 
of empirical data on the cell metabolic histories of model organisms will enable to 1) 
infer the relative contributions of various cellular processes to aging; and 2) define how 
interventions such as dietary restriction delay aging by modulating these processes [1, 8]. 
            The budding yeast Saccharomyces cerevisiae is a valuable model for studying the 
basic biology of aging and revealing longevity regulation mechanisms in multicellular 
eukaryotes [6, 34, 152]. There are two different paradigms of aging of this unicellular 
eukaryote amenable to comprehensive biochemical, genetic, cell biological, chemical 
biological and system biological analyses. In the replicative aging paradigm, yeast aging 
is defined by the maximum number of daughter cells that a mother cell can produce 
before becoming senescent (Figure 1.2) [6, 31]. Replicative aging in yeast mimics aging 
of dividing (“mitotic”) cells in a multicellular eukaryotic organism [6, 31]. In the 
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chronological aging paradigm, yeast aging is defined by the length of time during which 
a cell remains viable following entry into a non-proliferative state (Figure 1.2) [6, 63, 
152]. Chronological aging in yeast is an advantageous model for studying aging of non-
dividing (“post-mitotic”) cells in a multicellular eukaryotic organism [6, 63, 152]. Yeast 
chronological aging is assessed using a simple clonogenic assay, which measures the 
percentage of yeast cells that remain viable at different time points following the entry of 
a cell population into the non-proliferative stationary phase [63]. A CR diet, which in 
yeast can be imposed by reducing the initial glucose concentration in a growth medium 
from 2% to 0.5% or lower, decelerates both replicative and chronological aging of yeast 
[6, 35, 63, 151].   
            In studies described in this chapter, I made a first step towards the use of MCA 
for defining the molecular causes of cellular aging by elucidating the effect of CR on the 
metabolic history of chronologically aging yeast. My comparison of the metabolic 
histories of long-lived CR yeast and short-lived non-CR yeast led me to the conclusion 
that longevity in chronologically aging yeast is programmed by the level of metabolic 
capacity and organelle organization they developed, in a diet-specific fashion, prior to 
reproductive maturation. I therefore propose here that chronological aging in yeast is the 
final step of a developmental program. By unveiling the different scenarios for a stepwise 
establishment of patterns of metabolism, inter-organellar communications and 
mitochondrial morphology in chronologically aging CR and non-CR yeast, my study 
enabled to define a distinct group of cellular metabolites and processes that play an 




2.3 Materials and Methods 
Strains and media  
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 lys20 
ura30) and mutant strains tps1 (MAT his31 leu20 lys20 ura30 
tps1::kanMX4), tps2 (MAT his31 leu20 lys20 ura30 pex5::kanMX4), pex6 
(MAT his31 leu20 lys20 ura30 tps2::kanMX4), tps3 (MAT his31 leu20 
lys20 ura30 tps3::kanMX4), tsl1 (MAT his31 leu20 lys20 ura30 
tsl1::kanMX4), ath1 (MAT his31 leu20 lys20 ura30 ath1::kanMX4), nth1 
(MAT his31 leu20 lys20 ura30 nth1::kanMX4), nth2 (MAT his31 leu20 
lys20 ura30 nth2::kanMX4), tpk1 (MAT his31 leu20 lys20 ura30 
tpk1::kanMX4), glg2 (MAT his31 leu20 lys20 ura30 glg2::kanMX4), glc3 
(MAT his31 leu20 lys20 ura30 glc3::kanMX4), gsy2 (MAT his31 leu20 
lys20 ura30 gsy2::kanMX4), pig1 (MAT his31 leu20 lys20 ura30 
pig1::kanMX4), pcl8 (MAT his31 leu20 lys20 ura30 pcl8::kanMX4), gph1 
(MAT his31 leu20 lys20 ura30 gph1::kanMX4), gdb1 (MAT his31 leu20 
lys20 ura30 gdb1::kanMX4), snf1 (MAT his31 leu20 lys20 ura30 
snf1::kanMX4) and tpk1 (MAT his31 leu20 lys20 ura30 tpk1::kanMX4) were 
used in this study. Media components were as
 
follows: 1) YEPD (0.2% Glucose), 1% 
yeast extract, 2% peptone, 0.2% glucose; and 2) YEPD (2% Glucose), 1% yeast extract, 
2% peptone, 2% glucose.  
 
A plating assay for the analysis of chronological life span 
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Cells were grown in YEPD (0.2% Glucose) medium at 30
o
C with rotational shaking at 
200 rpm in Erlenmeyer flasks at a flask volume/medium volume ratio of 5:1. A sample of 
cells was removed from each culture at various time points. A fraction of the cell sample 
was diluted in order to determine the total number of cells per ml of culture using a 
hemacytometer. 10 l of serial dilutions (1:10 to 1:103) of cells were applied to the 
hemacytometer, where each large square is calibrated to hold 0.1 l. The number of cells 
in 4 large squares was then counted and an average was taken in order to ensure greater 
accuracy. The concentration of cells was calculated as follows: number of cells per large 
square x dilution factor × 10 × 1,000 = total number of cells per ml of culture. A second 




) of cells were 
plated onto YEPD (2% Glucose) plates in triplicate in order to count the number of viable 
cells per ml of each culture. 100 l of diluted culture was plated onto each plate. After a 
48-h incubation at 30
o
C, the number of colonies per plate was counted. The number of 
colony forming units (CFU) equals to the number of viable cells in a sample. Therefore, 
the number of viable cells was calculated as follows: number of colonies × dilution factor 
× 10 = number of viable cells per ml. For each culture assayed, % viability of the cells 
was calculated as follows: number of viable cells per ml / total number of cells per ml × 
100%. The % viability of cells in mid-logarithmic phase was set at 100% viability for that 
particular culture.  
 
Plating assays for the analysis of resistance to various stresses 





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
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phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of plates. One 
set of plates contained YEPD (2% Glucose) medium alone, whereas the other set 
contained YEPD (2% Glucose) medium supplemented with 5 mM hydrogen peroxide. 
Pictures were taken after a 3-day incubation at 30
o
C.   





wild-type and mutant cells removed from mid-logarithmic phase (day 1) and from 
diauxic phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of 
plates. One set of plates contained YEPD (2% Glucose) medium alone, whereas the other 
set contained YEPD (2% Glucose) medium supplemented with 2.5 mM of the 
superoxide/hydrogen peroxide-generating agent paraquat. Pictures were taken after a 3-
day incubation at 30
o
C.  





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of YEPD (2% 
Glucose) plates. One set of plates was incubated at 30
o
C. The other set of plates was 
initially incubated at 55
o
C for 30 min, and was then transferred to 30
o
C. Pictures were 
taken after a 3-day incubation at 30
o
C.  





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of plates. One 
set of plates contained YEPD (2% Glucose) medium alone, whereas the other set 
contained YEPD (2% Glucose) medium supplemented with 0.5 M NaCl. Pictures were 










wild-type and mutant cells removed from mid-logarithmic phase (day 1) and from 
diauxic phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of 
plates. One set of plates contained YEPD (2% Glucose) medium alone, whereas the other 
set contained YEPD (2% Glucose) medium supplemented with 1 M sorbitol. Pictures 




Monitoring the formation of ROS  
Wild-type and mutant cells grown in YEPD (0.2% Glucose) were tested microscopically 
for the production of ROS by incubation with dihydrorhodamine 123 (DHR). In the cell, 
this nonfluorescent compound can be oxidized to the fluorescent chromophore rhodamine 
123 by ROS. Cells were also probed with a fluorescent counterstain Calcofluor White 
M2R (CW), which stains the yeast cell walls fluorescent blue. CW was added to each 
sample in order to label all cells for their proper visualization. DHR was stored in the 
dark at –20oC as 50 l aliquots of a 1 mg/ml solution in ethanol. CW was stored in the 
dark at –20oC as the 5 mM stock solution in anhydrous DMSO (dimethylsulfoxide). 
          The concurrent staining of cells with DHR and CW was carried out as follows. The 
required amounts of the 50 l DHR aliquots (1 mg/ml) and of the 5 mM stock solution of 
CW were taken out of the freezer and warmed to room temperature. The solutions of 
DHR and CW were then centrifuged at 21,000 × g for 5 min in order to clear them of any 
aggregates of fluorophores. For cell cultures with a titre of ~ 10
7
 cells/ml, 100 l was 
taken out of the culture to be treated. If the cell titre was lower, proportionally larger 
volumes were used. 6 l of the 1 mg/ml DHR and 1 l of the 5 mM CW solutions were 
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added to each 100 l aliquot of culture. After a 2-h incubation in the dark at room 
temperature, the samples were centrifuged at 21,000 × g for 5 min. Pellets were 
resuspended in 10 l of PBS buffer (20 mM KH2PO4/KOH, pH 7.5, and 150 mM NaCl). 
Each sample was then supplemented with 5 l of mounting medium, added to a 
microscope slide, covered with a coverslip, and sealed using nail polish. Once the slides 
were prepared, they were visualized under the Zeiss Axioplan fluorescence microscope 
mounted with a SPOT Insight 2 megapixel color mosaic digital camera. Several pictures 
of the cells on each slide were taken, with two pictures taken of each frame. One of the 
two pictures was of the cells seen through a rhodamine filter in order to detect cells dyed 
with DHR. The second picture was of the cells seen through a DAPI filter in order to 
visualize CW, and therefore all the cells present in the frame. 
          For evaluating the percentage of DHR-positive cells, the UTHSCSA Image Tool 
(Version 3.0) software was used to calculate both the total number of cells and the 
number of stained cells. Fluorescence of individual DHR-positive cells in arbitrary units 
was determined by using the UTHSCSA Image Tool software (Version 3.0). In each of 3-
5 independent experiments, the value of median fluorescence was calculated by analyzing 
at least 800-1000 cells that were collected at each time point. The median fluorescence 
values were plotted as a function of the number of days cells were cultured. 
          
Immunofluorescence microscopy 
Cell cultures were fixed in 3.7% formaldehyde for 45 min at room temperature. The cells 
were washed in solution B (100 mM KH2PO4/KOH pH 7.5, 1.2 M sorbitol), treated with 
Zymolyase 100T (MP Biomedicals, 1 μg Zymolyase 100T/1 mg cells) for 30 min at 30oC 
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and then processed as previously described [249]. Monoclonal antibody raised against 
porin (Invitrogen, 0.25 μg/μl in TBSB buffer [20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 
mg/ml BSA]) was used as a primary antibody. Alexa Fluor 568 goat anti-mouse IgG 
(Invitrogen, 2 μg/μl in TBSB buffer) was used as a secondary antibody. The labeled 
samples were mounted in mounting solution (16.7 mM Tris/HCl pH 9.0, 1.7 mg/ml p-
phenylenediamine, 83% glycerol). Images were collected with a Zeiss Axioplan 
fluorescence microscope (Zeiss) mounted with a SPOT Insight 2 megapixel color mosaic 
digital camera (Spot Diagnostic Instruments). 
  
Oxygen consumption assay 
The rate of oxygen consumption by yeast cells recovered at various time points was 
measured continuously in a 2-ml stirred chamber using a custom-designed biological 
oxygen monitor (Science Technical Center of Concordia University) equipped with a 
Clark-type oxygen electrode. 1 ml of YEPD medium supplemented with 0.2% glucose 
was added to the electrode for approximately 5 minutes to obtain a baseline. Cultured 
cells of a known titre were spun down at 3,000 × g for 5 minutes. The resulting pellet was 
resuspended in YEPD medium supplemented with 0.2% glucose and then added to the 
electrode with the medium that was used to obtain a baseline. The resulting slope was 



















mutations in mitochondrial DNA (mtDNA) and spontaneous single-gene nuclear 
mutations (pet
-
) affecting essential mitochondrial components was evaluated by 
measuring the fraction of respiratory-competent (rho
+
) yeast cells remaining in their 
aging population. rho
+
 cells maintained intact their mtDNA and their nuclear genes 
encoding essential mitochondrial components. Therefore, rho
+
 cells were able to grow on 
glycerol, a non-fermentable carbon source. In contrast, mutant cells deficient in 
mitochondrial respiration were unable to grow on glycerol. Most of these mutant cells 




 mutations or large 
deletions rho
-
) or completely lacked this DNA (rho
o
 mutants), whereas some of them 
carried so-called pet
-
 mutations in nuclear genes that code for essential mitochondrial 
components [250]. Serial dilutions of cell samples removed from different phases of 
growth were plated in duplicate onto YP plates containing either 2% glucose or 3% 
glycerol as carbon source. Plates were incubated at 30
o
C. The number of CFU on YP 
plates containing 2% glucose was counted after 2 d of incubation, whereas the number of 
CFU on YP plates containing 3% glycerol was counted after 6 d of incubation. For each 










) cells was 
calculated as follows: 100 - [(number of CFU per ml on YP plates containing 3% 
glycerol/number of CFU per ml on YP plates containing 2% glucose) × 100]. The 
frequency of spontaneous point mutations in the rib2 and rib3 loci of mtDNA was 
evaluated by measuring the frequency of mtDNA mutations that caused resistance to the 
antibiotic erythromycin [251]. These mutations impair only mtDNA [252, 253]. In each 
of the seven independent experiments performed, ten individual yeast cultures were 
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grown in YP medium containing 0.2%, 0.5%, 1% or 2% glucose as carbon source. A 
sample of cells was removed from each culture at various time-points. Cells were plated 
in duplicate onto YP plates containing 3% glycerol and erythromycin (1 mg/ml). In 
addition, serial dilutions of each sample were plated in duplicate onto YP plates 
containing 3% glycerol as carbon source for measuring the number of respiratory-
competent (rho
+
) cells. The number of CFU was counted after 6 d of incubation at 30
o
C. 
For each culture, the frequency of mutations that caused resistance to erythromycin was 
calculated as follows: number of CFU per ml on YP plates containing 3% glycerol and 
erythromycin/number of CFU per ml on YP plates containing 3% glycerol.  
 
Preparation of total cell lysates 
An aliquot containing 1 × 10
9 
cells was centrifuged for 7 min at 3,000 rpm at room 
temperature. Pelleted cells were washed twice with distilled water and further centrifuged 
for 3 min at 16,000 × g at room temperature. The recovered cell pellet was then 
resuspended in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and centrifuged 
for 15 sec at 16,000 × g at room temperature. The cells were then washed again, first by 
resuspending them in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and then 
by centrifuging for 15 sec at 16,000 × g at room temperature. The pellet of washed cells 
was then resuspended in 1 ml of ice-cold 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5), 
divided into 5 equal aliquots of 200 μl each and placed in Eppendorf tubes kept on ice. 
Each 200 μl aliquot was supplemented with ~100 μl of glass beads and vortexed three 
times for 1 minute. Apart from the vortexing steps, the samples were kept on ice at all 





C.  The resulting supernatant of the glass bead lysate was immediately transferred 
into a pre-chilled Eppendorf tube and stored at -20
o
C for further analysis. 
 
Isolation of the crude mitochondrial fraction 
Yeast cells were pelleted at 3,000 × g for 5 min at room temperature, washed twice with 
distilled water, resuspended in DTT buffer (100 mM Tris-H2SO4, pH 9.4, 10 mM 
dithiothreitol [DTT]), and incubated for 20 min at 30
o
C to weaken the cell wall. The cells 
were then washed with Zymolyase buffer (1.2 M sorbitol, 20 mM potassium phosphate, 
pH 7.4), centrifuged at 3,000 × g for 5 min at room temperature, and incubated with 3 
mg/g (wet wt) of Zymolyase-100T in 7 ml/g (wet wt) Zymolyase buffer for 45 min at 
30°C.  Following an 8-min centrifugation at 2,200 × g at 4
o
C, the isolated spheroplasts 
were washed in ice-cold homogenization buffer (5 ml/g) (0.6 M sorbitol, 10 mM Tris-
HCl, pH7.4, 1 mM EDTA, 0.2% (w/v) BSA) and then centrifuged at 2,200 × g for 8 min 
at 4
o
C. Washed spheroplasts were homogenized in ice-cold homogenization buffer using 
15 strokes. The cell debris was removed by centrifuging the resulting homogenates at 
1,500 × g for 5 min at 4°C. The supernatant was further centrifuged at 3,000 × g for 5 
min at 4°C to remove residual cell debris. The resulting supernatant was then centrifuged 
at 12,000 × g for 15 min at 4°C to pellet mitochondria. The remnant cell debris was 
removed by centrifuging the mitochondrial fraction at 3,000 × g for 5 min at 4°C. The 
resulting supernatant was then centrifuged at 12,000 × g for 15 min at 4°C to obtain the 
crude mitochondrial pellet, which was then resuspended in 3 ml of SEM Buffer (250 mM 
sucrose, 1 mM EDTA, 10 mM MOPS, pH 7.2) and used for the purification of 




Purification of mitochondria devoid of microsomal and cytosolic contaminations 
A sucrose gradient was made by carefully overlaying 1.5 ml of 60% sucrose with 4 ml of 
32% sucrose, 1.5 ml of 23% sucrose, and then 1.5 ml of 15% sucrose (all in EM buffer; 1 
mM EDTA, 10 mM MOPS, pH 7.2). Finally, a 3-ml aliquot of the crude mitochondrial 
fraction in SEM buffer was applied to the gradient and centrifuged at 134,000 × g 
(33,000 rpm) overnight at 2°C in vacuum (Rotor SW50Ti, Beckman). The purified 
mitochondria found at the 60%/32% sucrose interface were carefully removed and stored 
at - 80°C. 
 
Protein precipitation, SDS-PAGE and silver staining of gels 
Protein concentration was determined using the RC DC protein assay kit (Bio-Rad) 
according to the manufacturer's instructions. Proteins were precipitated by adding 
trichloroacetic acid (TCA) to the final concentration of 10%, incubated on ice for 30 min, 
pelleted by centrifugation, and then washed with ice-cold 80% acetone. Dried protein 
pellets were then resuspended in the SDS-PAGE sample buffer and the pH was adjusted 
to neutral using 2 M Tris/HCl (pH 8.8). The samples were boiled for 5 min at 63°C, 
centrifuged for 30 sec at 16,000 x g, loaded onto a 7.5%, 10%, 12.5% or 16% gel and 
resolved by SDS-PAGE. Following an overnight incubation of the gels in 50% methanol, 
proteins were visualized by silver staining using the mass spectrometry-compatible silver 
staining kit (Bio-Rad Silver Staining Plus) according to the manufacturer’s instructions. 
The Bio-Rad unstained molecular marker and a 0.1 mg/ml solution of BSA in the SDS-
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PAGE sample buffer were also subjected to SDS-PAGE. The proteins were then 
visualized by silver staining.  
 
Analysis of proteins by mass spectrometry 
Proteins were resolved by SDS-PAGE and visualized by silver staining [254]. Protein 
bands were excised from the gel, reduced, alkylated and in-gel digested with trypsin 
[254]. The proteins were identified by matrix-assisted laser desorption/ionization mass 
spectrometric (MALDI MS) peptide mapping [255], using a Micromass M@LDI time-of-
flight (TOF) mass spectrometer (Waters). Database searching using peptide masses was 
performed with the Mascot web-based search engine. For evaluating relative levels of 
individual proteins recovered in total cell lysates or purified mitochondria, a selected 
protein band was excised from the silver-stained gel and placed into an Eppendorf tube. 
A band of BSA containing 2 μg of this protein, which was also excised from the silver-
stained gel, was added to each of the protein bands to be analyzed. Protein bands were 
reduced, alkylated and in-gel digested with trypsin [254]. The desalted peptide mixture 
was added to the surface of a MALDI target plate and allowed to air dry. The sample spot 
was then overlaid with MALDI matrix solution containing the Angiotensin I peptide 
standard (1:1 ratio). The presence of Angiotensin I in the sample carrying the analyzed 
mixture of peptides provided an additional estimate of the mass measurement accuracy 
after calibration, giving an opportunity to calculate the value of peptide mass tolerance 
for each individual mass spectrum. After the desalted peptide mixture was analyzed by 
MALDI-TOF, the monoisotopic masses of recovered BSA peptides and the intensities of 
their monoisotopic peaks were grouped separately from the masses and intensities of 
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peptides originated from the protein of interest. These data provided an additional 
estimate of the mass measurement accuracy and were used for the quantitation of relative 
levels of the same protein recovered in different samples. For evaluating relative levels of 
the protein of interest found in the samples to be compared, a ratio “the intensity of the 
monoisotopic peak of a peptide originated from the protein of interest/the intensity of the 
monoisotopic peak of a BSA peptide with the monoisotopic mass closest to the mass of 
the peptide of interest” was calculated for each peptide originated from the protein of 
interest. Based on these data, the average value for relative levels of the protein of 
interest found in the two compared samples was calculated. The method for evaluating 
relative levels of the protein of interest recovered in different samples was validated by 
calculating relative levels of several standard proteins in the samples supplemented with 
different quantities of each of these proteins. 
 
Miscellaneous procedures 
SDS-PAGE and immunoblotting using a Trans-Blot SD semi-dry electrophoretic transfer 
system (Bio-Rad) were performed as previously described [256]. Blots were decorated 
with monoclonal antibodies raised against actin (Abcam) or porin (Invitrogen) or 
polyclonal antisera raised against Aco1p (kind gift of Dr. Ronald A. Butow, University of 
Texas Southwestern Medical Center) or cytochrome c (kind gift of Dr. Roland Lill, 
Philipps Universität Marburg). Antigen-antibody complexes were detected by enhanced 
chemiluminescence using an Amersham ECL Western blotting detection reagents (GE 
Healthcare). Purification of in organello formaldehyde-fixed proteins that bind to 
mitochondrial DNA was performed as previously described [257]. Enzymatic activities 
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of cytochrome c oxidase [258], succinate dehydrogenase [259] and aconitase [260] were 
determined by established methods. Preparation of cellular extracts and microanalytic 
biochemical assays for measuring ATP, glucose, trehalose and glycogen concentrations 




2.4.1 My rationale for choosing a nutrient-rich growth medium for studying yeast 
chronological aging 
            To study the effect of CR on the chronological life span of yeast, I cultured the 
wild-type strain BY4742 in the nutrient-rich YP (1% yeast extract, 2% peptone) medium 
initially containing 0.2%, 0.5%, 1% or 2% glucose. I chose YP medium for chronological 
aging studies because, in contrast to a synthetic medium, it is rich in amino acids, 
nucleotides, vitamins and other nutrients. I therefore thought that the reduction of glucose 
concentration in YP medium would lower the number of available calories without 
compromising the supply of essential nutrients, thereby modeling a traditional CR dietary 
regimen established in experiments with laboratory rodents [65, 55, 135, 262]. An 
equally important reason for choosing YP medium for chronological aging studies was 
that the recent isolation of quiescent and nonquiescent cells from yeast stationary (ST)-
phase cultures grown in this medium provided a novel, valuable system for elucidating 
the mechanisms linking chronological aging to quiescence, the mitotic cell cycle and 
apoptosis [263, 264]. Furthermore, the shape of mortality curves for yeast grown in the 
nutrient-rich YP medium to ST phase was similar to mortality patterns observed in 
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multicellular eukaryotes; their mortality rates increased with age and then reached a 
plateau at advanced age [265]. This is in contrast to yeast grown in the nutrient-limited 
SC (synthetic complete) medium. Although this medium has been chosen for studies of 
chronologically aging yeast to mimic their survival in the wild [266], age-specific death 
rates of yeast that have reached ST phase in SC medium exhibited a complicated pattern 
that was not reminiscent of the shape of mortality curves seen in multicellular organisms 
[265]. I therefore thought that yeast cultured in the nutrient-rich YP medium would be a 
better model system for elucidating the mechanisms underlying chronological aging of 
multicellular eukaryotes, as compared to yeast incubated in the nutrient-limited SC 
medium.  
            Moreover, it is well known that homeostatic mechanisms maintain the pH values 
of body fluids (such as blood, semen, cerebrospinal fluid, pancreatic juice and bile) 
between 7.1 and 8.6 [267]. These pH values are much closer to those observed in yeast 
cultures grown in YP medium [24] than to the considerably more acidic pH of yeast 
cultures cultivated in SC medium [268]. This fact was another reason for which I chose 
YP medium for studying mechanisms of chronological aging.  
            My choice of the strain BY4742 was based on its relatively short chronological 
life span [269], thereby offering considerable time savings for chronological aging 
studies of yeast cultivated in YP medium. Importantly, this yeast strain serves as one of 
the two haploid genetic backgrounds of the widely used Open Biosystems’ Yeast Knock-
Out Collection.  
 
2.4.2 CR extends the chronological life span of yeast  
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            The full growth cycle of yeast cultured in YP medium initially containing 0.2%, 
0.5%, 1% or 2% glucose began with logarithmic (L) phase and progressed through 
diauxic (D) and post-diauxic (PD) phases to stationary (ST) phase (Figure 2.1A). The 
rates of growth (Figure 2.1A) and glucose consumption (Figure 2.1B) in L phase were 
similar for cells cultured in any of the four media, whereas the maximum cell density in 
ST-phase cultures varied within a 28-% range and correlated with the initial glucose 
concentration (Figure 2.1A). CR cells grown on 0.2% or 0.5% glucose lived significantly 
longer than cells grown under non-CR conditions on 1% or 2% glucose (Figure 2.1C). In 
fact, the mean chronological life span of cells grown on 0.2% glucose was extended by 
more than 60% and that of cells grown on 0.5% glucose was extended by almost 2-fold, 
as compared to the mean chronological life span of cells grown on 2% glucose (Figure 
2.1D).  
            Noteworthy, unlike yeast cells grown in the nutrient-limited SC medium [270, 
271], cells cultured in the nutrient-rich YP medium with 0.5% glucose lived longer than 
cells cultured in YP medium containing 0.05% glucose (Figure 2.2). Thus, the largest 
increase in the chronological life span of yeast grown under CR conditions in YP medium 
occurs at 0.5% glucose. The observed difference in the lowest concentration of glucose 
that is optimal for life-span extension under CR conditions between yeast grown in SC or 
YP medium could be due to at least two factors. First, YP medium is enriched, as 
compared to SC medium, in amino acids, nucleotides, vitamins and other essential 
nutrients. It is conceivable that at least some of these nutrients could modulate the effect 
of different glucose concentrations on chronological life span by influencing certain 
metabolic and/or nutrient-sensing signaling pathways operating in CR yeast. Second, the  
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Figure 2.1. CR extends the chronological life span of yeast. (A and B) Kinetics of growth (A) and glucose 
consumption (B) for the WT strain BY4742. Each plot shows a representative experiment repeated 4-6 
times in triplicate with similar results. (C) Survival of chronologically aging WT cells. Data are presented 
as mean  SEM (n = 16-28). p < 0.001 at days 10 to 33 for cells grown on 0.2% or 0.5% glucose vs. cells 
grown on 2% glucose. (D) The mean chronological life spans of WT cells. Data are presented as mean  
SEM (n = 16-28); *p < 0.01, **p < 0.001. (E) ATP levels in chronologically aging WT cells. Data are 
presented as mean  SEM (n = 3-5). (A-E) Cells were cultured in YP medium containing 0.2%, 0.5%, 1% 































































































































Figure 2.2. Survival of the chronologically aging wild-type strain BY4742 (A) and the mean chronological 
life spans of different cultures of BY4742 (B) grown in YP medium initially containing 0.02%, 0.05%, 
0.1%, 0.2% or 0.5% glucose. Data are presented as mean  SEM (n = 3 for cells grown on 0.02%, 0.05% or 
0.1% glucose; n = 35 for cells grown on 0.2% glucose; n = 24 for cells grown on 0.5% glucose). *p < 0.01 
(for cells grown on 0.02%, 0.05%, 0.1% or 0.2% glucose vs. cells grown on 0.5% glucose). Abbreviations: 
Diauxic (D), logarithmic (L), post-diauxic (PD) or stationary (ST) phase. 
 
initial pH in yeast cultures grown in SC medium was 3.9-4.0 [268], whereas in yeast 
cultures grown in YP medium it was 6.9 [24]. Furthermore, both the dynamics of age-
related changes in the pH of culture medium and the final medium pH reached after 
several days of growth in SC with 0.5% or 0.05% glucose [268] differ from those 
observed for yeast that aged chronologically in YP medium containing either of these two 
glucose concentrations [24]. It is feasible that such differences between SC and YP in the 
initial pH and/or its age-related homeostasis could contribute to the observed difference 
between these two media in the lowest concentration of glucose at which the highest 
beneficial effect of CR on chronological life span can be achieved. 
            Importantly, ATP levels and the dynamics of their change during chronological 
aging were very similar for CR and non-CR yeast (Figure 2.1E). Thus, CR yeast are not 
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starving. Based on this important conclusion, I hypothesized that: 1) CR yeast remodel 
their metabolism in order to match the level of ATP produced in non-CR yeast; and 2) 
such specific remodeling of metabolism in CR yeast prolongs their life span. 
 
2.4.3 CR remodels the metabolism of trehalose and glycogen 
            To examine how exactly CR yeast remodel their metabolism in order to match the 
level of ATP generated in non-CR yeast, I first monitored the intracellular levels of 
trehalose and glycogen, the two major glucose stores of yeast [272]. 
            Yeast began to accumulate trehalose when they entered PD phase (Figure 2.3B). 
Trehalose levels increased during PD and ST phases. The rise of trehalose was 
considerably greater in slowly aging CR yeast than in rapidly aging non-CR yeast (Figure 
2.3B). Thus, CR promotes the age-dependent accumulation of this non-reducing 
disaccharide. Noteworthy, trehalose in CR yeast grown on 0.5% glucose, a diet that 
provides the maximal benefit of CR for longevity, increased mainly in PD phase and 
reached a plateau soon after cells have entered ST phase (Figure 2.3B). Conversely, 
trehalose in CR yeast grown on 0.2% glucose, a diet providing only a modest CR-
dependent life-span extension, increased predominantly throughout ST phase and 
eventually reached the steady-state level exceeding that in CR yeast grown on 0.5% 
glucose (Figure 2.3B). 
            The intracellular levels of glycogen, the major reserve carbohydrate in yeast 
[272], increased sharply in L phase, regardless of initial glucose concentration in the 
medium (Figure 2.3C). During the subsequent D and PD phases, CR yeast continued to 
accumulate glycogen, whereas non-CR yeast rapidly consumed it (Figure 2.3D). In  
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Figure 2.3. CR remodels trehalose and glycogen metabolism. (A) Outline of metabolic pathways and 
interorganellar communications operating in chronologically aging yeast. (B-D) The dynamics of age-
dependent changes in the intracellular levels of trehalose (B) and glycogen (C and D) during chronological 
aging of yeast. Cells were cultured in YP medium initially containing 0.2%, 0.5%, 1% or 2% glucose. Data 
are presented as mean  SEM (n = 4-6). For trehalose and glycogen levels, p < 0.001 at days 3 to 21 for 
cells grown on 0.2% or 0.5% glucose versus cells grown on 2% glucose. Abbreviations: Ac-CoA, acetyl-
CoA; AcOH, acetic acid; DAG, diacylglycerols; EE, ethyl esters; ER, endoplasmic reticulum; ERG, 
ergosterol; EtOH, ethanol; FA-CoA, CoA esters of fatty acids; FFA, free fatty acids; LB, lipid bodies; PL, 
phospholipids; TAG, triacylglycerols; TCA, the tricarboxylic acid cycle in mitochondria. 
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contrast to non-CR yeast, yeast under CR began to degrade their reserved glycogen only 
when they entered ST phase (Figure 2.3D). Of note, the degree of CR influenced both 
glycogen storage and its consumption. In fact, CR yeast grown on 0.5% glucose reserved 
more glycogen by the end of PD phase and then consumed it in ST phase somewhat 
faster, as compared to CR yeast grown on 0.2% glucose (Figure 2.3D). 
 
2.4.4 Life-span extension by CR relies in part on the ability of yeast to maintain 
trehalose concentration at optimal level 
            To evaluate the importance of maintaining trehalose homeostasis through 
consecutive growth phases on the observed longevity-extending effect of CR, I cultured a 
WT strain and several mutant strains, each carrying a single-gene-deletion mutation that 
affected trehalose biosynthesis or degradation [272], in YP medium initially containing 
0.2% glucose. I monitored the chronological life spans of all these strains and assessed 
the dynamics of changes in trehalose concentration during their aging. I found that lack 
of trehalose or a substantial decrease in its concentration seen in CR cells of the tps1 
and tps2 mutants, each missing a catalytic subunit of the trehalose synthase complex 
(Figure 2.4A), shortened their life spans (Figures 2.4B and 2.4D). A considerable, 
exceeding the level seen in WT, rise of trehalose during early and late stages of 
chronological aging, as it was observed in mutant cells lacking the Nth1p isozyme of 
neutral trehalase, also shortened life span (Figures 2.4C and 2.4E). Moreover, as I found, 
even if trehalose concentration exceeded the level seen in WT only after yeast have 
entered ST phase, as it occurred in mutant cells lacking the Nth2p isozyme of neutral 
trehalase, cells had shortened life span (Figure 2.4C and 2.4E). Importantly, I found that 
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some genetic manipulations changing trehalose concentration during early and/or late 
stages of chronological aging extended the life span of CR yeast. In fact, in long-lived 
mutants lacking the Tsl1p or Tps3p regulatory subunit of the trehalose synthase complex, 
trehalose concentration increased until the end of PD phase with the rate similar to that in 
WT, but then reached a plateau at the level that was 60-70% of that in WT (Figures 2.4B 
and 2.4D). Furthermore, in long-lived mutants lacking acid trehalase Ath1p or the 
catalytic subunit Tpk1p of cAMP-dependent protein kinase, trehalose concentration 
increased until the end of PD phase with the rate exceeding that in WT, but then reached 
a plateau at the level that was 50-60% of that in WT (Figures 2.4C and 2.4E).  
            Altogether, my findings imply that the chronological life span of CR yeast can be 
further expended by genetic manipulations that 1) do not decrease trehalose concentration 
until the end of PD phase; and 2) reduce trehalose concentration by 30-50% during ST 
phase. Noteworthy, trehalose stabilizes cytosolic proteins in their native conformation 
and prevents aggregation of proteins that have been denatured due to their exposure to 
elevated temperature or ROS [273, 274]. However, because of the ability of trehalose to 
interfere with the chaperone-assisted refolding of denatured cytosolic proteins, it must be 
rapidly degraded in order for molecular chaperones to restore the native conformation of 
these proteins [275]. Thus, it is conceivable that the high level of trehalose in CR yeast 
during an early stage of aging protects from aggregation those proteins that have been 
denatured due to their exposure to ROS (As I discuss further in this chapter, CR yeast 
accumulated substantial quantities of ROS at this stage). I hypothesize that some of the 
mutations that decrease trehalose concentration later in life can prolong chronological life 
span by promoting the refolding of proteins that have been oxidatively damaged earlier. 
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Recent unpublished data of Pavlo Kyryakov (a graduate student in Dr. Titorenko’s 
laboratory) on protein unfolding/aggregation in response to elevated temperature or 
oxidative stress and on protein refolding following temperature or oxidative status 
restoration in various mutants impaired in different steps of the trehalose biosynthesis or 
degradation pathways (see Figure 2.4A) confirm the validity of my hypothesis.  
 
2.4.5 Proper balance between the biosynthesis and degradation of glycogen is 
obligatory for life-span extension by CR 
            I next used a collection of mutants, each lacking a single protein that functions in 
glycogen biosynthesis or degradation (Figure 2.4G) [272], for functional analysis of the 
role for age-dependent glycogen dynamics in life-span extension by CR. I found that any 
genetic manipulation that substantially reduced glycogen concentration in CR cells 
entering ST phase of growth on 0.2% glucose shortened their chronological life span. 
This pattern was seen in mutants that lacked 1) the Glg2p isoform of self-glucosylating 
glycogenin glucosyltransferase; 2) the Gsy2p isoform of glycogen synthase; 3) Gac1p, 
Pig1p or Snf1p, all of which promote the dephosphorylation and activation of Gsy2p; or 
4) the glycogen branching enzyme Glc3p (Figures 2.4F - 2.4I). My findings revealed that 
the chronological life span of CR yeast could be prolonged only by a genetic 
manipulation that simultaneously accelerates 1) glycogen biosynthesis during growth 
phases preceding ST phase; and 2) glycogen degradation during ST phase. In fact, lack of 
some proteins, although accelerated glycogen biosynthesis during growth phases 
preceding ST phase, impaired glycogen degradation during ST phase and resulted in a 
shortened life span. I observed this pattern in mutants that lacked 1) the Pcl8p or Pho85p,  
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Figure 2.4. CR extends life span in part by maintaining a proper balance between the biosynthesis and 
degradation of trehalose and glycogen. (A) Outline of metabolic pathways of trehalose biosynthesis and 
degradation. (B and C) Trehalose concentrations in cells of WT and mutant strains. Each mutant carried a 
single-gene-deletion mutation that affects trehalose biosynthesis or degradation. Each plot shows a 
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representative experiment repeated 2-3 times with similar results. (D and E) The mean life spans of WT and 
mutant strains. Each mutant lacked a single enzyme that functions in trehalose biosynthesis or degradation. 
Each plot represents the average of 2-3 experiments; error bars show SEM. (F) Outline of metabolic 
pathways of glycogen biosynthesis and degradation. (G) The mean life spans of WT and mutant strains. 
Each mutant lacked a single enzyme that functions in glycogen biosynthesis or degradation. Each plot 
represents the average of 2-3 experiments; error bars show SEM. (H and I) Glycogen concentrations in 
cells of a WT strain and mutant strains. Each mutant carried a single-gene-deletion mutation that affects 
glycogen biosynthesis or degradation. Each plot shows a representative experiment repeated 2-3 times with 
similar results. (B-E and G-I) Cells were cultured in YP medium initially containing 0.2% glucose. 
 
each promoting the phosphorylation and inactivation of Gsy2p; or 2) the Gph1p isoform 
of glycogen phosphorylase (Figures 2.4F - 2.4I). Only in the tpk1 mutant, which lacked 
the catalytic subunit Tpk1p of cAMP-dependent protein kinase, the acceleration of both 
glycogen biosynthesis prior to ST phase and glycogen degradation during ST phase led to 
a substantially extended life span (Figures 2.4G and 2.45I). Of note, I found that life span 
was not affected by any of the single-gene-deletion mutations that, by eliminating a low-
abundance redundant component functioning in glycogen biosynthesis or degradation, 
did not have an effect on concentration of this major reserve carbohydrate. This pattern 
was seen in mutants that lacked 1) the Glg1p isoform of self-glucosylating glycogenin 
glucosyltransferase; 2) the Gsy1p isoform of glycogen synthase; or 3) the Gdb1p 
glycogen debranching enzyme (Figures 2.4G and 2.4I). In sum, my findings imply that 
life-span extension by CR relies in part on the establishment of a proper balance between 
the biosynthesis and degradation of glycogen. Current studies in Dr. Titorenko’s 
laboratory are aimed at establishing molecular mechanisms underlying the longevity-




2.4.6 CR alters the abundance of many mitochondrial proteins, modulates 
oxidation-reduction processes in mitochondria and changes the age-related 
dynamics of mitochondrially produced ROS 
            To examine how CR influences mitochondria-confined processes that define 
longevity, I conducted the mass spectrometry-based identification and quantitation of 
proteins recovered from purified mitochondria of chronologically aging CR and non-CR 
cells. My comparative analysis of cellular and mitochondrial proteomes of CR and non-
CR yeast revealed that CR altered the levels of numerous proteins that function in 
essential processes confined to mitochondria (Figure 2.5; Tables 2.1 and 2.2). I therefore 
sought to define the spectrum of mitochondrial processes affected by CR. 
            I found that, through D, PD and ST phases, mitochondria of CR yeast maintained 
the amplified rate of oxygen consumption, elevated the mitochondrial membrane 
potential (), and increased enzymatic activities of cytochrome c oxidase (CCO), 
succinate dehydrogenase (SDH) and aconitase (ACO), as compared to mitochondria of 
non-CR yeast (Figure 2.6). The observed amplification of these essential mitochondrial 
processes in CR yeast can be adequately explained by the CR-promoted rise in the levels 
of mitochondrial proteins that serve the formation of acetyl-CoA from pyruvate and its 
subsequent oxidation via the tricarboxylic acid (TCA) cycle, electron transport, and ATP-
producing oxidative phosphorylation (Figure 2.5; Tables 2.1 and 2.2). Despite the 
elevated levels of cytosolic and mitochondrial ROS scavenging proteins in CR yeast 
(Figure 2.5; Tables 2.1 and 2.2), CR elevated the level of intracellular ROS (Figure 2.6E). 
ROS are mostly generated as by-products of mitochondrial respiration [276 - 278]. Thus, 
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Figure 2.5. CR alters the abundance of a distinct set of proteins in mitochondria of chronologically aging 
yeast. Relative levels (fold difference relative to that on 2% glucose) of proteins recovered in purified yeast 
mitochondria. Proteins were identified and quantitated using mass spectrometry. The complete list of 
proteins and their relative levels are provided in Tables 2.1 and 2.2, respectively. From the data of 
proteomic analysis, I inferred an outline of mitochondria-confined processes that were activated (red 
arrows) or inhibited (green arrows) by CR prior to entry of yeast into the non-proliferative ST phase. 
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Abbreviations: Ac-CoA, acetyl-CoA; ETC, the mitochondrial electron transport chain; mtDNA, 
mitochondrial DNA; mtDNA-bp, mitochondrial DNA-binding proteins; PDH, the mutienzyme pyruvate 
dehydrogenase complex; ROS, reactive oxygen species; TCA, the tricarboxylic acid cycle in mitochondria. 
 
transport chain (ETC), CR enhanced the ROS-generating transfer of a single electron to 
oxygen in mitochondria. 
            Importantly, I found that the degree of CR influenced essential mitochondrial 
processes and activities such as oxygen consumption and ROS production, the 
establishment and maintenance of , and enzymatic activities of CCO, SDH and ACO. 
In fact, in CR yeast grown on 0.2% glucose, a glucose concentration providing only a 
moderate CR-dependent life-span extension, the efficiencies of all these processes and 
enzymatic activities were 1) greatly amplified when yeast entered D phase; and 2) 
sharply declined through the following PD and ST phases (Figure 2.6). Of note, the 
sharply declined activity of ACO recovered from CR yeast grown on 0.2% glucose could 





2.6F), which are able to restore the oxidation-dependent loss of one iron from the [4Fe-
4S] cluster of ACO [279]. As I found, in CR yeast grown on 0.5% glucose, a glucose 
concentration that provides the maximal benefit of CR for longevity, the efficiencies of 
all these mitochondrial processes and enzymatic activities were 1) amplified to a much 
lesser extent during D phase than they were amplified in yeast grown on 0.2% glucose; 
and 2) reached a plateau in PD phase and remained mainly unchanged during the 
following ST phase (Figure 2.6). During the non-proliferative ST phase, the efficiencies 
and activities of all monitored mitochondrial processes and enzymes in CR yeast grown 
on 0.5% glucose exceeded those seen in CR yeast grown on 0.2% glucose. Altogether, 
these findings suggest that the observed early spike in oxygen consumption by  
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Table 2.1. List of proteins recovered in mitochondria purified from wild-type cells grown in YP media 
initially containing 0.2%, 0.5%, 1% or 2% glucose. Mitochondria were purified from wild-type cells 
collected at day 1 (L phase), day 2 (D phase), day 4 (PD phase) and day 9 (ST phase). Proteins were 
identified using matrix-assisted laser desorption/ionization mass spectrometric (MALDI MS) peptide 
mapping. 
1The probability based Mowse score for comparing the calculated peptide masses for each entry in the 
sequence database with the set of experimental mass spectrometry data; Mowse scores greater than 54 are 
significant (p < 0.05). 
2The expectation value for the matching peptides, which provides the number of matches with equal or 
better Mowse scores that are expected to occur by chance alone. 
 














YP + 0.2% glucose; Day 1 (L phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
4 11 66 0.004   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
6 25 111 1.2e-07   
Lat1p NP_014328 Mitochondrial PDH 
complex  
11 27 161 1.2e-12   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
10 33 174  6e-14   
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
5 15 85 4.7e-05 
Cit1p NP_014398 Mitochondrial TCA cycle 11 28 185 4.8e-15   
Cit2p NP_009931 Mitochondrial TCA cycle 10 30 173 7.6e-14   
Cit3p NP_015325 Mitochondrial TCA cycle 10 23 166 3.8e-13 
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
6 11 90 1.3e-05   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
4 16 73 0.00083   
Idh2p NP_014779 Mitochondrial TCA cycle 9 34 164 6e-13 
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
5 6 63 0.0079 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
4 11 66 0.004 
Lsc1p NP_014785 Mitochondrial TCA cycle; 
binds to mtDNA 
8 37 152 9.5e-12 
Lsc2p NP_011760 Mitochondrial TCA cycle 10 27 164  6e-13   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
11 23 174 6e-14   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 21 89 1.9e-05   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
7 50 146 3.8e-11 
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
5 33 103 7.6e-07   
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Fum1p NP_015061 Mitochondrial TCA cycle 9 21 151 1.2e-11   
Mdh1p NP_012838 Mitochondrial TCA cycle 9 39 168 2.4e-13   
Ndi1p NP_013586 Mitochondrial ETC 8 18 128 2.4e-09 
Cyt1p NP_014708 Mitochondrial ETC 6 26 113 7.6e-08 
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
6 17 102 9.5e-07   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
7 17 116 3.8e-08 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
6 20 102 9.5e-07 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
9 20 140 1.5e-10 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
6 30 119 1.9e-08 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
5 21 93  6.9e-06 
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
7 12 102 9.5e-07 
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
7 16 113 7.6e-08 
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
7 18 113 7.6e-08   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
5 13 84 6.1e-05   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
5 31 96 3.7e-06 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
5 18 89 1.9e-05   
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mitochondria; binds to 
mtDNA 
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
6 14 97 3.2e-06   
YP + 0.5% glucose; Day 1 (L phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
5 13 81 0.00013   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
7 27 128 2.4e-09 
Lat1p NP_014328 Mitochondrial PDH 
complex  
9 25 147     3e-11   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
8 28 142 9.5e-11 
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
6 16 102 9.5e-07   
Cit1p NP_014398 Mitochondrial TCA cycle 9 24 152 9.5e-12 
Cit2p NP_009931 Mitochondrial TCA cycle 8 25 139 1.9e-10 
Cit3p NP_015325 Mitochondrial TCA cycle 8 20 134 6e-10   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
7 12 104 6e-07   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
5 18 87 2.9e-05   
Idh2p NP_014779 Mitochondrial TCA cycle 7 29 129 1.9e-09   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 75 0.00048   
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
5 13 80 0.00016   
Lsc1p NP_014785 Mitochondrial TCA cycle 6 30 116 3.8e-08   
Lsc2p NP_011760 Mitochondrial TCA cycle 8 23 132 9.5e-10   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
9 20 144 6e-11   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
4 18 72 0.001   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 40 106 3.8e-07   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 29 83 8.1e-05   
Fum1p NP_015061 Mitochondrial TCA cycle 7 18 119 1.9e-08 
Mdh1p NP_012838 Mitochondrial TCA cycle 7 31 131 1.2e-09   
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
7 19 118 2.4e-08   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   




Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 100 1.7e-06 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
9 14 128 2.4e-09 
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
8 18 128 2.4e-09 
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
8 19 127 3e-09   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
6 15 100 1.7e-06 
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
6 34 113 7.6e-08   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
6 20 104 6e-07  
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
7 15 112 9.5e-08   
YP + 1% glucose; Day 1 (L phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
6 14 96 4.2e-06   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
8 31 146 3.8e-11 
Lat1p NP_014328 Mitochondrial PDH 
complex  
7 19 102 9.5e-07   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
6 23 108 2.4e-07   
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
7 19 119 1.9e-08   
Cit1p NP_014398 Mitochondrial TCA cycle 7 20 119 1.9e-08 
Cit2p NP_009931 Mitochondrial TCA cycle 6 20 106 3.8e-07 
Cit3p NP_015325 Mitochondrial TCA cycle 6 16 102 9.5e-07   
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Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
8 13 118  2.4e-08   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
6 21 103 7.6e-07   
Idh2p NP_014779 Mitochondrial TCA cycle 5 23 94 6.4e-06   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 82 1e-04   
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
6 16 96 3.7e-06   
Lsc1p NP_014785 Mitochondrial TCA cycle; 
binds to mtDNA 
5 23 95 4.8e-06   
Lsc2p NP_011760 Mitochondrial TCA cycle  6 19 101 1.2e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
7 17 113 7.6e-08   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
6 20 104 6e-07   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
4 35 86 3.5e-05   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
6 31 123 7.6e-09   
Fum1p NP_015061 Mitochondrial TCA cycle 5 15 86 3.7e-05 
Mdh1p NP_012838 Mitochondrial TCA cycle 5 24 95 4.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 6 14 97 3.2e-06   
Cyt1p NP_014708 Mitochondrial ETC 5 23 95 4.8e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
8 20 134 6e-10   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
11 23 169 1.9e-13 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
9 15 129 1.9e-09   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
9 19 142 9.5e-11   
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Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
9 21 142 9.5e-11   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
7 17 116 3.8e-08   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
7 39 131 1.2e-09 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
7 22 121 1.2e-08   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
8 16 112 9.5e-08   
YP + 2% glucose; Day 1 (L phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
7 17 109 1.9e-07   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
9 34 164 6e-13   
Lat1p NP_014328 Mitochondrial PDH 
complex  
5 16 85  
Pdx1p NP_011709 Mitochondrial PDH 
complex 
5 19 90  
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
8 21 136  3.8e-10   
Cit1p NP_014398 Mitochondrial TCA cycle 5 15 86 3.8e-05 
Cit2p NP_009931 Mitochondrial TCA cycle 5 16 88 2.5e-05   
Cit3p NP_015325 Mitochondrial TCA cycle 5 14 85 4.3e-05   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
9 14 132 9.5e-10 
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
7 21 105 4.8e-07 
Idh2p NP_014779 Mitochondrial TCA cycle 5 15 88 2.2e-05   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
7 8 93 6.9e-06 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
7 18 111 1.2e-07   
Lsc1p NP_014785 Mitochondrial TCA cycle 5 14 90 1.7e-05   
Lsc2p NP_011760 Mitochondrial TCA cycle 5 16 84 5.5e-05   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
6 14 97 2.7e-06   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 18 88 2.5e-05   




Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 19 81 0.00011   
Fum1p NP_015061 Mitochondrial TCA cycle 6 13 99 1.9e-06   
Mdh1p NP_012838 Mitochondrial TCA cycle 5 20 93 7.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
9 21 148 2.4e-11   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06  
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 30 147 3e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
10 16 145 4.8e-11   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
10 21 156 3.8e-12   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
11 20 157 3e-12   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
8 19 132 9.5e-10   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 




Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
8 25 138 2.4e-10   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
9 19 143 7.6e-11   
YP + 0.2% glucose; Day 2 (D phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
4 11 66 0.004   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
6 25 111 1.2e-07   
Lat1p NP_014328 Mitochondrial PDH 
complex  
11 27 161 1.2e-12   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
10 33 174  6e-14   
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
5 15 85 4.7e-05 
Cit1p NP_014398 Mitochondrial TCA cycle 11 28 185 4.8e-15   
Cit2p NP_009931 Mitochondrial TCA cycle 10 30 173 7.6e-14   
Cit3p NP_015325 Mitochondrial TCA cycle 10 23 166 3.8e-13 
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
6 11 90 1.3e-05   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
4 16 73 0.00083   
Idh2p NP_014779 Mitochondrial TCA cycle 9 34 164 6e-13 
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
5 6 63 0.0079 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
4 11 66 0.004 
Lsc1p NP_014785 Mitochondrial TCA cycle; 
binds to mtDNA 
8 37 152 9.5e-12 
Lsc2p NP_011760 Mitochondrial TCA cycle 10 27 164  6e-13   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
11 23 174 6e-14   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 21 89 1.9e-05   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
7 50 146 3.8e-11 
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
5 33 103 7.6e-07   
Fum1p NP_015061 Mitochondrial TCA cycle 9 21 151 1.2e-11   
Mdh1p NP_012838 Mitochondrial TCA cycle 9 39 168 2.4e-13   
Ndi1p NP_013586 Mitochondrial ETC 8 18 128 2.4e-09 
Cyt1p NP_014708 Mitochondrial ETC 6 26 113 7.6e-08 
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
6 17 102 9.5e-07   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
7 17 116 3.8e-08 




Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
9 20 140 1.5e-10 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
6 30 119 1.9e-08 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
5 21 93  6.9e-06 
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
7 12 102 9.5e-07 
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
7 16 113 7.6e-08 
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
7 18 113 7.6e-08   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
5 13 84 6.1e-05   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
5 31 96 3.7e-06 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
5 18 89 1.9e-05   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
6 14 97 3.2e-06   
YP + 0.5% glucose; Day 2 (D phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
5 13 81 0.00013   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
7 27 128 2.4e-09 
Lat1p NP_014328 Mitochondrial PDH 
complex  
9 25 147     3e-11   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
8 28 142 9.5e-11 
Lpd1p NP_116635 Mitochondrial PDH 6 16 102 9.5e-07   
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complex; binds to mtDNA 
Cit1p NP_014398 Mitochondrial TCA cycle 9 24 152 9.5e-12 
Cit2p NP_009931 Mitochondrial TCA cycle 8 25 139 1.9e-10 
Cit3p NP_015325 Mitochondrial TCA cycle 8 20 134 6e-10   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
7 12 104 6e-07   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
5 18 87 2.9e-05   
Idh2p NP_014779 Mitochondrial TCA cycle 7 29 129 1.9e-09   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 75 0.00048   
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
5 13 80 0.00016   
Lsc1p NP_014785 Mitochondrial TCA cycle 6 30 116 3.8e-08   
Lsc2p NP_011760 Mitochondrial TCA cycle 8 23 132 9.5e-10   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
9 20 144 6e-11   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
4 18 72 0.001   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 40 106 3.8e-07   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 29 83 8.1e-05   
Fum1p NP_015061 Mitochondrial TCA cycle 7 18 119 1.9e-08 
Mdh1p NP_012838 Mitochondrial TCA cycle 7 31 131 1.2e-09   
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
7 19 118 2.4e-08   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 4.8e-09 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 100 1.7e-06 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 




Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
8 18 128 2.4e-09 
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
8 19 127 3e-09   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
6 15 100 1.7e-06 
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
6 34 113 7.6e-08   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
6 20 104 6e-07  
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
7 15 112 9.5e-08   
YP + 1% glucose; Day 2 (D phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
6 14 96 4.2e-06   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
8 31 146 3.8e-11 
Lat1p NP_014328 Mitochondrial PDH 
complex  
7 19 102 9.5e-07   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
6 23 108 2.4e-07   
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
7 19 119 1.9e-08   
Cit1p NP_014398 Mitochondrial TCA cycle 7 20 119 1.9e-08 
Cit2p NP_009931 Mitochondrial TCA cycle 6 20 106 3.8e-07 
Cit3p NP_015325 Mitochondrial TCA cycle 6 16 102 9.5e-07   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
8 13 118  2.4e-08   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
6 21 103 7.6e-07   
Idh2p NP_014779 Mitochondrial TCA cycle 5 23 94 6.4e-06   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 82 1e-04   
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
6 16 96 3.7e-06   
Lsc1p NP_014785 Mitochondrial TCA cycle; 
binds to mtDNA 
5 23 95 4.8e-06   
Lsc2p NP_011760 Mitochondrial TCA cycle  6 19 101 1.2e-06 




Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
6 20 104 6e-07   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
4 35 86 3.5e-05   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
6 31 123 7.6e-09   
Fum1p NP_015061 Mitochondrial TCA cycle 5 15 86 3.7e-05 
Mdh1p NP_012838 Mitochondrial TCA cycle 5 24 95 4.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 6 14 97 3.2e-06   
Cyt1p NP_014708 Mitochondrial ETC 5 23 95 4.8e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
8 20 134 6e-10   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
11 23 169 1.9e-13 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
9 15 129 1.9e-09   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
9 19 142 9.5e-11   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
9 21 142 9.5e-11   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 7 17 116 3.8e-08   
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dehydrogenase; binds to 
mtDNA 
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
7 39 131 1.2e-09 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
7 22 121 1.2e-08   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
8 16 112 9.5e-08   
YP + 2% glucose; Day 2 (D phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
7 17 109 1.9e-07   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
9 34 164 6e-13   
Lat1p NP_014328 Mitochondrial PDH 
complex  
5 16 85  
Pdx1p NP_011709 Mitochondrial PDH 
complex 
5 19 90  
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
8 21 136  3.8e-10   
Cit1p NP_014398 Mitochondrial TCA cycle 5 15 86 3.8e-05 
Cit2p NP_009931 Mitochondrial TCA cycle 5 16 88 2.5e-05   
Cit3p NP_015325 Mitochondrial TCA cycle 5 14 85 4.3e-05   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
9 14 132 9.5e-10 
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
7 21 105 4.8e-07 
Idh2p NP_014779 Mitochondrial TCA cycle 5 15 88 2.2e-05   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
7 8 93 6.9e-06 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
7 18 111 1.2e-07   
Lsc1p NP_014785 Mitochondrial TCA cycle 5 14 90 1.7e-05   
Lsc2p NP_011760 Mitochondrial TCA cycle 5 16 84 5.5e-05   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
6 14 97 2.7e-06   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 18 88 2.5e-05   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 22 100 1.6e-06   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 19 81 0.00011   
Fum1p NP_015061 Mitochondrial TCA cycle 6 13 99 1.9e-06   
Mdh1p NP_012838 Mitochondrial TCA cycle 5 20 93 7.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
9 21 148 2.4e-11   
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Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06  
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 30 147 3e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
10 16 145 4.8e-11   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
10 21 156 3.8e-12   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
11 20 157 3e-12   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
8 19 132 9.5e-10   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
8 44 149 1.9e-11   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
8 25 138 2.4e-10   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
9 19 143 7.6e-11   
YP + 0.2% glucose; Day 4 (PD phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
7 17 109 1.9e-07   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
9 34 164 6e-13   
Lat1p NP_014328 Mitochondrial PDH 
complex  
5 16 85  
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Pdx1p NP_011709 Mitochondrial PDH 
complex 
5 19 90  
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
8 21 136  3.8e-10   
Cit1p NP_014398 Mitochondrial TCA cycle 5 15 86 3.8e-05 
Cit2p NP_009931 Mitochondrial TCA cycle 5 16 88 2.5e-05   
Cit3p NP_015325 Mitochondrial TCA cycle 5 14 85 4.3e-05   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
9 14 132 9.5e-10 
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
7 21 105 4.8e-07 
Idh2p NP_014779 Mitochondrial TCA cycle 5 15 88 2.2e-05   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
7 8 93 6.9e-06 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
7 18 111 1.2e-07   
Lsc1p NP_014785 Mitochondrial TCA cycle 5 14 90 1.7e-05   
Lsc2p NP_011760 Mitochondrial TCA cycle 5 16 84 5.5e-05   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
6 14 97 2.7e-06   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 18 88 2.5e-05   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 22 100 1.6e-06   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 19 81 0.00011   
Fum1p NP_015061 Mitochondrial TCA cycle 6 13 99 1.9e-06   
Mdh1p NP_012838 Mitochondrial TCA cycle 5 20 93 7.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
9 21 148 2.4e-11   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06  
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 30 147 3e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
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Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
10 16 145 4.8e-11   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
10 21 156 3.8e-12   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
11 20 157 3e-12   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
8 19 132 9.5e-10   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
8 44 149 1.9e-11   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
8 25 138 2.4e-10   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
9 19 143 7.6e-11   
YP + 0.5% glucose; Day 4 (PD phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
5 13 81 0.00013   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
7 27 128 2.4e-09 
Lat1p NP_014328 Mitochondrial PDH 
complex  
9 25 147     3e-11   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
8 28 142 9.5e-11 
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
6 16 102 9.5e-07   
Cit1p NP_014398 Mitochondrial TCA cycle 9 24 152 9.5e-12 
Cit2p NP_009931 Mitochondrial TCA cycle 8 25 139 1.9e-10 
Cit3p NP_015325 Mitochondrial TCA cycle 8 20 134 6e-10   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
7 12 104 6e-07   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
5 18 87 2.9e-05   
Idh2p NP_014779 Mitochondrial TCA cycle 7 29 129 1.9e-09   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 75 0.00048   
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
5 13 80 0.00016   
Lsc1p NP_014785 Mitochondrial TCA cycle 6 30 116 3.8e-08   
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Lsc2p NP_011760 Mitochondrial TCA cycle 8 23 132 9.5e-10   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
9 20 144 6e-11   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
4 18 72 0.001   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 40 106 3.8e-07   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 29 83 8.1e-05   
Fum1p NP_015061 Mitochondrial TCA cycle 7 18 119 1.9e-08 
Mdh1p NP_012838 Mitochondrial TCA cycle 7 31 131 1.2e-09   
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
7 19 118 2.4e-08   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 4.8e-09 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 100 1.7e-06 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
9 14 128 2.4e-09 
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
8 18 128 2.4e-09 
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
8 19 127 3e-09   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 




Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
6 15 100 1.7e-06 
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
6 34 113 7.6e-08   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
6 20 104 6e-07  
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
7 15 112 9.5e-08   
YP + 1% glucose; Day 4 (PD phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
6 14 96 4.2e-06   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
8 31 146 3.8e-11 
Lat1p NP_014328 Mitochondrial PDH 
complex  
7 19 102 9.5e-07   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
6 23 108 2.4e-07   
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
7 19 119 1.9e-08   
Cit1p NP_014398 Mitochondrial TCA cycle 7 20 119 1.9e-08 
Cit2p NP_009931 Mitochondrial TCA cycle 6 20 106 3.8e-07 
Cit3p NP_015325 Mitochondrial TCA cycle 6 16 102 9.5e-07   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
8 13 118  2.4e-08   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
6 21 103 7.6e-07   
Idh2p NP_014779 Mitochondrial TCA cycle 5 23 94 6.4e-06   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 82 1e-04   
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
6 16 96 3.7e-06   
Lsc1p NP_014785 Mitochondrial TCA cycle; 
binds to mtDNA 
5 23 95 4.8e-06   
Lsc2p NP_011760 Mitochondrial TCA cycle  6 19 101 1.2e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
7 17 113 7.6e-08   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
6 20 104 6e-07   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
4 35 86 3.5e-05   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
6 31 123 7.6e-09   
Fum1p NP_015061 Mitochondrial TCA cycle 5 15 86 3.7e-05 
Mdh1p NP_012838 Mitochondrial TCA cycle 5 24 95 4.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 6 14 97 3.2e-06   
Cyt1p NP_014708 Mitochondrial ETC 5 23 95 4.8e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
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Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
8 20 134 6e-10   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
11 23 169 1.9e-13 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
9 15 129 1.9e-09   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
9 19 142 9.5e-11   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
9 21 142 9.5e-11   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
7 17 116 3.8e-08   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
7 39 131 1.2e-09 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
7 22 121 1.2e-08   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
8 16 112 9.5e-08   
YP + 2% glucose; Day 4 (PD phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
4 11 66 0.004   
Pdb1p NP_009780 Mitochondrial PDH 6 25 111 1.2e-07   
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complex; binds to mtDNA 
Lat1p NP_014328 Mitochondrial PDH 
complex  
11 27 161 1.2e-12   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
10 33 174  6e-14   
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
5 15 85 4.7e-05 
Cit1p NP_014398 Mitochondrial TCA cycle 11 28 185 4.8e-15   
Cit2p NP_009931 Mitochondrial TCA cycle 10 30 173 7.6e-14   
Cit3p NP_015325 Mitochondrial TCA cycle 10 23 166 3.8e-13 
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
6 11 90 1.3e-05   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
4 16 73 0.00083   
Idh2p NP_014779 Mitochondrial TCA cycle 9 34 164 6e-13 
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
5 6 63 0.0079 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
4 11 66 0.004 
Lsc1p NP_014785 Mitochondrial TCA cycle; 
binds to mtDNA 
8 37 152 9.5e-12 
Lsc2p NP_011760 Mitochondrial TCA cycle 10 27 164  6e-13   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
11 23 174 6e-14   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 21 89 1.9e-05   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
7 50 146 3.8e-11 
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
5 33 103 7.6e-07   
Fum1p NP_015061 Mitochondrial TCA cycle 9 21 151 1.2e-11   
Mdh1p NP_012838 Mitochondrial TCA cycle 9 39 168 2.4e-13   
Ndi1p NP_013586 Mitochondrial ETC 8 18 128 2.4e-09 
Cyt1p NP_014708 Mitochondrial ETC 6 26 113 7.6e-08 
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
6 17 102 9.5e-07   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
7 17 116 3.8e-08 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
6 20 102 9.5e-07 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
5 20 93 7.2e-06 
Hem14p NP_010930 Heme synthesis in 
mitochondria 
9 20 140 1.5e-10 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
6 22 113 7.6e-08 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
6 30 119 1.9e-08 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
5 21 93  6.9e-06 
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Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
7 12 102 9.5e-07 
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
7 16 113 7.6e-08 
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
7 18 113 7.6e-08   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
5 13 84 6.1e-05   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
5 31 96 3.7e-06 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
5 18 89 1.9e-05   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
6 14 97 3.2e-06   
YP + 0.2% glucose; Day 9 (ST phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
6 14 96 4.2e-06   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
8 31 146 3.8e-11 
Lat1p NP_014328 Mitochondrial PDH 
complex  
7 19 102 9.5e-07   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
6 23 108 2.4e-07   
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
7 19 119 1.9e-08   
Cit1p NP_014398 Mitochondrial TCA cycle 7 20 119 1.9e-08 
Cit2p NP_009931 Mitochondrial TCA cycle 6 20 106 3.8e-07 
Cit3p NP_015325 Mitochondrial TCA cycle 6 16 102 9.5e-07   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
8 13 118  2.4e-08   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
6 21 103 7.6e-07   
Idh2p NP_014779 Mitochondrial TCA cycle 5 23 94 6.4e-06   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 82 1e-04   
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Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
6 16 96 3.7e-06   
Lsc1p NP_014785 Mitochondrial TCA cycle; 
binds to mtDNA 
5 23 95 4.8e-06   
Lsc2p NP_011760 Mitochondrial TCA cycle  6 19 101 1.2e-06 
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
7 17 113 7.6e-08   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
6 20 104 6e-07   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
4 35 86 3.5e-05   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
6 31 123 7.6e-09   
Fum1p NP_015061 Mitochondrial TCA cycle 5 15 86 3.7e-05 
Mdh1p NP_012838 Mitochondrial TCA cycle 5 24 95 4.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 6 14 97 3.2e-06   
Cyt1p NP_014708 Mitochondrial ETC 5 23 95 4.8e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
8 20 134 6e-10   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
9 20 148 2.4e-11   
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 27 130 1.5e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
11 23 169 1.9e-13 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 18 94 5.6e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 99 1.7e-06   
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 31 148 2.4e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
9 15 129 1.9e-09   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
9 19 142 9.5e-11   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
9 21 142 9.5e-11   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 




Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
7 17 116 3.8e-08   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
7 39 131 1.2e-09 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
7 22 121 1.2e-08   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
8 16 112 9.5e-08   
YP + 0.5% glucose; Day 9 (ST phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
7 17 109 1.9e-07   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
9 34 164 6e-13   
Lat1p NP_014328 Mitochondrial PDH 
complex  
5 16 85  
Pdx1p NP_011709 Mitochondrial PDH 
complex 
5 19 90  
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
8 21 136  3.8e-10   
Cit1p NP_014398 Mitochondrial TCA cycle 5 15 86 3.8e-05 
Cit2p NP_009931 Mitochondrial TCA cycle 5 16 88 2.5e-05   
Cit3p NP_015325 Mitochondrial TCA cycle 5 14 85 4.3e-05   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
9 14 132 9.5e-10 
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
7 21 105 4.8e-07 
Idh2p NP_014779 Mitochondrial TCA cycle 5 15 88 2.2e-05   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
7 8 93 6.9e-06 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
7 18 111 1.2e-07   
Lsc1p NP_014785 Mitochondrial TCA cycle 5 14 90 1.7e-05   
Lsc2p NP_011760 Mitochondrial TCA cycle 5 16 84 5.5e-05   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
6 14 97 2.7e-06   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 18 88 2.5e-05   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 22 100 1.6e-06   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 19 81 0.00011   
Fum1p NP_015061 Mitochondrial TCA cycle 6 13 99 1.9e-06   
Mdh1p NP_012838 Mitochondrial TCA cycle 5 20 93 7.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
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Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
9 21 148 2.4e-11   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06  
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 30 147 3e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59  
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
10 16 145 4.8e-11   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
10 21 156 3.8e-12   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
11 20 157 3e-12   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
8 19 132 9.5e-10   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
8 44 149 1.9e-11   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
8 25 138 2.4e-10   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
9 19 143 7.6e-11   
YP + 1% glucose; Day 9 (ST phase) 
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Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
5 13 81 0.00013   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
7 27 128 2.4e-09 
Lat1p NP_014328 Mitochondrial PDH 
complex  
9 25 147     3e-11   
Pdx1p NP_011709 Mitochondrial PDH 
complex 
8 28 142 9.5e-11 
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
6 16 102 9.5e-07   
Cit1p NP_014398 Mitochondrial TCA cycle 9 24 152 9.5e-12 
Cit2p NP_009931 Mitochondrial TCA cycle 8 25 139 1.9e-10 
Cit3p NP_015325 Mitochondrial TCA cycle 8 20 134 6e-10   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
7 12 104 6e-07   
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
5 18 87 2.9e-05   
Idh2p NP_014779 Mitochondrial TCA cycle 7 29 129 1.9e-09   
Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
6 7 75 0.00048   
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
5 13 80 0.00016   
Lsc1p NP_014785 Mitochondrial TCA cycle 6 30 116 3.8e-08   
Lsc2p NP_011760 Mitochondrial TCA cycle 8 23 132 9.5e-10   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
9 20 144 6e-11   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
4 18 72 0.001   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 40 106 3.8e-07   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 29 83 8.1e-05   
Fum1p NP_015061 Mitochondrial TCA cycle 7 18 119 1.9e-08 
Mdh1p NP_012838 Mitochondrial TCA cycle 7 31 131 1.2e-09   
Ndi1p NP_013586 Mitochondrial ETC 6 15 98 2.7e-06 
Cyt1p NP_014708 Mitochondrial ETC 5 28 99 1.8e-06 
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
7 19 118 2.4e-08   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06 
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
5 17 85 5.2e-05 
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 125 4.8e-09 
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06 
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 26 100 1.7e-06 
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Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
4 18 75 0.00046 
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
9 14 128 2.4e-09 
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
8 18 128 2.4e-09 
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
8 19 127 3e-09   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
6 15 100 1.7e-06 
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
6 34 113 7.6e-08   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
6 20 104 6e-07  
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
7 15 112 9.5e-08   
YP + 2% glucose; Day 9 (ST phase) 
Pda1p NP_011105 Mitochondrial PDH 
complex; binds to mtDNA  
7 17 109 1.9e-07   
Pdb1p NP_009780 Mitochondrial PDH 
complex; binds to mtDNA 
9 34 164 6e-13   
Lat1p NP_014328 Mitochondrial PDH 
complex  
5 16 85  
Pdx1p NP_011709 Mitochondrial PDH 
complex 
5 19 90  
Lpd1p NP_116635 Mitochondrial PDH 
complex; binds to mtDNA 
8 21 136  3.8e-10   
Cit1p NP_014398 Mitochondrial TCA cycle 5 15 86 3.8e-05 
Cit2p NP_009931 Mitochondrial TCA cycle 5 16 88 2.5e-05   
Cit3p NP_015325 Mitochondrial TCA cycle 5 14 85 4.3e-05   
Aco1p NP_013407 Mitochondrial TCA cycle; 
binds to mtDNA 
9 14 132 9.5e-10 
Idh1p NP_014361 Mitochondrial TCA cycle; 
binds to mtDNA 
7 21 105 4.8e-07 
Idh2p NP_014779 Mitochondrial TCA cycle 5 15 88 2.2e-05   
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Kgd1p NP_012141 Mitochondrial TCA cycle; 
binds to mtDNA 
7 8 93 6.9e-06 
Kgd2p NP_010432 Mitochondrial TCA cycle; 
binds to mtDNA 
7 18 111 1.2e-07   
Lsc1p NP_014785 Mitochondrial TCA cycle 5 14 90 1.7e-05   
Lsc2p NP_011760 Mitochondrial TCA cycle 5 16 84 5.5e-05   
Sdh1p NP_012774 Mitochondrial TCA cycle 
and ETC 
6 14 97 2.7e-06   
Sdh2p NP_013059 Mitochondrial TCA cycle 
and ETC 
5 18 88 2.5e-05   
Sdh3p NP_012781 Mitochondrial TCA cycle 
and ETC 
5 22 100 1.6e-06   
Sdh4p NP_010463 Mitochondrial TCA cycle 
and ETC 
4 19 81 0.00011   
Fum1p NP_015061 Mitochondrial TCA cycle 6 13 99 1.9e-06   
Mdh1p NP_012838 Mitochondrial TCA cycle 5 20 93 7.6e-06   
Ndi1p NP_013586 Mitochondrial ETC 7 16 113 7.6e-08 
Cyt1p NP_014708 Mitochondrial ETC 5 22 94 5.5e-06   
Rip1p NP_010890 Mitochondrial ETC 6 51 80 0.00019 
Cox4p NP_011328 Mitochondrial ETC 5 49 74 0.00081 
Cox5Ap NP_014346 Mitochondrial ETC 6 58 86 5e-05 
Pet100p NP_010364 Mitochondrial ETC 5 46 66 0.0054 
Atp1p NP_009453 Mitochondrial ATP 
synthase; binds to mtDNA  
9 21 148 2.4e-11   
Atp2p NP_012655 Mitochondrial ATP 
synthase 
6 15 100 1.6e-06  
Pet9p NP_009523 Mitochondrial ADP/ATP 
carrier 
8 27 136 8.1e-08   
Mir1p NP_012611 Mitochondrial phosphate 
carrier 
7 26 129 1.9e-09   
Hem14p NP_010930 Heme synthesis in 
mitochondria 
8 18 124 6e-09   
Cyc3p NP_009361 Heme attachment to apo-
cytochrome c 
5 19 95 5.2e-06   
Sod2p NP_011872 Detoxification of ROS in 
mitochondria 
5 29 102 9.5e-07 
Prx1p NP_009489 Detoxification of ROS in 
mitochondria 
8 30 147 3e-11   
Ccp1p NP_012992 Detoxification of ROS in 
mitochondria 
12 50 135 6.7e-10 
Trr2p NP_011974 Detoxification of ROS in 
mitochondria 
7 39 78 0.00037 
Trx3p NP_010006 Detoxification of ROS in 
mitochondria 
5 37 59 0.026 
Ssq1p NP_013473 Assembly of Fe/S clusters 
into proteins 
10 16 145 4.8e-11   
Ssc1p NP_012579 Mitochondrial chaperone; 
binds to mtDNA 
10 21 156 3.8e-12   
Hsp60p NP_013360 Mitochondrial chaperone; 
binds to mtDNA 
11 20 157 3e-12   
Caf4p NP_012962 Mitochondrial fission 11 25 83 0.00011 
Mdv1p NP_012423 Mitochondrial fission 13 28 111 1.7e-07 
Fis1p NP_012199 Mitochondrial fission 5 45 66 0.0048 
Mgm1p NP_014854 Mitochondrial fusion 14 23 64 0.0083 
98 
 
Pgs1p NP_009923 Cardiolipin synthesis in 
mitochondria 
8 21 57 0.041 
Crd1p NP_010139 Cardiolipin synthesis in 
mitochondria 
7 30 89 2.9e-05 
Taz1p NP_015466 Cardiolipin synthesis in 
mitochondria 
9 32 71 0.0018 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to 
mtDNA 
8 19 132 9.5e-10   
Abf2p NP_013788 Mitochondrial genome 
maintenance; binds to 
mtDNA 
8 44 149 1.9e-11   
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in 
mitochondria; binds to 
mtDNA 
8 25 138 2.4e-10   
Sls1p NP_013240 Mitochondrial chaperone; 
binds to mtDNA  
9 19 143 7.6e-11   
 
 
Table 2.2. Relative levels of proteins recovered in mitochondria purified from wild-type cells grown in YP 
media initially containing 0.2%, 0.5%, 1% or 2% glucose. Mitochondria were purified from wild-type cells 
collected at day 1 (L phase), day 2 (D phase), day 4 (PD phase) and day 9 (ST phase). Proteins were 
identified and quantified using MALDI MS peptide mapping. Relative protein levels are presented as fold 
difference relative to that on 2% glucose. 
Protein  NCBI 
accession 
no. 
Function Protein level 
Glucose concentration (%)  
0.2 0.5 1 2 
Day 1 (L phase) 
Pda1p NP_011105 Mitochondrial PDH complex; binds to 
mtDNA  
2.49 ± 0.34 1.76 ± 0.23 1.24 ± 0.16 1 
Pdb1p NP_009780 Mitochondrial PDH complex; binds to 
mtDNA 
2.79 ± 0.42 1.53 ± 0.34 0.87 ± 0.29 1 
Lat1p NP_014328 Mitochondrial PDH complex  2.67 ± 0.42 1.49 ± 0.33 0.83 ± 0.18 1 
Pdx1p NP_011709 Mitochondrial PDH complex 1.79 ± 0.30 1.62 ± 0.27 1.19 ± 0.12 1 
Lpd1p NP_116635 Mitochondrial PDH complex; binds to 
mtDNA 
1.63 ± 0.31 1.24 ± 0.22 0.96 ± 0.13 1 
Cit1p NP_014398 Mitochondrial TCA cycle 1.54 ± 0.25 1.28 ± 0.14 0.77 ± 0.09 1 
Cit2p NP_009931 Mitochondrial TCA cycle 1.88 ± 0.34 1.34 ± 0.30 1.29 ± 0.16 1 
Cit3p NP_015325 Mitochondrial TCA cycle 1.47 ± 0.19 1.23 ± 0.22 1.38 ± 0.35 1 
Aco1p NP_013407 Mitochondrial TCA cycle; binds to 
mtDNA 
2.82 ± 0.55 1.38 ± 0.16 0.81 ± 0.11 1 
Idh1p NP_014361 Mitochondrial TCA cycle; binds to 
mtDNA 
1.35 ± 0.24 0.88 ± 0.29 0.73 ± 0.08 1 
Idh2p NP_014779 Mitochondrial TCA cycle 1.84 ± 0.21 1.35 ± 0.14 0.91 ± 0.27  
Kgd1p NP_012141 Mitochondrial TCA cycle; binds to 
mtDNA 
1.67 ± 0.19 1.23 ± 0.32 1.17 ± 0.15 1 
Kgd2p NP_010432 Mitochondrial TCA cycle; binds to 
mtDNA 
1.39 ± 0.23 1.68 ± 0.19 0.83 ± 0.21 1 
Lsc1p NP_014785 Mitochondrial TCA cycle; binds to 
mtDNA 
1.66 ± 0.13 1.27 ± 0.28 1.19 ± 0.19 1 
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Lsc2p NP_011760 Mitochondrial TCA cycle 1.71 ± 0.35 1.53 ± 0.21 0.89 ± 0.07 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 1.32 ± 0.11 0.87 ± 0.06  1.18 ± 0.21 1 
Sdh2p NP_013059 Mitochondrial TCA cycle and ETC 1.86 ± 0.23 1.52 ± 0.18 0.76 ± 0.08 1 
Sdh3p NP_012781 Mitochondrial TCA cycle and ETC 1.39 ± 0.32 1.28 ± 0.24 0.93 ± 0.15  1 
Sdh4p NP_010463 Mitochondrial TCA cycle and ETC 1.56 ± 0.14 1.19 ± 0.23 0.75 ± 0.09 1 
Fum1p NP_015061 Mitochondrial TCA cycle 1.33 ± 0.22 1.47 ± 0.15 0.84 ± 0.17 1 
Mdh1p NP_012838 Mitochondrial TCA cycle 1.45 ± 0.13 1.26 ± 0.17 1.05 ± 0.23 1 
Ndi1p NP_013586 Mitochondrial ETC 1.69 ± 0.20 1.31 ± 0.08 1.09 ± 0.15 1 
Cyt1p NP_014708 Mitochondrial ETC 1.39 ± 0.11 1.12 ± 0.17 0.87 ± 0.13 1 
Rip1p NP_010890 Mitochondrial ETC 1.26 ± 0.19 1.48 ± 0.16 0.95 ± 0.11 1 
Cox4p NP_011328 Mitochondrial ETC 1.43 ± 0.17 1.11 ± 0.13 1.04 ± 0.25 1 
Cox5Ap NP_014346 Mitochondrial ETC 1.67 ± 0.29 1.32 ± 0.25 0.84 ± 0.18 1 
Pet100p NP_010364 Mitochondrial ETC 1.51 ± 0.13 1.59 ± 0.31 1.09 ± 0.15 1 
Atp1p NP_009453 Mitochondrial ATP synthase; binds to 
mtDNA  
1.29 ± 0.18 1.43 ± 0.24 1.18 ± 0.07 1 
Atp2p NP_012655 Mitochondrial ATP synthase 1.49± 0.09 1.31 ± 0.14 1.06 ± 0.21 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 1.17 ± 0.21 1.28 ± 0.26 0.95 ± 0.17 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 1.29 ± 0.14 1.46 ± 0.09 1.11 ± 0.33 1 
Hem14p NP_010930 Heme synthesis in mitochondria 1.56 ± 0.27 1.67 ± 0.16 0.87 ± 0.06 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 1.72 ± 0.32 1.23 ± 0.08 1.09 ± 0.16 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 1.24 ± 0.15 1.48 ± 0.19 0.94 ± 0.12 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 1.57 ± 0.33 1.69 ± 0.21 1.18 ± 0.19 1 
Ccp1p NP_012992 Detoxification of ROS in mitochondria 1.45 ± 0.23 1.78 ± 0.34 1.07 ± 0.08 1 
Trr2p NP_011974 Detoxification of ROS in mitochondria 1.28 ± 0.12 1.53 ± 0.27 0.88 ± 0.14 1 
Trx3p NP_010006 Detoxification of ROS in mitochondria 1.52 ± 0.17 1.27 ± 0.13 1.12 ± 0.18 1 
Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 1.74 ± 0.41 1.58 ± 0.23 1.04 ± 0.13 1 
Ssc1p NP_012579 Mitochondrial chaperone; binds to 
mtDNA 
1.34 ± 0.18 1.15 ± 0.09 0.79 ± 0.06 1 
Hsp60p NP_013360 Mitochondrial chaperone; binds to 
mtDNA 
1.76 ± 0.21 1.52 ± 0.18 0.83 ± 0.13 1 
Caf4p NP_012962 Mitochondrial fission 0.69 ± 0.11 0.43 ± 0.09 1.13 ± 0.18 1 
Mdv1p NP_012423 Mitochondrial fission 0.87 ± 0.23 0.73 ± 0.12 0.92 ± 0.15 1 
Fis1p NP_012199 Mitochondrial fission 0.93 ± 0.15 1.07 ± 0.24 1.20 ± 0.32 1 
Mgm1p NP_014854 Mitochondrial fusion 1.32 ± 0.21 1.49 ± 0.15 0.89 ± 0.13 1 
Pgs1p NP_009923 Cardiolipin synthesis in mitochondria 0.81 ± 0.19 0.97 ± 0.12 0.93 ± 0.19 1 
Crd1p NP_010139 Cardiolipin synthesis in mitochondria 0.96 ± 0.23 1.05 ± 0.14 0.87 ± 0.27 1 
Taz1p NP_015466 Cardiolipin synthesis in mitochondria 0.88 ± 0.17 0.67 ± 0.11 1.06 ± 0.13 1 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to mtDNA 
1.43 ± 0.23 1.22 ± 0.11 0.83 ± 0.09 1 
Abf2p NP_013788 Mitochondrial genome maintenance; 
binds to mtDNA 
0.71 ± 0.21 0.92 ± 0.08 1.14 ± 0.29 1 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in mitochondria; binds to 
mtDNA 
0.63 ± 0.13 0.88 ± 0.26 0.92 ± 0.14 1 
Sls1p NP_013240 Mitochondrial chaperone; binds to 
mtDNA  
1.57 ± 0.13 0.93 ± 0.11 1.34 ± 0.29 1 
Day 2 (D phase) 
Pda1p NP_011105 Mitochondrial PDH complex; binds to 
mtDNA  
3.67 ± 0.42 2.53 ± 0.34 1.34 ± 0.23 1 
Pdb1p NP_009780 Mitochondrial PDH complex; binds to 
mtDNA 
3.89 ± 0.27 2.76 ± 0.39 1.17 ± 0.18 1 
Lat1p NP_014328 Mitochondrial PDH complex  3.87 ± 0.45 2.56 ± 0.32 1.34 ± 0.19 1 
Pdx1p NP_011709 Mitochondrial PDH complex 3.79 ± 0.31 2.67 ± 0.24 1.46 ± 0.15 1 




Cit1p NP_014398 Mitochondrial TCA cycle 2.65 ± 0.23 1.83 ± 0.17 0.84 ± 0.23 1 
Cit2p NP_009931 Mitochondrial TCA cycle 2.48 ± 0.15 2.39 ± 0.28 1.32 ± 0.19 1 
Cit3p NP_015325 Mitochondrial TCA cycle 2.79 ± 0.34 1.38 ± 0.14 0.76 ± 0.08 1 
Aco1p NP_013407 Mitochondrial TCA cycle; binds to 
mtDNA 
3.44 ± 0.43  2.78 ± 0.35 1.34 ± 0.17 1 
Idh1p NP_014361 Mitochondrial TCA cycle; binds to 
mtDNA 
2.67 ± 0.18 1.29 ± 0.24 0.83 ± 0.21 1 
Idh2p NP_014779 Mitochondrial TCA cycle 2.56 ± 0.22 1.83 ± 0.33 1.19 ± 0.17 1 
Kgd1p NP_012141 Mitochondrial TCA cycle; binds to 
mtDNA 
2.75 ± 0.42 1.45 ± 0.25 1.29 ± 0.09 1 
Kgd2p NP_010432 Mitochondrial TCA cycle; binds to 
mtDNA 
2.53 ± 0.30 2.69 ± 0.17 1.17 ± 0.23 1 
Lsc1p NP_014785 Mitochondrial TCA cycle; binds to 
mtDNA 
2.89 ± 0.21 1.67 ± 0.06 0.85 ± 0.12 1 
Lsc2p NP_011760 Mitochondrial TCA cycle 2.73 ± 0.43 1.69 ± 0.15 1.24 ± 0.37 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 2.69 ± 0.28 1.44 ± 0.22 0.86 ± 0.12 1 
Sdh2p NP_013059 Mitochondrial TCA cycle and ETC 2.92 ± 0.41 2.57 ± 0.34 1.37 ± 0.28 1 
Sdh3p NP_012781 Mitochondrial TCA cycle and ETC 2.85 ± 0.33 1.69 ± 0.19 1.24 ± 0.07 1 
Sdh4p NP_010463 Mitochondrial TCA cycle and ETC 2.42 ± 0.27 1.73 ± 0.14 0.78 ± 0.19 1 
Fum1p NP_015061 Mitochondrial TCA cycle 2.65 ± 0.08 1.48 ± 0.22 1.17 ± 0.28 1 
Mdh1p NP_012838 Mitochondrial TCA cycle 3.54 ± 0.43 2.76 ± 0.31 1.49 ± 0.17 1 
Ndi1p NP_013586 Mitochondrial ETC 3.87 ± 0.12 2.54 ± 0.17 1.24 ± 0.15 1 
Cyt1p NP_014708 Mitochondrial ETC 2.41 ± 0.24 1.69 ± 0.18 1.06 ± 0.13 1 
Rip1p NP_010890 Mitochondrial ETC 2.77 ± 0.14 2.89 ± 0.32 1.19 ± 0.18 1 
Cox4p NP_011328 Mitochondrial ETC 2.58 ± 0.21 1.78 ± 0.14 0.93 ± 0.21 1 
Cox5Ap NP_014346 Mitochondrial ETC 2.69 ± 0.33 1.85 ± 0.26 1.21 ± 0.42 1 
Pet100p NP_010364 Mitochondrial ETC 2.44 ± 0.21 2.58 ± 0.17 0.92 ± 0.19 1 
Atp1p NP_009453 Mitochondrial ATP synthase; binds to 
mtDNA  
2.76 ± 0.51 2.87 ± 0.32 1.34 ± 0.05 1 
Atp2p NP_012655 Mitochondrial ATP synthase 2.54 ± 0.23 2.75 ± 0.15 1.16 ± 0.19 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 2.79 ± 0.14 3.49 ± 0.23 1.07 ± 0.28 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 2.83 ± 0.31 3.57 ± 0.35 0.91 ± 0.18 1 
Hem14p NP_010930 Heme synthesis in mitochondria 2.92 ± 0.27 2.43 ± 0.14 1.19 ± 0.22 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 2.64 ± 0.18 1.65 ± 0.23 1.07 ± 0.14 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 1.65 ± 0.15 2.49 ± 0.27 0.93 ± 0.19 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 2.77 ± 0.26 2.58 ± 0.32 1.16 ± 0.09 1 
Ccp1p NP_012992 Detoxification of ROS in mitochondria 2.39 ± 0.13 3.67 ± 0.25 1.25 ± 0.34 1 
Trr2p NP_011974 Detoxification of ROS in mitochondria 1.78 ± 0.15 2.63 ± 0.19 0.87 ± 0.26 1 
Trx3p NP_010006 Detoxification of ROS in mitochondria 1.84 ± 0.22 2.74 ± 0.31 1.11 ± 0.09 1 
Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 4.19 ± 0.14 2.58 ± 0.16 0.92 ± 0.11 1 
Ssc1p NP_012579 Mitochondrial chaperone; binds to 
mtDNA 
2.78 ± 0.23 1.51 ± 0.14 1.18 ± 0.28 1 
Hsp60p NP_013360 Mitochondrial chaperone; binds to 
mtDNA 
3.34 ± 0.30 2.56 ± 0.42 1.39 ± 0.24 1 
Caf4p NP_012962 Mitochondrial fission 0.81 ± 0.13 0.41 ± 0.07 0.92 ± 0.32 1 
Mdv1p NP_012423 Mitochondrial fission 1.11 ± 0.24 0.76 ± 0.11 1.08 ± 0.23 1 
Fis1p NP_012199 Mitochondrial fission 0.93 ± 0.19 1.12 ± 0.30 0.86 ± 0.18 1 
Mgm1p NP_014854 Mitochondrial fusion 1.23 ± 0.15 1.49 ± 0.24 1.16 ± 0.13 1 
Pgs1p NP_009923 Cardiolipin synthesis in mitochondria 0.63 ± 0.17 0.85 ± 0.11 1.03 ± 0.24 1 
Crd1p NP_010139 Cardiolipin synthesis in mitochondria 1.15 ± 0.22 0.92 ± 0.31 0.95 ± 0.25 1 
Taz1p NP_015466 Cardiolipin synthesis in mitochondria 0.88 ± 0.11 0.65 ± 0.18 1.14 ± 0.13 1 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to mtDNA 
2.38 ± 0.17 1.34 ± 0.21 1.18 ± 0.27 1 
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Abf2p NP_013788 Mitochondrial genome maintenance; 
binds to mtDNA 
0.35 ± 0.09 0.74 ± 0.17 1.25 ± 0.21 1 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in mitochondria; binds to 
mtDNA 
0.39 ± 0.15 0.68 ± 0.19 0.87 ± 0.12 1 
Sls1p NP_013240 Mitochondrial chaperone; binds to 
mtDNA  
2.72 ± 0.43 1.65 ± 0.21 1.16 ± 0.07 1 
Day 4 (PD phase) 
Pda1p NP_011105 Mitochondrial PDH complex; binds to 
mtDNA  
4.65 ± 0.54 3.87 ± 0.42 1.43 ± 0.21 1 
Pdb1p NP_009780 Mitochondrial PDH complex; binds to 
mtDNA 
4.78 ± 0.41 3.54 ± 0.27 1.21 ± 0.13 1 
Lat1p NP_014328 Mitochondrial PDH complex  4.57 ± 0.18 3.49 ± 0.28 1.56 ± 0.27 1 
Pdx1p NP_011709 Mitochondrial PDH complex 3.69 ± 0.45 2.66 ± 0.21 1.27 ± 0.34 1 
Lpd1p NP_116635 Mitochondrial PDH complex; binds to 
mtDNA 
3.56 ± 0.32 2.74 ± 0.35 1.18 ± 0.19 1 
Cit1p NP_014398 Mitochondrial TCA cycle 3.84 ± 0.32 2.76 ± 0.16 1.49 ± 0.13 1 
Cit2p NP_009931 Mitochondrial TCA cycle 2.68 ± 0.14 2.89 ± 0.28 1.33 ± 0.22 1 
Cit3p NP_015325 Mitochondrial TCA cycle 3.85 ± 0.29 2.63 ± 0.35 1.26 ± 0.41 1 
Aco1p NP_013407 Mitochondrial TCA cycle; binds to 
mtDNA 
3.72 ± 0.49 2.37 ± 0.18 0.84 ± 0.23 1 
Idh1p NP_014361 Mitochondrial TCA cycle; binds to 
mtDNA 
3.59 ± 0.52 2.62 ± 0.36 1.24 ± 0.28 1 
Idh2p NP_014779 Mitochondrial TCA cycle 3.43 ± 0.30 2.72 ± 0.17 1.67 ± 0.25 1 
Kgd1p NP_012141 Mitochondrial TCA cycle; binds to 
mtDNA 
3.75 ± 0.41 2.88 ± 0.28 1.18 ± 0.17 1 
Kgd2p NP_010432 Mitochondrial TCA cycle; binds to 
mtDNA 
4.39 ± 0.25 3.65 ± 0.42 1.56 ± 0.12 1 
Lsc1p NP_014785 Mitochondrial TCA cycle; binds to 
mtDNA 
3.64 ± 0.19 2.72 ± 0.36 1.33 ± 0.23 1 
Lsc2p NP_011760 Mitochondrial TCA cycle 3.87 ± 0.45 2.56 ± 0.33 0.86 ± 0.17 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 3.49 ± 0.36 2.85 ± 0.27 1.28 ± 0.19 1 
Sdh2p NP_013059 Mitochondrial TCA cycle and ETC 4.53 ± 0.28 3.77 ± 0.16 1.61 ± 0.22 1 
Sdh3p NP_012781 Mitochondrial TCA cycle and ETC 2.56 ± 0.17 2.83 ± 0.25 1.24 ± 0.33 1 
Sdh4p NP_010463 Mitochondrial TCA cycle and ETC 2.77 ± 0.08 2.69 ± 0.13 1.13 ± 0.05 1 
Fum1p NP_015061 Mitochondrial TCA cycle 3.84 ± 0.14 2.76 ± 0.25 1.29 ± 0.14 1 
Mdh1p NP_012838 Mitochondrial TCA cycle 3.72 ± 0.28 2.88 ± 0.17 1.18 ± 0.25 1 
Ndi1p NP_013586 Mitochondrial ETC 4.65 ± 0.19 3.59 ± 0.28 1.45 ± 0.18 1 
Cyt1p NP_014708 Mitochondrial ETC 4.53 ± 0.31 3.78 ± 0.15 1.28 ± 0.11 1 
Rip1p NP_010890 Mitochondrial ETC 4.32 ± 0.24 4.49 ± 0.35 1.13 ± 0.22 1 
Cox4p NP_011328 Mitochondrial ETC 3.65 ± 0.19 2.73 ± 0.26 1.18 ± 0.25 1 
Cox5Ap NP_014346 Mitochondrial ETC 3.78 ± 0.24 2.85 ± 0.17 1.27 ± 0.19 1 
Pet100p NP_010364 Mitochondrial ETC 2.66 ± 0.13 2.79 ± 0.23 1.06 ± 0.31 1 
Atp1p NP_009453 Mitochondrial ATP synthase; binds to 
mtDNA  
3.76 ± 0.44 4.48 ± 0.31 1.75 ± 0.32 1 
Atp2p NP_012655 Mitochondrial ATP synthase 3.49 ± 0.19 4.53 ± 0.38 0.95 ± 0.11 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 3.61 ± 0.25 3.78 ± 0.16 1.08 ± 0.17 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 3.34 ± 0.13 3.63 ± 0.27 1.24 ± 0.33 1 
Hem14p NP_010930 Heme synthesis in mitochondria 4.87 ± 0.36 3.58 ± 0.18 1.16 ± 0.21 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 3.59 ± 0.28 2.66 ± 0.14 1.13 ± 0.17 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 2.73 ± 0.17 4.20 ± 0.36 1.31 ± 0.28 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 4.65 ± 0.26 3.39 ± 0.18 0.94 ± 0.36 1 
Ccp1p NP_012992 Detoxification of ROS in mitochondria 3.49 ± 0.32 4.72 ± 0.21 1.26 ± 0.24 1 
Trr2p NP_011974 Detoxification of ROS in mitochondria 2.72 ± 0.21 3.83 ± 0.35 1.09 ± 0.17 1 
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Trx3p NP_010006 Detoxification of ROS in mitochondria 2.54 ± 0.15 3.39 ± 0.11 1.28 ± 0.33 1 
Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 4.81 ± 0.37 3.56 ± 0.28 1.41 ± 0.42 1 
Ssc1p NP_012579 Mitochondrial matrix ATPase; binds to 
mtDNA 
3.65 ± 0.44 2.71 ± 0.36 1.34 ± 0.15 1 
Hsp60p NP_013360 Mitochondrial chaperone; binds to 
mtDNA 
3.84 ± 0.26 2.56 ± 0.39 1.45 ± 0.23 1 
Caf4p NP_012962 Mitochondrial fission 0.23 ± 0.04 0.24 ± 0.08 0.88 ± 0.15 1 
Mdv1p NP_012423 Mitochondrial fission 0.44 ± 0.13 0.39 ± 0.11 0.97 ± 0.24 1 
Fis1p NP_012199 Mitochondrial fission 0.36 ± 0.08 0.41 ± 0.15 0.84 ± 0.31 1 
Mgm1p NP_014854 Mitochondrial fusion 2.42 ± 0.17 3.57 ± 0.28 1.17 ± 0.13 1 
Pgs1p NP_009923 Cardiolipin synthesis in mitochondria 0.30 ± 0.11 0.44 ± 0.09 0.92 ± 0.21 1 
Crd1p NP_010139 Cardiolipin synthesis in mitochondria 0.44 ± 0.17 0.76 ± 0.22 1.23 ± 0.34 1 
Taz1p NP_015466 Cardiolipin synthesis in mitochondria 0.38 ± 0.06 0.27 ± 0.05 0.92 ± 0.17 1 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to mtDNA 
4.67 ± 0.53 3.56 ± 0.24 1.22 ± 0.19 1 
Abf2p NP_013788 Mitochondrial genome maintenance; 
binds to mtDNA 
0.27 ± 0.06 0.41 ± 0.14 0.89 ± 0.13 1 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in mitochondria; binds to 
mtDNA 
0.31 ± 0.09 0.36 ± 0.11 0.91 ± 0.27 1 
Sls1p NP_013240 Mitochondrial chaperone; binds to 
mtDNA  
3.59 ± 0.41 2.74 ± 0.26 1.66 ± 0.34 1 
Day 9 (ST phase) 
Pda1p NP_011105 Mitochondrial PDH complex; binds to 
mtDNA  
2.88 ± 0.31 2.45 ± 0.28 1.32 ± 0.19 1 
Pdb1p NP_009780 Mitochondrial PDH complex; binds to 
mtDNA 
2.87 ± 0.51 2.54 ± 0.39 1.46 ± 0.17 1 
Lat1p NP_014328 Mitochondrial PDH complex  2.76 ± 0.21 2.32 ± 0.32 1.45 ± 0.27 1 
Pdx1p NP_011709 Mitochondrial PDH complex 2.93 ± 0.42 2.67 ± 0.17 1.32 ± 0.34 1 
Lpd1p NP_116635 Mitochondrial PDH complex; binds to 
mtDNA 
2.65 ± 0.32 2.37 ± 0.44 1.34 ± 0.38 1 
Cit1p NP_014398 Mitochondrial TCA cycle 2.59 ± 0.33 1.56 ± 0.27 0.84 ± 0.13 1 
Cit2p NP_009931 Mitochondrial TCA cycle 2.88 ± 0.46 2.91 ± 0.39 1.39 ± 0.26 1 
Cit3p NP_015325 Mitochondrial TCA cycle 2.61 ± 0.41 1.82 ± 0.21 0.78 ± 0.09 1 
Aco1p NP_013407 Mitochondrial TCA cycle; binds to 
mtDNA 
2.84 ± 0.48  2.52 ± 0.25 1.14 ± 0.17 1 
Idh1p NP_014361 Mitochondrial TCA cycle; binds to 
mtDNA 
2.77 ± 0.31 1.85 ± 0.38 0.84 ± 0.12 1 
Idh2p NP_014779 Mitochondrial TCA cycle 2.73 ± 0.24 1.45 ± 0.16 0.97 ± 0.14 1 
Kgd1p NP_012141 Mitochondrial TCA cycle; binds to 
mtDNA 
2.56 ± 0.23 1.63 ± 0.46 0.76 ± 0.09 1 
Kgd2p NP_010432 Mitochondrial TCA cycle; binds to 
mtDNA 
3.75 ± 0.45 2.87 ± 0.29 1.34 ± 0.31 1 
Lsc1p NP_014785 Mitochondrial TCA cycle; binds to 
mtDNA 
2.79 ± 0.39 1.73 ± 0.32 1.15 ± 0.11 1 
Lsc2p NP_011760 Mitochondrial TCA cycle 2.87 ± 0.17 1.29 ± 0.06 0.73 ± 0.25 1 
Sdh1p NP_012774 Mitochondrial TCA cycle and ETC 2.66 ± 0.28 1.78 ± 0.14 1.12 ± 0.33 1 
Sdh2p NP_013059 Mitochondrial TCA cycle and ETC 3.78 ± 0.41 2.69 ± 0.28 1.45 ± 0.16 1 
Sdh3p NP_012781 Mitochondrial TCA cycle and ETC 2.85 ± 0.18 1.81 ± 0.09 1.18 ± 0.23 1 
Sdh4p NP_010463 Mitochondrial TCA cycle and ETC 2.69 ± 0.26 1.74 ± 0.18 1.26 ± 0.14 1 
Fum1p NP_015061 Mitochondrial TCA cycle 2.96 ± 0.32 1.68 ± 0.29 1.09 ± 0.27 1 
Mdh1p NP_012838 Mitochondrial TCA cycle 2.77 ± 0.13 2.53 ± 0.30 0.87 ± 0.19 1 
Ndi1p NP_013586 Mitochondrial ETC 2.89 ± 0.21 2.37 ± 0.14 1.12 ± 0.25 1 
Cyt1p NP_014708 Mitochondrial ETC 3.65 ± 0.37 2.54 ± 0.19 0.95 ± 0.14 1 
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Rip1p NP_010890 Mitochondrial ETC 4.88 ± 0.41 3.67 ± 0.31 1.27 ± 0.22 1 
Cox4p NP_011328 Mitochondrial ETC 2.64 ± 0.21 2.42 ± 0.27 1.13 ± 0.18 1 
Cox5Ap NP_014346 Mitochondrial ETC 3.58 ± 0.37 2.83 ± 0.19 1.34 ± 0.36 1 
Pet100p NP_010364 Mitochondrial ETC 3.77 ± 0.24 2.61 ± 0.40 1.19 ± 0.24 1 
Atp1p NP_009453 Mitochondrial ATP synthase; binds to 
mtDNA  
3.65 ± 0.38 4.72 ± 0.44 1.12 ± 0.33 1 
Atp2p NP_012655 Mitochondrial ATP synthase 3.43 ± 0.21 4.56 ± 0.33 1.32 ± 0.46 1 
Pet9p NP_009523 Mitochondrial ADP/ATP carrier 2.58 ± 0.16 3.38 ± 0.25 1.14 ± 0.21 1 
Mir1p NP_012611 Mitochondrial phosphate carrier 2.75 ± 0.32 3.59 ± 0.17 0.94 ± 0.36 1 
Hem14p NP_010930 Heme synthesis in mitochondria 2.49 ± 0.18 1.76 ± 0.21 1.17 ± 0.25 1 
Cyc3p NP_009361 Heme attachment to apo-cytochrome c 3.58 ± 0.26 2.77 ± 0.34 1.26 ± 0.37 1 
Sod2p NP_011872 Detoxification of ROS in mitochondria 2.71 ± 0.31 4.69 ± 0.42 1.15 ± 0.19 1 
Prx1p NP_009489 Detoxification of ROS in mitochondria 2.48 ± 0.23 4.55 ± 0.36 1.34 ± 0.42 1 
Ccp1p NP_012992 Detoxification of ROS in mitochondria 4.53 ± 0.39 4.71 ± 0.42 1.21 ± 0.16 1 
Trr2p NP_011974 Detoxification of ROS in mitochondria 3.67 ± 0.25 4.29 ± 0.21 1.09 ± 0.25 1 
Trx3p NP_010006 Detoxification of ROS in mitochondria 3.88 ± 0.32 4.64 ± 0.25 1.35 ± 0.38 1 
Ssq1p NP_013473 Assembly of Fe/S clusters into proteins 2.75 ± 0.24 2.29 ± 0.11 0.88 ± 0.14 1 
Ssc1p NP_012579 Mitochondrial chaperone; binds to 
mtDNA 
2.56 ± 0.12 1.45 ± 0.28 0.87 ± 0.28 1 
Hsp60p NP_013360 Mitochondrial chaperone; binds to 
mtDNA 
3.78 ± 0.28 2.81 ± 0.37 1.27 ± 0.13 1 
Caf4p NP_012962 Mitochondrial fission 0.41 ± 0.12 0.32 ± 0.09 0.92 ± 0.15 1 
Mdv1p NP_012423 Mitochondrial fission 0.37 ± 0.08 0.23 ± 0.04 1.17 ± 0.22 1 
Fis1p NP_012199 Mitochondrial fission 0.72 ± 0.21 0.37 ± 0.12 0.89 ± 0.36 1 
Mgm1p NP_014854 Mitochondrial fusion 3.69 ± 0.35 4.72 ± 0.26 1.15 ± 0.25 1 
Pgs1p NP_009923 Cardiolipin synthesis in mitochondria 0.28 ± 0.11 0.39 ± 0.08 0.95 ± 0.17 1 
Crd1p NP_010139 Cardiolipin synthesis in mitochondria 0.31 ± 0.07 0.42 ± 0.14 1.23 ± 0.26 1 
Taz1p NP_015466 Cardiolipin synthesis in mitochondria 0.42 ± 0.13 0.36 ± 0.11 1.19 ± 0.34 1 
Ald4p NP_015019 Mitochondrial aldehyde 
dehydrogenase; binds to mtDNA 
3.84 ± 0.27 2.68 ± 0.21 0.87 ± 0.18 1 
Abf2p NP_013788 Mitochondrial genome maintenance; 
binds to mtDNA 
0.27 ± 0.08 0.61 ± 0.17 0.87 ± 0.21  1 
Ilv5p NP_013459 Branched-chain amino acid 
biosynthesis in mitochondria; binds to 
mtDNA 
0.31 ± 0.11 0.73 ± 0.09 1.27 ± 0.32 1 
Sls1p NP_013240 Mitochondrial chaperone; binds to 
mtDNA  
3.85 ± 0.34 2.76 ± 0.31 1.63 ± 0.15 1 
 
mitochondria of yeast grown on 0.2% glucose, which exceeded the modest increase seen 
in yeast grown on 0.5% glucose, resulted in a greatly elevated level of mitochondrial 
ROS. This, in turn, led to the oxidative damage and inactivation of CCO, SDH, ACO 
and, perhaps, some other components of the mitochondrial ETC and TCA cycle. Late in 
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Figure 2.6. CR influences oxidation-reduction processes in mitochondria and modulates the level of 
mitochondrially produced ROS. (A) The dynamics of age-dependent changes in the rate of oxygen 
consumption by cells. Data are presented as mean  SEM (n = 15-19). (B) The dynamics of age-dependent 
changes in the mitochondrial membrane potential () during chronological aging of yeast.  was 
visualized using R123. At least 800 cells were used for quantitation of R123 staining for each of 3 
independent experiments. Data are presented as mean  SEM (n = 15-19). (C and D) Enzymatic activities 
of CCO (C) and SDH (D) in purified mitochondria. Data are presented as mean  SEM (n = 6-10). (E) The 
dynamics of age-dependent changes in the intracellular levels of ROS during chronological aging of yeast. 
ROS were visualized using DHR. At least 800 cells were used for quantitation of DHR staining for each of 
5 independent experiments. Data are presented as mean  SEM (n = 8-13). (F) Enzymatic activities of ACO 
in total cell lysates. The ACO activity was measured with or without the reactivation agents Fe3+ and Na2S. 
Data are presented as mean  SEM (n = 5). (A-E) Cells were cultured in YP media initially containing four 
different concentrations of glucose. (F) Cells were cultured in YP medium initially containing 0.2% or 2% 
glucose. 
 
ETC of yeast grown on 0.2% glucose substantially decreased mitochondrial ROS below 
the level observed in mitochondria of yeast grown on 0.5% glucose (Figure 2.6).  
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2.4.7 CR influences the frequency of mitochondrial DNA (mtDNA) mutations and 
modulates the abundance and mtDNA-binding activity of mitochondrial 
nucleoid-associated proteins 
My data imply that the observed during D and PD phases spike in ROS production by 
mitochondria of CR yeast grown on 0.2% glucose can oxidatively damage their 
mitochondrial DNA (mtDNA), eventually (i.e., during ST phase) introducing deletions 
and point mutations into it. In fact, during ST phase, the population of these CR cells 
accumulated an increasing fraction of respiratory-deficient mutants (Figure 2.7A). Most 





 mutations or large deletions rho
-
) or completely lack mtDNA (rho
o
 mutants), 
whereas some of them carry so-called pet
-
 mutations in nuclear genes that code for 
essential mitochondrial components [250, 280]. Furthermore, I found that only cells 
under CR at 0.2% glucose exhibited an increased frequency of mtDNA mutations that 
caused resistance to erythromycin (Figure 2.7B). Resistance to this antibiotic can be 
acquired only through a distinct set of point mutations in the mitochondrial rib2 and rib3 
genes that encode two different rRNAs confined to mitochondria [251 - 253]. 
Importantly, the highest amplitude of the early spike in ROS production by yeast under 
CR at 0.2% glucose (Figure 2.6E) correlated with their elevated frequencies of mtDNA 
mutations (Figures 2.7A and 2.7B) and shortened life span (Figures 2.1C and 2.1D), as 
compared to yeast under CR at 0.5% glucose. Thus, it is conceivable that the frequency 
of ROS-induced deletions and point mutations in mtDNA influence yeast longevity under 
CR conditions. This hypothesis could satisfactorily explain my observation that yeast 




Figure 2.7. CR modulates the frequency of mtDNA mutations and influences the efficiency of aconitase 
binding to mtDNA. (A) The percentage of respiratory-deficient cells that were unable to grow in medium 
containing 3% glycerol because they carried large mtDNA deletions (rho-) or lacked mtDNA (rhoo). Data 
are presented as mean  SEM (n = 7). (B) Relative frequencies (fold difference relative to that on 2% 
glucose) of mtDNA point mutations that caused resistance to erythromycin. Data are presented as mean  
SEM (n = 70); *p < 0.01, **p < 0.001. (C) Western blot analysis of aconitase (Aco1p) recovery in fractions 
of a CsCl gradient that was used for the purification of mitochondrial nucleoids. The peak fraction for the 
mitochondrial Aco1p-DNA complex (arrow) is indicated. (A and B) Cells were cultured in YP media 
initially containing four different concentrations of glucose. (C) Cells were cultured in YP medium initially 
containing 0.2% glucose. 
 
it seems that the frequency of mtDNA deletions and point mutations does not affect the 
longevity of chronologically aging yeast grown on 1% or 2% glucose, i.e. under non-CR 
conditions. In fact, I found that, despite these yeast had much lower frequencies of 
mtDNA mutations than CR yeast grown on 0.2% glucose (Figures 2.7A and 2.7B), they 
lived a shorter life (Figures 2.1C and 2.1D). 
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            Of note, I found that the observed elevated frequencies of mtDNA deletions and 
point mutations in CR yeast grown on 0.2% glucose occurred despite an effort that these 
yeast have made to protect the stability of mtDNA by remodeling mitochondrial 
nucleoids early in their life. In fact, during D and PD phases, these CR yeast induced the 
synthesis of a distinct set of mtDNA-binding proteins (Figure 2.5; Tables 2.1 and 2.2) 
known for their essential role in maintaining mtDNA and protecting it from oxidative 
damage [280]. One of these proteins, the TCA-cycle enzyme aconitase (Aco1p) known 
for its ability to interact with mtDNA and to maintain its integrity when cells are shifted 
to respiratory conditions [281], associated with mtDNA of aging CR yeast grown on 
0.2% glucose (Figure 2.7C). Importantly, I found that the efficiency of such Aco1p 
binding to mtDNA at different stages of the aging process (Figure 2.7C) correlated with 
the concentration of ROS generated by mitochondria of these CR yeast (Figure 2.6E). 
Noteworthy, CR decreased the levels of mitochondrial Abf2p and Ilv5p (Figure 2.5), the 
two mtDNA-binding proteins that associate with mitochondrial nucleoids under 
conditions of low respiration or amino-acid starvation, respectively [280]. Therefore, I 
suggest the following scenario for metabolic remodeling of mitochondrial nucleoids in 
chronologically aging CR yeast. In response to the early spike in oxygen consumption 
and ROS generation by their mitochondria, CR yeast induce the synthesis of Aco1p and 
other bifunctional mitochondrial proteins that, in addition to their essential role in 
respiratory metabolism, are able to interact specifically with mtDNA. Concomitantly, CR 
yeast repress the synthesis of both Abf2p and Ilv5p. Because of their increased 
concentrations and due to their partial oxidation by mitochondrial ROS, Aco1p and other 
mtDNA-binding proteins bind to mtDNA in order to protect it from oxidative damage. 
108 
 
Such binding of Aco1p and other respiratory-metabolism sensing proteins to mtDNA 
may substitute for Abf2p and Ilv5p, thereby remodeling mitochondrial nucleoids by 
converting them into the conformation that is more resistant to oxidative damage. 
Noteworthy, the level of Aco1p in yeast cells is known to be modulated by the 
mitochondrial retrograde (RTG) signaling pathway. This pathway activates transcription 
of the ACO1 gene in response to a decline in mitochondrial respiratory function caused 
by mtDNA damage [282, 283]. It is conceivable therefore that chronologically aging CR 
yeast respond to the partial oxidative damage of their mtDNA by turning on the RTG 
pathway. By activating transcription of ACO1 and, perhaps, other genes encoding 
bifunctional mtDNA-binding proteins known to maintain the integrity of mtDNA in yeast 
shifted to respiratory conditions [280, 281], this signaling pathway may govern the 
resulting conversion of mitochondrial nucleoids into the conformation that is more 
resistant to oxidative damage. 
 
2.4.8 CR alters mitochondrial morphology and delays mitochondria-controlled 
apoptosis 
            My findings imply that CR yeast influenced the aforementioned oxidation-
reduction processes in mitochondria and modulated the levels of a distinct set of 
mitochondrial proteins not by altering the abundance of mitochondria. In fact, I found 
that the intracellular levels of porin, one of the most abundant mitochondrial proteins, 
were very similar in chronologically aging CR and non-CR yeast (Figure 2.8A). Rather, 
the CR diet provided mitochondria of aging yeast with an ability to maintain the shape of 
a tubular network (Figures 2.8B and 2.8C). In contrast, this tubular network in non-CR 
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yeast entering ST phase was fragmented into individual mitochondria (Figures 2.8B and 
2.8C), consistent with the increased levels of some protein components of the 
mitochondrial fission machine and decreased level of the Mgm1p component of the 
mitochondrial fusion machine in their cells (Figure 2.5; Tables 2.1 and 2.2). In fact, it is 
known that the morphology of mitochondria depends on a balance between the processes 
of mitochondrial fission and fusion [284 - 286].  
            Furthermore, my fluorescence microscopy analysis revealed that chronologically 
aging non-CR yeast died exhibiting characteristic markers of apoptosis such as nuclear 
fragmentation, phosphatidylserine (PS) translocation from the inner to the outer leaflet of 
the plasma membrane, and cleavage of chromosomal DNA (Figures 2.8D - 2.8F). A CR 
diet - which prevented the fragmentation of the mitochondrial tubular network early in 
ST phase (Figures 2.8B and 2.8C) - delayed such age-related apoptosis (Figures 2.8D - 
2.8F). Moreover, I found that the ability of CR to delay mitochondrial fragmentation in 
early ST phase and attenuate the age-related form of apoptotic cell death coincided with 
its ability to slow down the release of cytochrome c from mitochondria into the cytosol 
(Figure 2.8G). Of note, although some data suggest that - akin to its essential role in 
triggering the apoptotic caspase cascade in mammalian cells [287] - cytochrome c in the 
cytosol of yeast cells promotes mitochondria-controlled apoptosis by activating the 
metacaspase Yca1p [288 - 292], the involvement of cytosolic cytochrome c in Yca1p 
activation and apoptotic death in yeast remains a controversial issue [293, 294]. 
            Altogether, these findings imply that the premature chronological aging of non-
CR yeast grown in the nutrient-rich YP medium is linked to an apoptosis-like cell death. 




Figure 2.8. CR influences mitochondrial morphology and delays age-related apoptosis. (A) Western blot 
analysis of porin, the Cyc1p isoform of cytochrome c and actin in cells taken at the indicated time-points. 
Proteins recovered in total cell lysates were resolved by SDS-PAGE and detected by immunoblotting. (B) 
Morphology of mitochondria in yeast cells recovered from ST phase. Mitochondria were visualized by 
indirect immunofluorescence microscopy using monoclonal anti-porin primary antibodies and Alexa Fluor 
568-conjugated goat anti-mouse IgG secondary antibodies. Representative images are shown. (C) The 
percentage of cells exhibiting a tubular mitochondrial network or fragmented mitochondria was calculated. 
At least 800 cells were used for quantitation at each time point. Data are presented as mean ± SEM (n = 3). 
(D and E) Fluorescence microscopy of cells stained with DAPI (D) or Annexin V (E) was used for analysis 
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of nuclear morphology or the presence of phosphatidylserine (PS) in the outer leaflet of the plasma 
membrane, respectively. The percentage of cells exhibiting fragmented nuclei (D) or externalized PS (E) 
was calculated. At least 800 cells were used for quantitation at each time point. Data are presented as mean 
± SEM (n = 3). (F) DNA fragmentation was monitored using a TUNEL (terminal deoxynucleotidyl 
transferase dUTP nick-end labelling) assay. The percentage of cells exhibiting cleaved chromosomal DNA 
was calculated. At least 800 cells were used for quantitation at each time point. Data are presented as mean 
± SEM (n = 2). (G) Western blot analysis of cytochrome c in purified mitochondria (M) and in the 
cytosolic fraction (C) recovered from cells taken at the indicated time-points. Equal portions of 
mitochondrial and cytosolic fractions were analyzed by immunoblotting to cytochrome c. Cells were 
cultured in YP media initially containing four different concentrations of glucose. 
 
efflux of cytochrome c (and, maybe, several other pro-apoptotic proteins) from the 
intermembrane space of mitochondria undergoing massive fragmentation in non-CR 
yeast that have reached ST phase. 
 
2.4.9 CR increases the resistance of aging yeast to chronic thermal and oxidative 
stresses 
            As I found, consistent with the elevated levels of cytosolic and mitochondrial 
stress-protecting and ROS scavenging proteins in CR yeast entering the non-proliferative 
ST phase (Figure 2.5; Tables 2.1 and 2.2), the CR diet enhanced the resistance of aging 
yeast to chronic thermal and oxidative stresses (Figure 2.9). 
 
2.5 Discussion 
            Along with published data from Dr. Titorenko’s laboratory on the molecular 
mechanism underlying the ability of CR to extend longevity of chronologically aging 
yeast by specifically remodelling lipid metabolism in the endoplasmic reticulum, lipid 




Figure 2.9. CR enhances the resistance of aging yeast to chronic thermal and oxidative stress. Heat-shock 
and oxidative stress resistance of yeast cells taken for a stress-resistance spot assay at the indicated time-
points. Serial dilutions of cells were spotted onto four sets of YP plates containing 2% glucose as carbon 
source. The first set of plates (control) was placed at 30oC immediately after spotting. The second set of 
plates (heat-shocked) was initially incubated at 55oC for 30 min, and was then transferred to 30oC. The 
third set of plates, which contained 5 mM hydrogen peroxide, was placed at 30oC immediately after 
spotting. The fourth set of plates, which contained 2.5 mM paraquat, was placed at 30oC immediately after 
spotting. All pictures were taken after 3 d of incubation at 30
o
C. Cell were cultured in YP media initially 
containing four different concentrations of glucose.  
 
 
chronologically aging yeast outlined in this chapter of my thesis provides evidence that, 
before yeast enter the non-proliferative ST phase, they establish a diet-specific pattern of 
metabolism and organelle dynamics during D and PD phases. Both CR and non-CR yeast 
develop such a pattern after they entirely consume glucose during L phase. Due to their 
different metabolic histories prior to entry into a non-proliferative state, CR and non-CR 
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yeast that reach ST phase have different patterns of metabolism, inter-organellar 
communications and mitochondrial morphology (Figure 2.10). Combined, my findings 
and other data from Dr. Titorenko’s laboratory [24, 246, 247, 278] suggest the following 
scenario for a stepwise establishment of such patterns prior to reproductive maturation 
(Figure 2.10). 
            Chronologically aging CR yeast shift carbohydrate metabolism toward glucose 
formation via gluconeogenesis by elevating the levels of the key enzymes involved in this 
reverse to glycolysis process. By activating the synthesis of enzymes catalyzing the 
biosynthesis of trehalose and glycogen and by suppressing the synthesis of enzymes 
required for their degradation, CR promotes the accumulation of these two major glucose 
stores (Figure 2.10) [24, 278]. CR yeast avoid ethanol accumulation by differentially 
modulating the levels of Adh1p or Adh2p, which are required for ethanol synthesis or 
degradation, respectively [24, 246, 278]. While CR yeast amass glucose stores, they 
rapidly hydrolyze their two major lipid stores, the neutral lipids triacylglycerols and 
ergosteryl esters, prior to entry into ST phase. Such lipolysis of lipid bodies-deposited 
neutral lipids in CR yeast produces substantial amounts of free fatty acids (Figure 2.10) 
[24, 246, 247, 278]. Free fatty acids are then rapidly oxidized to acetyl-CoA via a 
peroxisome-confined pathway greatly activated by CR. The subsequent oxidation of the 
peroxisome-derived acetyl-CoA in mitochondria generates the bulk of ATP in CR yeast 
(Figure 2.10). This process also generates considerable quantities of mitochondrial ROS. 
Within the mitochondrion, ROS are decomposed in antioxidant scavenger reactions 
catalyzed by a distinct set of enzymes, all of which are induced by CR (Figure 2.5; Tables 
2.1 and 2.2). ROS homeostasis in chronologically aging CR yeast is also maintained by a 
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group of ROS scavenging enzymes that detoxify ROS released from mitochondria into 
the cytosol [24, 278]. CR increases levels of all these cytosolic antioxidant enzymes. The 
observed elevated levels of numerous mitochondrial and cytosolic anti-stress chaperones 
in chronologically aging CR yeast (Figure 2.5; Tables 2.1 and 2.2; [24]) are likely to be 
responsible for the observed increase in their resistance to chronic thermal and oxidative 
stresses (Figure 2.9). Consistent with the altered levels of several protein components of 
the mitochondrial fission and fusion machines in their cells (Figure 2.5; Tables 2.1 and 
2.2), CR yeast that enter ST phase avoid fragmentation of their mitochondrial tubular 
network into individual mitochondria (Figures 2.8B and 2.8C).  
            Unlike CR yeast, chronologically aging non-CR yeast that enter ST phase 
generate the bulk of ATP via glycolytic oxidation of glycogen- and trehalose-derived 
glucose (Figure 2.10). The glycolytic oxidation of glucose to pyruvate in non-CR yeast is 
followed by its conversion to ethanol, which accumulates in non-CR yeast (Figure 2.10) 
[24, 246, 278]. In contrast to CR yeast, non-CR yeast entering ST phase amass substantial 
quantities of triacylglycerols and ergosteryl esters in their lipid bodies and endoplasmic 
reticulum (Figure 2.10) [24, 246, 247, 278]. Such accumulation of the two major lipid 
stores in non-CR yeast is due to the observed high levels of lipid bodies- and 
endoplasmic reticulum-associated enzymes involved in their biosynthesis and low levels 
of lipid bodies-bound enzymes that function in their degradation [24, 246, 278]. 
Furthermore, the low levels of enzymes functioning in the formation of FA-CoA and in 
their uptake and subsequent oxidation by peroxisomes seen in non-CR yeast that reached 




Figure 2.10. CR and non-CR yeast that enter ST phase have different patterns of metabolism, 
interorganellar communications and mitochondrial morphology. Before yeast enter the non-proliferative ST 
phase, they establish a diet-specific pattern of metabolism and organelle dynamics during D and PD phases. 
By designing such specific pattern prior to entry into a non-proliferative state, yeast could define their long-
term viability. See text for details. The thickness of arrows correlates with the rates of the processes taking 
place in CR and non-CR yeast that have reached ST phase. The metabolites accumulated in bulk quantities 
are shown in bold. T bars denote inhibition of the process. The processes that may play an essential role in 
regulating the longevity of ST-phase yeast are displayed in red color. Dotted line denotes a proposed 
negative regulatory effect of ethanol on fatty acid oxidation in peroxisomes. Abbreviations: Ac-CoA, 
acetyl-CoA; AcOH, acetic acid; DAG, diacylglycerols; EE, ethyl esters; ER, endoplasmic reticulum; ERG, 
ergosterol; EtOH, ethanol; FA-CoA, CoA esters of fatty acids; FFA, free fatty acids; LB, lipid bodies; 
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mtDNA, mitochondrial DNA; mtDNA-bp, mtDNA-binding proteins; PL, phospholipids; ROS, reactive 
oxygen species; TAG, triacylglycerols; TCA, the tricarboxylic acid cycle in mitochondria. 
 
peroxisome-confined pathway (Figure 2.10) [24, 246, 247, 278]. Because of the low 
efficiency of acetyl-CoA formation in peroxisomes of non-CR yeast they are unable to 
generate significant quantities of ATP by oxidizing peroxisome-derived acetyl-CoA in 
mitochondria. The resulting low efficiency of electron flow through the mitochondrial 
ETC of non-CR yeast reduces the transfer of a single electron to oxygen in mitochondria, 
thereby greatly decreasing mitochondrial ROS production (Figure 2.10) [24, 246, 247, 
278]. The reduced (as compared to CR yeast) levels of cytosolic and mitochondrial 
stress-protecting proteins in non-CR yeast (Figure 2.5; Tables 2.1 and 2.2; [24, 246, 278]) 
can adequately explain why they are more sensitive to chronic thermal and oxidative 
stresses than CR yeast (Figure 2.9). The mitochondrial tubular network in non-CR yeast 
entering ST phase is fragmented into individual mitochondria (Figures 2.8B and 2.8C). 
Such fragmentation of mitochondria in non-CR yeast could be due to the increased levels 
of some protein components of the mitochondrial fission machine and decreased level of 
the Mgm1p component of the mitochondrial fusion machine in their cells (Figure 2.5; 
Tables 2.1 and 2.2). 
            Based on my comparison of the metabolic histories of long-lived CR yeast and 
short-lived non-CR yeast and on published data from Dr. Titorenko’s laboratory [24, 246, 
247, 278], I propose that, by designing a diet-specific pattern of metabolism and 
organelle dynamics prior to entry into a non-proliferative state, yeast define their long-
term viability. I hypothesize that longevity in chronologically aging yeast is programmed 
by the level of metabolic capacity and organelle organization they developed, in a diet-
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specific fashion, prior to reproductive maturation. In my hypothesis, the following 
metabolites and processes could play an essential role in regulating the chronological life 
span of yeast by defining their viability during ST phase (Figure 2.10).  
            Trehalose. Although trehalose has been long considered only as a reserve 
carbohydrate [272], it seems that the major function of this non-reducing disaccharide in 
yeast consists in enabling the survival of cells exposed to elevated temperature or ROS 
[273, 274]. In fact, trehalose in yeast cells prevents aggregation of proteins denatured 
during and immediately after their exposure to these stresses [274, 275]. I therefore 
propose that the elevated levels of trehalose seen in CR yeast during PD phase (Figure 
2.3B) protect from aggregation those proteins that have been denatured due to their 
exposure to ROS accumulated during this growth phase (Figure 2.6E). Such protective 
effect of high trehalose concentrations could contribute to the enhanced (as compared to 
non-CR yeast) survival of CR yeast during the following ST phase. Moreover, because of 
the ability of trehalose to interfere with the chaperone-assisted refolding of denatured 
cytosolic proteins, it must be rapidly degraded in order for molecular chaperones to 
restore the native conformation of these proteins [273, 275]. Hence, one could expect that 
a diet providing yeast with the ability to maintain trehalose concentration at a certain 
“optimal” level (at which trehalose prevents aggregation of oxidatively damaged proteins 
and does not inhibit their refolding) would extend their longevity. It should be stressed, 
therefore, that 1) trehalose in CR yeast grown on 0.5% glucose, a diet that provides the 
maximal benefit of CR for longevity, increased mainly in PD phase and reached a plateau 
soon after cells have entered ST phase (Figure 2.3B); and 2) trehalose in CR yeast grown 
on 0.2% glucose, a diet providing only a modest CR-dependent life-span extension, 
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increased predominantly throughout ST phase and eventually reached the steady-state 
level exceeding that in CR yeast grown on 0.5% glucose (Figure 2.3B). Of note, recent 
unpublished data of Pavlo Kyryakov (a graduate student in Dr. Titorenko’s laboratory) on 
protein unfolding/aggregation in response to elevated temperature or oxidative stress and 
on protein refolding following temperature or oxidative status restoration in various 
mutants impaired in different steps of the trehalose biosynthesis or degradation pathways 
(see Figure 2.4A) confirm the validity of my hypothesis on the essential role of trehalose 
in regulating the chronological life span of yeast and defining their viability during ST 
phase.  
            Ethanol. It is plausible that the observed stimulatory effect of CR on ethanol 
catabolism could play a role in longevity extension by CR (Figure 2.10). In fact, it has 
been shown that CR yeast completely consumed ethanol by day 2, at least 10 days before 
the beginning of their viability decline [24]. Conversely, it has been found that non-CR 
yeast are unable to consume substantial quantities of ethanol prior to the age-dependent 
decline of their viability [24]. Of note, ethanol in yeast cells suppresses the synthesis of 
certain proteins localized to peroxisomes [24, 246, 278, 296]. Furthermore, recent 
proteomic analysis revealed that CR elevated the levels of Fox1p, Fox2p and Fox3p [24], 
all of which are the core enzymes of peroxisomal β-oxidation of free fatty acids [297]. 
This finding can adequately explain the recently reported low levels of free fatty acids in 
CR yeast and their fast consumption throughout PD phase [24, 246], suggesting that the 
elevated levels of Fox1p, Fox2p and Fox3p in these yeast are due to the rapid depletion 
of ethanol in their cells (Figure 2.10). Therefore, it has been proposed that the 
accumulation of ethanol in non-CR yeast cultures suppresses peroxisomal oxidation of 
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free fatty acids by repressing the synthesis of Fox1p, Fox2p and Fox3p (Figure 2.10) [24, 
246]. In this hypothesis, because of the low efficiency of free fatty acid oxidation in 
peroxisomes of aging non-CR yeast, they die during ST phase in part due to the induced 
by free fatty acids age-related form of necrotic cell death (Figure 2.10) [24, 246]. Of note, 
soon-to-be submitted for publication data of Simon Bourque (a graduate student in Dr. 
Titorenko’s laboratory) on the molecular mechanism underlying the ability of CR to 
extend longevity of chronologically aging yeast by specifically remodelling lipid 
metabolism in the endoplasmic reticulum, lipid bodies   and   peroxisomes confirm the 
validity of the above hypothesis on the essential role of ethanol in regulating the 
chronological life span of yeast and defining their viability during ST phase.  
            ROS. Based on the findings presented in this chapter of my thesis, I hypothesize 
that ROS, which are mostly generated as by-products of mitochondrial respiration [276, 
277], play a dual role in regulating the longevity of chronologically aging yeast (Figure 
2.10). First, if yeast mitochondria are unable (due to a dietary regimen) to maintain ROS 
concentration below a toxic threshold, ROS promote aging by oxidatively damaging 
certain mitochondrial proteins (such as CCO, SDH and ACO) and mtDNA. In fact, I 
found that the highest amplitude of the early spike in ROS production in CR yeast 
entering D phase on 0.2% glucose (Figure 2.6E) correlated with their 1) shortened (as 
compared to CR yeast grown on 0.5% glucose) life span (Figures 2.1C and 2.1D); 2) 
sharply declined activities of CCO, SDH and ACO through the following PD and ST 
phases (Figures 2.6C, 2.6D and 2.6F); and 3) elevated frequencies of mtDNA deletions 
and point mutations, as compared to yeast under CR at 0.5% glucose (Figures 2.7A and 
2.7B). Second, if yeast mitochondria can (due to a dietary regimen) maintain ROS 
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concentration at a certain “optimal” level, ROS delay chronological aging. I propose that 
this “optimal” level of ROS is insufficient to damage cellular macromolecules but can 
activate certain signaling networks [278, 277, 298] that extend life span by increasing the 
abundance or activity of stress-protecting and other anti-aging proteins (Figure 2.10); the 
term “mitohormesis” has been coined for such anti-aging role of mitochondrially 
produced ROS [299]. Indeed, I found that elevated (as compared to non-CR yeast) ROS 
concentrations in CR yeast (Figure 2.6E) correlated with their extended chronological 
longevity (Figures 2.1C and 2.1D), increased abundance of numerous mitochondrial and 
cytosolic anti-stress chaperones and mtDNA-binding proteins (Figure 2.5; Tables 2.1 and 
2.2; [24]), and augmented resistance to chronic thermal and oxidative stresses (Figure 
2.9). Moreover, although the low concentration of ROS seen in non-CR yeast could play 
a key role in protecting their mtDNA from “spontaneous” mutagenesis (Figures 2.7A and 
2.7B), the inability of these yeast to generate ROS in sufficiently high, “optimal” 
quantities could contribute to their lowered (as compared to CR yeast) levels of cytosolic 
and mitochondrial stress-protecting proteins (Figure 2.5; Tables 2.1 and 2.2; [24]) and 
reduced resistance to chronic thermal and oxidative stresses (Figure 2.9). Noteworthy, the 
view that mitochondrially produced ROS in “optimal” concentrations contribute to 
extension of yeast life span by promoting “mitohormesis” is controversial [300, 301]. 
            Accumulation of mtDNA mutations. My data imply that mtDNA mutations do 
not contribute to longevity regulation in non-CR yeast grown on 1% or 2% glucose. In 
fact, despite these yeast lived a shorter life than CR yeast grown on 0.2% glucose 
(Figures 2.1C and 2.1D), they had much lower frequencies of mtDNA deletions and point 
mutations, as compared to yeast under CR at 0.2% glucose (Figures 2.7A and 2.7B). In 
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contrast, it seems that the frequency of mtDNA mutations is an important contributing 
factor to yeast longevity under CR conditions (Figure 2.10). Indeed, the elevated 
frequencies of mtDNA mutations in yeast under CR at 0.2% glucose (Figures 2.7A and 
2.7B) correlated with their shortened life span, as compared to yeast under CR at 0.5% 
glucose (Figures 2.1C and 2.1D). 
            Mitochondria-controlled, age-related apoptosis. The observed ability of CR to 
delay mitochondrial fragmentation in early ST phase (Figures 2.8B and 2.8C) could be 
responsible for the demonstrated capability of this diet to attenuate the age-related form 
of apoptotic cell death (Figures 2.8D, 2.8E and 2.8F), perhaps by preventing the efflux of 
cytochrome c (and, maybe, several other pro-apoptotic proteins) from the intermembrane 
space of mitochondria (Figure 2.8G). Moreover, the observed in non-CR yeast 
fragmentation of the mitochondrial tubular network could trigger age-related apoptosis by 
causing the age-related exit of cytochrome c (and, possibly, other pro-apoptotic proteins) 
from the intermembrane space of their fragmented mitochondria (Figure 2.8). Therefore, 
I propose that mitochondria-controlled, age-related apoptosis could play an essential role 
in regulating the chronological life span of yeast by defining their viability during ST 
phase (Figure 2.10). 
 
2.6 Conclusions 
            As my comparison of the metabolic histories of long-lived CR yeast and short-
lived non-CR yeast reported here revealed, yeast define their long-term viability by 
designing a diet-specific pattern of metabolism and organelle dynamics prior to 
reproductive maturation. My data imply that longevity in chronologically aging yeast is 
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programmed by the level of metabolic capacity and organelle organization they 
developed, in a diet-specific fashion, prior to entry into a non-proliferative state. 
Therefore, my conclusion is that chronological aging in yeast is the final step of a 
developmental program progressing through a series of checkpoints. 
            The major challenges now are 1) to validate my hypothesis that the longevity of 
chronologically aging yeast is programmed by the level of metabolic capacity and 
organelle organization they developed, in a diet-specific fashion, prior to reproductive 
maturation; and 2) to rank the relative contributions of different metabolites and 
processes (see Figure 2.10) to the chronological aging of yeast. To address these 
challenges, Dr. Titorenko’ laboratory is currently evaluating how genetic manipulations 
that alter concentrations of these critical metabolites and affect these essential processes 
influence yeast longevity by modulating age-related protein aggregation, mitochondria-
controlled apoptosis, free fatty acid- and diacylglycerol-induced necrosis, susceptibility 
to oxidative stress, and frequency of mtDNA mutations. A challenge for the future will be 
to elucidate how a longevity regulatory network centered on the 
Ras2p/cAMP/PKA/Rim15p/Msn2p/Msn4p and Tor1p/Sch9p/Rim15p/Gis1p nutrient-
sensing pathways [278, 296, 301] governs the development of the diet-specific pattern of 
metabolism and organelle dynamics in chronologically aging yeast under CR conditions. 
Moreover, it would be interesting to examine whether the pattern established in yeast 
cells grown under CR conditions can be reversed upon their transfer to calorie-rich 
medium. Another challenge for the future will be to test the validity of my hypothesis that 
chronologically aging CR yeast protect their mitochondrial nucleoids from oxidative 
damage by turning on the RTG signaling pathway, which then activates transcription of 
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ACO1 and other genes encoding bifunctional mtDNA-binding proteins known to 
maintain the integrity of mtDNA under respiratory conditions. 
            Finally, I expect that this knowledge will be instrumental for designing high-
throughput screening of novel anti-aging drugs that can extend longevity by modulating 






















3 Chemical genetic screen identifies lithocholic acid as an anti-aging compound 
that extends yeast chronological life span in a TOR-independent manner, by 
modulating housekeeping longevity assurance processes 
 
3.1 Abstract 
            In chronologically aging yeast, longevity can be extended by administering a 
caloric restriction (CR) diet [6, 7, 10, 24, 35, 63] or some small molecules [101, 110, 114, 
134]. These life-extending interventions target the adaptable target of rapamycin (TOR) 
and cAMP/protein kinase A (cAMP/PKA) signaling pathways that are under the stringent 
control of calorie availability [6, 7, 10, 35, 101, 110, 114, 134]. I designed a chemical 
genetic screen for small molecules that increase the chronological life span (CLS) of 
yeast under CR by targeting lipid metabolism and modulating housekeeping longevity 
pathways that regulate longevity irrespective of the number of available calories. My 
screen identifies lithocholic acid (LCA) as one of such molecules. My evaluation of the 
life-extending efficacy of LCA in WT strain on a high- or low-calorie diet revealed that 
this compound extends yeast CLS irrespective of the number of available calories. I 
found that the extent to which LCA extends longevity is highest under CR conditions, 
when the pro-aging processes modulated by the adaptable TOR and cAMP/PKA 
pathways are suppressed and the anti-aging processes are activated [6, 7, 10]. 
Furthermore, the life-extending efficacy of LCA in CR yeast significantly exceeded that 
in yeast on a high-calorie diet, in which the adaptable TOR and cAMP/PKA pathways 
greatly activate the pro-aging processes and suppress the anti-aging processes [4, 5, 7, 35, 
279]. Altogether, my findings suggest that, consistent with its sought-after effect on a 
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longevity signaling network, LCA mostly targets certain housekeeping longevity 
assurance pathways that do not overlap (or only partially overlap) with the adaptable 
TOR and cAMP/PKA pathways modulated by calorie availability.  
            Consistent with my assumption that LCA extends longevity not by modulating the 
adaptable TOR pathway, I found that lack of Tor1p does not impair the life-extending 
efficacy of LCA under CR. I also revealed that, LCA extends longevity of the tor1 
mutant strain to a very similar degree under CR and non-CR conditions. Thus, by 
eliminating a master regulator of this key adaptable pathway that shortens the CLS of 
yeast on a high-calorie diet, the tor1 mutation abolished the dependence of the anti-
aging efficacy of LCA on the number of available calories.  
            My findings, along with some recently published data from Dr. Titorenko’s 
laboratory, revealed two mechanisms underlying the life-extending effect of LCA in 
chronologically aging yeast. One mechanism operates in a calorie availability-
independent fashion and involves the LCA-governed modulation of housekeeping 
longevity assurance pathways that do not overlap with the adaptable TOR and 
cAMP/PKA pathways. The other mechanism extends yeast longevity under non-CR 
conditions and consists in LCA-driven unmasking of the previously unknown anti-aging 
potential of PKA. I provide evidence that LCA modulates housekeeping longevity 
assurance pathways by 1) attenuating mitochondrial fragmentation, a hallmark event of 
age-related cell death; 2) altering oxidation-reduction processes in mitochondria, 
including oxygen consumption, the maintenance of membrane potential, and reactive 
oxygen species production; 3) enhancing resistance to oxidative and thermal stresses; 4) 
126 
 




            Aging of multicellular and unicellular eukaryotic organisms is a multifactorial 
biological phenomenon that has various causes and affects a plethora of cellular activities 
[1 - 3, 5, 8, 10, 24]. These numerous activities are modulated by only a few nutrient- and 
energy-sensing signaling pathways that are conserved across phyla and include the 
insulin/insulin-like growth factor 1 (IGF-1), AMP-activated protein kinase/target of 
rapamycin (AMPK/TOR) and cAMP/protein kinase A (cAMP/PKA) pathways [4, 10, 
36]. By sharing a compendium of protein kinases and adaptor proteins, the insulin/IGF-1, 
AMPK/TOR and cAMP/PKA pathways in yeast, worms, fruit flies and mammals 
converge into a network regulating longevity [4, 10, 36 - 38, 301]. This network may also 
include several proteins that currently are not viewed as being in any of these three 
pathways [4, 10, 36, 73, 74]. Moreover, this network responds to the age-related partial 
mitochondrial dysfunction and is modulated by mitochondrially produced reactive 
oxygen species (ROS) [36, 73, 75, 147]. By sensing the nutritional status of the whole 
organism as well as the intracellular nutrient and energy status, functional state of 
mitochondria, and concentration of ROS produced in mitochondria, the longevity 
network regulates life span across species by coordinating information flow along its 
convergent, divergent and multiply branched signaling pathways. 
            By defining the organismal and intracellular nutrient and energy status, nutrient 
intake plays an important role in modulating life span and influences age-related 
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pathologies [7, 208]. Two dietary regimens are known to have the most profound life-
extending effects across species and to improve overall health by delaying the onset of 
age-related diseases. They include: 1) caloric restriction (CR), a diet in which only 
calorie intake is reduced but the supply of amino acids, vitamins and other nutrients is not 
compromised [13, 76, 77, 80, 208]; and 2) dietary restriction (DR), in which the intake of 
nutrients (but not necessarily of calories) is reduced by limiting food supply without 
causing malnutrition [66, 76, 77, 91]. In a “TOR-centric” view of longevity regulation, 
TOR alone governs the life-extending and health-improving effects of CR/DR by: 1) 
integrating the flow of information on the organismal and intracellular nutrient and 
energy status from the protein kinases AMPK, PKA, PKB/AKT (the insulin/IGF-1 
pathway) and ERK1/2 (the PKA-inhibited Raf/MEK/ERK protein kinase cascade) as well 
as from the mitochondrial redox protein P66
Shc
; 2) sensing the intracellular levels of 
amino acids in an AMPK-independent manner; and 3) operating as a control center 
which, based on the information it has gathered and processed, modulates many 
longevity-related processes in a sirtuin-independent fashion [84 - 86]. The inability of CR 
to increase the replicative life span (RLS) of yeast mutants lacking components of the 
TOR pathway [87] and the lack of the beneficial effect of DR on life span in worms with 
reduced TOR signaling [88, 89] support the proposed central role for TOR in 
orchestrating the life-extending effect of CR/DR in these two longevity paradigms. 
Moreover, while the postulated by the TOR-centric model dispensability of sirtuins for 
the longevity benefit associated with DR has been confirmed in worms [89], the 
importance of the sirtuin Sir2p in mediating the life-extending effect of CR in 
replicatively aging yeast is debated [56, 87, 145, 151]. Noteworthy, while TOR is a 
128 
 
central regulator of the life-extending effect of CR in replicatively aging yeast, the 
longevity benefit associated with CR in chronologically aging yeast is mediated by a 
signaling network that includes: 1) the TOR and cAMP/PKA pathways converged on 
Rim15p, which therefore acts as a nutritional integrator; and 2) some other, currently 
unknown pathways that are not centered on Rim15p [301]. Considering the likely 
convergence of the insulin/IGF-1, AMPK/TOR and cAMP/PKA signaling pathways into 
a network regulating longevity in worms, fruit flies and mammals (see above), it is 
conceivable that - akin to TOR - the insulin/IGF-1 and cAMP/PKA pathways may 
contribute to the beneficial effect of CR/DR on their longevity. Although some findings 
in worms, fruit flies and mammals support the involvement of the insulin/IGF-1 pathway 
in the longevity benefit associated with CR/DR, other data imply that such benefit is 
independent of insulin/IGF-1 (reviewed by Narasimhan et al. [36]). The role of 
cAMP/PKA signaling in the life-extending effect of CR/DR in these multicellular 
eukaryotes remains to be tested. Importantly, the recently reported in worms involvement 
of both independent and overlapping pathways in life span extension by different DR 
regimens [100] supports the notion that the longevity benefit associated with nutrient 
limitation is mediated by a signaling network that integrates several pathways.  
            Akin to CR and DR regimens, certain pharmacological interventions can extend 
longevity across phyla and improve health by beneficially influencing age-related 
pathologies. Noteworthy, all of the currently known anti-aging compounds increase life 
span under non-CR or non-DR conditions (see chapter 1 of my thesis for a detailed 
discussion of this topic). Under such conditions, these compounds have been shown to: 1) 
provide the longevity and health benefits associated with CR and DR, but without 
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restricting caloric and nutrient intake; and 2) mimic numerous life-extending effects of 
CR and DR on gene expression pattern, metabolic and physiological processes, and stress 
response pathways. Therefore, the names “CR mimetics” and “DR mimetics” have been 
coined for them [149, 150]. Importantly, most CR mimetics and DR mimetics target 
signaling pathways that modulate longevity in response to the organismal and 
intracellular nutrient and energy status, including the insulin/IGF-1 and AMPK/TOR 
pathways as well as the sirtuin-governed protein deacetylation module of the longevity 
signaling network integrating these pathways (see chapter 1 of my thesis for a detailed 
discussion of this topic). Furthermore, such compounds as resveratrol, metformin and 
mianserin increase life span only under non-CR or non-DR conditions, but are unable to 
do so if the supply of calories or nutrients is limited [107, 112, 119 - 121]. Hence, one 
could envision that most, if not all, longevity pathways are “adaptable” by nature, i.e., 
that they modulate longevity only in response to certain changes in the extracellular and 
intracellular nutrient and energy status of an organism. However, Li
+
 in worms and 
rapamycin in fruits flies extend life span even under DR conditions [103, 113]. It is likely 
therefore that some longevity pathways could be “constitutive” or “housekeeping” by 
nature, i.e., that they: 1) modulate longevity irrespective of the organismal and 
intracellular nutrient and energy status; and 2) do not overlap (or only partially overlap) 
with the adaptable longevity pathways that are under the stringent control of calorie 
and/or nutrient availability. The challenge is to identify such housekeeping longevity 
pathways, perhaps by using a chemical screen for compounds that can extend longevity 
even under CR/DR conditions. Because under such conditions the adaptable pro-aging 
pathways are fully suppressed and the adaptable anti-aging pathways are fully activated, 
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a compound that can increase life span is expected to target the housekeeping longevity 
pathways.  
            Noteworthy, two anti-aging compounds alter lipid levels in mammals and fruit 
flies under non-DR conditions. In fact, resveratrol treatment reduces the levels of the 
neutral lipids triacylglycerols (TAG) and increases free fatty acid (FFA) levels in mouse 
adipocytes [127]. Furthermore, feeding rapamycin to fruit flies results in elevated TAG 
levels [113]. Although it remains to be seen if such effects of resveratrol and rapamycin 
on lipid levels play a casual role in their anti-aging action under non-DR conditions, it 
should be stressed that lipid metabolism has been shown to be involved in longevity 
regulation in yeast [24, 246], worms [50, 74, 302, 303], fruit flies [302, 304] and mice 
[127, 302, 305 - 308]. Recently, our laboratory proposed a mechanism linking yeast 
longevity and lipid dynamics in the endoplasmic reticulum (ER), lipid bodies and 
peroxisomes. In this mechanism, a CR diet extends yeast CLS by activating FFA 
oxidation in peroxisomes [24, 246]. It is conceivable that the identification of small 
molecules targeting this mechanism could yield novel anti-aging compounds. Such 
compounds can be used as research tools for defining the roles for different longevity 
pathways in modulating lipid metabolism and in integrating lipid dynamics with other 
longevity-related processes. Furthermore, the availability of such compounds would 
enable a quest for housekeeping longevity assurance pathways that do not overlap (or 
only partially overlap) with the adaptable TOR and cAMP/PKA pathways. Moreover, 
such compounds would have a potential to be used as pharmaceutical agents for 
increasing life span and promoting healthy aging by delaying the onset of age-related 
diseases, regardless of an organism’s dietary regimen. 
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            I sought to identify small molecules that increase the CLS of yeast under CR 
conditions by targeting lipid metabolism and modulating housekeeping longevity 
assurance pathways. My chemical genetic screen identified lithocholic acid (LCA) as one 
of such small molecules. My analysis of how LCA influences various longevity-related 
processes and how it affects the CLS of yeast mutants impaired in the adaptable longevity 
pathways provided important new insights into mechanisms of longevity regulation, as 
outlined below. 
 
3.3 Materials and Methods 
Strains and media  
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT his31 leu20 lys20 
ura30) and mutant strains pex5 (MAT his31 leu20 lys20 ura30 
pex5::kanMX4), tor1 (MAT his31 leu20 lys20 ura30 tor1::kanMX4), ras2 
(MAT his31 leu20 lys20 ura30 ras2::kanMX4) and rim15 (MAT his31 
leu20 lys20 ura30 rim15::kanMX4) were used in this study. Media components 
were as
 
follows: 1) YEPD (0.2% Glucose), 1% yeast extract, 2% peptone, 0.2% glucose; 
2) YEPD (0.5% Glucose), 1% yeast extract, 2% peptone, 0.5% glucose; 3) YEPD (1% 
Glucose), 1% yeast extract, 2% peptone, 1% glucose; and 4) YEPD (2% Glucose), 1% 
yeast extract, 2% peptone, 2% glucose.  
 
A plating assay for the analysis of chronological life span 
Cells were grown in YEPD medium initially containing 0.2%, 0.5%, 1% or 2% glucose 
as carbon source at 30
o
C with rotational shaking at 200 rpm in Erlenmeyer flasks at a 
132 
 
flask volume/medium volume ratio of 5:1. A sample of cells was removed from each 
culture at various time points. A fraction of the cell sample was diluted in order to 
determine the total number of cells per ml of culture using a hemacytometer. 10 l of 
serial dilutions (1:10 to 1:10
3
) of cells were applied to the hemacytometer, where each 
large square is calibrated to hold 0.1 l. The number of cells in 4 large squares was then 
counted and an average was taken in order to ensure greater accuracy. The concentration 
of cells was calculated as follows: number of cells per large square x dilution factor × 10 
× 1,000 = total number of cells per ml of culture. A second fraction of the cell sample 




) of cells were plated onto YEPD (2% 
Glucose) plates in triplicate in order to count the number of viable cells per ml of each 
culture. 100 l of diluted culture was plated onto each plate. After a 48-h incubation at 
30
o
C, the number of colonies per plate was counted. The number of colony forming units 
(CFU) equals to the number of viable cells in a sample. Therefore, the number of viable 
cells was calculated as follows: number of colonies × dilution factor × 10 = number of 
viable cells per ml. For each culture assayed, % viability of the cells was calculated as 
follows: number of viable cells per ml / total number of cells per ml × 100%. The % 
viability of cells in mid-logarithmic phase was set at 100% viability for that particular 
culture. 
 
Plating assays for the analysis of resistance to various stresses 





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of plates. One 
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set of plates contained YEPD (2% Glucose) medium alone, whereas the other set 
contained YEPD (2% Glucose) medium supplemented with 5 mM hydrogen peroxide. 
Pictures were taken after a 3-day incubation at 30
o
C.   





wild-type and mutant cells removed from mid-logarithmic phase (day 1) and from 
diauxic phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of 
plates. One set of plates contained YEPD (2% Glucose) medium alone, whereas the other 
set contained YEPD (2% Glucose) medium supplemented with 2.5 mM of the 
superoxide/hydrogen peroxide-generating agent paraquat. Pictures were taken after a 3-
day incubation at 30
o
C.  





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of YEPD (2% 
Glucose) plates. One set of plates was incubated at 30
o
C. The other set of plates was 
initially incubated at 55
o
C for 30 min, and was then transferred to 30
o
C. Pictures were 
taken after a 3-day incubation at 30
o
C.  





type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of plates. One 
set of plates contained YEPD (2% Glucose) medium alone, whereas the other set 
contained YEPD (2% Glucose) medium supplemented with 0.5 M NaCl. Pictures were 










wild-type and mutant cells removed from mid-logarithmic phase (day 1) and from 
diauxic phase (days 2 and 3) in YEPD (0.2% Glucose) were spotted onto two sets of 
plates. One set of plates contained YEPD (2% Glucose) medium alone, whereas the other 
set contained YEPD (2% Glucose) medium supplemented with 1 M sorbitol. Pictures 




Chemical genetic screen for compounds that increase chronological life span (CLS) 
The screen was conducted at the High Throughput/Content Screening Facility at McGill 
University. The single-gene-deletion mutant strain pex5 (MAT his31 leu20 lys20 
ura30 pex5::kanMX4) from Open Biosystems was grown in YPA0.5D medium (1% 
yeast extract, 2% peptone, 50 µg/ml ampicillin, 0.5% glucose). 3-µl aliquots of the pex5 
culture recovered from mid-logarithmic phase at a cell titre of 2  107 cells/ml were 
aliquoted into 96-well master microplates using a Beckman Coulter high density Biomek 
FXII replica pinning robot. Each well of a master microplate contained 96 µl of 
YPA0.5D medium. 1 µl of a compound stock solution from a commercially available 
library (each compound at 5 mM in dimethylsulfoxide (DMSO)) was added to each well 
using a Beckman Coulter high density Biomek FXII replica pinning robot. Wells of a 
master microplate supplemented with 1% DMSO (1 µl of DMSO per a well containing 3 
µl of the pex5 culture and 96 µl of YPA0.5D medium) were used as negative controls. 
Each master plate was created in duplicate. The master microplates were sealed and 
incubated without shaking at 30
o
C in a moist chamber. At days 1, 7, 10 and 14 of the 
incubation of master microplates, a 3-µl aliquot of each culture was transferred into 
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individual wells of a new (replica) microplate containing 97 µl of YPA0.5D medium. 
Following incubation of sealed replica microplates in a moist chamber for 16 hours at 
30
o
C (to allow for growth of cells that were still viable), the optical density at 600 nm 
(OD600) of the culture in each well of the replica microplate was measured using a 
Molecular Devices Analyst HT plate reader. To calculate survival at each time point, the 
OD600 at a particular time point was divided by the OD600 at day 1. “Cherry-picking” of 
the identified “lead” compounds for possible “hits” was carried out as described above, 
with each lead compound being used at a final concentration of 5, 10, 25 or 50 µM and 
assessed in triplicate for validation. Commercially available structural analogs of hit 
compounds were identified using the web-based eMolecules searching engine. In total, 
approximately 19,000 representative compounds from the BIOMOL, Chembridge, 
Maybridge, MicroSource Discovery, NIH Clinical Collection, Prestwick Chemical Inc. 
and Sigma-LOPAC commercial libraries were tested using the screen for chemical 
modulators of longevity.   
 
Pharmacological manipulation of CLS 
CLS analysis was performed as described above in this section. The chenodeoxycholic 
(C9377), cholic (C1129), dehydrocholic (D3750), deoxycholic (D2510), hyodeoxycholic 
(H3878), lithocholic (L6250) and ursodeoxycholic (U5127) bile acids were from Sigma. 
Their stock solutions in DMSO were made on the day of adding each of these compounds 
to cell cultures. Compounds were added to growth medium at the indicated concentration 
immediately following cell inoculation. The final concentration of DMSO in yeast 
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cultures supplemented with a bile acid (and in the corresponding control cultures 
supplemented with drug vehicle) was 1% (v/v). 
 
Monitoring the formation of ROS  
Wild-type and mutant cells grown in YEPD (0.2% Glucose) were tested microscopically 
for the production of ROS by incubation with dihydrorhodamine 123 (DHR). In the cell, 
this nonfluorescent compound can be oxidized to the fluorescent chromophore rhodamine 
123 by ROS. Cells were also probed with a fluorescent counterstain Calcofluor White 
M2R (CW), which stains the yeast cell walls fluorescent blue. CW was added to each 
sample in order to label all cells for their proper visualization. DHR was stored in the 
dark at –20oC as 50 l aliquots of a 1 mg/ml solution in ethanol. CW was stored in the 
dark at –20oC as the 5 mM stock solution in anhydrous DMSO (dimethylsulfoxide). 
          The concurrent staining of cells with DHR and CW was carried out as follows. The 
required amounts of the 50 l DHR aliquots (1 mg/ml) and of the 5 mM stock solution of 
CW were taken out of the freezer and warmed to room temperature. The solutions of 
DHR and CW were then centrifuged at 21,000 × g for 5 min in order to clear them of any 
aggregates of fluorophores. For cell cultures with a titre of ~ 10
7
 cells/ml, 100 l was 
taken out of the culture to be treated. If the cell titre was lower, proportionally larger 
volumes were used. 6 l of the 1 mg/ml DHR and 1 l of the 5 mM CW solutions were 
added to each 100 l aliquot of culture. After a 2-h incubation in the dark at room 
temperature, the samples were centrifuged at 21,000 × g for 5 min. Pellets were 
resuspended in 10 l of PBS buffer (20 mM KH2PO4/KOH, pH 7.5, and 150 mM NaCl). 
Each sample was then supplemented with 5 l of mounting medium, added to a 
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microscope slide, covered with a coverslip, and sealed using nail polish. Once the slides 
were prepared, they were visualized under the Zeiss Axioplan fluorescence microscope 
mounted with a SPOT Insight 2 megapixel color mosaic digital camera. Several pictures 
of the cells on each slide were taken, with two pictures taken of each frame. One of the 
two pictures was of the cells seen through a rhodamine filter in order to detect cells dyed 
with DHR. The second picture was of the cells seen through a DAPI filter in order to 
visualize CW, and therefore all the cells present in the frame. 
          For evaluating the percentage of DHR-positive cells, the UTHSCSA Image Tool 
(Version 3.0) software was used to calculate both the total number of cells and the 
number of stained cells. Fluorescence of individual DHR-positive cells in arbitrary units 
was determined by using the UTHSCSA Image Tool software (Version 3.0). In each of 3-
5 independent experiments, the value of median fluorescence was calculated by analyzing 
at least 800-1000 cells that were collected at each time point. The median fluorescence 
values were plotted as a function of the number of days cells were cultured. 
          
Immunofluorescence microscopy 
Cell cultures were fixed in 3.7% formaldehyde for 45 min at room temperature. The cells 
were washed in solution B (100 mM KH2PO4/KOH pH 7.5, 1.2 M sorbitol), treated with 
Zymolyase 100T (MP Biomedicals, 1 μg Zymolyase 100T/1 mg cells) for 30 min at 30oC 
and then processed as previously described [249]. Monoclonal antibody raised against 
porin (Invitrogen, 0.25 μg/μl in TBSB buffer [20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 
mg/ml BSA]) was used as a primary antibody. Alexa Fluor 568 goat anti-mouse IgG 
(Invitrogen, 2 μg/μl in TBSB buffer) was used as a secondary antibody. The labeled 
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samples were mounted in mounting solution (16.7 mM Tris/HCl pH 9.0, 1.7 mg/ml p-
phenylenediamine, 83% glycerol). Images were collected with a Zeiss Axioplan 
fluorescence microscope (Zeiss) mounted with a SPOT Insight 2 megapixel color mosaic 
digital camera (Spot Diagnostic Instruments). 
  
Oxygen consumption assay 
The rate of oxygen consumption by yeast cells recovered at various time points was 
measured continuously in a 2-ml stirred chamber using a custom-designed biological 
oxygen monitor (Science Technical Center of Concordia University) equipped with a 
Clark-type oxygen electrode. 1 ml of YEPD medium supplemented with 0.2% glucose 
was added to the electrode for approximately 5 minutes to obtain a baseline. Cultured 
cells of a known titre were spun down at 3,000 × g for 5 minutes. The resulting pellet was 
resuspended in YEPD medium supplemented with 0.2% glucose and then added to the 
electrode with the medium that was used to obtain a baseline. The resulting slope was 






Measurement of mitochondrial mutations and nuclear mutations affecting 
mitochondrial components 









mutations in mitochondrial DNA (mtDNA) and spontaneous single-gene nuclear 
mutations (pet
-
) affecting essential mitochondrial components was evaluated by 
measuring the fraction of respiratory-competent (rho
+
) yeast cells remaining in their 
aging population. rho
+
 cells maintained intact their mtDNA and their nuclear genes 
139 
 
encoding essential mitochondrial components. Therefore, rho
+
 cells were able to grow on 
glycerol, a non-fermentable carbon source. In contrast, mutant cells deficient in 
mitochondrial respiration were unable to grow on glycerol. Most of these mutant cells 




 mutations or large 
deletions rho
-
) or completely lacked this DNA (rho
o
 mutants), whereas some of them 
carried so-called pet
-
 mutations in nuclear genes that code for essential mitochondrial 
components [250]. Serial dilutions of cell samples removed from different phases of 
growth were plated in duplicate onto YP plates containing either 2% glucose or 3% 
glycerol as carbon source. Plates were incubated at 30
o
C. The number of CFU on YP 
plates containing 2% glucose was counted after 2 d of incubation, whereas the number of 
CFU on YP plates containing 3% glycerol was counted after 6 d of incubation. For each 










) cells was 
calculated as follows: 100 - [(number of CFU per ml on YP plates containing 3% 
glycerol/number of CFU per ml on YP plates containing 2% glucose) × 100]. The 
frequency of spontaneous point mutations in the rib2 and rib3 loci of mtDNA was 
evaluated by measuring the frequency of mtDNA mutations that caused resistance to the 
antibiotic erythromycin [251]. These mutations impair only mtDNA [252, 253]. In each 
of the seven independent experiments performed, ten individual yeast cultures were 
grown in YP medium containing 0.2%, 0.5%, 1% or 2% glucose as carbon source. A 
sample of cells was removed from each culture at various time-points. Cells were plated 
in duplicate onto YP plates containing 3% glycerol and erythromycin (1 mg/ml). In 
addition, serial dilutions of each sample were plated in duplicate onto YP plates 





) cells. The number of CFU was counted after 6 d of incubation at 30
o
C. 
For each culture, the frequency of mutations that caused resistance to erythromycin was 
calculated as follows: number of CFU per ml on YP plates containing 3% glycerol and 
erythromycin/number of CFU per ml on YP plates containing 3% glycerol.  
 
Preparation of total cell lysates 
An aliquot containing 1 × 10
9 
cells was centrifuged for 7 min at 3,000 rpm at room 
temperature. Pelleted cells were washed twice with distilled water and further centrifuged 
for 3 min at 16,000 × g at room temperature. The recovered cell pellet was then 
resuspended in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and centrifuged 
for 15 sec at 16,000 × g at room temperature. The cells were then washed again, first by 
resuspending them in 500 μl of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and then 
by centrifuging for 15 sec at 16,000 × g at room temperature. The pellet of washed cells 
was then resuspended in 1 ml of ice-cold 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5), 
divided into 5 equal aliquots of 200 μl each and placed in Eppendorf tubes kept on ice. 
Each 200 μl aliquot was supplemented with ~100 μl of glass beads and vortexed three 
times for 1 minute. Apart from the vortexing steps, the samples were kept on ice at all 
times. Glass beads and cell debris were then pelleted by 5 min centrifugation at 16,000 × 
g at 4
o
C.  The resulting supernatant of the glass bead lysate was immediately transferred 
into a pre-chilled Eppendorf tube and stored at -20
o
C for further analysis. 
 
Isolation of the crude mitochondrial fraction 
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Yeast cells were pelleted at 3,000 × g for 5 min at room temperature, washed twice with 
distilled water, resuspended in DTT buffer (100 mM Tris-H2SO4, pH 9.4, 10 mM 
dithiothreitol [DTT]), and incubated for 20 min at 30
o
C to weaken the cell wall. The cells 
were then washed with Zymolyase buffer (1.2 M sorbitol, 20 mM potassium phosphate, 
pH 7.4), centrifuged at 3,000 × g for 5 min at room temperature, and incubated with 3 
mg/g (wet wt) of Zymolyase-100T in 7 ml/g (wet wt) Zymolyase buffer for 45 min at 
30°C.  Following an 8-min centrifugation at 2,200 × g at 4
o
C, the isolated spheroplasts 
were washed in ice-cold homogenization buffer (5 ml/g) (0.6 M sorbitol, 10 mM Tris-
HCl, pH7.4, 1 mM EDTA, 0.2% (w/v) BSA) and then centrifuged at 2,200 × g for 8 min 
at 4
o
C. Washed spheroplasts were homogenized in ice-cold homogenization buffer using 
15 strokes. The cell debris was removed by centrifuging the resulting homogenates at 
1,500 × g for 5 min at 4°C. The supernatant was further centrifuged at 3,000 × g for 5 
min at 4°C to remove residual cell debris. The resulting supernatant was then centrifuged 
at 12,000 × g for 15 min at 4°C to pellet mitochondria. The remnant cell debris was 
removed by centrifuging the mitochondrial fraction at 3,000 × g for 5 min at 4°C. The 
resulting supernatant was then centrifuged at 12,000 × g for 15 min at 4°C to obtain the 
crude mitochondrial pellet, which was then resuspended in 3 ml of SEM Buffer (250 mM 
sucrose, 1 mM EDTA, 10 mM MOPS, pH 7.2) and used for the purification of 
mitochondria as described below. 
 
Purification of mitochondria devoid of microsomal and cytosolic contaminations 
A sucrose gradient was made by carefully overlaying 1.5 ml of 60% sucrose with 4 ml of 
32% sucrose, 1.5 ml of 23% sucrose, and then 1.5 ml of 15% sucrose (all in EM buffer; 1 
142 
 
mM EDTA, 10 mM MOPS, pH 7.2). Finally, a 3-ml aliquot of the crude mitochondrial 
fraction in SEM buffer was applied to the gradient and centrifuged at 134,000 × g 
(33,000 rpm) overnight at 2°C in vacuum (Rotor SW50Ti, Beckman). The purified 
mitochondria found at the 60%/32% sucrose interface were carefully removed and stored 
at - 80°C. 
 
Purification of the ER 
Reagents and solutions 
1. TSD reduction buffer: 0.1 M Tris/Sulfate (pH 9.4), 10 mM DTT 
2. HEPES lysis buffer: 20 mM HEPES/KOH, pH 6.8, 50 mM KCl, 200 mM sorbitol, 2 
mM EDTA, 1 mM DTT 
3. Spheroplast medium A (pH 7.5): 0.67% yeast nitrogen base (w/o) amino acids, 2 % 
(w/v) glucose, 1 M sorbitol, 20 mM Tris/HCl (pH 7.5) 
4. Spheroplast medium B: 0.67% yeast nitrogen base (w/o) amino acids, 2 % (w/v) 
glucose, 1 M sorbitol 
5. 1.2 M sucrose/ HEPES, 36% (w/w): 7.2 g sucrose + 12.8 ml HEPES lysis buffer 
6. 1.5 M sucrose/ HEPES, 43% (w/w): 8.6 g sucrose + 11.4 ml HEPES lysis buffer 
7. MES buffer 1 (MES breaking buffer): 10 mM MES/Tris (pH 6.9), 12 % (w/w) Ficoll 
400, 0.2 mM EDTA 
8. MES buffer 2: 10 mM MES/Tris (pH 6.9), 8 % (w/w) Ficoll 400, 0.2 mM EDTA 
9. MES buffer 3: 10 mM MES/Tris (pH 6.9), 0.6 M sorbitol, 8 % (w/w) Ficoll 400, 0.2 
mM EDTA 
10. MES buffer 4: 10 mM MES/Tris (pH 6.9), 0.25 M sorbitol, 0.2 mM EDTA 
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11. KPi buffer (pH 7.4): 20 mM KH2PO4/KOH (pH 7.4), 1.2 M sorbitol 
 
Procedure 
Wild-type and mutant cells were grown in YEPD medium initially containing 0.2%, 
0.5%, 1% or 2% glucose as carbon source. Cultures were harvested at mid-exponential 
and diauxic phases, checked for contamination by bright-field microscopy and used to 
measure cell density at OD600. The non-contaminated wild-type and mutant cells were 
pelleted at 4,000 × g for 5 min at room temperature. Cells were then resuspended at 10 
OD600 units/ml in TSD reduction buffer, incubated for 10 min at room temperature and 
centrifuged for 5 min at 4,000 × g at room temperature. Pelleted cells were then 
resuspended at 20 OD600 units/ml in Spheroplast medium A and supplemented with 
Zymolyase 100T at a concentration of 7.5 μg per OD600 units of cells. 10 μl of each cell 
suspension was then removed, diluted in 990 μl of H2O and used to measure the OD600. 
The remaining cell suspensions were incubated at 30°C for 30 min and the efficiency of 
cell wall removal was monitored by measuring the OD600. Cell wall digestion was 
allowed to proceed until the OD600 measurement of the diluted cell suspension became 
5% of the original value, with the total digestion time not exceeding 1 hour. Spheroplasts 
were then harvested by centrifugation at 1,500 × g for 5 min at room temperature, 
followed by resuspending at 1 to 5 OD600 units/ml in Spheroplast medium B by gentle 
swirling of the tube or gentle stirring with a glass rod. Spheroplasts were then harvested 
by centrifugation at 1,500 × g for 5 min at 4°C and then resuspended at a concentration of 
1,000 OD600 units/ml of ice-cold HEPES lysis buffer with freshly-added DTT. 
Spheroplasts were then homogenized using 20 strokes and resulting lysates were 
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centrifuged at 1, 000 × g for 10 min at 4°C. The supernatants (S1000) were subjected to 
another round of centrifugation at 1, 000 × g for 10 min at 4°C, and resulting 
supernatants were further centrifuged at 27,000 × g for 10 min at 4°C. The pelleted 
membranes (P27,000) were resuspended in 1.0 ml of HEPES lysis buffer (5,000 OD600 
equivalents per ml) using a trimmed 1-ml pipette tip and carefully layered on top of a 
sucrose gradient prepared in advance (2.1 ml of 1.5 M sucrose/HEPES solution was 
deposited to the bottom of a Beckman Ultra-Clear centrifuge tube for the Beckman MLS-
50 rotor, and then overlaid with 2.1 ml of 1.2 M sucrose/HEPES solution). The gradient 
tubes were then placed in the pre-chilled swinging bucket Beckman MLS-50 rotor and 
centrifuged at 100,000 × g (36,000 rpm) for 1 hr at 4°C using the slow acceleration and 
deceleration setting to minimize disruption of gradients. 18 gradient fractions of 227 μl 
each were then collected starting from the top of the sucrose gradient and stored at -20°C 
for further analyses.  
 
Protein precipitation, SDS-PAGE and silver staining of gels 
Protein concentration was determined using the RC DC protein assay kit (Bio-Rad) 
according to the manufacturer's instructions. Proteins were precipitated by adding 
trichloroacetic acid (TCA) to the final concentration of 10%, incubated on ice for 30 min, 
pelleted by centrifugation, and then washed with ice-cold 80% acetone. Dried protein 
pellets were then resuspended in the SDS-PAGE sample buffer and the pH was adjusted 
to neutral using 2 M Tris/HCl (pH 8.8). The samples were boiled for 5 min at 63°C, 
centrifuged for 30 sec at 16,000 x g, loaded onto a 7.5%, 10%, 12.5% or 16% gel and 
resolved by SDS-PAGE. Following an overnight incubation of the gels in 50% methanol, 
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proteins were visualized by silver staining using the mass spectrometry-compatible silver 
staining kit (Bio-Rad Silver Staining Plus) according to the manufacturer’s instructions. 
The Bio-Rad unstained molecular marker and a 0.1 mg/ml solution of BSA in the SDS-
PAGE sample buffer were also subjected to SDS-PAGE. The proteins were then 
visualized by silver staining.  
 
Analysis of proteins by mass spectrometry 
Proteins were resolved by SDS-PAGE and visualized by silver staining [254]. Protein 
bands were excised from the gel, reduced, alkylated and in-gel digested with trypsin 
[254]. The proteins were identified by matrix-assisted laser desorption/ionization mass 
spectrometric (MALDI MS) peptide mapping [255], using a Micromass M@LDI time-of-
flight (TOF) mass spectrometer (Waters). Database searching using peptide masses was 
performed with the Mascot web-based search engine. For evaluating relative levels of 
individual proteins recovered in total cell lysates or purified mitochondria, a selected 
protein band was excised from the silver-stained gel and placed into an Eppendorf tube. 
A band of BSA containing 2 μg of this protein, which was also excised from the silver-
stained gel, was added to each of the protein bands to be analyzed. Protein bands were 
reduced, alkylated and in-gel digested with trypsin [254]. The desalted peptide mixture 
was added to the surface of a MALDI target plate and allowed to air dry. The sample spot 
was then overlaid with MALDI matrix solution containing the Angiotensin I peptide 
standard (1:1 ratio). The presence of Angiotensin I in the sample carrying the analyzed 
mixture of peptides provided an additional estimate of the mass measurement accuracy 
after calibration, giving an opportunity to calculate the value of peptide mass tolerance 
146 
 
for each individual mass spectrum. After the desalted peptide mixture was analyzed by 
MALDI-TOF, the monoisotopic masses of recovered BSA peptides and the intensities of 
their monoisotopic peaks were grouped separately from the masses and intensities of 
peptides originated from the protein of interest. These data provided an additional 
estimate of the mass measurement accuracy and were used for the quantitation of relative 
levels of the same protein recovered in different samples. For evaluating relative levels of 
the protein of interest found in the samples to be compared, a ratio “the intensity of the 
monoisotopic peak of a peptide originated from the protein of interest/the intensity of the 
monoisotopic peak of a BSA peptide with the monoisotopic mass closest to the mass of 
the peptide of interest” was calculated for each peptide originated from the protein of 
interest. Based on these data, the average value for relative levels of the protein of 
interest found in the two compared samples was calculated. The method for evaluating 
relative levels of the protein of interest recovered in different samples was validated by 
calculating relative levels of several standard proteins in the samples supplemented with 




3.4.1 My rationale for choosing a mutant strain and growth conditions to screen 
compound libraries for anti-aging small molecules 
            To perform a chemical genetic screen for small molecules that increase the CLS 
of yeast by targeting lipid metabolism, I chose the single-gene-deletion mutant strain 
pex5. Because pex5 lacks a cytosolic shuttling receptor for peroxisomal import of 
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Fox1p and Fox2p, these two enzymes of the β-oxidation of FFA reside in the cytosol of 
pex5 cells [309] (Figure 3.1A). In contrast, the Pex5p-independent peroxisomal import 
of Fox3p, the third enzyme of the FFA β-oxidation pathway, sorts it to the peroxisome in 
pex5 cells [309]. By spatially separating Fox1p and Fox2p from Fox3p within a cell, the 
pex5 mutation impairs FFA oxidation (Figure 3.1A). In chronologically aging yeast 
grown under CR conditions on 0.2% or 0.5% glucose, peroxisomal FFA oxidation 
regulates longevity by 1) efficiently generating acetyl-CoA to synthesize the bulk of ATP 
in mitochondria; and 2) acting as a rheostat that modulates the age-related dynamics of 
FFA and diacylglycerol (DAG), two regulatory lipids known to promote longevity-
defining cell death [24, 246, 278, 310]. Unlike CR yeast, chronologically aging non-CR 
yeast grown on 1% or 2% glucose are unable to generate significant quantities of ATP by 
oxidizing peroxisome-derived acetyl-CoA in mitochondria and, instead, produce the bulk 
of ATP via glycolytic oxidation of glycogen- and trehalose-derived glucose [24, 246, 
278]. Consistent with the essential role of peroxisomal FFA oxidation as a longevity 
assurance process only under CR, the pex5 mutation substantially shortened the CLS of 
CR yeast but caused a significantly lower reduction of longevity in non-CR yeast, 
especially in yeast grown on 2% glucose (Figures 3.1B - 3.1F). 
            In chronologically aging CR yeast, peroxisomal FFA oxidation modulates, 
perhaps via several negative feedback loops, the following three processes: 1) the ER-
confined biosynthesis of TAG from FFA and DAG; 2) the subsequent deposition of 
TAG, the major neutral lipid reserves, in lipid bodies; and 3) the consequent lipolysis of 
deposited TAG and the resulting formation of FFA and DAG [24, 246, 278]. By 



































































































































































































































































Figure 3.1. The pex5Δ mutation shortens chronological life span (CLS). (A) Outline of subcellular 
localization of the Fox1p, Fox2p and Fox3p enzymes of fatty acid ß-oxidation in WT and pex5Δ cells. (B - 
F) Survival and the mean life spans of chronologically aging WT and pex5Δ yeast cultured in medium 
initially containing 0.2%, 0.5%, 1% or 2% glucose. Data are presented as means ± SEM (n = 16-38; ***p < 
0.001; **p < 0.01). Abbreviations: Cta1p, peroxisomal catalase; D, diauxic growth phase; FA-CoA, CoA 
esters of fatty acids; L, logarithmic growth phase; PD, post-diauxic growth phase; ST, stationary growth 
phase.  
 
cellular aging by modulating the age-related dynamics of FFA, DAG and TAG in the ER 
and lipid bodies, the pex5 mutation has been found to cause the accumulation of the 
closely apposed ER membranes and ER-originated lipid bodies in CR yeast [24]. 
Noteworthy, these morphological features of pex5 yeast under CR were similar to those 
observed in a mouse model for the peroxisome biogenesis disorder Zellweger syndrome 
with hepatocyte-specific elimination of the PEX5 gene [311]. Furthermore, it has been 
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demonstrated that the pex5 mutation 1) increases the concentrations of FFA, DAG and 
TAG in CR yeast, promoting their build-up in the ER and lipid bodies; and 2) causes the 
accumulation of the ER-derived and lipid bodies-deposited ergosteryl esters (EE), neutral 
lipid species [24]. Moreover, a brief exposure of WT cells grown under CR conditions to 
exogenous FFA or DAG has been shown to cause their necrotic, not apoptotic, death 
[24]. Importantly, it has been also demonstrated that the pex5 mutation enhances the 
susceptibility of CR yeast to necrotic death caused by a short-term exposure to exogenous 
FFA or DAG, perhaps due to the increased concentrations of endogenous FFA and DAG 
seen in pex5 cells under CR [24].  
            As I found, in addition to such profound effect of the pex5 mutation on lipid 
metabolism and lipid-induced necrotic cell death, this mutation also altered mitochondrial 
morphology and oxidation-reduction processes in mitochondria of CR yeast. In fact, this 
mutation caused the fragmentation of a tubular mitochondrial network into individual 
mitochondria under CR conditions (Figures 3.2A and 3.2B). Furthermore, in CR yeast the 
pex5 mutation 1) greatly reduced the rate of oxygen consumption by mitochondria 
(Figure 3.2C); 2) substantially decreased the mitochondrial membrane potential (Figure 
3.2D); and 3) diminished the level of intracellular ROS (Figure 3.2E), known to be 
generated mostly as by-products of mitochondrial respiration [75, 276]. Interestingly, all 
these mitochondrial abnormalities in pex5 yeast under CR were reminiscent of changes 
in mitochondrial morphology and functions seen in mice with hepatocyte-specific 
elimination of the PEX5 gene, a model for the peroxisome biogenesis disorder Zellweger 
syndrome [311]. 




Figure 3.2. The pex5Δ mutation alters mitochondrial morphology and functions in CR yeast. (A) 
Morphology of mitochondria in WT and pex5Δ cells. Mitochondria were visualized by indirect 
immunofluorescence microscopy using monoclonal anti-porin primary antibodies and Alexa Fluor 568-
conjugated goat anti-mouse IgG secondary antibodies. (B) Percent of WT and pex5Δ cells exhibiting a 
tubular mitochondrial network or fragmented mitochondria. (C - E) Oxygen consumption (C) by WT and 
pex5Δ cells, their mitochondrial membrane potential ΔΨ (D) and their ROS levels (E). ΔΨ and ROS were 
visualized in living cells by fluorescence microscopy using fluorescent dyes Rhodamine 123 or 
Dihydrorhodamine 123, respectively. CR yeast grown on 0.2% glucose were taken for analyses at the 
indicated time-points. Data in B - E are presented as means ± SEM (n = 4-15; ***p < 0.001; **p < 0.01; *p 
< 0.05).  Abbreviation: D, diauxic growth phase.  
 
mitochondrial morphology and functions, the pex5 mutation also 1) reduced the 
resistance of chronologically aging CR yeast to chronic oxidative, thermal and osmotic 




Figure 3.3. The pex5Δ mutation reduces the resistance of CR yeast to stresses, sensitizes them to 
exogenously induced apoptosis and elevates the frequencies of mutations in their mitochondrial and nuclear 
DNA. (A) The resistance of WT and pex5Δ to chronic oxidative, thermal and osmotic stresses. (B) 
Viability of WT and pex5Δ cells treated for 1 h with hydrogen peroxide or acetic acid (AcOH) to induce 
mitochondria-controlled apoptosis. (C - E) The frequencies of rho- and rho0 deletion mutations in 
mitochondrial DNA (C), rib2 and rib3 point mutations in mitochondrial DNA (D), and of can1 point 
mutations in nuclear DNA (E) of WT and pex5Δ cells. CR yeast grown on 0.2% glucose were taken for 
analyses at the indicated time-points. Data in B to E are presented as means ± SEM (n = 6-9; ***p < 0.001; 
**p < 0.01; *p < 0.05). Abbreviations: AcOH, acetic acid; D, diauxic growth phase; L, logarithmic growth 
phase; PD, post-diauxic growth phase.  
 
short-term exposure to exogenous hydrogen peroxide or acetic acid (Figure 3.3B) and 
that is known to be caused by mitochondria-controlled apoptosis [312, 313]; and 3) 
elevated the frequencies of deletion and point mutations in mitochondrial and nuclear 
DNA of CR yeast (Figures 3.3C to 3.3E). 




Figure 3.4. The pex5Δ mutation alters the abundance of many proteins recovered in total cell lysates, 
purified ER and mitochondria of CR yeast. (A) The spectra of proteins recovered in total cell lysates, 
purified ER and mitochondria of WT and pex5Δ cells that were grown under CR on 0.2% glucose and 
taken for analyses at the indicated time-points. (B) Functional categories of proteins that were enriched or 
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depleted in the total cell lysate, ER and mitochondria of pex5Δ cells (as compared to WT cells) under CR 
conditions. Lack of 91 of these proteins increased the CLS of yeast under CR, suggesting their essential 
pro-aging role in longevity regulation when calorie supply is limited.  
 
As I found, the profound changes in cell morphology and physiology, stress resistance, 
susceptibility to lipid-induced necrosis and mitochondria-controlled apoptosis, and 
stability of nuclear and mitochondrial DNA seen in pex5 yeast under CR conditions (see 
above) coincided with considerable changes in their proteome. Indeed, my mass 
spectrometry-based quantitative proteomic analysis of proteins recovered in total cell 
lysates as well as in purified ER and mitochondria revealed that the pex5 mutation 
altered the abundance of many proteins (Figure 3.4A). Protein species that were depleted 
or enriched in the total cell lysate, ER and mitochondria of pex5 yeast grown under CR 
conditions included proteins involved in a number of cellular processes (Figure 3.4B). 
Importantly, my unpublished data and unpublished findings of Pavlo Kyryakov, Simon 
Bourque, Adam Beach, Michelle Tali Burstein and Vincent Richard (all are graduate 
students in Dr. Titorenko’s laboratory) revealed that lack of 91 of these proteins increased 
the CLS of yeast under CR (Figure 3.4B), suggesting their essential pro-aging role in 
longevity regulation when calorie supply is limited. Noteworthy, the above graduate 
students and I together found that 58 of the genes encoding these proteins and termed 
gerontogenes (i.e., the genes whose mutant alleles extend life span; [79]) have not been 
previously known as being critical for defining the CLS of yeast. The identities of protein 
species that were depleted or enriched in pex5 yeast grown under CR conditions, the 
extent to which their levels were altered and the names of gerontogenes identified in our 
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Figure 3.5. For many proteins, the fold increase or decrease in the level of a protein enriched or depleted in 
pex5Δ yeast under CR correlates with the fold increase or decrease (respectively) in the mean CLS of a 
mutant strain lacking it. Plots comparing the fold increase or decrease in the levels of proteins enriched or 
depleted in pex5Δ yeast when calorie supply is limited and the fold increase or decrease (respectively) in 
the mean CLS of the single-gene-deletion mutant strains that lack these proteins and grow under CR. Each 
point shows the data for a single protein and a mutant strain that lacks it. Data are presented only for 
proteins whose levels were increased or decreased by more than 50% in pex5Δ cells (as compared to WT 




preparation). Importantly, for most of these proteins (with some exceptions, see Figures 
3.5C and 3.5D) the fold increase or decrease in the level of a protein enriched or depleted 
in pex5 was found to be in good correlation with the fold increase or decrease 
(respectively) in the mean CLS of a mutant strain lacking it (Figures 3.5A and 3.5B). 
            Altogether, these findings imply that, by impairing peroxisomal FFA oxidation 
and affecting lipid metabolism in the ER and lipid bodies, the pex5 mutation alters the 
levels of numerous pro- and anti-aging proteins and impacts many longevity-related 
processes, thereby shortening the CLS of yeast when calorie supply is limited. I therefore 
chose the short-lived pex5 strain to carry out a chemical genetic screen for anti-aging 
compounds that target lipid metabolism to extend CLS in yeast placed on a CR diet. 
 
3.4.2 A chemical genetic screen for small molecules that extend the CLS of yeast 
under CR conditions 
            To facilitate a high-throughput screen of compound libraries for anti-aging small 
molecules, I adopted a previously described microplate assay [110] for measuring CLS 
by monitoring optical density at 600 nm (OD600) (Figure 3.6A). In the microplate assay 
that I developed, a small aliquot of the pex5 culture grown in a nutrient-rich medium 
containing 0.5% glucose and recovered from mid-logarithmic phase was transferred into 
each well of a 96-well master microplate containing the same growth medium and a 
compound from a commercially available library. At days 1, 7, 10 and 14 of the 
incubation of master microplates, a small aliquot of each culture was transferred into 
individual wells of a new (replica) microplate containing growth medium only. Following 
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Figure 3.6. A high-throughput screen of compound libraries for small molecules that extend the CLS of 
yeast under CR conditions. (A) A microplate assay for measuring yeast CLS by monitoring optical density 
at 600 nm (OD600) was used for screening representative compounds from several commercial libraries for 
small molecules that extend the CLS of pex5Δ cells grown under CR on 0.5% glucose. (B) The OD600 of a 
cell culture in the replica microplate following incubation for 16 to 24 hours correlates with the number of 
viable cells present in this culture before it was taken from the master microplate for replica plating. (C) 
The effect of various concentrations of the identified anti-aging small molecules on the CLS of the pex5Δ 
(Δ) strain under CR conditions. The “OD600 at day 14/OD600 at day 1” ratio was used as a measure of CLS. 
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Data are presented as means ± SEM (n = 3-5; ***p < 0.001; **p < 0.01; *p < 0.05). The anti-aging small 
molecules LCA, AS, BT, NF and ID belong to five chemical groups. 
 
replica microplate was measured. Importantly, I found that under such conditions the 
OD600 of a cell culture in a well of the replica microplate correlates with the number of 
viable cells in the corresponding well of the master microplate (Figure 3.6B). To 
calculate survival at each time point, the OD600 at a particular time point was divided by 
the OD600 at day 1. By translating my microplate assay into high-throughput format and 
screening representative compounds from the NIH Clinical Collection, Prestwick 
Chemical Inc. and Sigma-LOPAC commercial libraries, I identified “lead” compounds. 
The subsequent “cherry-picking” analysis of these small molecules revealed “hit” 
compounds that in my microplate assay reproducibly extended the CLS of pex5. Using 
the web-based eMolecules searching engine, I identified commercially available 
structural analogs of the hit compounds and then tested their life-extending efficacy in the 
microplate assay that I developed for measuring the CLS of pex5. By screening the total 
of approximately 19,000 representative compounds from seven commercial libraries, I 
identified 24 small molecules that greatly extend the CLS of pex5 under CR and belong 
to 5 chemical groups (Figure 3.6C). Group I consisted of 6 bile acids, including 
lithocholic acid (LCA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), cholic 
acid (CA), dehydrocholic acid (DHCA) and hyodeoxycholic acid (HDCA) (Figures 3.6C 
and 3.7). Noteworthy, I found that the anti-aging efficacy of these bile acids correlated 
with their hydrophobicity. In fact, LCA - the most hydrophobic bile acid species [314] - 
displayed the highest ability to delay chronological aging of pex5 under CR conditions 
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Figure 3.7. The life-extending potential of a bile acid correlates with its hydrophobicity. In the microplate 
assay, lithocholic acid (LCA) - the most hydrophobic bile acid species - displays the greatest ability to 
extend the CLS of the short-lived pex5Δ mutant strain under CR conditions. The effect of various 
concentrations of different bile acids on the CLS of the short-lived pex5Δ mutant strain grown under CR on 
0.5% glucose is shown. The “OD600 at day 14/OD600 at day 1” ratio was used as a measure of CLS. Data 




groups II to V (Figure 3.6C) of the anti-aging compounds identified in the high-
throughput screen and the structure-activity analysis of their life-extending potential will 
be reported elsewhere (Richard et al., manuscript in preparation). 
            Noteworthy, I found that none of the small molecules that has been previously 
shown to extend CLS (i.e., caffeine, methionine sulfoximine, rapamycin and spermidine; 
see chapter 1 of my thesis for a detailed discussion of this topic [101, 110, 134]) and/or 
RLS (i.e., rapamycin and resveratrol; see chapter 1 of my thesis for a detailed discussion 
of this topic; [56, 119]) in yeast has been identified in my screen for compounds capable 
of increasing the CLS of pex5 under CR. Furthermore, none of these currently known 
life-extending molecules is structurally related to the anti-aging compounds that I 
revealed. Thus, it is likely that LCA and all other novel anti-aging compounds identified 
in my screen target longevity-related cellular processes that are not modulated by the 
presently known anti-aging small molecules. 
 
3.4.3 Pharmacophore modeling of the anti-aging potential of bile acids 
            Similar to their effect on pex5, some of the group I anti-aging compounds 
extended the CLS of WT strain under CR conditions. Specifically, I found that LCA and 
two other bile acids - DCA and CDCA - increased both the mean and maximum CLS of 
WT yeast grown under CR on 0.2% glucose (Figures 3.8A to 3.8D). Moreover, DHCA 
increased only the mean CLS of WT yeast under CR at 0.2% glucose, whereas HDCA 
increased only their maximum CLS (Figures 3.8A to 3.8D). Akin to its highest life-
extending efficacy in pex5 under CR, the most hydrophobic bile acid - LCA [314] - 
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Figure 3.8. LCA and some other bile acids extend the CLS of WT strain under CR conditions. (A - D) 
Effect of various bile acids on survival (A) and on the mean and maximum life spans (B - D) of 
chronologically aging WT strain grown under CR conditions on 0.2% glucose. Data are presented as means 
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± SEM (n = 3-28; ***p < 0.001; **p < 0.01; *p < 0.05). (E) Structure and hydrophilic/hydrophobic 
properties of bile acids. The R1 (α), R3 (α) and R5 (α) hydroxyl groups at the positions 6, 7 and 12 in the 
six-member rings B and C of the steroid nucleus increase polarity of the hydrophilic (concave) side [α-face] 
of the nucleus by being located below the nucleus and axially to its plane. The R4 (β) hydroxyl group at the 
position 7 in the six-member ring B of the steroid nucleus confers polarity of the hydrophobic (convex) side 
[β-face] of the nucleus by being located above the nucleus and equatorially to its plane.  
 
fact, I found that LCA increased the mean CLS of WT strain under CR at 0.2% glucose 
by almost 250% and its maximum CLS by more than 200% (Figures 3.8A - 3.8D). My 
comparative analysis of the structural differences between various bile acids and their 
relative life-extending efficacies revealed that the positions 6, 7 and 12 in the six-member 
rings B and C of the steroid nucleus are important for the anti-aging potential of a bile 
acid. Indeed, the ability of LCA to extend both the mean and maximum CLS of WT yeast 
under CR can be: 1) eliminated (with respect to the mean CLS) or greatly reduced (with 
respect to the maximum CLS) by attaching an α-oriented hydroxyl group at the position 6 
(as in HDCA); 2) greatly reduced (with respect to both the mean and maximum CLS) by 
attaching an α-oriented hydroxyl group at the position 7 (as in CDCA); and 3) greatly 
reduced (with respect to both the mean and maximum CLS) by attaching an α-oriented 
hydroxyl group at the position 12 (as in DCA) (Figures 3.8B to 3.8E). All these 
modifications to the structure of LCA increase polarity of the hydrophilic (concave) side 
[α-face] of the steroid nucleus by positioning a hydroxyl group below the nucleus and 
axially to its plane (Figure 3.8E). Furthermore, the anti-aging potential of LCA can be 
abolished by attaching a β-oriented hydroxyl group at the position 7 (as in UDCA), 
thereby conferring polarity to the hydrophobic (convex) side [β-face] of the steroid 
nucleus by positioning a hydroxyl group above the nucleus and equatorially to its plane 
(Figures 3.8B to 3.8E). Moreover, the simultaneous attachments of two α-oriented 
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hydroxyl groups (as in CA) or two keto groups (as in DHCA) at the positions 7 and 12 
eliminated the ability of LCA to extend both the mean and maximum CLS of WT yeast 
under CR (Figures 3.8B to 3.8E).  
            Altogether, the results of my pharmacophore modeling of the anti-aging potential 
of bile acids imply that the maintenance of the minimal polarity of both the hydrophilic 
(concave) and hydrophobic (convex) sides of the steroid nucleus - by avoiding the 
presence of polar substituents at the positions 6, 7 and 12 - is mandatory for the extreme 
life-extending efficacy of LCA under CR conditions. Such stringent structural 
requirements are consistent with a target specificity of LCA action as an anti-aging small 
molecule.  
 
3.4.4 LCA extends the CLS of WT yeast under both CR and non-CR conditions, 
although to a different extent 
            I found that, if added to growth medium at the time of cell inoculation, LCA 
increased both the mean and maximum CLS of WT strain not only under CR at 0.2% or 
0.5% glucose (Figures 3.9A, 3.9B and 3.9G – 3.9I) but also under non-CR conditions 
administered by culturing yeast in medium initially containing 1% or 2% glucose 
(Figures 3.9C, 3.9D and 3.9G - 3.9I). At any tested concentration of glucose in growth 
medium, LCA displayed the greatest beneficial effect on both the mean and maximum 
CLS of WT strain if used at a final concentration of 50 μM (Figures 3.9E and 3.9F). It 
should be stressed that the life-extending efficacy of 50 μM LCA under CR exceeded that 
under non-CR conditions, being inversely proportional to the concentration of glucose in 
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Figure 3.9. In chronologically aging WT yeast, the life-extending efficacy of LCA under CR exceeds that 
under non-CR conditions. (A - F) Effect of various concentrations of LCA on survival (A - D) and on the 
fold increase in the mean (E) or maximum (F) life span of chronologically aging WT strain cultured in 
medium initially containing 0.2%, 0.5%, 1% or 2% glucose. Data are presented as means ± SEM (n = 3-
28). (G - I) Effect of 50 μM LCA on the mean or maximum CLS of WT yeast cultured in medium initially 
containing 0.2%, 0.5%, 1% or 2% glucose. Data are presented as means ± SEM (n = 12-28; ***p < 0.001).  
164 
 
(Figures 3.9G to 3.9I). Importantly, although 50 μM LCA displayed a profound effect on 
CLS, it did not cause significant changes in growth of WT strain at any tested 
concentration of glucose in medium. In fact, I found that both growth rate in logarithmic 
phase and time prior to entry into stationary (ST) phase were similar for WT cells 












































































































































































































































































































































































































Figure 3.10. LCA does not cause significant changes in growth pattern of wild-type (WT) strain at any 
tested concentration of glucose in medium. Kinetics of growth for WT strain in medium initially containing 
0.2%, 0.5%, 1.0% or 2.0% glucose in the presence of LCA (50 μM ) or in its presence. Each plot shows a 
representative experiment repeated 4-7 times in triplicate with similar results. Abbreviations: D, diauxic 
growth phase; L, logarithmic growth phase; PD, post-diauxic growth phase; ST, stationary growth phase. 
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3.4.5 LCA extends the CLS of WT yeast under CR by modulating several 
longevity-related processes  
            My chemical genetic screen identified LCA as a compound that under CR 
conditions extends the CLS of pex5, a prematurely aging mutant strain displaying 
profound changes in lipid metabolism, lipid-induced necrotic cell death, mitochondrial 
morphology and functions, stress resistance, mitochondria-controlled apoptosis, and 
stability of nuclear and mitochondrial DNA (see sections 3.4.1 and 3.4.2 of my thesis). I 
found that LCA also greatly increases the mean and maximum CLS of WT yeast limited 
in calorie supply (see sections 3.4.3 and 3.4.4 of my thesis). This finding prompted me 
and other graduate students in Dr. Titorenko’s laboratory to investigate how the exposure 
of WT cells to LCA under CR conditions influences a compendium of longevity-related 
processes impaired in pex5.        
            As Simon Bourque (a graduate student in Dr. Titorenko’s laboratory) has shown, 
in chronologically aging WT yeast that reached reproductive maturation by entering into 
ST phase under CR conditions on 0.2% glucose, LCA 1) elevated the concentration of 
TAG; 2) substantially reduced the intracellular levels of FFA and DAG; and 3) greatly 
reduced the susceptibility of these yeast cells to necrotic cell death that was caused by a 
short-term exposure to exogenous FFA or DAG [24, 246]. 
            I found that the exposure of reproductively mature WT cells to LCA under CR 
conditions also influenced other longevity-related processes impaired in pex5, including 
those confined to mitochondria. Indeed, in WT cells that entered the non-proliferative ST 
phase under CR at 0.2% glucose, LCA 1) attenuated the fragmentation of a tubular 




Figure 3.11. In reproductively mature WT yeast that entered the non-proliferative stationary (ST) phase 
under CR, LCA modulates mitochondrial morphology and functions, enhances stress resistance, attenuates 
mitochondria-controlled apoptosis, and increases stability of nuclear and mitochondrial DNA. (A) Percent 
of WT cells grown in medium with or without LCA and exhibiting a tubular mitochondrial network or 
fragmented mitochondria. Mitochondria were visualized by indirect immunofluorescence microscopy using 
monoclonal anti-porin primary antibodies and Alexa Fluor 568-conjugated goat anti-mouse IgG secondary 
antibodies. (B - D) Oxygen consumption by WT cells grown in medium with or without LCA (B), their 
mitochondrial membrane potential ΔΨ (C) and their ROS levels (D). ΔΨ and ROS were visualized in living 
cells by fluorescence microscopy using fluorescent dyes Rhodamine 123 or Dihydrorhodamine 123, 
167 
 
respectively. (E) The resistance of WT cells pre-grown in medium with or without LCA to chronic 
oxidative, thermal and osmotic stresses. (F) Viability of WT cells pre-grown in medium with or without 
LCA and then treated for 1 h with hydrogen peroxide or acetic acid (AcOH) to induce mitochondria-
controlled apoptosis. (G - I) The frequencies of rho- and rho0 mutations in mitochondrial DNA (G), rib2 
and rib3 mutations in mitochondrial DNA (H), and of can1 (Canr) mutations in nuclear DNA (I) of WT 
cells grown in medium with or without LCA. Data in A - D and F - I are presented as means ± SEM (n = 4-
17; ***p < 0.001; **p < 0.01). WT cells grown on 0.2% glucose in the presence or absence of LCA were 
taken for analyses at day 7, when they reached reproductive maturation by entering into ST phase. 
 
of oxygen consumption by mitochondria (Figure 3.11B); 3) reduced the mitochondrial 
membrane potential (Figure 3.11C); and 4) decreased the level of intracellular ROS 
(Figure 3.11D) known to be generated mainly in mitochondria [276, 277]. 
            Moreover, I also demonstrated that in WT yeast that under CR conditions on 
0.2% glucose reached reproductive maturation by entering into ST phase, LCA 1) 
enhanced cell resistance to chronic oxidative and thermal (but not to osmotic) stresses 
(Figure 3.11E); 2) reduced cell susceptibility to death triggered by a short-term exposure 
to exogenous hydrogen peroxide or acetic acid (Figure 3.11F) known to be caused by 
mitochondria-controlled apoptosis [294, 312]; and 3) decreased the frequencies of 
deletions and point mutations in mitochondrial and nuclear DNA (Figures 3.11G to 
3.11I). 
 
3.4.6 LCA extends yeast CLS independent of TOR, by modulating housekeeping 
longevity assurance pathways 
            My chemical genetic screen was aimed at identifying small molecules that can 
increase the CLS of yeast under CR by modulating housekeeping longevity pathways. 
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Figure 3.12. LCA increases the CLS of WT strain to the highest extent under CR conditions. (A and B) 
Effect of LCA on the mean (A) and maximum (B) life spans of chronologically aging WT strain. Data are 
presented as means ± SEM (n = 12-28; ***p < 0.001). (C - E) Effect of LCA on the fold increase in the 
mean (C) or maximum (D) life span of chronologically aging WT strain. Data are presented as means ± 
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SEM (n = 12-28). Cells in A to D were cultured in medium initially containing 0.2%, 0.5%, 1% or 2% 
glucose in the presence of LCA (50 μM) or in its absence. Survival data are provided in Figure 3.13 below. 
(E and F) Outline of pro- and anti-aging processes that are controlled by the TOR and/or cAMP/PKA 
signaling pathways and are modulated by LCA in WT cells grown under non-CR (E) or CR (F) conditions. 
Activation arrows and inhibition bars denote pro-aging processes (displayed in green color), anti-aging 
processes (displayed in red color) or processes whose role in longevity regulation is presently unknown 
(displayed in black color). Doted lines denote hypothetical processes. Abbreviations: PM, plasma 
membrane. 
 
calories and may not necessarily overlap (or may only partially overlap) with the 
adaptable longevity pathways that are under the stringent control of calorie availability. 
In chronologically aging yeast, the TOR and cAMP/PKA signaling pathways are the two 
adaptable longevity pathways that govern the life-extending effect of CR (Figure 3.16A) 
[10, 35, 44, 45, 58]. Reduction of the Tor1p protein kinase activity in yeast placed on a 
CR diet or exposed to rapamycin prevents inhibitory phosphorylation of Atg13p, a key 
positive regulator of autophagy, thereby activating this essential anti-aging process 
(Figure 3.16A) [315, 316]. Under CR conditions or in response to rapamycin, Tor1p is 
also unable to phosphorylate and activate the nutrient-sensory protein kinase Sch9p [44, 
317]. The resulting inhibition of the Sch9p kinase activity suppresses its ability to 
attenuate protein synthesis in mitochondria, thus turning on this essential anti-aging 
process [45]. Furthermore, by inhibiting the Sch9p kinase activity, CR restrains Sch9p 
from activating protein synthesis in the cytosol, thereby slowing down this essential pro-
aging process [44, 58, 317]. Moreover, the attenuation of the Sch9p kinase activity in CR 
yeast prevents the retention of Rim15p in the cytosol, hence allowing this nutrient-
sensory protein kinase to enter the nucleus where it orchestrates an anti-aging 






































































































































































































Figure 3.13. Chronological survival data for WT strain cultured in medium initially containing 0.2%, 
0.5%, 1% or 2% glucose in the presence of LCA (50 μM) or in its absence. Dataset for Figure 3.12. 
 
Msn4p and Gis1p [58, 101]. The longevity benefit associated with CR in chronologically 
aging yeast is also due to the attenuation of signaling through the cAMP/PKA pathway, 
which is driven by glucose deprivation [10, 35, 58]. By preventing inhibitory 
phosphorylation of Atg13p, the reduction of the PKA kinase activity in CR yeast results 
in activation of autophagy (Figure 10A) [315, 318]. In addition, by inhibiting the PKA 
kinase activity, CR suppresses the ability of PKA to activate protein synthesis in the 
cytosol [58]. Moreover, reduced PKA kinase activity in CR yeast enables nuclear import 
of Msn2p and Msn4p, thus turning on an anti-aging transcriptional program driven - in a 






















































































































































tor1; Maximum life span
40






















0 2.00.5 1.0 1.5































Sch9 Protein synthesis in the cytosol


























Sch9 Protein synthesis in the cytosol






























Figure 3.14. Lack of Tor1p does not impair the life-extending effect of LCA and abolishes the dependence 
of the anti-aging efficacy of LCA on the number of available calories. (A and B) Effect of LCA on the 
mean (A) and maximum (B) life spans of chronologically aging tor1 strain. Data are presented as means ± 
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SEM (n = 4-7; ***p < 0.001). (C and D) Effect of LCA on the fold increase in the mean (C) or maximum 
(D) life spans of chronologically aging tor1 and WT strains. Data are presented as means ± SEM (n = 4-
7). Cells in A to D were cultured in medium initially containing 0.2%, 0.5%, 1% or 2% glucose in the 
presence of LCA (50 μM) or in its absence. Survival data are provided in Figure 3.15 below. (E and F) 
Outline of pro- and anti-aging processes that are controlled by the TOR and/or cAMP/PKA signaling 
pathways and are modulated by LCA in tor1 cells grown under non-CR (E) or CR (F) conditions.  
 
Noteworthy, the kinase activity of the cytosolic pool of Rim15p is inactivated through 
PKA-dependent phosphorylation (Figure 3.16A) [58]. Although some of the Rim15p 
phosphorylation targets are involved in longevity regulation and reside outside the 
nucleus [320], a role of such phosphorylation in the life-extending effect of CR in yeast 
remains to be established. 
            My evaluation of the life-extending efficacy of LCA in WT strain on a high- or 
low-calorie diet revealed that this compound increased CLS irrespective of the number of 
available calories (Figures 3.12A and 3.12B). Intriguingly, I found that the extent to 
which LCA extended longevity was highest under CR conditions (Figures 3.12C and 
3.12D), when the pro-aging processes modulated by the adaptable TOR and cAMP/PKA 
pathways are suppressed and the anti-aging processes are activated (Figure 3.12F). The 
life-extending efficacy of LCA in CR yeast significantly exceeded that in yeast on a high-
calorie diet (Figures 3.12C and 3.12D), in which the adaptable TOR and cAMP/PKA 
pathways greatly activate the pro-aging processes and suppress the anti-aging processes 
(Figure 3.12E). Altogether, these findings suggest that, consistent with its sought-after 
effect on a longevity signaling network, LCA mostly targets certain housekeeping 
longevity assurance pathways that do not overlap (or only partially overlap) with the 
adaptable TOR and cAMP/PKA pathways modulated by calorie availability (Figures 


















































































Figure 3.15. Chronological survival data for tor1 strain cultured in medium initially containing 0.2%, 
0.5%, 1% or 2% glucose in the presence of LCA (50 μM) or in its absence. Dataset for Figure 3.14. 
 
            Consistent with my assumption that LCA extends longevity not by modulating the 
adaptable TOR pathway (Figures 3.14E and 3.14F), I found that lack of Tor1p did not 
impair the life-extending efficacy of LCA under CR (Figures 3.14A to 3.14D). 
Importantly, by eliminating a master regulator of this key adaptable pathway that 
shortens the CLS of yeast on a high-calorie diet, the tor1 mutation abolished the 
dependence of the anti-aging efficacy of LCA on the number of available calories. In 
fact, LCA extended longevity of the tor1 mutant strain to a very similar degree under 
CR and non-CR conditions (Figures 3.14C and 3.14D). 
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Figure 3.16. Outline of pro- and anti-aging processes that are controlled by the TOR and/or cAMP/PKA 
signaling pathways and are modulated by LCA or rapamycin (RAP) in chronologically aging yeast.  The 
currently accepted (A) and updated, based on this study (B), outlines of pro- and anti-aging processes are 
shown. Activation arrows and inhibition bars denote pro-aging processes (displayed in green color), anti-
aging processes (displayed in red color) or processes whose role in longevity regulation was unknown 
(displayed in black color). Doted lines denote hypothetical, until this study, processes. See text for details.  
 
how the adaptable cAMP/PKA pathway influences the life-extending efficacy of LCA in 
yeast on a high- or low-calorie diet. He found that: 1) although the ras2 mutation 
greatly decreases the PKA protein kinase activity by eliminating a GTP-binding protein 
that activates adenylate cyclase responsible for the synthesis of the PKA activator cAMP 
[58], it did not abolish the ability of LCA to extend CLS under CR and non-CR 
conditions [247]; 2) the life-extending efficacy of LCA was decreased by the ras2 
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mutation, as compared to that seen in WT cells exposed to this compound [247]; and 3) 
in spite of such partial reduction of the anti-aging potential of LCA in ras2, LCA still 
significantly increased its CLS under CR and non-CR conditions [247]. 
            The TOR and cAMP/PKA pathways converge on Rim15p whose nuclear pool 
plays a pivotal role in governing the life-extending effect of CR by enabling the 
establishment of an anti-aging transcriptional program driven by Msn2p, Msn4p and 
Gis1p (Figure 3.16A) [10, 35, 58, 115]. Vincent Richard (a graduate student in Dr. 
Titorenko’s laboratory) evaluated the life-extending efficacy of LCA in yeast lacking 
Rim15p. His findings supported the notion that one of the two mechanisms underlying 
the anti-aging effect of this bile acid involves its ability to modulate certain housekeeping 
longevity assurance pathways that are not centered on Rim15p and do not overlap with 
the adaptable TOR and cAMP/PKA pathways [247]. In fact, he found that: 1) although 
the life-extending potential of LCA in rim15 was partially reduced due to the 
impairment of the Rim15p-centered mechanism of its anti-aging action, LCA still 
significantly increased the CLS of rim15 under CR and non-CR conditions [247]; and 
2) by eliminating a key nutrient-sensory protein kinase on which the adaptable TOR and 
cAMP/PKA pathways converge to regulate longevity in a calorie availability-dependent 
fashion, the rim15 mutation abolished the dependence of the anti-aging efficacy of LCA 
on the number of available calories [247]. 
 
3.5 Discussion 
            In studies described in this chapter of my thesis, I designed a chemical genetic 
screen for small molecules that increase the CLS of yeast under CR conditions by 
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targeting lipid metabolism and modulating housekeeping longevity pathways that 
regulate longevity irrespective of the number of available calories. My screen identified 
LCA as one of such molecules. My analysis of how LCA influences various longevity-
related processes and how it affects the CLS of yeast mutants impaired in the adaptable 
TOR longevity pathway provided important new insights into mechanisms of longevity 
regulation, as outlined below. 
            My findings described in this chapter of the thesis, along with some recently 
published data from Dr. Titorenko’s laboratory [247], imply that LCA extends yeast CLS 
by modulating housekeeping longevity assurance processes that are not regulated by the 
adaptable TOR and cAMP/PKA signaling pathways. Based on these findings, I 
concluded that LCA extends longevity of chronologically aging yeast by targeting two 
different mechanisms. One mechanism extends longevity regardless of the number of 
available calories. This mechanism involves the LCA-governed modulation of certain 
housekeeping longevity assurance pathways that do not overlap with the adaptable TOR 
and cAMP/PKA pathways (Figure 3.16B). My findings presented in this chapter, together 
with some recently published data from Dr. Titorenko’s laboratory [247], identify a 
compendium of processes that compose LCA-targeted housekeeping longevity assurance 
pathways. These findings imply that LCA modulates such pathways by 1) suppressing 
the pro-aging process [24, 246, 310] of lipid-induced necrotic cell death, perhaps due to 
its observed ability to reduce the intracellular levels of FFA and DAG that trigger such 
death; 2) attenuating the pro-aging process [321, 322] of mitochondrial fragmentation, a 
hallmark event of age-related cell death; 3) altering oxidation-reduction processes in 
mitochondria - such as oxygen consumption, the maintenance of membrane potential and 
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ROS production - known to be essential for longevity regulation [73, 75, 132, 147]; 4) 
enhancing cell resistance to oxidative and thermal stresses, thereby activating the anti-
aging process [24, 147, 246, 299, 323] of stress response; 5) suppressing the pro-aging 
process [321, 322] of mitochondria-controlled apoptosis; and 6) enhancing stability of 
nuclear and mitochondrial DNA, thus activating the anti-aging process [324, 325] of 
genome maintenance. The observed pleiotropic effect of LCA on a compendium of 
housekeeping longevity assurance processes implies that this bile acid is a multi-target 
life-extending compound that increases CLS in yeast by modulating a network of the 
highly integrated processes that are not controlled by the adaptable TOR and cAMP/PKA 
pathways. The major challenge now is to define the molecular mechanisms by which 
LCA modulates each of these pro- and anti-aging housekeeping processes and integrates 
them in chronologically aging yeast. 
            The other mechanism underlying the life-extending effect of LCA in 
chronologically aging yeast increases life span only under non-CR conditions. This 
mechanism consists in LCA-driven unmasking of the previously unknown anti-aging 
potential of PKA, a key player in the adaptable cAMP/PKA pathway. I propose that LCA 
unveils the anti-aging potential of PKA by activating PKA-dependent phosphorylation of 
the cytosolic pool of Rim15p, a key nutrient-sensory protein kinase on which the 
adaptable TOR and cAMP/PKA pathways converge to regulate longevity in a calorie 
availability-dependent fashion (Figure 3.16B). Of note, the nuclear pool of Rim15p is 
well known for its anti-aging role in governing the life-extending effect of CR by 
enabling a pro-longevity transcriptional program driven by Msn2p, Msn4p and Gis1p 
(Figure 3.16B) [35, 58]. In my hypothesis 1) unlike its nuclear pool, the cytosolic pool of 
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Rim15p has an essential pro-aging function in phosphorylating a compendium of its 
cytosolic target proteins [320] some of which promote aging only if phosphorylated 
(Figure 3.16B); 2) under non-CR conditions LCA activates the PKA-dependent 
phosphorylation of Rim15p (Figure 3.16B); and 3) because the phosphorylation of 
Rim15p inactivates its protein kinase activity [58], the dephosphorylation of pro-aging 
target proteins of Rim15p in the cytosol by phosphatases inhibits the ability of these 
target proteins to promote aging (Figure 3.16B). To test the validity of this hypothesis, 
Dr. Titorenko laboratory is currently evaluating how genetic manipulations that alter the 
abundance of various extra-nuclear target proteins of Rim15p or affect their 
phosphorylation status influence the life-extending efficacy of LCA. 
            It should be stressed that, although I found that LCA greatly extends yeast 
longevity, yeast do not synthesize this or any other bile acid found in mammals [314, 
326]; a recent mass spectrometry-based analysis of the total yeast lipidome conducted by 
Simon Bourque and Adam Beach in Dr. Titorenko’s laboratory has confirmed lack of 
endogenous bile acids. One could envision that during evolution yeast have lost the 
ability to synthesize bile acids but have maintained the life-extending response to these 
biologically active molecules by retaining certain longevity-related processes that are 
sensitive to regulation by bile acids. Alternatively, one could think that during evolution 
yeast have developed the ability to sense bile acids produced by mammals (and/or bile 
acid-like lipids synthesized by worms), recognize these mildly toxic molecules as 
environmental stressors providing hormetic benefits and/or as indicators of the state of 
the environment or food supply, and then to respond by undergoing certain life-extending 
changes to their physiology that ultimately increase their chances of survival. It is 
179 
 
conceivable therefore that the life-extending potential of LCA and other bile acids as well 
as, probably, the mechanisms underlying their anti-aging action are evolutionarily 
conserved.  
            In fact, following their synthesis from cholesterol in the intestine, hypodermis, 
spermatheca and sensory neurons of worms, bile acid-like dafachronic acids (including 3-
keto-LCA) have been shown to be delivered to other tissues where they activate the 
DAF-12/DAF-16 signaling cascade that in turn orchestrates an anti-aging transcriptional 
program, thereby increasing the life span of the entire organism [302]. Bile acids also 
provide health benefits to mammals. Synthesized from cholesterol in hepatocytes of the 
liver, these amphipathic molecules have been for a long time considered to function only 
as trophic factors for the enteric epithelium and as detergents for the emulsification and 
absorption of dietary lipids and fat-soluble vitamins [314, 326, 327]. Recent years have 
been marked by a significant progress in our understanding of the essential role that bile 
acids play as signaling molecules regulating lipid, glucose and energy homeostasis and 
activating detoxification of xenobiotics [314, 327, 328]. By stimulating the G-protein-
coupled receptor TGR5, bile acids activate the cAMP/PKA signaling pathway that 1) 
enhances energy expenditure in brown adipose tissue and muscle by stimulating 
mitochondrial oxidative phosphorylation and uncoupling; 2) improves liver and 
pancreatic function by activating the endothelial nitric oxide synthase; and 3) enhances 
glucose tolerance in obese mice by inducing intestinal glucagon-like peptide-1 release 
[314, 327, 328]. Furthermore, by activating the farnesoid X receptor (FXR) and several 
other nuclear hormone receptors inside mammalian cells, bile acids 1) modulate the 
intracellular homeostasis of cholesterol, neutral lipids and fatty acids; 2) regulate glucose 
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metabolism by enhancing glycogenesis and attenuating gluconeogenesis; and 3) stimulate 
clearance of xenobiotic and endobiotic toxins by activating transcription of numerous 
xenobiotic detoxification genes [314, 326 - 329]. All these health-improving, beneficial 
metabolic effects of bile acids prevent the development of obesity following 
administration of high-fat diet [314, 326, 327]. Thus, bile acids have a great potential as 
pharmaceutical agents for the treatment of diabetes, obesity and various associated 
metabolic disorders, all of which are age-related [314, 326]. Moreover, bile acids have 
been shown to inhibit neuronal apoptosis in experimental rodent models of 
neurodegenerative disorders by promoting mitochondrial membrane stability, preventing 
the release of cytochrome c from mitochondria,  reducing activities of various caspases, 
and activating the NF-κB, PI3K and MAPK survival pathways [329, 330]. 
            It should be stressed that many of the metabolic, stress response and apoptotic 
processes modulated by bile acids in mammals are essential for healthy aging and 
longevity regulation. Importantly, I found that, by modulating several of these health- and 
longevity-related processes in chronologically aging yeast, LCA increases their life span. 
Moreover, the long-lived Ghrhr
lit/lit
 mice displayed elevated levels of several bile acids 
and exhibited increased FXR-dependent transcription of numerous xenobiotic 
detoxification genes; if administered to food consumed by wild-type mice, cholic acid - 
one of these bile acids - mimicked the FXR-governed gene expression pattern observed 
in Ghrhr
lit/lit
 mice [331, 332]. It has been therefore proposed that, by promoting chemical 
hormesis in mammals, these mildly toxic molecules with detergent-like properties may 
extend their longevity by acting as endobiotic regulators of aging [323, 332, 333]. 
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            Altogether, these findings support the notion that bile acids act as endobiotic and 
xenobiotic regulators of aging that are beneficial to health and longevity across phyla. A 
comparative analysis of the mechanisms underlying such health-improving and life-




            My high-throughput chemical genetic screen identified LCA as a novel anti-aging 
compound that extends yeast chronological life span under CR conditions by targeting 
lipid metabolism and modulating housekeeping longevity assurance pathways. My 
analysis of how LCA influences various longevity-related processes and how it affects 
the chronological life span of yeast mutants impaired in the adaptable longevity pathways 
provided important new insights into mechanisms of longevity regulation. I revealed two 
mechanisms underlying the life-extending effect of LCA in chronologically aging yeast. 
One mechanism operates in a calorie availability-independent fashion and involves the 
LCA-governed modulation of housekeeping longevity assurance pathways that do not 
overlap with the adaptable TOR and cAMP/PKA pathways. The other mechanism 
extends yeast longevity under non-CR conditions and consists in LCA-driven unmasking 
of the previously unknown anti-aging potential of PKA. I provided evidence that LCA 
modulates housekeeping longevity assurance pathways by 1) attenuating mitochondrial 
fragmentation, a hallmark event of age-related cell death; 2) altering oxidation-reduction 
processes in mitochondria, including oxygen consumption, the maintenance of membrane 
potential, and reactive oxygen species production; 3) enhancing resistance to oxidative 
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and thermal stresses; 4) suppressing mitochondria-controlled apoptosis; and 5) enhancing 
stability of nuclear and mitochondrial DNA. I expect that this knowledge will be 
instrumental for defining molecular mechanisms underlying the ability of LCA to extend 
longevity by impacting these various housekeeping longevity assurance processes and by 






















4 Xenohormetic, hormetic, and cytostatic forces may drive the evolution of 
longevity regulation mechanisms within ecosystems: A hypothesis and its 
empirical verification  
 
4.1 Abstract 
            In my chemical genetic screen described in chapter 3, I identified lithocholic acid 
(LCA), as a novel anti-aging molecule that extends yeast longevity. Yeast do not 
synthesize this or any other bile acids produced by mammals [314, 326]; a recent mass 
spectrometry-based analysis of the total yeast lipidome conducted in Dr. Titorenko’s 
laboratory has confirmed lack of endogenous bile acids. Therefore, I propose here that 
bile acids released into the environment by mammals may act as interspecies chemical 
signals providing longevity benefits to yeast and, perhaps, other species within an 
ecosystem. I hypothesize that, because bile acids are known to be mildly toxic 
compounds, they may create selective pressure for the evolution of yeast species that can 
respond to the bile acids-induced mild cellular damage by developing the most efficient 
stress protective mechanisms. It is likely that such mechanisms may provide effective 
protection of yeast against molecular and cellular damage accumulated with age. Thus, I 
propose that yeast species that have been selected for the most effective mechanisms 
providing protection against bile acids may evolve the most effective anti-aging 
mechanisms that are sensitive to regulation by bile acids. I extend my hypothesis on 
longevity regulation by bile acids by suggesting a hypothesis of the xenohormetic, 
hormetic and cytostatic selective forces driving the evolution of longevity regulation 
mechanisms at the ecosystemic level.  
184 
 
            To verify my hypothesis empirically, I carried out the LCA-driven multistep 
selection of long-lived yeast species under laboratory conditions. I found that a lasting 
exposure of wild-type yeast to LCA results in selection of yeast species that live longer in 
the absence of this bile acid than their ancestor. My data enabled to rank different 
concentrations of LCA with respect to the efficiency with which they cause the 
appearance of long-lived yeast species. I revealed that, if used at the most efficient 
concentration of 5 μM, this bile acid induced life-extending mutations with the frequency 
of about 4 × 10
8
/generation. At the concentration of 50 μM, LCA caused the appearance 
of long-lived species with the frequency of 1 × 10
8
/generation, whereas a lasting 
exposure of yeast to 250 μM LCA did not result in selection of such species. Because the 
lowest used concentration of LCA resulted in the highest frequency of long-lived species 
appearance, I believe that it is unlikely that the life-extending mutations they carry are 
due to mutagenic action of this bile acid.  
            I outline here the most critical questions needed to be addressed empirically in the 
near future to test the validity of other aspects of my hypothesis on the ecosystemic 
evolution of longevity regulation mechanisms.       
 
4.2 Introduction 
            I recently found that LCA greatly (and some other bile acids to a lesser degree) 
increases the chronological life span of yeast under caloric restriction (CR) conditions 
[247]. My findings provided evidence that LCA extends longevity of chronologically 
aging yeast through two different mechanisms (see chapter 3 for a detailed discussion of 







Sch9 Protein synthesis in the cytosol
Tor1




















• lipid-induced necrosis 
• mitochondrial ROS production 
• mitochondrial membrane potential 




• oxidative stress resistance 
• thermal stress resistance 
• stability of nuclear DNA 































Figure 4.1. Lithocholic acid (LCA) extends longevity of chronologically aging yeast through two different 
mechanisms. (A and B) Outline of pro- and anti-aging processes that are controlled by the TOR and/or 
cAMP/PKA signaling pathways and are modulated by LCA in yeast cells grown under non-CR (A) or CR 
(B) conditions. Activation arrows and inhibition bars denote pro-aging (displayed in green color) or anti-
aging (displayed in red color) processes. Under both non-CR and CR conditions, LCA targets 
housekeeping longevity assurance processes listed in (C). Under non-CR conditions only, LCA also targets 
the adaptable cAMP/PKA pathway. By activating PKA-dependent phosphorylation of the cytosolic pool of 
the key nutrient-sensory protein kinase Rim15p, LCA causes the inactivation of Rim15p. The resulting 
reduction of the phosphorylation status of several Rim15p target proteins in the cytosol lowers their pro-




control chronological aging irrespective of the number of calories available to yeast. 
Because these pathways modulate longevity regardless of calorie availability, I called 
them “constitutive” or “housekeeping” (see chapter 3) [247]. LCA modulates these 
housekeeping longevity assurance pathways by suppressing lipid-induced necrosis, 
attenuating mitochondrial fragmentation, altering oxidation-reduction processes in 
mitochondria, enhancing resistance to oxidative and thermal stresses, suppressing 
mitochondria-controlled apoptosis, and enhancing stability of nuclear and mitochondrial 
DNA ([247]; Figure 4.1C). The housekeeping longevity pathways do not overlap with the 
TOR (target of rapamycin) and cAMP/PKA (cAMP/protein kinase A) signaling pathways 
([247]; Figure 4.1A), both of which are “adaptable” by nature because they are under the 
stringent control of calorie and/or nutrient availability ([4, 7, 10, 36, 334, 335]; Figure 
4.1B). In the other mechanism, LCA targets the adaptable cAMP/PKA pathway by 
unmasking an anti-aging potential of PKA under non-CR conditions, perhaps by 
activating PKA-dependent phosphorylation of the cytosolic pool of the key nutrient-
sensory protein kinase Rim15p (see chapter 3) [247]. The phosphorylation of Rim15p by 
PKA inactivates its protein kinase activity [58]. Hence, the LCA-driven inactivation of 
Rim15p may reduce the phosphorylation status of its known [320] target proteins in the 
cytosol, thereby lowering their pro-aging efficacy ([247]; Figure 4.1A).         
            Although bile acids in mammals have been traditionally considered only as 
trophic factors for the enteric epithelium and detergents for the emulsification and 
absorption of dietary lipids [314, 326, 327], they are now also recognized for their 
essential role as signaling molecules regulating lipid, glucose and energy homeostasis and 
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Figure 4.2. Bile acids are beneficial to health and longevity in animals. (A) In mammals, bile acids (BA) 
function not only as trophic factors for the enteric epithelium and detergents for the emulsification and 
absorption of dietary lipids, but also as signaling molecules that regulate lipid, glucose and energy 
homeostasis and activate detoxification of xenobiotics. By improving overall health, BA may delay the 
onset of age-related diseases and have beneficial effect on longevity. By activating transcription of 
numerous xenobiotic detoxification genes and thus promoting chemical hormesis, BA may extend their 
longevity by acting as endobiotic regulators of aging. (B) In worms, following their synthesis from 
cholesterol in the intestine, hypodermis, spermatheca and sensory neurons, bile acid-like dafachronic acids 
(DCA) are delivered to other tissues where they activate the DAF-12/DAF-16 signaling cascade, thereby 




numerous health-improving metabolic effects caused by bile acids and their demonstrated 
ability to protect mammals from xenobiotic toxins ([326 - 330]; Figure 4.2A) suggest 
that, by improving overall health, these amphipathic molecules may delay the onset of 
age-related diseases and have beneficial effect on longevity. Furthermore, because of the 
elevated levels of several bile acids in the long-lived Ghrhr
lit/lit
 mice and due to the ability 
of cholic acid administered to food of wild-type mice to activate transcription of 
numerous xenobiotic detoxification genes, it has been proposed that, by promoting 
chemical hormesis in mammals, these mildly toxic molecules with detergent-like 
properties may extend their longevity by acting as endobiotic regulators of aging [323, 
331 - 333]. Moreover, bile acid-like dafachronic acids (including 3-keto-LCA) in worms 
function as endocrine regulators of aging by activating an anti-aging transcriptional 
program governed by the DAF-12/DAF-16 signaling cascade ([302, 336, 337]; Figure 
4.2B). Altogether, these findings support the notion that bile acids are beneficial to health 
and longevity in animals because of their ability to operate as potent signaling molecules 
that modulate a compendium health- and longevity-related processes. Noteworthy, by 
modulating many of these processes also in yeast, LCA extends their longevity [247]. It 
is likely therefore that the life-extending capacity of LCA and other bile acids as well as, 
perhaps, the mechanisms underlying their anti-aging action are conserved across animal 
species and other phyla.  
 
4.3 Materials and Methods 
Strains and media 
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The wild type strain Saccharomyces cerevisiae BY4742 (MATα, his3Δ leu2Δ0 lys2Δ 
ura3Δ0) was cultured in liquid YP medium (1% yeast extract, 2% peptone) contained 
0.2% glucose as a carbon source, with or without LCA, as detailed in the “Results” 
section. Cell cultures were incubated at 30°C with rotational shaking at 200 rpm in 
Erlenmeyer flasks at a “flask volume/medium volume” ratio of 5:1. For a spot assay of 
cell viability, serial 10-fold dilutions of cell cultures were spotted onto plates with solid 




4.4.1 Bile acids may function as interspecies chemical signals extending yeast 
longevity within ecosystems 
            As I mentioned in section 4.1, yeast do not synthesize LCA or any other bile acid 
found in mammals [247, 326, 329]. Therefore, I hypothesize that bile acids released into 
the environment by mammals may act as interspecies chemical signals providing 
longevity benefits to yeast. In my hypothesis, these mildly toxic compounds released into 
the environment by mammals may create selective pressure for the evolution of yeast 
species that can respond to the resulting mild cellular damage by developing the most 
efficient stress protective mechanisms. Such mechanisms may provide effective 
protection of yeast not only against cellular damage caused by bile acids (and, perhaps, 
by other environmental xenobiotics) but also against molecular and cellular damage 
accumulated with age. In my hypothesis, yeast species that have been selected for the 
most effective mechanisms providing protection against bile acids (and other 
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environmental xenobiotics) are expected to evolve the most effective anti-aging 
mechanisms that are sensitive to regulation by bile acids (and, perhaps, by other 
environmental xenobiotics). Thus, the ability of yeast to sense bile acids produced by 
mammals and then to respond by undergoing certain life-extending changes to their 
physiology (Figure 4.1) is expected to increase their chances of survival, thereby creating 
selective force aimed at maintaining such ability. 
 
4.4.2 Natural variations of bile acid levels within ecosystems may modulate both 
housekeeping and adaptable longevity pathways in yeast 
            Of note, the bulk quantity of bile acids in mammals exists as an organismal pool 
which cycles between intestine and liver in the enterohepatic circulation due to the 
efficient reabsorption of bile acids in the terminal ileum [326, 327]. However, about 5% 
(up to 600 mg/day) of this pool escapes each reabsorption cycle, being continuously 
released into the large intestine and ultimately into the environment [326, 327]. Thus, 
yeast are permanently exposed to bile acids due to their fecal loss by mammals. It is 
conceivable therefore that, in yeast exposed to bile acids released by mammals, these 
interspecies chemical signals modulate housekeeping longevity assurance pathways that 
1) regulate yeast longevity irrespective of the state of the environment or food supply 
(i.e., the number of available calories and nutrients); and 2) do not overlap (or only 
partially overlap) with the adaptable TOR and cAMP/PKA longevity pathways that are 
under the stringent control of calorie and nutrient availability.  
            It should be stressed, however, that the quantity of bile acids released into the 
environment by mammals could vary due to changes in the density of mammalian 
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population and, perhaps, due to other environmental factors (including the abundance of 
food available to mammals, its nutrient and caloric content, and its fat mass and quality). 
In fact, the organismal pool of bile acids in mammals is under the stringent control of 
regulatory mechanisms operating in the liver during the fasting-refeeding transition [314, 
326, 327]. Hence, it is likely that, in addition to the ability of yeast to respond to the 
permanently available exogenous pool of bile acids by modulating some housekeeping 
longevity assurance pathways, they have also evolved the ability to sense the 
environmental status-dependent variations of bile acids abundance by modulating the 
adaptable TOR and cAMP/PKA longevity pathways. Importantly, my recent study 
provided evidence for two mechanisms underlying the life-extending effect of LCA in 
yeast (see chapter 3 of my thesis); one mechanism involves the calorie supply-
independent modulation of a compendium of housekeeping longevity assurance 
processes that are not regulated by the TOR and cAMP/PKA pathways, whereas the other 
mechanism operates only in yeast on a calorie-rich diet by unmasking the previously 
unknown anti-aging potential of the calorie supply-dependent PKA [247]. 
            It remains to be seen if my hypothesis on the essential role of bile acids as 
interspecies chemical signals regulating longevity in yeast is applicable to other species 
routinely exposed to bile acids within an ecosystem, such as plants and bacteria. 
 
4.4.3 Rapamycin may also act as an interspecies chemical signal modulating 
longevity at the ecosystemic level 
            My hypothesis on longevity regulation by bile acids within ecosystems may 
explain the evolutionary origin of the life-extending effect of another anti-aging 
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compound, called rapamycin. Synthesized by soil bacteria to inhibit growth of fungal 
competitors, this macrocyclic lactone provides longevity benefit to yeast, fruit flies and 
mice by specifically inhibiting TOR (Tor1p in yeast), a nutrient-sensory protein kinase 
that operates as a master negative regulator of the key adaptable longevity pathway [110, 
113, 116, 334, 335]. Because rapamycin delays proliferative growth of organisms across 
phyla by causing G1 cell cycle arrest [102, 334, 335], it could be considered as a mildly 
cytotoxic compound, akin to bile acids (recent unpublished data from Dr. Titorenko’s 
laboratory revealed that rapamycin is a more toxic hormetic molecule than LCA and 
other bile acids). Therefore, I propose that, following its release into the environment by 
soil bacteria, rapamycin may create selective pressure for the evolution of new yeast, fly 
and mammalian species. These new species can respond to rapamycin-induced growth 
retardation by developing certain mechanisms aimed at such remodeling of their anabolic 
and catabolic processes that would increase their chances of survival under conditions of 
slow growth. It is plausible that some of these mechanisms delay aging by optimizing 
essential longevity-related processes and remain sensitive to modulation by rapamycin. 
Hence, the ability of yeast, fruit flies and mice to sense rapamycin produced by soil 
bacteria and then to respond by undergoing certain life-extending changes to their 
physiology is expected to increase their chances of survival, thereby creating selective 
force for maintaining such ability.  
            Interestingly, rapamycin has been shown to increase life span in fruit flies under 
dietary restriction conditions [113], when the TOR-governed adaptable pro-aging 
pathways are fully suppressed and the TOR-governed adaptable anti-aging pathways are 
fully activated [334, 335]. It is plausible therefore that - similar to the proposed above 
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anti-aging mechanism of LCA in yeast - rapamycin in fruit flies can modulate both the 
housekeeping (TOR-independent) and adaptable (TOR-dependent) longevity pathways. 
Hence, it is tempting to speculate that, in addition to the ability of fruit flies to respond to 
the permanently available exogenous pool of rapamycin by modulating some 
housekeeping longevity assurance pathways, they have also evolved the ability to sense 
the environmental status-dependent variations of rapamycin abundance (due to, e.g., 
changes in the density of soil bacteria population) by modulating the TOR-governed 
adaptable longevity pathways. Of note, recent findings in yeast imply that - in addition to 
its role as a master negative regulator of the key adaptable longevity pathway - Tor1p 
may also operate as a positive longevity regulator, in particular by stimulating nuclear 
import of the transcriptional factors Sfp1p, Rtg1 and Rtg3 in response to partial 
mitochondrial dysfunction or changes in the exogenous and endogenous levels of 
glutamate and glutamine [338 - 340]. The ability of these transcriptional factors to 
regulate metabolism, ribosome biogenesis and growth is crucial for longevity [339 - 342]. 
 
4.4.4 The “xenohormesis” hypothesis: a case of xenohormetic phytochemicals  
            My hypothesis on longevity regulation by bile acids and rapamycin within 
ecosystems complements the “xenohormesis” hypothesis, in which plants and other 
autotrophic organisms respond to various environmental stresses (i.e., UV light, 
dehydration, infection, predation, cellular damage and nutrient deprivation) by 
synthesizing a compendium of secondary metabolites [119, 343, 344]. Within plants and 
other autotrophs producing these phytochemicals in response to environmental stresses, 
they activate defence systems protecting the host organisms against such stresses. In 
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addition, these phytochemicals constitute a chemical signature of the environmental 
status of an ecosystem. As such, they provide to heterotrophic organisms (i.e., animals 
and fungi) within the ecosystem an advance warning about deteriorating environmental 
conditions [343]. By operating as interspecies chemical signals, they could create 
selective pressure for the evolution of heterotrophic organisms that can sense these 
signals and then to respond by altering their metabolism in defensive preparation for the 
imminent adversity while conditions are still favourable. The resulting metabolic 
remodeling causes such specific changes in physiology of heterotrophs that are beneficial 
to their health and longevity [343]. Although xenohormetic phytochemicals are produced 
by autotrophic organisms only in response to hormetic environmental stresses, it is 
unlikely that they function as mildly toxic hormetic molecules within heterotrophic 
organisms; rather, the xenohormesis hypothesis proposes that the beneficial to health and 
longevity effects of xenohormetic phytochemicals are due to their well known ability to 
modulate the key enzymes of stress-response pathways governing numerous longevity-
related processes in heterotrophic organisms [343 - 352]. The xenohormetic mode of 
positive selection for the most efficient longevity regulation mechanisms has been 
proposed to be driven by such phytochemicals as resveratrol, butein, fisetin and other 
polyphenols, as well as by curcumin [119, 343, 344]. The ability of caffeine to increase 
yeast chronological life span by decreasing the catalytic activity of Tor1p [101] suggests 
that this xanthine alkaloid could also operate as a xenohormetic phytochemical signal 
providing an advance warning about deteriorating environmental conditions to yeast, 
thereby driving the evolution of their longevity regulation mechanisms. 
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4.4.5 The “anti-aging side effect” hypothesis: delaying aging by attenuating the 
growth-promoting TOR signaling pathway 
            A common feature of many anti-aging compounds - some of which are mildly 
toxic hormetic molecules, whereas the others are non-toxic xenohormetic phytochemicals 
- is that they exhibit a cytostatic effect by inhibiting TOR, a nutrient-sensing signaling 
pathway that promotes proliferative growth in all heterotrophic organisms. A recently 
proposed “anti-aging side effect” hypothesis envisions that the primary objective for the 
synthesis of these cytostatic compounds by a group of the organisms composing an 
ecosystem is to suppress growth of other group(s) of organisms within this ecosystem, 
thereby killing competitors and/or protecting themselves from predators [349]. Due to its 
central role in promoting proliferative growth of all heterotrophic organisms, the TOR 
signaling pathway is a preferable target of such cytostatic compounds [102, 334, 349, 
353, 354]. Because the TOR pathway provides a molecular link between growth and 
aging by driving a so-called quasi-programmed aging [334, 353, 354], these compounds 
exhibit a side effect of suppressing aging [349]. In fact, soil bacteria synthesize 
rapamycin to suppress growth of fungal competitors by inhibiting the TOR protein 
kinase, a master positive regulator of the TOR signaling pathway that drives 
developmental growth of young organisms [110, 113, 116, 334]. However, since - 
according to the anti-aging side effect hypothesis - in heterotrophic organisms across 
phyla this pathway also drives aging after their developmental growth is completed [353, 
354], rapamycin has a side effect of suppressing aging of all groups of heterotrophic 
organisms within an ecosystem [349]. Moreover, the anti-aging side effect hypothesis 
predicts that plants synthesize resveratrol in part to protect their grapes by inhibiting 
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fungal growth [349]. Yet, because this small polyphenol attenuates the TOR signaling 
pathway by modulating key upstream regulators and downstream targets of the TOR 
protein kinase [345 - 352], resveratrol also displays a side effect of slowing down quasi-
programmed TOR-driven aging of various species of heterotrophic organisms within an 
ecosystem [349]. 
            In the anti-aging side effect hypothesis, cytostatic compounds attenuating the 
TOR pathway operate as interspecies chemical signals that provide longevity benefits to a 
range of heterotrophic organisms composing an ecosystem [349]. I propose that, 
following their release into the environment by soil bacteria or plants, these growth 
suppressing chemical compounds may create selective pressure for the evolution of yeast, 
worm, fly and mammalian species that can respond to the resulting retardation of their 
growth by developing certain mechanisms aimed at specific remodeling of the TOR-
governed signaling network. By targeting the TOR protein kinase itself and/or its 
numerous upstream regulators and downstream targets, such mechanisms may attenuate 
the hyper-activation of TOR-governed cellular signaling pathways and cellular functions 
that - according to the concept of quasi-programmed TOR-driven aging [353, 354] - are 
initiated after developmental growth of a heterotrophic organism is completed. In my 
hypothesis, the species of heterotrophic organisms that have been selected for the most 
efficient mechanisms preventing the hyper-activation of TOR-governed cellular signaling 
pathways and cellular functions following the completion of developmental growth are 
expected to evolve the most effective anti-aging mechanisms. Such mechanisms may be 
sensitive to various environmental factors, including the density of organism population 
and abundance of nutrients within an ecosystem. 
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4.4.6 The xenohormetic, hormetic and cytostatic selective forces may drive the 
evolution of longevity regulation mechanisms within ecosystems 
            Unlike xenohormetic phytochemicals that are non-toxic compounds transiently 
synthesized and released by autotrophs only in response to environmental stresses [343, 
344], bile acids are mildly toxic hormetic molecules that are permanently synthesized and 
released by mammals [314, 323, 326 - 328, 331 - 333]. Furthermore, rapamycin is a more 
toxic hormetic molecule than bile acids (recent unpublished data from Dr. Titorenko’s 
laboratory) that is permanently synthesized and released by soil bacteria [355]. Moreover, 
many xenohormetic phytochemicals and mildly toxic hormetic molecules exhibit a 
cytostatic effect by attenuating TOR-governed cellular signaling pathways and cellular 
functions [349]. Therefore, by fusing the xenohormesis hypothesis [119, 343, 344], the 
anti-aging side effect hypothesis [349] and the proposed here hypothesis on longevity 
regulation by bile acids and rapamycin within ecosystems, I put forward a unified 
hypothesis of the xenohormetic, hormetic and cytostatic selective forces driving the 
evolution of longevity regulation mechanisms at the ecosystemic level.  
            In my unified hypothesis (Figure 4.3), organisms from all domains of life (i.e., 
bacteria, fungi, plants and animals) within an ecosystem are able to synthesize chemical 
compounds that 1) are produced and then released into the environment permanently or 
only in response to deteriorating environmental conditions, increased population density 
of competitors and/or predators, or changes in food availability and its nutrient and/or 
caloric content; 2) are mildly toxic compounds that trigger a hormetic response in an 
organism that senses them or, alternatively, are not toxic for any organism within the 




Figure 4.3. The xenohormetic, hormetic and cytostatic selective forces may drive the evolution of 
longevity regulation mechanisms within an ecosystem. I propose that organisms from all domains of life 
within an ecosystem synthesize chemical compounds that 1) are produced and then released into the 
environment permanently or only in response to deteriorating environmental conditions, increased 
population density of competitors and/or predators, or changes in food availability and its nutrient and/or 
caloric content; 2) are mildly toxic compounds that trigger a hormetic response in an organism that senses 
them or, alternatively, are not toxic for any organism within the ecosystem and do not cause a hormetic 
response; 3) are cytostatic compounds that attenuate the TOR-governed signaling network or, alternatively, 
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do not modulate this growth-promoting network; and 4) extend longevity of organisms that can sense these 
compounds (red arrows), thereby increasing their chances of survival and creating selective force aimed at 
maintaining the ability of organisms composing the ecosystem to respond to these compounds by 
undergoing specific life-extending changes to their physiology. In my hypothesis, the evolution of 
longevity regulation mechanisms in each group of the organisms composing an ecosystem is driven by the 
ability of this group of organisms to undergo specific life-extending changes to their physiology in response 
to a compendium of “critical” chemical compounds that are permanently or transiently released to the 
ecosystem by other groups of organisms. Abbreviations: LCA, lithocholic acid; DCA, bile acid-like 
dafachronic acids. 
 
attenuate the TOR-governed signaling network (e.g., rapamycin and resveratrol) or, 
alternatively, do not modulate this growth-promoting network (e.g., LCA and other bile 
acid) and 4) extend longevity of organisms that can sense these compounds, thereby 
increasing their chances of survival and creating selective force aimed at maintaining the 
ability of organisms composing the ecosystem to respond to these compounds by 
undergoing specific life-extending changes to their physiology. My hypothesis implies 
that the evolution of longevity regulation mechanisms in each group of the organisms 
composing an ecosystem is driven by the ability of this group of organisms to undergo 
specific life-extending physiological changes in response to a compendium of “critical” 
chemical compounds that are permanently or transiently released to the ecosystem by 
other groups of organisms. 
 
4.4.7 The empirical verification of my hypothesis of the xenohormetic, hormetic 
and cytostatic selective forces driving the evolution of longevity regulation 
mechanisms at the ecosystemic level  
            To empirically verify my hypothesis of the xenohormetic, hormetic and cytostatic 
selective forces driving the evolution of longevity regulation mechanisms at the 
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ecosystemic level, I carried out a 3-step selection of long-lived yeast species by a lasting 
exposure to LCA under laboratory conditions. For the first step of such selection, yeast 
cells from an overnight culture were inoculated into a fresh YP medium (with or without 
LCA) containing 0.2% glucose to the initial cell titre of 1 x 10
5
 cells/ml (Figure 4.4). 
After one week of the incubation in this medium and following approximately 45 cell 
generations, yeast entered into a non-proliferative state by reaching stationary (ST) 
growth phase at the cell titre of 2 x 10
8
 cells/ml (Figure 4.5). Following their entry into a 
non-proliferative state, yeast cells were cultured for additional 5 weeks. By the end of this 
cultivation, only ~ 0.02% of cells in the medium without LCA remained viable. In the 
cell cultures that were supplemented with LCA, ~ 1% of cells remained viable – due to 
the ability of LCA to increase the chronological life span (CLS) of non-dividing 
(senescent) yeast cells. Thus, the enrichment factor for long-lived mutants by the end of 
each selection step was 10
2
 (Figure 4.6). Five cultures were used to carry out the 
selection of long-lived yeast species: the first culture lacked LCA; the second culture 
contained 5 μM LCA added at the moment of cell inoculation; the third culture contained 
50 μM LCA added at the moment of cell inoculation; the fourth culture contained 250 
μM LCA added at the moment of cell inoculation; and the fifth culture was supplemented 
with 10 doses of 5 μM LCA each by adding this bile acid every 3 or 4 days (Figure 4.7). 
At the end of the first selection step, aliquots of each of the five cultures were plated onto 
plates with solid YP medium containing 2% glucose. After 2 days, each of the 10 
randomly chosen colonies was inoculated into a liquid medium without LCA to carry out 
a viability testing step (Figure 4.4). Every week, an aliquot of each culture was used for a 
spot  assay of cell viability to identify long-lived mutants (if any) induced due to a lasting  
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STEP 1: 1 week (~45 
generations) + 5 
weeks (ST phase)
LA
Initial cell titre: 1×105/ml 
Cell viability: 100% (both)
Cell titre: 2×108/ml 
Cell viability: 0.02% (- LA) 
















Inoculate each of the 
10 randomly chosen 
colonies in a flask with 
medium without LA
- LA - LA
Freeze an aliquot of 













Figure 4.4. A 3-step process of the LCA-driven experimental evolution of longevity regulation 
mechanisms by conducting selection of long-lived yeast species through a lasting exposure to LCA. See 
text for details. 
 
exposure of yeast to LCA during the selection step (Figure 4.4). If such mutants were 
detected, an aliquot of their culture in medium lacking LCA was frozen at -80
o
C. To 
conduct the second selection step, an aliquot of the culture recovered at the end of the 
first step of selection was diluted 100 folds in a fresh YP medium containing 0.2% 
glucose, with or without LCA; if added to a culture for the second selection step, LCA 
was present at the same final concentration as that in the medium used for the first step of 
selection  (Figure 4.4).  From  that point, the second selection step was carried out exactly  
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Spot assays for 
identifying a long-
lived mutant
The number of cell 
generations in each of 
the selection steps 
prior to entry into a 
non-proliferative state 
(i.e., stationary phase 
[ST] of senescence):
(2 x 108 cells/ml) : 
(105 cells/ml) = 2,000 
~ 45 generations
 
Figure 4.5. A 3-step process of the LCA-driven experimental evolution of longevity regulation 
mechanisms by conducting selection of long-lived yeast species through a lasting exposure to LCA. The 
number of cell generations in each of the selection steps prior to entry into a non-proliferative state is 
calculated. See text for details. 
 
as the first one and was followed by a spot-assay viability step described above (Figure 
4.4). The second selection step was followed by the third selection step and then by a 
spot-assay viability step, both conducted as described previously (Figure 4.4). 
            The 3-step selection of long-lived yeast species depicted in Figures 4.4 to 4.7 was 
expected to result in the increased fraction of long-lived mutants in a population of yeast 
exposed  to  LCA  (Figure 4.8).  Moreover,  the  fraction  of  such long-lived mutants in a  
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Initial cell titre: 1×105/ml 
Cell viability: 100% (both)
Cell titre: 2×108/ml 
Cell viability: 0.02% (- LA) 
















Inoculate each of the 
10 randomly chosen 
colonies in a flask with 
medium without LA
- LA - LA
Freeze an aliquot of 






Spot assays for 
identifying a long-
lived mutant
Enrichment factor for 
long-lived mutants by 
the end of each of the 5-
weeks selection steps 
(in LA-treated samples):
100% viable cells 
(start) : 1% viable long-
lived cells (end) = 102
 
Figure 4.6. A 3-step process of the LCA-driven experimental evolution of longevity regulation 
mechanisms by conducting selection of long-lived yeast species through a lasting exposure to LCA. The 
enrichment factor for long-lived mutants by the end of each of the selection steps is calculated. See text for 
details. 
 
population was anticipated to progressively increase at each of the consecutive selection 
steps (Figure 4.8 and Table 4.1).  By carrying out this 3-step selection of long-lived yeast 
species under laboratory conditions, I found no such mutants at the end of the first 
selection step, one mutant at the end of the second selection step, and several mutants at 
the end of the third selection step (Figures 4.9, 4.10 and 4.11, respectively). I therefore 
concluded  that a long-term exposure of wild-type yeast to LCA following the 3 selection  
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STEP 1: 1 week (~45 
generations) + 5 
weeks (ST phase)
LA
Initial cell titre: 1×105/ml 
Cell viability: 100% (both)
Cell titre: 2×108/ml 
Cell viability: 0.02% (- LA) 
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Freeze an aliquot of 










used during each of the 
selection steps:
Sample 1: no LA
Sample 2: 5 μM LA
Sample 3: 50 μM LA
Sample 4: 250 μM LA
Sample 5: 10 doses x 5 
μM LA added every 3-4 
days
 
Figure 4.7. A 3-step process of the LCA-driven experimental evolution of longevity regulation 
mechanisms by conducting selection of long-lived yeast species through a lasting exposure to LCA. 
Concentrations of LCA used during each of the selection steps are shown. See text for details. 
 
steps did result in selection of yeast species that live longer in the absence of LCA than 
their ancestor. My findings revealed the following order of different LCA concentrations 
ranked by the efficiency with which they cause the appearance of long-lived species 
(frequencies of such appearance are shown): 5 μM LCA (~4 x 10-8/generation) > 10 
doses x 5 μM LCA (~3 x 10-8/generation) > 50 μM LCA (~1 x 10-8/generation) > 250 μM 
LCA (no long-lived species found). It should be stressed that, because the lowest used 
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Figure 4.8. The fraction of long-lived mutants in a population of yeast is increased by the end of each of 
the 3 steps of the LCA-driven experimental evolution of longevity regulation mechanisms. 
 




            By fusing the xenohormesis hypothesis [119, 343, 344], the “anti-aging side 
effect” hypothesis [349] and the proposed in this chapter my hypothesis on longevity 
regulation by bile acids and rapamycin within ecosystems, I put forward a unified 
hypothesis of the xenohormetic, hormetic and cytostatic selective forces that may drive 
the evolution of longevity regulation mechanisms at the ecosystemic level. In my unified 
hypothesis (Figure 4.3), organisms from all domains of life (i.e., bacteria, fungi, plants 
and animals) within an ecosystem are able to synthesize chemical compounds that 1) are 
produced  and  then  released  into  the  environment  permanently  or  only in response to  
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Table 4.1. The fraction of long-lived mutants in a population of yeast is increased by the end of each of the 
3 steps of the LCA-driven experimental evolution of longevity regulation mechanisms. 
4-5 out of 
1,000
STEP 1: (10-6 × 45 generations) × 102 = 4.5 × 10-3 
10210-6/ 
generation
4-5 out of 
10
STEP 2: [(4.5 × 10-3) + (10-6 × 45 gen.)] × 102 ~ 4.5 × 10-1
ALLSTEP 3: [(4.5 × 10-1) + (10-6 × 30 gen.)] × 102 ~ 4.5 × 101
4-5 out of 
10,000
STEP 1: (10-7 × 45 generations) × 102 = 4.5 × 10-4 
10210-7/ 
generation
4-5 out of 
100
STEP 2: [(4.5 × 10-4) + (10-7 × 45 gen.)] × 102 ~ 4.5 × 10-2
ALLSTEP 3: [(4.5 × 10-2) + (10-7 × 45 gen.)] × 102 ~ 4.5 × 100
4-5 out of 
10
STEP 3: [(4.5 × 10-3) + (10-8 × 45 gen.)] × 102 ~ 4.5 × 10-1
4-5 out of 
1,000
STEP 2: [(4.5 × 10-5) + (10-8 × 45 gen.)] × 102 ~ 4.5 × 10-3
4-5 out of 
100,000




The fraction of long-lived mutants & their number in a population of 












deteriorating environmental conditions, increased population density of competitors 
and/or predators, or changes in food availability and its nutrient and/or caloric content; 2) 
are mildly toxic compounds that trigger a hormetic response in an organism that senses 
them or, alternatively, are not toxic for any organism within the ecosystem  and  do  not  
cause  a  hormetic  response;  3)  are  cytostatic  compounds  that attenuate the TOR-
governed signaling network (e.g., rapamycin and resveratrol) or, alternatively, do not 
modulate this growth-promoting network (e.g., LCA and other bile acid); and 4) extend 
longevity of organisms that can sense these compounds, thereby increasing their chances 
of survival and creating selective force aimed at maintaining the ability of organisms 
composing the ecosystem to respond to these compounds by undergoing specific life-




Figure 4.9. A spot-assay of cell survival for the 1st step of the LCA-driven experimental evolution of 
longevity regulation mechanism.  
 
longevity regulation mechanisms in each group of the organisms composing an 
ecosystem is driven by the ability of this group of organisms to undergo specific life-
extending physiological changes in response to a compendium of “critical” chemical 
compounds that are permanently or transiently released to the ecosystem by other groups 
of organisms. 
            To verify my hypothesis empirically, I carried out the LCA-driven multistep 
selection of long-lived yeast species under laboratory conditions. I found that a lasting 
exposure of wild-type yeast to LCA results in selection of yeast species that live longer in 




Figure 4.10. A spot-assay of cell survival for the 2nd step of the LCA-driven experimental evolution of 
longevity regulation mechanism.  
 
concentrations of LCA with respect to the efficiency with which they cause the 
appearance of long-lived yeast species. Because the lowest used concentration of LCA 
resulted in the highest frequency of long-lived species appearance, I believe that it is 








Figure 4.11. A spot-assay of cell survival for the 3rd step of the LCA-driven experimental evolution of 
longevity regulation mechanism.  
 
4.6 Conclusions 
            To test the validity of other aspects of my hypothesis on the ecosystemic 
evolution of longevity regulation mechanisms, future studies need to address the 
following most critical questions: 1) what genes are affected by mutations responsible for 
the extended longevity of selected long-lived yeast species? 2) how these mutations 
influence a compendium of the housekeeping longevity-related processes modulated by 
LCA in chronologically aging yeast ([247]; Figure 4.1)?; 3) 3) will these mutations affect 
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the growth rate of yeast in media with or without LCA? 4) will selected long-lived yeast 
species be able to maintain their ability to live longer than wild-type yeast if they undergo 
several successive passages in medium without LCA? - and, thus, is there selective 
pressure aimed at maintaining of an “optimal” rather than a “maximal” chronological life 
span of yeast (due to, e.g., a proposed selective advantage of the envisioned “altruistic” 
program [356 - 361] of chronological aging in yeast)? and 5) if mixed with an equal 
number of wild-type yeast cells, will selected long-lived yeast species out-grow and/or 
out-live them in medium without LCA or the opposite will happen (due to selective 
pressure on yeast aimed at maintaining of the so-called “altruistic” program [356 - 361] 















5 Lithocholic acid exhibits a potent and selective anti-tumor effect in cultured 
human neuroblastoma cells by activating both intrinsic and extrinsic 
pathways of their apoptotic death, sensitizing them to hydrogen peroxide-
induced apoptotic death, and preventing growth and proliferation of their 
neighboring neuroblastoma cells in the culture  
 
5.1 Abstract 
            Aging is one of the major risk factors in the onset and incidence of cancer [154 - 
156], and cancer is considered as one of the numerous age-associated diseases whose 
onset can be delayed and incidence reduced by anti-aging interventions [157 - 162]. As I 
mentioned in chapter 1, the interplay between aging and cancer is intricate as these two 
complex and dynamic biological phenomena have both convergent and divergent 
underlying mechanisms [157 - 223]. One of the major objectives of my thesis was to 
examine if lithocholic acid (LCA), a novel anti-aging compound that I identified in a 
high-throughput chemical genetic screen (see chapter 3), also exhibits an anti-tumor 
effect in cultured human cancer cells by activating certain anti-cancer processes that may 
(or may not) play an essential role in cellular aging. As a model system for addressing 
this important question (and if LCA indeed displays an anti-tumor effect, for establishing 
the mechanism underlying such effect), I choose several cell lines of the human 
neuroblastoma (NB) tumor.  
            In this chapter of my thesis, I describe findings providing strong evidence that 
LCA exhibits a potent anti-tumor effect in cultured human NB cells by: 1) activating both 
intrinsic (mitochondrial) and extrinsic (death receptor) pathways of apoptotic death in 
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these cells; 2) sensitizing them to hydrogen peroxide-induced apoptotic death; and 3) 
preventing growth and proliferation of their neighbouring NB cells in the culture. 
Importantly, my findings imply that LCA does not display any of these deleterious effects 
in human neurons and, therefore, is a selective anti-tumor compound. Moreover, my mass 
spectrometry-based measurement of intracellular and extracellular levels of exogenously 
added LCA revealed that this bile acid does not enter cultured NB cells. Thus, LCA 
prevents proliferation of human NB cells and selectively kills these cancer cells by 
binding to their surface and then initiating intracellular signaling cascades that not only 
impair their growth and division, but also cause their apoptotic death. The demonstrated 
inability of LCA to enter cultured human NB cells suggests that this potent and selective 
anti-cancer compound is unlikely to display undesirable side effects in non-cancerous 
human neurons. 
            Of note, a recent collaborative effort of the laboratories of Dr. Troy Harkness 
(Department of Anatomy and Cell Biology, University of Saskatchewan) and Dr. 
Vladimir Titorenko has revealed that in low concentrations LCA kills cultured MCF7 
human breast cancer cells and F98 rat glioblastoma cells. Thus, LCA exhibits a universal 
anti-tumor effect, as it has a very broad cytotoxic effect on cancer cells derived from 
different tissues and from different organisms. 
 
5.2 Introduction 
            In the commonly accepted paradigm of the relationship between aging and cancer, 
these two complex and dynamic biological phenomena share common aetiology (i.e., an 
age-related progressive accumulation of cellular damage) and have coalescent underlying 
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mechanisms [157 - 159]. In this paradigm: 1) genetic interventions that accelerate the 
age-related accumulation of cellular damage (or hasten some other common aetiologies 
of aging and cancer) and target some of the common mechanisms underlying aging and 
cancer are expected to exhibit both pro-aging and pro-cancer effects; and 2) genetic, 
pharmacological and/or dietary interventions that reduce the age-related accumulation of 
cellular damage (or attenuate some other common aetiologies of aging and cancer) and 
target some of the common mechanisms underlying aging and cancer are expected to 
exhibit both anti-aging and anti-cancer effects [157 - 159]. A body of evidence supports 
the validity of this hypothesis (see chapter 1 of my thesis for a detailed discussion of this 
topic). The predicted by the commonly accepted paradigm of the relationship between 
aging and cancer convergent underlying mechanisms linking these two biological 
phenomena include: 1) a longevity-defining signaling network that integrates the pro-
aging AMP-activated protein kinase/target of rapamycin (AMPK/TOR), cAMP/protein 
kinase A (cAMP/PKA) and insulin/insulin-like growth factor 1 (IGF-1) signaling 
pathways and also includes a sirtuin-governed protein deacetylation module [156 - 208]; 
2) autophagy, a cytoprotective process in which old and damaged cellular proteins and 
organelles are delivered to the lysosome for degradation that allows cells to recycle their 
damaged components under various cellular stress conditions [157, 158, 364 - 378];  and 
3) mitochondrial TCA cycle and respiration as well as ROS production and detoxification 
in mitochondria [157, 158, 379 - 389].  
            In the conceptual framework of the above paradigm of the relationship between 
aging and cancer, pharmacological interventions that attenuate common aetiologies of 
these complex biological phenomena and target their common underlying mechanisms 
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are expected to exhibit both anti-aging and anti-cancer effects [157 - 159]. In a series of 
experiments described in this chapter of my thesis, I examined if the recently discovered 
anti-aging compound LCA (see chapter 3) also exhibits an anti-tumor effect in cultured 
human NB cancer cells. As I found, this bile acid indeed displays a potent and specific 
anti-tumor effect. My elucidation of mechanisms underlying such effect of LCA provided 
strong evidence that this bile acid: 1) activates both intrinsic (mitochondrial) and extrinsic 
(death receptor) pathways of apoptotic death in cultured human NB cancer cells; 2) 
sensitizes these cells to hydrogen peroxide-induced death; and 3) prevents growth and 
proliferation of their neighbouring NB cells in the culture. 
 
5.3 Materials and Methods 
Cell cultures  
Human NB cell lines SK-n-MCIXC, BE(2)-m17 and SH-SY5Y were cultured in a 
mixture (ratio 1:1) of Dulbecco’s modified Eagle’s medium (DMEM) and Hamm’s F12 
nutrient mixture (Gibco, Carlsbad, CA) with 10% fetal bovine serum (FBS) (HyClone, 
Logan, UT), while SK-n-SH cells were cultured in Eagle’s minimal essential medium 
(MEM) (Gibco) with 10% FBS. Lan-1 cells were cultured in DMEM (Gibco) with 10% 
bovine calf serum (BCS) (HyClone). Human primary neurons were prepared from fetal 
cerebrum tissue and cultured as previously described [362], in accordance with the 
Canadian Institute of Health Research regulations and as approved by the McGill 
University Institutional Review Board. All cell lines were cultured at 37°C with 5% CO2. 
 
Treatment of cells with LCA, hydrogen peroxide and z-DEVD-fmk  
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Stock solutions of LCA (Sigma-Aldrich, St Louis, MI) in varying concentrations were 
first made in 100% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MI). These 
stock solutions were then diluted to a certain final concentration of LCA (the final 
concentration of DMSO was always kept at 1%) in either DMEM/Hamm’s F12 mixture 
with 10% FBS (for SK-n-MXIXC and BE(2)-m17 cells), MEM with 10% FBS (for SK-
n-SH cells) or DMEM with 10% BCS (for Lan-1 cells). For treatment of human primary 
neurons, stock solutions of LCA in varying concentrations made in 100% DMSO were 
diluted in MEM containing 0.225%
 
sodium bicarbonate, 1 mM sodium pyruvate, 2 mM 
L-glutamine, 0.1%
 
dextrose (all from Life Technologies,
 
Gaithersburg, MD) and 5% FBS 
(HyClone,
 
Logan, UT) to a certain final concentration of LCA (the final concentration of 
DMSO was always kept at 1%). In experiments involving cell treatment with z-DEVD-
fmk, this caspase-3 inhibitor was added to a final concentration of 5 μM simultaneously 
with LCA.  
            For hydrogen peroxide treatment, 30% hydrogen peroxide (Fisher Scientific, 
Waltham, MA) was diluted in sterile H2O and added directly to the cultures after 24 h of 
pre-treatment with LCA. Cell cultures supplemented with hydrogen peroxide were 
incubated for 24 h.  
 
Cell viability assays 
Chromatin in cells exposed to LCA and/or hydrogen peroxide was visualized with the 
fluorescent dye Hoechst used at a final concentration of 4 μM in culture media and 
viewed using fluorescence microscopy. For each cell culture, the percentage of viable 
non-apoptotic cells carrying intact, non-fragmented nuclei containing non-condensed 
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chromatin was calculated. Dead apoptotic cells carried fragmented nuclei containing 
condensed chromatin, a hallmark event of apoptotic death.  
            The number of viable cells in cultures exposed to LCA was measured using the 
MTT (3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide)-based CellTiter 96 
Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI). In this assay, only 
viable, metabolically active cells were able to reduce the yellow tetrazolium salt of MTT 
to form a purple formazan product. This insoluble product was solubilized by the addition 
of a detergent. The resulting intracellular purple formazan was then detected 
spectrophotometrically using a 96-well plate reader at a wavelength of 570 nm. The 
signal was corrected to account for cellular debris using a wavelength of 630 nm.  
 
Visualization of mitochondria and measurement of the mitochondrial membrane 
potential by fluorescence microscopy  
Mitochondrial morphology of cells treated with LCA was visualized using MitoTracker 
Red CMXRos (Molecular Probes, San Diego, CA) used at a concentration of 125 nM in 
the culture media. Cells were viewed using fluorescence microscopy, and the percentage 
of cells displaying fragmented mitochondria was calculated.  
            The mitochondrial membrane potential () was measured using 
tetramethylrhodamine ethyl ester (TMRE), a
 
cell-permeant, cationic fluorescent dye. The 
extent of reversible sequestration of TMRE by mitochondria is proportional to the value 
of . Cells were incubated in 50 nM of TMRE for 20 minutes and directly viewed 
using fluorescence microscopy. The percentage of TMRE-positive cells displaying a 





For all cells and fluorescent dyes, images were collected with a Nikon Eclipse (TE2000-
U) inverted fluorescence microscope under
 
20 × magnification. A filter cube with an 
excitation wavelength of 330-380 nm was used to visualize Hoechst-stained cells. Cells 
stained with MitoTracker Red CMXRos and TMRE were visualized using filter cubes 
with excitations of 590-650 nm and 532-587 nm, respectively. 
 
Subcellular fractionation, isolation of the crude mitochondrial fraction, protein 
separation by SDS-PAGE and immunoblotting 
Cells were washed with PBS, resuspended in homogenization buffer (8% sucrose, 20 mM 
Tricine pH 7.8, 1 mM EDTA) and homogenized with a dounce homogenizer (VWR, 
Mississauga, ON). Cell debris was sedimented by centrifugation for 10 min at 2000 rpm. 
The resulting supernatant was then centrifuged for 10 min at 13000 rpm at 4
o
C. The 
pellet containing the crude mitochondrial fraction was resuspended in lysis buffer (150 
mM NaCl, 2 mM EDTA, 0.5% Triton X-100 (v/v), 0.5% sodium deoxycholate (w/v) and 
50 mM Tris-HCl pH 7.5).  
            Proteins recovered in the mitochondrial (pellet) and cytoplasmic (supernatant) 
fractions were resolved by SDS-PAGE in a 15% polyacrylamide gel and then transferred 
to a PVDF Immobilon-P membrane. Following wash with 5% milk, blots were incubated 
with 1/500 anti-cytochrome-c antibody (Pharmingen, San Diego, CA) or 1/500 anti-
mitoHsp70 antibody (ABR Affinity BioReagents, Golden, CO). Immunoreactivity was 
detected using 1/1000 anti-mouse horseradish peroxidase-conjugated antibody 
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(Amersham, Oakville, ON). Antigen-antibody complexes were visualized by enhanced 
chemiluminescence using an ECL plus chemiluminescence Western blotting detection 
reagents (Amersham Pharmacia Biotech, Piscataway, NJ). 
     
Caspase activity assays 
Proteins were extracted from harvested cells using an ice-cold lysis buffer containing 50 
mM HEPES, 0.1% CHAPS, 0.1 mM EDTA and protease inhibitors (0.1μg/ml TLCK, 0.5 
μg/ml leupeptin, 38 mg/ml AEBSF and 0.1 μg/ml pepstatin A). The cell lysate was 
centrifuged at 13000 × g for 5 min at 4
o
C to remove cell debris and any detergent-
insoluble proteins. The supernatant was collected and frozen at -80
o
C. Extracts were 
thawed and protein concentrations were quantified with the Pierce BCA assay (Thermo 
Scientific, Waltham, MA). The extracts were then assayed for caspase activities using 
fluorogenic substrates specific for caspase-1 (10 μM Ac-YVAD-AFC), caspase-3 (5 μM 
Ac-DEVD-AFC), caspase-6 (10 μM Ac-VEID-AFC), caspase-8 (10 μM Ac-IETD-AFC) 
or caspase-9 (10 μM Ac-LEHD-AFC) in caspase reaction buffer (20 mM PIPES, 30 mM 
NaCl, 10 mM DTT, 1 mM EDTA, 0.1% CHAPS and
 
10% sucrose, pH 7.2). The time-
dependent release of the fluorescent compound 7-amino-4-trifluoromethyl coumarin 
(AFC) was
 
monitored using a Bio-Rad Fluoromark fluorometer (Hercules, CA) at an 
excitation wavelength of 390 nm and an emission wavelength of 538
 
nm. Measurements 
were recorded at 2 min
 
intervals for 1 h. A standard curve of AFC fluorescence was used 
to calculate AFC (in picomoles) released in the
 
reactions. Specific activities were 
expressed as picomoles of
 
AFC released per microgram of protein per minute, based on
 






Pro-caspase-3 and pro-caspase-6 cleavage assays 
50 μg of protein from crude cellular extracts were resolved by SDS-PAGE in a 15% 
polyacrylamide gel and then transferred to a PVDF Immobilon-P membrane (Millipore, 
Bedford, MA). Following wash with 5% milk, blots were incubated with antibodies used 
at the following dilutions: 1/500 anti-cleaved-caspase-3 p17 (Cell Signaling, Beverly, 
MA), 1/250 anti-cleaved-caspase-6 p10 (Pharmingen, San Diego, CA) and 1/5000 anti--
Actin (Sigma-Aldrich, St Louis, MI). Immunoreactivity was detected using 1/2000 (for 
anti-rabbit) and 1/5000 (for anti-mouse) horseradish peroxidase-conjugated secondary 
antibodies (Amersham, Oakville, ON). Antigen-antibody complexes were detected by 
enhanced chemiluminescence using an ECL plus chemiluminescence Western blotting 
detection reagents (Amersham Pharmacia Biotech, Piscataway, NJ). 
 
Mass spectrometric measurement of LCA  
Mass spectrometry-based quantitative analysis of LCA was performed as previously 
reported [363].  In brief, lipids were extracted by a modified Bligh and Dyer method 
[363] from cells pelleted by centrifugation for 16000 × g for 5 min at 4
o
C and from the 
supernatant of cultural medium. The extracted lipids were dried under nitrogen and 
resuspended in chloroform. Immediately prior to injection the extracted lipids were 
combined with 2:1 methanol:chloroform with 0.1% (v/v) ammonium hydroxide. This was 
injected directly into a Q-TOF 2 mass spectrometer (Waters, Milford, MA) using a nano-
ESI spray source at 1 µl/min. Spectra were obtained in a negative-ion mode. Acquired 
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spectra were centroided using the Masslynx software then deconvoluted and deisotoped 
with Excel macros. 
 
Statistical analysis  
Statistical analysis was performed using Systat (version 10.2) and Microsoft Excel’s 
(2007) Analysis ToolPack-VBA. Comparisons between multiple groups were done using 
multiple t-tests followed by a Bonferroni correction. All data are presented as group 




5.4.1 LCA selectively kills cultured human NB cells by causing their apoptotic 
death if used at concentrations that are not cytotoxic to primary cultures of 
human neurons  
            In addition to its great life-extending efficacy in yeast, LCA also exhibits a potent 
and selective anti-tumor effect in several lines of cultured human NB cells. In fact, I 
found that this bile acid kills cultured human NB cell lines BE(2)-m17, Lan-1, SK-n-SH 
and SK-n-MCIXC if used at concentrations that are not cytotoxic or only mildly 
cytotoxic (as in case of Lan-1 cells) to primary cultures of human neurons (Figures 5.1 - 
5.4). The percentage of viable cells in these cell viability experiments was calculated as a 
portion of their population displaying a detectable level of redox potential which was 
visualized using the yellow tetrazolium salt of MTT (3-(4,5-dimethylthiozol-2-yl)-2,5-
diphenyltetrazolium bromide). In this assay, only viable, metabolically active cells were 
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able to reduce the yellow tetrazolium salt of MTT to form a purple formazan product, 
which was detected spectrophotometrically at a wavelength of 570 nm [397 - 400]. 
1. LA kills M 17, SK-n-SH and M C-IXC cells but not LAN-1 or neurons - M TT 
staining      ( Fi l e  "LA_ Ra nge _ Vi a bi l i t y _ M TT_ Ne ur ons_ v s_ Ne ur obl a st oma s"; a t  l e a st  3  

































Figure 5.1. LCA kills cultured human NB cell lines BE(2)-m17, Lan-1, SK-n-SH and SK-n-MCIXC if 
used at concentrations that are not cytotoxic or only mildly cytotoxic (as in case of Lan-1 cells) to primary 
cultures of human neurons. The percentage of viable cells was calculated as a portion of their population 
displaying a detectable level of redox potential which was visualized using the MTT (3-(4,5-
dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide)-based CellTiter 96 Non-Radioactive Cell 
Proliferation Assay. In this assay, only viable, metabolically active cells were able to reduce the yellow 
tetrazolium salt of MTT to form a purple formazan product, which was detected spectrophotometrically at a 




            The NB cell line SK-n-MCIXC was the most sensitive (as compared to other NB 
cell lines tested and especially as compared to primary cultures of human neurons) to the 
cytotoxic effect of LCA; I found that less than 10% of SK-n-MCIXC cells remain viable 
when exposed to 200 μM LCA, a concentration which was not cytotoxic to primary 
cultures of human neurons (Figure 5.2). 
Figure 5.2.
2 . 200 uM  LA kills M 17, SK-n-SH and M C-IXC cells but not LAN-1 or 
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Figure 5.2. The NB cell line SK-n-MCIXC is the most sensitive (as compared to other NB cell lines tested 
and especially as compared to primary cultures of human neurons) to the cytotoxic effect of LCA. Less 
than 10% of SK-n-MCIXC cells remain viable when exposed to 200 μM LCA, a concentration which is not 
cytotoxic to primary cultures of human neurons (Figure 5.2). The percentage of viable cells was calculated 
as a portion of their population displaying a detectable level of redox potential which was visualized using 
the MTT (3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide)-based CellTiter 96 Non-
Radioactive Cell Proliferation Assay. In this assay, only viable, metabolically active cells were able to 
reduce the yellow tetrazolium salt of MTT to form a purple formazan product, which was detected 




            Two NB cell lines, BE(2)-m17 and SK-n-SH, exhibited much higher sensitivity to 
LCA than primary cultures of human neurons (or than the NB cell line Lan-1); in fact, I 
found that less than 10% of BE(2)-m17 and SK-n-SH cells remain viable when exposed 
to 300 μM LCA, a concentration which was not cytotoxic to primary cultures of human 



































Figure 5.3. The NB cell lines BE(2)-m17 and SK-n-SH exhibit much higher sensitivity to LCA than 
primary cultures of human neurons (or than the NB cell line Lan-1). Less than 10% of BE(2)-m17 and SK-
n-SH cells remain viable when exposed to 300 μM LCA, a concentration which is not cytotoxic to primary 
cultures of human neurons and only mildly cytotoxic to Lan-1 cells. The percentage of viable cells was 
calculated as a portion of their population displaying a detectable level of redox potential which was 
visualized using the MTT (3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide)-based CellTiter 
96 Non-Radioactive Cell Proliferation Assay. In this assay, only viable, metabolically active cells were able 
to reduce the yellow tetrazolium salt of MTT to form a purple formazan product, which was detected 




            Although being less sensitive to the cytotoxic effect of LCA than the three other 
NB cell lines tested, the NB cell line Lan-1 was significantly more sensitive to LCA than 
primary cultures of human neurons; I found that less than 10% of Lan-1 cells remain 
viable when exposed to 500 μM LCA, a concentration which was only mildly cytotoxic 
































Figure 5.4. Although the NB cell line Lan-1 is less sensitive to the cytotoxic effect of LCA than the three 
other NB cell lines tested (see Figures 5.1 to 5.3), it is significantly more sensitive to LCA than primary 
cultures of human neurons. Less than 10% of Lan-1 cells remain viable when exposed to 500 μM LCA, a 
concentration which is only mildly cytotoxic to primary cultures of human neurons. The percentage of 
viable cells was calculated as a portion of their population displaying a detectable level of redox potential 
which was visualized using the MTT (3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide)-
based CellTiter 96 Non-Radioactive Cell Proliferation Assay. In this assay, only viable, metabolically 
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active cells were able to reduce the yellow tetrazolium salt of MTT to form a purple formazan product, 
which was detected spectrophotometrically at a wavelength of 570 nm. Data are presented as means ± SD 
(n = 4-5); *p < 0.05. 
 
            My data imply that if LCA is used at concentrations that are not cytotoxic to 
primary cultures of human neurons, it selectively kills the NB cell lines BE(2)-m17, SK-
n-SH and SK-n-MCIXC by causing their apoptotic death. In experiments that support this 
notion, I used the fluorescent dye Hoechst to visualize chromatin in various NB cell 
cultures and in primary cultures of human neurons exposed to LCA or remained 
untreated. For each cell culture, I calculated the percentage of viable non-apoptotic cells 
carrying intact, non-fragmented nuclei containing non-condensed chromatin. Dead 
apoptotic cells carried condensed and/or fragmented nuclei, a major hallmark event of 
apoptotic death that is not seen under any other modes of cell death [401 - 403]. I found 
that the NB cell line SK-n-MCIXC is the most sensitive (as compared to other NB cell 
lines tested and especially as compared to primary cultures of human neurons) to LCA-
induced apoptotic death (Figures 5.5 and 5.6). Furthermore, my findings imply that two 
NB cell lines, BE(2)-m17 and SK-n-SH, exhibit much higher sensitivity to LCA-induced 
apoptotic death than primary cultures of human neurons (or than the NB cell line Lan-1); 
however, these two NB cell lines are less sensitive to LCA-induced apoptotic cell death 
than the NB cell line SK-n-MCIXC (Figures 5.5 and 5.6). 
            Moreover, although at certain concentrations of LCA the NB cell line Lan-1 was 















































































Figure 5.5. If used at concentrations that are not cytotoxic to primary cultures of human neurons (see 
Figure 5.1 to 5.4), LCA selectively kills the NB cell lines BE(2)-m17, SK-n-SH and SK-n-MCIXC by 
causing their apoptotic death. The fluorescent dye Hoechst was used to visualize chromatin in various NB 
cell cultures and in primary cultures of human neurons exposed to LCA or remained untreated. For each 
cell culture, the percentage of viable non-apoptotic cells carrying intact, non-fragmented nuclei containing 
non-condensed chromatin was calculated. Dead apoptotic cells carried fragmented nuclei containing 
condensed chromatin, a hallmark event of apoptotic death. Data are presented as means ± SD (n = 4-6).  
 
cultures of human neurons (Figure 5.4), this cell line did not exhibit higher sensitivity to 
LCA-induced apoptotic cell death than primary cultures of human neurons did (Figures 
















































































Figure 5.6. The NB cell line SK-n-MCIXC is the most sensitive (as compared to other NB cell lines tested 
and especially as compared to primary cultures of human neurons) to LCA-induced apoptotic death. Two 
other NB cell lines, BE(2)-m17 and SK-n-SH, exhibit much higher sensitivity to LCA-induced apoptotic 
death than primary cultures of human neurons (or than the NB cell line Lan-1); however, these two NB cell 
lines are less sensitive to LCA-induced apoptotic cell death than the NB cell line SK-n-MCIXC. The 
fluorescent dye Hoechst was used to visualize chromatin in various NB cell cultures and in primary cultures 
of human neurons exposed to LCA or remained untreated. For each cell culture, the percentage of viable 
non-apoptotic cells carrying intact, non-fragmented nuclei containing non-condensed chromatin was 
calculated. Dead apoptotic cells carried fragmented nuclei containing condensed chromatin, a hallmark 
event of apoptotic death. Data are presented as means ± SD (n = 4-6); *p < 0.05. 
 
cultures of human neurons but exhibit strong MTT-monitored cytotoxic effect in Lan-1 
cells (Figure 5.4), it selectively kills this NB cell line not by causing its apoptotic death. 
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One could speculate that LCA selectively kills Lan-1 cells by causing their necrotic or 
some other non-apoptotic kind of death, which is not characterized by such major 
distinctive (i.e., not seen under any other modes of cell death) event of apoptotic cell 
death as nuclear condensation and fragmentation.  
 
5.4.2 LCA sensitizes cultured human NB cells to hydrogen peroxide-induced 
apoptotic cell death 
            The exogenously added hydrogen peroxide has been shown to cause 
mitochondria-controlled apoptotic death in various types of cultured eukaryotic cells [390 
- 396]. I found that LCA protects primary cultures of human neurons – but not cultured 
human NB cell lines BE(2)-m17 or SK-n-MCIXC – against mitochondria-controlled 
apoptosis induced in response to exogenously added 0.1 mM hydrogen peroxide (Figures 
5.7 and 5.8). In these experiments, chromatin condensation and nuclear fragmentation 
were visualized with the fluorescent dye Hoechst and were used as a measure of the 
efficacy of hydrogen peroxide-induced apoptotic cell death. Importantly, I found that 
LCA greatly enhances the susceptibility of cultured human NB cell lines BE(2)-m17 and 
SK-n-MCIXC to such hydrogen peroxide-induced form of mitochondria-controlled 
apoptotic cell death (Figures 5.7 and 5.8), even when this bile acid was used at 
concentrations that in the absence of hydrogen peroxide do not compromise their viability 
(compare Figures 5.1 and 5.5 to Figures 5.7 and 5.8).  It should be stressed that, while 75 
μM LCA caused apoptotic death of all or most of the BE(2)-m17 and SK-n-MCIXC cells 
exposed to 0.1 mM hydrogen peroxide, in this concentration LCA greatly increased the 
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resistance of primary cultures of human neurons to the hydrogen peroxide-induced form 
of  mitochondria-controlled  apoptotic  cell  death (Figures  5.7  and  5.8). Based  on these  
Figure 5.7.
LCA protects primary cultures of human neurons but not NB cells 






































































Figure 5.7. LCA protects primary cultures of human neurons – but not cultured human NB cell lines 
BE(2)-m17 or SK-n-MCIXC – against mitochondria-controlled apoptosis induced in response to 
exogenously added 0.1 mM hydrogen peroxide. Moreover, LCA greatly enhances the susceptibility of 
cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC to such hydrogen peroxide-induced form of 
mitochondria-controlled apoptotic cell death, even when this bile acid is used at concentrations that in the 
absence of hydrogen peroxide do not compromise their viability (compare to Figures 5.1 and 5.5). Nuclear 
fragmentation and chromatin condensation were visualized with the fluorescent dye Hoechst and were used 
as a measure of the efficacy of hydrogen peroxide-induced apoptotic cell death. For each cell culture, the 
percentage of viable non-apoptotic cells carrying intact, non-fragmented nuclei containing non-condensed 




observations, it seems likely that the exposure of a mixed population of various NB cell 









































































Figure 5.8. While 75 μM LCA causes apoptotic death of all or most of the cells of cultured human NB cell 
lines BE(2)-m17 and SK-n-MCIXC exposed to 0.1 mM hydrogen peroxide, in this concentration LCA 
greatly increases the resistance of primary cultures of human neurons to the hydrogen peroxide-induced 
form of  mitochondria-controlled  apoptotic  cell  death in the absence of hydrogen peroxide do not 
compromise their viability (compare to Figures 5.1 and 5.5). Nuclear fragmentation and chromatin 
condensation were visualized with the fluorescent dye Hoechst and were used as a measure of the efficacy 
of hydrogen peroxide-induced apoptotic cell death. For each cell culture, the percentage of viable non-
apoptotic cells carrying intact, non-fragmented nuclei containing non-condensed chromatin was calculated. 




peroxide and LCA may concurrently 1) kill all NB cells by causing their apoptotic death; 
and 2) promote the viability of non-cancerous neurons by increasing their resistance to 
hydrogen peroxide-induced apoptosis. 
 
5.4.3 In two NB cell lines, LCA causes the efflux of cytochrome c from 
mitochondria, activation of the initiator caspase-9, mitochondrial 
fragmentation and loss of mitochondrial transmembrane potential - all 
characteristic of the intrinsic (mitochondrial) apoptotic death pathway  
            As described above in this chapter of my thesis, I found that LCA: 1) selectively 
kills the NB cell lines BE(2)-m17, SK-n-SH and SK-n-MCIXC by causing nuclear 
condensation and fragmentation, a major hallmark event of apoptotic cell death; and 2) 
greatly enhances the susceptibility of cultured human NB cell lines BE(2)-m17 and SK-n-
MCIXC to hydrogen peroxide-induced form of mitochondria-controlled apoptotic cell 
death. Therefore, I sought to investigate if LCA kills these cultured human NB cell lines 
by activating the intrinsic (mitochondrial) apoptotic death pathway.  
            The key feature of the mitochondrial pathway of apoptosis is mitochondrial outer 
membrane permeabilization (MOMP), which leads to the release of cytochrome c (and 
several other pro-apoptotic proteins) from the mitochondrial intermembrane space into 
the cytosol [404 - 407]. Following its efflux from mitochondria, cytochrome c binds an 
apoptotic protease-activating factor 1 (APAF-1) monomer whose oligomerization into the 
heptameric apoptosome complex recruits caspase-9 and ultimately activates this initiator 
caspase [403, 404, 408, 409]. I found that in cultured human NB cell line SK-n-MCIXC, 
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LCA triggers the release of cytochrome c from the mitochondrial intermembrane space 
into the cytosol (Figure 5.9).  
Figure 5.9.







Figure 5.9. In cultured human NB cell line SK-n-MCIXC, LCA triggers the release of cytochrome c from 
the mitochondrial (M) intermembrane space into the cytosol (C). Unlike mitochondrial Hsp70p, whose 
significant quantities remain associated with mitochondria purified from SK-n-MCIXC cells exposed to 
LCA, the bulk quantities of cytochrome c exit mitochondria in these human NB cells. Proteins recovered in 
the mitochondrial (M) and cytoplasmic (C) fractions were resolved by SDS-PAGE in a 15% 
polyacrylamide gel and then transferred to a PVDF Immobilon-P membrane. Following wash with 5% 
milk, blots were incubated with 1/500 anti-cytochrome-c antibody or 1/500 anti-mitoHsp70 antibody. 
Immunoreactivity was detected using 1/1000 anti-mouse horseradish peroxidase-conjugated antibody. 
Antigen-antibody complexes were visualized by enhanced chemiluminescence using an ECL plus 
chemiluminescence Western blotting detection reagents. 
 
The observed efflux of cytochrome c from mitochondria in LCA-treated SK-n-MCIXC 
cells was not an artifact of the mitochondrial purification procedure. Indeed, unlike 
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cytochrome c (whose bulk quantities were recovered in the cytoplasmic fraction), 
significant quantities of the mitochondrial protein Hsp70p remained associated with 
mitochondria purified from SK-n-MCIXC cells exposed to LCA (Figure 5.9).   
            Furthermore, I also revealed that LCA significantly increases the activity of the 
initiator caspase-9 in cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC (Figure 
5.10). Of note, the higher LCA-induced activity of caspase-9 in SK-n-MCIXC cells - as 
compared to that in BE(2)-m17 cells – correlated with the higher sensitivity of SK-n-
MCIXC (as compared to that of BE(2)-m17) to the cytotoxic and apoptotic cell death 
effects of LCA on human NB cell lines in culture (compare Figures 5.1 and 5.5 to Figure 
5.10). It should be stressed that, unlike the stimulating effect of LCA on caspase-9 seen in 
BE(2)-m17 and SK-n-MCIXC cells, this bile acid did not increase caspase-9 activity in 
cultured human NB cell line Lan-1 (Figure 5.10). As I mentioned above, LCA selectively 
kills Lan-1 cells (Figures 5.1 and 5.4) not by causing their apoptotic death (Figures 5.5 
and 5.6), but perhaps by promoting their necrotic or some other non-apoptotic kind of 
death – the one which is not characterized by such major hallmark event of apoptotic cell 
death as nucleus condensation and fragmentation. 
            One of the earliest distinctive events of the mitochondrial pathway of apoptosis is 
the fragmentation of a tubular mitochondrial network into individual mitochondria 
(mitochondrial fragmentation) [403 - 406, 410, 411]. This hallmark event of 
mitochondria-dependent cell death occurs before caspase-9 activation, around the point 
of MOMP and cytochrome c efflux from mitochondria, and is caspase-independent [403, 
404, 410, 411]. I found that LCA causes mitochondrial fragmentation in cultured human 












































































































































Figure 5.10. LCA significantly increases the activity of the initiator caspase-9 in cultured human NB cell 
lines BE(2)-m17 and SK-n-MCIXC. Proteins were extracted from harvested cells using an ice-cold lysis 
buffer. The cell lysate was centrifuged at 13000 × g for 5 min at 4oC to remove cell debris and any 
detergent-insoluble proteins. The supernatant was collected and frozen at -80oC. Extracts were thawed and 
then assayed for caspase-9 activity using 10 μM Ac-LEHD-AFC as a fluorogenic substrate specific for this 
caspase. The time-dependent release of the fluorescent compound 7-amino-4-trifluoromethyl coumarin 
(AFC) was monitored using a Bio-Rad Fluoromark fluorometer at an excitation wavelength of 390 nm and 
an emission wavelength of 538 nm. Measurements were recorded at 2 min intervals for 1 h.  
 
efficacy of LCA-induced mitochondrial fragmentation observed in SK-n-MCIXC cells - 
as compared to that seen in BE(2)-m17 cells - correlated with the higher sensitivity of 
SK-n-MCIXC (as compared to that of BE(2)-m17) to the cytotoxic and apoptotic cell 
death effects of LCA on human NB cell lines in culture (compare Figures 5.1 and 5.5 to 
Figure 5.11B). Moreover, if used at a concentration that leads to fragmentation of the 
entire mitochondrial network (i.e., 125 μM - 150 μM) in BE(2)-m17 and SK-n-MCIXC 




Figure 5.11. LCA causes mitochondrial fragmentation in cultured human NB cell lines BE(2)-m17 and 
SK-n-MCIXC. If used at a concentration that leads to fragmentation of the entire mitochondrial network 
(i.e., 125 μM - 150 μM) in BE(2)-m17 and SK-n-MCIXC cells,  LCA  did  not  cause  such mitochondrial 
fragmentation in cultured human NB cell line Lan-1 – whose LCA-induced death in culture was not due to 
apoptosis. Mitochondrial morphology of cells treated with LCA was visualized using MitoTracker Red 
CMXRos used at a concentration of 125 nM in the culture media. Cells were viewed using fluorescence 
microscopy, and the percentage of cells displaying fragmented mitochondria was calculated.  
   
line Lan-1 (Figure 5.11B) – whose LCA-induced death in culture (Figures 5.1 and 5.4) 
was not due to apoptosis (see Figures 5.5 and 5.6 and discussion in section 5.4.1).   




Figure 5.12. LCA triggers the dissipation of the electrochemical potential across the inner mitochondrial 
membrane in cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC. The mitochondrial membrane 
potential () was measured using tetramethylrhodamine ethyl ester (TMRE), a cell-permeant, cationic 
fluorescent dye. The extent of reversible sequestration of TMRE by mitochondria is proportional to the 
value of . Cells were incubated in 50 nM of TMRE for 20 minutes and directly viewed using 
fluorescence microscopy. The percentage of TMRE-positive cells displaying a detectable level of  was 
calculated.  
  
            A progressive decline in mitochondrial function during mitochondria-controlled 
apoptosis, including a gradual dissipation and eventual loss of mitochondrial 
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transmembrane potential, follows MOMP and occurs in both caspase-dependent and 
caspase-independent fashion [403 - 405, 412 - 415]. I found that LCA triggers the 
dissipation of the electrochemical potential across the inner mitochondrial membrane in 
cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC (Figure 5.12). Again, the 
higher efficacy of LCA-induced mitochondrial inner membrane depolarization observed 
in SK-n-MCIXC cells - as compared to that seen in BE(2)-m17 cells - correlated with the 
higher sensitivity of SK-n-MCIXC (as compared to that of BE(2)-m17) to the cytotoxic 
and apoptotic cell death effects of LCA on human NB cell lines in culture (compare 
Figures 5.1 and 5.5 to Figure 5.12B). Moreover, if used at a concentration that leads to a 
complete loss of mitochondrial transmembrane potential (i.e., 150 μM - 200 μM) in all 
cells of the cultured NB lines BE(2)-m17 and SK-n-MCIXC, LCA did not cause 
mitochondrial inner membrane depolarization or caused only minor reduction of 
mitochondrial transmembrane potential in cultured human NB cell line Lan-1 (Figure 
5.12B) – whose LCA-induced death in culture (Figures 5.1 and 5.4) was not due to 
apoptosis (see Figures 5.5 and 5.6 and discussion in section 5.4.1).  
 
5.4.4 In two NB cell lines, LCA triggers a proteolytic cascade of events leading to 
activation of two executioner caspases, caspase-3 and caspase-6  
            The apoptosome-driven activation of caspase-9 during mitochondria-controlled 
apoptosis initiates a branched cascade of events resulting in a step-wise proteolytic 
activation of several executioner caspases [403, 416, 417]. The caspase-9-dependent 
proteolytic activation of the executioner caspases-3 and -7 is followed by the caspase-3-



























































Figure 5.13. LCA increases the activity of caspase-3 in cultured human NB cell lines BE(2)-m17 and SK-
n-MCIXC (A) by promoting a proteolytic conversion of a zymogen pro-caspase-3 form of this executioner 
caspase into its enzymatically active 17 kDa form (B). In contrast, if used even at a higher concentration 
(i.e., 250 μM) than the ones causing the highest extent of the LCA-induced proteolytic activation of 
caspase-3 (i.e., 125 μM or 150 μM) in SK-n-MCIXC and BE(2)-m17 cells, LCA does not promote its 
proteolysis-driven activation in cultured human NB cell line Lan-1 (C). Data in (A) are presented as means 
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Figure 5.14. z-DEVD-fmk, a potent and specific inhibitor of caspase-3, completely inhibits the LCA-
induced activity of this caspase in cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC. z-DEVD-
fmk was used at the concentration of 5 μM. DMSO was used as a solvent at the standard concentration of 
1%. Data are presented as means ± SD (n = 3-4); *p < 0.05. 
 
caspase-6-driven proteolytic activation of the executioner caspase-10 [403, 416, 417]. 
When the full complement of executioner caspases that are necessary for the proper 
execution of the mitochondria-controlled apoptotic program becomes activated, these 
caspases complete the demolition phase of the program by cleaving their respective 
protein substrates and producing the morphological features characteristic of apoptotic 
cell death [403 - 405].  
            I found that LCA increases the activity of caspase-3 in cultured human NB cell 
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Figure 5.15. z-DEVD-fmk, a potent and specific inhibitor of caspase-3, weakens the anti-tumor effect of 
LCA in cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC. z-DEVD-fmk was used at the 
concentration of 5 μM. DMSO was used as a solvent at the standard concentration of 1%. The percentage 
of alive human cells was calculated as a portion of their population carrying intact, non-fragmented nuclei 
containing non-condensed chromatin that were visualized using the Hoechst fluorescent dye. Dead human 
cells carried condensed and/or fragmented nuclei, a major hallmark event of apoptotic death that is not seen 
under any other modes of cell death. Data are presented as means ± SD (n = 3-4); *p < 0.05. 
 
conversion of a zymogen pro-caspase-3 form of this executioner caspase into its 
enzymatically active 17 kDa form (Figure 5.13B). It should be stressed that the anti-
tumor effect of LCA in these two NB cell lines was due, at least in part, to the ability of 
this bile acid to increase the activity of the executioner caspase-3. In fact, I found that z-
DEVD-fmk – a potent and specific inhibitor of caspase-3 (see Figure 5.14) – significantly 





















































Figure 5.16. LCA increases the activity of caspase-6 in cultured human NB cell lines BE(2)-m17 and SK-
n-MCIXC (A) by promoting a proteolytic conversion of a 32-kDa zymogen pro-caspase-6 form of this 
executioner caspase into its enzymatically active 10 kDa form (B). In contrast, if used even at a higher 
concentration (i.e., 250 μM) than the ones causing the highest extent of the LCA-induced proteolytic 
activation of caspase-6 (i.e., 125 μM or 150 μM) in SK-n-MCIXC and BE(2)-m17 cells, LCA does not 
promote its proteolysis-driven activation in cultured human NB cell line Lan-1 (B). Data in (A) are 
presented as means ± SD (n = 3-4); *p < 0.05. 
 
MCIXC cells in culture (Figure 5.15). The incomplete reduction by z-DEVD-fmk of the 
anti-tumor efficacy of LCA in cultured human NB cell lines BE(2)-m17 and SK-n-
MCIXC (Figure 5.15) suggests that the LCA-triggered, mitochondria-driven selective 
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apoptotic death of both these NB cell lines could be due not only to a caspase-dependent 
mechanism, but also to a caspase-independent progressive decline in mitochondrial 
function - which leads to the observed LCA-dependent loss of mitochondrial 
transmembrane potential (Figure 5.12) among other effects.   
            My findings also imply that, following its LCA-driven activation in cultured 
human NB cell lines BE(2)-m17 and SK-n-MCIXC, the executioner caspase-3 activates 
the downstream executioner caspase-6 in these cell lines (Figure 5.16A). (Caspase-6 is a 
well established executioner caspase known to be activated in vivo only following the 
caspase-3-driven proteolytic cleavage of pro-caspase-6, an enzymatically inactive 
zymogen form of caspase-6 [403, 416, 417]). Indeed, in both these NB cell lines, LCA 
promoted such cleavage of a 32-kD form of pro-caspase-6 and induced the formation of 
its enzymatically active 10-kD form (Figure 5.16B).  
            Of note, the higher extent of the LCA-induced proteolytic activation of caspase-3 
and caspase-6 observed in SK-n-MCIXC cells - as compared to that seen in BE(2)-m17 
cells – correlated with the higher sensitivity of SK-n-MCIXC (as compared to that of 
BE(2)-m17) to the cytotoxic and apoptotic cell death effects of LCA on human NB cell 
lines in culture (compare Figures 5.1 and 5.5 to Figures 5.13 and 5.16). 
            Importantly, if used at a concentration that causes the highest extent of the LCA-
induced proteolytic activation of caspase-3 and caspase-6 (i.e., 125 μM - 150 μM) in SK-
n-MCIXC and BE(2)-m17 cells, LCA did not promote their proteolysis-driven activation 
in cultured human NB cell line Lan-1 (Figures 5.13A, 5.13C and 5.16B) – whose LCA-
induced death in culture (Figures 5.1 and 5.4) was not due to apoptosis (see Figures 5.5 
and 5.6 and discussion in section 5.4.1).  
243 
 
5.4.5 In two NB cell lines, LCA increases the activity of caspase-8, an initiator 
caspase that functions in the extrinsic (death receptor) apoptotic death 
pathway but can also cause MOMP and trigger the intrinsic (mitochondrial) 
pathway of apoptosis 
            The proteolytic cleavage of pro-caspase-3 and the resulting increase of caspase-3 
activity, which in turn cleaves pro-caspase-6 and activates the downstream executioner 
caspase-6, can be triggered not only through the intrinsic (mitochondrial) apoptotic death 
pathway but also through the extrinsic (death receptor) pathway of apoptosis [403, 404]. 
This extrinsic pathway is initiated when specific extracellular death ligands cause the 
ligation of death receptors in the plasma membrane, thus triggering a process eventually 
leading to activation of the initiator caspase-8 [403, 404]. In addition to its role in the 
proteolytic activation of caspase-3, caspase-8 can also cause MOMP and trigger the 
intrinsic (mitochondrial) pathway of apoptosis [418, 419]. Indeed, following its activation 
in response to death receptor ligation caspase-8 can cleave and activate the BH-3 only 
protein BH3-interacting domain death agonist (BID), thereby causing MOMP and 
initiating the intrinsic (mitochondrial) apoptotic death pathway [403 - 404, 418, 419]. 
            As I found, LCA significantly increases the activity of the initiator caspase-8 in 
cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC (Figure 5.17). Of note, the 
higher LCA-induced activity of caspase-8 in SK-n-MCIXC cells - as compared to that in 
BE(2)-m17 cells – correlated with the higher sensitivity of SK-n-MCIXC (as compared to 
that of BE(2)-m17) to the cytotoxic and apoptotic cell death effects of LCA on human 
NB cell lines in culture (compare Figures 5.1 and 5.5 to Figure 5.17). It should be 


























































































































































Figure 5.17. LCA significantly increases the activity of the initiator caspase-8 in cultured human NB cell 
lines BE(2)-m17 and SK-n-MCIXC. In contrast, if used even at a higher concentration (i.e., 250 μM) than 
the ones causing the highest extent of the LCA-induced activation of caspase-8 (i.e., 125 μM or 150 μM) in 
SK-n-MCIXC and BE(2)-m17 cells, LCA does not promote its activation in cultured human NB cell line 
Lan-1. Proteins were extracted from harvested cells using an ice-cold lysis buffer. The cell lysate was 
centrifuged at 13000 × g for 5 min at 4oC to remove cell debris and any detergent-insoluble proteins. The 
supernatant was collected and frozen at -80oC. Extracts were thawed and then assayed for caspase-8 
activity using 10 μM Ac-IETD-AFC as a fluorogenic substrate specific for this caspase. The time-
dependent release of the fluorescent compound 7-amino-4-trifluoromethyl coumarin (AFC) was
 
monitored 
using a Bio-Rad Fluoromark fluorometer at an excitation wavelength of 390 nm and an emission 
wavelength of 538 nm. Measurements were recorded at 2 min intervals for 1 h. Data are presented as means 
± SD (n = 3-4); *p < 0.05. 
 
SK-n-MCIXC cells, this bile acid did not increase caspase-8 activity in cultured human 
NB cell line Lan-1 (Figure 5.17). As I mentioned above, LCA selectively kills Lan-1 
cells (Figures 5.1 and 5.4) not by causing their apoptotic death (Figures 5.5 and 5.6), but 
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perhaps by promoting their necrotic or some other non-apoptotic kind of death – the one 
which is not characterized by such major hallmark event of apoptotic cell death as 
nucleus condensation and fragmentation. 
            These findings suggest that LCA could kill both BE(2)-m17 and SK-n-MCIXC 
cell lines by activating not only the intrinsic (mitochondrial) apoptotic death pathway 
dependent on the initiating caspase-9 (see sections 5.4.3 and 5.4.4) but also the extrinsic 
(death receptor) apoptotic death pathway driven by the initiator caspase-8. The LCA-
dependent activation of caspase-8 in BE(2)-m17 and SK-n-MCIXC cells (Figure 5.17) 
could be responsible not only for the observed in these cells direct proteolytic activation 
of caspase-3 (Figure 5.13), but also for MOMP and the resulting efflux of cytochrome c 
from mitochondria of these cells (Figure 5.9). These LCA-induced, caspase-8-mediated 
events could ultimately trigger the intrinsic (mitochondrial) apoptotic pathway in BE(2)-
m17 and SK-n-MCIXC cells, thereby enhancing the extent of LCA-driven cellular 
demise.  
 
5.4.6 In two NB cell lines, LCA reduces the activity of caspase-1, an inflammatory 
caspase that drives the processing and secretion of the cytokines interleukin-
1β and interleukin-18 
            My findings also revealed that LCA significantly reduces the activity of caspase-1 
in cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC, but not in cultured Lan-1 
cell line (Figure 5.18). Caspase-1 is known to be an inflammatory caspase that drives the 
processing and unconventional secretion of the cytokines interleukin-1β and interleukin-







































































































































































Figure 5.18. LCA significantly reduces the activity of the inflammatory caspase-1 in cultured human NB 
cell lines BE(2)-m17 and SK-n-MCIXC. In contrast, if used even at a higher concentration (i.e., 250 μM) 
than the ones causing the highest extent of the LCA-induced inhibition of caspase-1 (i.e., 125 μM or 150 
μM) in SK-n-MCIXC and BE(2)-m17 cells, LCA does not promote its inhibition in cultured human NB 
cell line Lan-1. Proteins were extracted from harvested cells using an ice-cold lysis buffer. The cell lysate 
was centrifuged at 13000 × g for 5 min at 4oC to remove cell debris and any detergent-insoluble proteins. 
The supernatant was collected and frozen at -80oC. Extracts were thawed and then assayed for caspase-1 
activity using 10 μM Ac-YVAD-AFC as a fluorogenic substrate specific for this caspase. The time-
dependent release of the fluorescent compound 7-amino-4-trifluoromethyl coumarin (AFC) was monitored 
using a Bio-Rad Fluoromark fluorometer at an excitation wavelength of 390 nm and an emission 
wavelength of 538 nm. Measurements were recorded at 2 min intervals for 1 h. Data are presented as means 
± SD (n = 3-4); *p < 0.05. 
 
growth and proliferation of neighbouring cells in the same tissue [424 - 427]. Hence, it is 
tempting to speculate that, by reducing caspase-1 activity in cultured cells of NB lines 
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BE(2)-m17 and SK-n-MCIXC and thereby impairing their ability to process and secrete 
cytokines, LCA could prevent growth and proliferation of neighbouring NB cells in 
culture. 
            Of note, it has been shown that under some conditions in serum-deprived primary 
human neurons caspase-1 could function not as an inflammatory caspase, but as a 
positive regulator of a caspase-6-mediated apoptotic death [428]. Such pro-apoptotic 
potential of caspase-1 in primary human neurons requires an additional stress factor (a 
stress co-activator and/or removal of a caspase-1 inhibitor) [428]. A possible role of the 
observed inhibitory effect of LCA on caspase-1 activity in BE(2)-m17 and SK-n-MCIXC 
cells in modulating such pro-apoptotic activity of caspase-1 in these NB cell lines 
remains to be investigated. 
 
5.4.7 LCA does not enter cultured NB cells 
            My mass spectrometry-based measurement of intracellular and extracellular levels 
of exogenously added LCA revealed that this bile acid does not enter cultured human NB 
cell lines BE(2)-m17 (Figure 5.19), SK-n-MCIXC (Figure 5.20) and Lan-1 (Figure 5.21). 
Thus, LCA prevents proliferation of human NB cells and selectively kills these cancer 
cells (see sections 5.4.1 to 5.4.6) by binding to their surface and then initiating 
intracellular signaling cascades that not only impair their growth and division, but also 
cause their apoptotic death. The demonstrated inability of LCA to enter cultured human 
NB cells suggests that this potent and selective anti-cancer compound is unlikely to 




% of the total recovered LCA_BE(2)-m17
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Figure 5.19. Exogenously added LCA does not enter cultured human NB cell lines BE(2)-m17. LCA was 
added to cultured cells at the indicated final concentrations. Lipids were extracted from cells pelleted by 
centrifugation for 16000 × g for 5 min at 4oC and from the supernatant of cultural medium. The extracted 
lipids were dried under nitrogen and resuspended in chloroform. Immediately prior to injection the 
extracted lipids were combined with 2:1 methanol:chloroform with 0.1% (v/v) ammonium hydroxide. This 
was injected directly into a Q-TOF 2 mass spectrometer using a nano-ESI spray source at 1 µl/min. Spectra 
were obtained in a negative-ion mode. Acquired spectra were centroided using the Masslynx software then 
deconvoluted and deisotoped with Excel macros. 
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Figure 5.20. Exogenously added LCA does not enter cultured human NB cell lines SK-n-MCIXC. LCA 
was added to cultured cells at the indicated final concentrations. Lipids were extracted from cells pelleted 
by centrifugation for 16000 × g for 5 min at 4oC and from the supernatant of cultural medium. The 
extracted lipids were dried under nitrogen and resuspended in chloroform. Immediately prior to injection 
the extracted lipids were combined with 2:1 methanol:chloroform with 0.1% (v/v) ammonium hydroxide. 
This was injected directly into a Q-TOF 2 mass spectrometer using a nano-ESI spray source at 1 µl/min. 
Spectra were obtained in a negative-ion mode. Acquired spectra were centroided using the Masslynx 
software then deconvoluted and deisotoped with Excel macros. 
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Figure 5.21. Exogenously added LCA does not enter cultured human NB cell lines Lan-1. LCA was added 
to cultured cells at the indicated final concentrations. Lipids were extracted from cells pelleted by 
centrifugation for 16000 × g for 5 min at 4oC and from the supernatant of cultural medium. The extracted 
lipids were dried under nitrogen and resuspended in chloroform. Immediately prior to injection the 
extracted lipids were combined with 2:1 methanol:chloroform with 0.1% (v/v) ammonium hydroxide. This 
was injected directly into a Q-TOF 2 mass spectrometer using a nano-ESI spray source at 1 µl/min. Spectra 
were obtained in a negative-ion mode. Acquired spectra were centroided using the Masslynx software then 




            Findings presented in this chapter of my thesis provide strong evidence that LCA, 
a bile acid that greatly extends longevity in yeast (see chapter 3), exhibits a potent anti-
tumor effect in cultured human NB cells. Bile acids have been shown to provide health 
benefits to mammals. Synthesized from cholesterol in hepatocytes of the liver, these 
amphipathic molecules have been for a long time considered to function only as trophic 
factors for the enteric epithelium and as detergents for the emulsification and absorption 
of dietary lipids and fat-soluble vitamins [314, 326, 327]. Recent years have been marked 
by a significant progress in our understanding of the essential role that bile acids play as 
signaling molecules regulating lipid, glucose and energy homeostasis and activating 
detoxification of xenobiotics [314, 327, 328]. By stimulating the G-protein-coupled 
receptor TGR5, bile acids activate the cAMP/PKA signaling pathway that 1) enhances 
energy expenditure in brown adipose tissue and muscle by stimulating mitochondrial 
oxidative phosphorylation and uncoupling; 2) improves liver and pancreatic function by 
activating the endothelial nitric oxide synthase; and 3) enhances glucose tolerance in 
obese mice by inducing intestinal glucagon-like peptide-1 release [314, 327, 328]. 
Furthermore, by activating the farnesoid X receptor (FXR) and several other nuclear 
hormone receptors inside mammalian cells, bile acids 1) modulate the intracellular 
homeostasis of cholesterol, neutral lipids and fatty acids; 2) regulate glucose metabolism 
by enhancing glycogenesis and attenuating gluconeogenesis; and 3) stimulate clearance 
of xenobiotic and endobiotic toxins by activating transcription of numerous xenobiotic 
detoxification genes [314, 326 - 329]. All these health-improving, beneficial metabolic 
effects of bile acids prevent the development of obesity following administration of high-
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fat diet [314, 326, 327]. Thus, bile acids have a great potential as pharmaceutical agents 
for the treatment of diabetes, obesity and various associated metabolic disorders, all of 
which are age-related [314, 326]. Moreover, bile acids have been shown to inhibit 
neuronal apoptosis in experimental rodent models of neurodegenerative disorders by 
promoting mitochondrial membrane stability, preventing the release of cytochrome c 
from mitochondria,  reducing activities of various caspases, and activating the NF-κB, 
PI3K and MAPK survival pathways [329, 330]. 
            My findings presented in this chapter provide the following model for a 
mechanism underlying a potent and selective anti-tumor effect of LCA in cultured human 
NB cell lines BE(2)-m17 and SK-n-MCIXC (Figure 5.22). The demonstrated in chapter 5 
inability of LCA to enter these cultured human NB cells suggests that this most 
hydrophobic bile acid species first binds to the G-protein-coupled receptor TGR5, the 
only known receptor for such compounds in the plasma membrane. In response to such 
binding, TGR5 and its associated protein partners: 1) transmit, by a yet to be established 
mechanism,  the signal from the plasma membrane to the mitochondrial surface to 
activate MOMP (process a in Figure 5.22); 2) activate, perhaps by a mechanism similar 
to the one involved in activation of the extrinsic (death receptor) pathway of apoptosis 
through ligation of death receptors in the plasma membrane [403, 404], the initiator 
caspase-8 (process b in Figure 5.22); and 3) inhibit the inflammatory caspase-1 (process c 
in Figure 5.23). The LCA/TGR5-induced MOMP results in efflux of cytochrome c from 
mitochondria, thereby causing apoptosome formation and initiator caspase-9 activation 
(process d in Figure 5.23). The proteolytic cleavage of pro-caspase-3 by the 
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Figure 5.22. A model for a mechanism underlying a potent and selective anti-tumor effect of LCA in 
cultured human NB cell lines BE(2)-m17 and SK-n-MCIXC. See text for details. 
 
3-driven cleavage of pro-caspase-6 and activation of the downstream executioner 
caspase-6 (process e in Figure 5.23). Together, activated caspase-3 and caspase-6 (and 
perhaps other executioner caspases that are necessary for the proper execution of the 
LCA-driven, mitochondria-mediated apoptotic program) complete the demolition phase 
of the program by cleaving their respective protein substrates and producing the 
morphological features characteristic of apoptotic cell death (process f in Figure 5.23). In 
LCA-exposed NB cells, the proteolytic cleavage of pro-caspase-3 and the resulting 
increase of caspase-3 activity (which in turn cleaves pro-caspase-6 and activates the 
downstream executioner caspase-6; process e in Figure 5.23) is also triggered by the 
initiator caspase-8 acting in the LCA-driven extrinsic pathway of apoptosis (process g in 
Figure 5.23). In addition, activated in LCA-exposed NB cells caspase-8 causes MOMP 
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and triggers the intrinsic (mitochondrial) pathway of apoptosis by cleaving and activating 
BID (processes h and i in Figure 5.23). In my model, the LCA-driven inhibition of the 
inflammatory caspase-1 (process c in Figure 5.23) contributes to the anti-tumor effect of 
LCA in cultured cells of NB lines BE(2)-m17 and SK-n-MCIXC by attenuating the 
processing and unconventional secretion of the cytokines interleukin-1β and interleukin-
18 (process j in Figure 5.23) – thereby preventing growth and proliferation of 
neighbouring NB cells in culture (process k in Figure 5.23). 
            Importantly, I found that LCA greatly enhances the susceptibility of cultured 
human NB cell lines BE(2)-m17 and SK-n-MCIXC to a hydrogen peroxide-induced form 
of mitochondria-controlled apoptotic cell death, even when this bile acid was used at 
concentrations that in the absence of hydrogen peroxide do not compromise their 
viability.  Furthermore, while 75 μM LCA caused apoptotic death of all or most of the 
BE(2)-m17 and SK-n-MCIXC cells exposed to 0.1 mM hydrogen peroxide, in this 
concentration LCA greatly increased the resistance of primary cultures of human neurons 
to the hydrogen peroxide-induced form of  mitochondria-controlled  apoptotic  cell  
death. Based on these observations, I propose that the exposure of a mixed population of 
various NB cell lines and non-cancerous neurons to low concentrations of simultaneously 
added hydrogen peroxide and LCA may concurrently 1) kill all NB cells by causing their 
apoptotic death; and 2) promote the viability of non-cancerous neurons by increasing 
their resistance to hydrogen peroxide-induced apoptosis. 
            A different, yet to be defined mechanism underlies the observed ability of LCA to 
selectively kill cultured human NB cell line Lan-1. I propose that the anti-tumor effect of 
LCA in cultured Lan-1 cells is due to the ability of this bile acid to cause necrotic or 
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some other non-apoptotic kind of death, which is not characterized by such major 
distinctive (i.e., not seen under any other modes of cell death) event of apoptotic cell 
death as nuclear condensation and fragmentation.  
             Of note, a recent collaborative effort of the laboratories of Dr. Troy Harkness 
(Department of Anatomy and Cell Biology, University of Saskatchewan) and Dr. 
Vladimir Titorenko has revealed that in low concentrations LCA kills cultured MCF7 
human breast cancer cells and F98 rat glioblastoma cells. Thus, LCA exhibits a universal 
anti-tumor effect, as it has a very broad cytotoxic effect on cancer cells derived from 
different tissues and from different organisms. 
 
5.6 Conclusions 
            My findings imply that LCA exhibits a potent anti-tumor effect in cultured human 
NB cells by: 1) activating both intrinsic (mitochondrial) and extrinsic (death receptor) 
pathways of apoptotic death in these cells; 2) sensitizing them to hydrogen peroxide-
induced apoptotic death; and 3) preventing growth and proliferation of their neighbouring 
NB cells in the culture. Importantly, LCA does not display any of these deleterious 
effects in human neurons and, therefore, is a selective anti-tumor compound. 
Furthermore, the demonstrated here inability of LCA to enter cultured human NB cells 
suggests that this potent and selective anti-tumor compound is unlikely to display 
undesirable side effects in non-cancerous human neurons. My findings suggest a 
mechanism underlying a potent and selective anti-tumor effect of LCA in cultured human 




6 Conclusions and suggestions for future work 
6.1 General conclusions 
6.1.1 Chronological aging in yeast is the final step of a developmental program 
progressing through a series of checkpoints 
            To address the inherent complexity of aging from a systems perspective and to 
build an integrative spatiotemporal model of aging process, I used the concepts and 
methodologies of so-called metabolic control analysis [1, 8]. In studies described in 
chapter 2, I investigated how caloric restriction (CR) - a low-calorie dietary regimen 
known to extend longevity and improve health in evolutionarily distant organisms 
ranging from yeast to rhesus monkeys [76 - 83] - influences the metabolic history of 
chronologically aging yeast. I examined how CR influences the age-related dynamics of 
changes in the intracellular levels of numerous proteins and metabolites, carbohydrate 
metabolism, interorganellar metabolic flow, concentration of reactive oxygen species 
(ROS), mitochondrial morphology, essential oxidation-reduction processes in 
mitochondria, mitochondrial proteome, frequency of mitochondrial DNA mutations, 
dynamics of mitochondrial nucleoid, susceptibility to mitochondria-controlled apoptosis, 
and stress resistance. Based on my comparison of the metabolic histories of long-lived 
CR yeast and short-lived non-CR yeast reported in chapter 2, I concluded that yeast 
define their long-term viability by designing a diet-specific pattern of metabolism and 
organelle dynamics prior to reproductive maturation. My data imply that longevity in 
chronologically aging yeast is programmed by the level of metabolic capacity and 
organelle organization they developed, in a diet-specific fashion, prior to entry into a 
non-proliferative state. Therefore, my conclusion is that chronological aging in yeast is 
257 
 
the final step of a developmental program progressing through a series of checkpoints. By 
unveiling the different scenarios for a stepwise establishment of patterns of metabolism, 
inter-organellar communications and mitochondrial morphology in chronologically aging 
CR and non-CR yeast, my studies described in chapter 2 enabled to define a distinct 
group of cellular metabolites and processes that play an essential role in longevity 
regulation. 
 
6.1.2 My chemical genetic screen identifies lithocholic acid as an anti-aging 
compound that extends yeast chronological life span in a TOR-independent 
manner, by modulating housekeeping longevity assurance processes 
            In studies described in chapter 3, I designed a chemical genetic screen for small 
molecules that increase the chronological life span (CLS) of yeast under CR by targeting 
lipid metabolism and modulating housekeeping longevity pathways that regulate 
longevity irrespective of the number of available calories. My screen identified 
lithocholic acid (LCA) as one of such molecules. My evaluation of the life-extending 
efficacy of LCA in WT strain on a high- or low-calorie diet revealed that this compound 
extends yeast CLS irrespective of the number of available calories. I found that the extent 
to which LCA extends longevity is highest under CR conditions, when the pro-aging 
processes modulated by the adaptable TOR and cAMP/PKA pathways are suppressed 
and the anti-aging processes are activated [6, 7, 10]. I also found that the life-extending 
efficacy of LCA in CR yeast significantly exceeded that in yeast on a high-calorie diet, in 
which the adaptable TOR and cAMP/PKA pathways greatly activate the pro-aging 
processes and suppress the anti-aging processes [4, 5, 7, 35, 279]. Altogether, my 
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findings suggest that, consistent with its sought-after effect on a longevity signaling 
network, LCA mostly targets certain housekeeping longevity assurance pathways that do 
not overlap (or only partially overlap) with the adaptable TOR and cAMP/PKA pathways 
modulated by calorie availability.  
            Consistent with my assumption that LCA extends longevity not by modulating the 
adaptable TOR pathway, in studies described in chapter 3 I found that lack of Tor1p does 
not impair the life-extending efficacy of LCA under CR. I also revealed that, LCA 
extends longevity of the tor1 mutant strain to a very similar degree under CR and non-
CR conditions. Thus, by eliminating a master regulator of this key adaptable pathway that 
shortens the CLS of yeast on a high-calorie diet, the tor1 mutation abolished the 
dependence of the anti-aging efficacy of LCA on the number of available calories.  
            My findings described in chapter 3, along with some recently published data from 
Dr. Titorenko’s laboratory, revealed two mechanisms underlying the life-extending effect 
of LCA in chronologically aging yeast. One mechanism operates in a calorie availability-
independent fashion and involves the LCA-governed modulation of housekeeping 
longevity assurance pathways that do not overlap with the adaptable TOR and 
cAMP/PKA pathways. The other mechanism extends yeast longevity under non-CR 
conditions and consists in LCA-driven unmasking of the previously unknown anti-aging 
potential of PKA. I provide evidence that LCA modulates housekeeping longevity 
assurance pathways by 1) attenuating mitochondrial fragmentation, a hallmark event of 
age-related cell death; 2) altering oxidation-reduction processes in mitochondria, 
including oxygen consumption, the maintenance of membrane potential, and reactive 
oxygen species production; 3) enhancing resistance to oxidative and thermal stresses; 4) 
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suppressing mitochondria-controlled apoptosis; and 5) enhancing stability of nuclear and 
mitochondrial DNA. 
 
6.1.3 A hypothesis on xenohormetic, hormetic and cytostatic forces driving the 
evolution of longevity regulation mechanisms within ecosystems and its 
empirical verification 
            In my chemical genetic screen described in chapter 3, I identified lithocholic acid 
(LCA), as a novel anti-aging molecule that extends yeast longevity. Yeast do not 
synthesize this or any other bile acids produced by mammals [314, 326]; a recent mass 
spectrometry-based analysis of the total yeast lipidome conducted in Dr. Titorenko’s 
laboratory has confirmed lack of endogenous bile acids. Therefore, in chapter 4 I 
proposed that bile acids released into the environment by mammals may act as 
interspecies chemical signals providing longevity benefits to yeast and, perhaps, other 
species within an ecosystem. I hypothesized that, because bile acids are known to be 
mildly toxic compounds, they may create selective pressure for the evolution of yeast 
species that can respond to the bile acids-induced mild cellular damage by developing the 
most efficient stress protective mechanisms. It is likely that such mechanisms may 
provide effective protection of yeast against molecular and cellular damage accumulated 
with age. Thus, I proposed in chapter 4 that yeast species that have been selected for the 
most effective mechanisms providing protection against bile acids may evolve the most 
effective anti-aging mechanisms that are sensitive to regulation by bile acids. I extended 
my hypothesis on longevity regulation by bile acids by suggesting in chapter 4 a 
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hypothesis of the xenohormetic, hormetic and cytostatic selective forces driving the 
evolution of longevity regulation mechanisms at the ecosystemic level.  
            To verify my hypothesis empirically, I carried out the LCA-driven multistep 
selection of long-lived yeast species under laboratory conditions. As outlined in chapter 
4, I found that a lasting exposure of wild-type yeast to LCA results in selection of yeast 
species that live longer in the absence of this bile acid than their ancestor. My data 
enabled to rank different concentrations of LCA with respect to the efficiency with which 
they cause the appearance of long-lived yeast species. I revealed that, if used at the most 
efficient concentration of 5 μM, this bile acid induced life-extending mutations with the 
frequency of about 4 × 10
8
/generation. At the concentration of 50 μM, LCA caused the 
appearance of long-lived species with the frequency of 1 × 10
8
/generation, whereas a 
lasting exposure of yeast to 250 μM LCA did not result in selection of such species. 
Because the lowest used concentration of LCA resulted in the highest frequency of long-
lived species appearance, I believe that it is unlikely that the life-extending mutations 
they carry are due to mutagenic action of this bile acid.  
 
6.1.4 The molecular mechanism underlying a potent and selective anti-tumor 
effect of LCA in cultured human neuroblastoma cells   
            Aging is one of the major risk factors in the onset and incidence of cancer [154 - 
156], and cancer is considered as one of the numerous age-associated diseases whose 
onset can be delayed and incidence reduced by anti-aging interventions [157 - 162]. The 
interplay between aging and cancer is intricate as these two complex and dynamic 
biological phenomena have both convergent and divergent underlying mechanisms [157 - 
261 
 
223]. The objective of my studies described in chapter 5 was to examine if lithocholic 
acid (LCA), a novel anti-aging compound that I identified in a high-throughput chemical 
genetic screen, also exhibits an anti-tumor effect in cultured human cancer cells by 
activating certain anti-cancer processes that may (or may not) play an essential role in 
cellular aging. As a model system for addressing this important question (and if LCA 
indeed displays an anti-tumor effect, for establishing the mechanism underlying such 
effect), I choose several cell lines of the human neuroblastoma (NB) tumor.  
            In chapter 5 of my thesis, I described findings providing strong evidence that 
LCA exhibits a potent anti-tumor effect in cultured human NB cells by: 1) activating both 
intrinsic (mitochondrial) and extrinsic (death receptor) pathways of apoptotic death in 
these cells; 2) sensitizing them to hydrogen peroxide-induced apoptotic death; and 3) 
preventing growth and proliferation of their neighbouring NB cells in the culture. 
Importantly, my findings described in chapter 5 imply that LCA does not display any of 
these deleterious effects in human neurons and, therefore, is a selective anti-tumor 
compound. Moreover, my mass spectrometry-based measurement of intracellular and 
extracellular levels of exogenously added LCA revealed that this bile acid does not enter 
cultured NB cells. Thus, LCA prevents proliferation of human NB cells and selectively 
kills these cancer cells by binding to their surface and then initiating intracellular 
signaling cascades that not only impair their growth and division, but also cause their 
apoptotic death. The demonstrated inability of LCA to enter cultured human NB cells 
suggests that this potent and selective anti-cancer compound is unlikely to display 




6.2 Suggestions for future work 
            As my comparison of the metabolic histories of long-lived CR yeast and short-
lived non-CR yeast reported in chapter 2 revealed, yeast define their long-term viability 
by designing a diet-specific pattern of metabolism and organelle dynamics prior to 
reproductive maturation. These findings imply that longevity in chronologically aging 
yeast is programmed by the level of metabolic capacity and organelle organization they 
developed, in a diet-specific fashion, prior to entry into a non-proliferative state. 
Therefore, my conclusion is that chronological aging in yeast is the final step of a 
developmental program progressing through a series of checkpoints. 
            The major challenges for the future research are 1) to validate my hypothesis that 
the longevity of chronologically aging yeast is programmed by the level of metabolic 
capacity and organelle organization they developed, in a diet-specific fashion, prior to 
reproductive maturation; and 2) to rank the relative contributions of different metabolites 
and processes to the chronological aging of yeast. To address these challenges, one could 
evaluate how genetic manipulations that alter concentrations of these critical metabolites 
and affect these essential processes influence yeast longevity by modulating age-related 
protein aggregation, mitochondria-controlled apoptosis, free fatty acid- and 
diacylglycerol-induced necrosis, susceptibility to oxidative stress, and frequency of 
mtDNA mutations. A challenge for the future will be to elucidate how a longevity 
regulatory network centered on the Ras2p/cAMP/PKA/Rim15p/Msn2p/Msn4p and 
Tor1p/Sch9p/Rim15p/Gis1p nutrient-sensing pathways [278, 296, 301] governs the 
development of the diet-specific pattern of metabolism and organelle dynamics in 
chronologically aging yeast under CR conditions. Moreover, it would be interesting to 
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examine whether the pattern established in yeast cells grown under CR conditions can be 
reversed upon their transfer to calorie-rich medium. Another challenge for the future will 
be to test the validity of my hypothesis that chronologically aging CR yeast protect their 
mitochondrial nucleoids from oxidative damage by turning on the RTG signaling 
pathway, which then activates transcription of ACO1 and other genes encoding 
bifunctional mtDNA-binding proteins known to maintain the integrity of mtDNA under 
respiratory conditions. 
            Finally, I expect that in the near future this knowledge will be instrumental for 
designing high-throughput screening of novel anti-aging drugs that can extend longevity 
by modulating the envisioned here developmental program of chronological aging 
operating in yeast.  
            In chapter 3, I provided evidence that LCA - a novel anti-aging compound 
identified in my high-throughput chemical genetic screen - modulates housekeeping 
longevity assurance pathways by 1) attenuating mitochondrial fragmentation, a hallmark 
event of age-related cell death; 2) altering oxidation-reduction processes in mitochondria, 
including oxygen consumption, the maintenance of membrane potential, and reactive 
oxygen species production; 3) enhancing resistance to oxidative and thermal stresses; 4) 
suppressing mitochondria-controlled apoptosis; and 5) enhancing stability of nuclear and 
mitochondrial DNA. I expect that in the near future this knowledge will be instrumental 
for defining molecular mechanisms underlying the ability of LCA to extend longevity by 
impacting these various housekeeping longevity assurance processes and by modulating 
signaling pathways governing them. 
            In chapter 4, I suggested a hypothesis on the xenohormetic, hormetic and 
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cytostatic selective forces driving the evolution of longevity regulation mechanisms at the 
ecosystemic level. As a first step towards empirical verification of my hypothesis, I 
carried out the LCA-driven multistep selection of long-lived yeast species under 
laboratory conditions. As outlined in chapter 4, I found that a lasting exposure of wild-
type yeast to LCA results in selection of yeast species that live longer in the absence of 
this bile acid than their ancestor. To test the validity of other aspects of my hypothesis on 
the ecosystemic evolution of longevity regulation mechanisms, future studies need to 
address the following most critical questions: 1) what genes are affected by mutations 
responsible for the extended longevity of selected long-lived yeast species? 2) how these 
mutations influence a compendium of the housekeeping longevity-related processes 
modulated by LCA in chronologically aging yeast and described in chapter 3?; 3) 3) will 
these mutations affect the growth rate of yeast in media with or without LCA? 4) will 
selected long-lived yeast species be able to maintain their ability to live longer than wild-
type yeast if they undergo several successive passages in medium without LCA? - and, 
thus, is there selective pressure aimed at maintaining of an “optimal” rather than a 
“maximal” chronological life span of yeast (due to, e.g., a proposed selective advantage 
of the envisioned “altruistic” program [356 - 361] of chronological aging in yeast)? and 
5) if mixed with an equal number of wild-type yeast cells, will selected long-lived yeast 
species out-grow and/or out-live them in medium without LCA or the opposite will 
happen (due to selective pressure on yeast aimed at maintaining of the so-called 
“altruistic” program [356 - 361] of their chronological aging)? 
            As described in chapter 5, my findings imply that LCA exhibits a potent anti-
tumor effect in cultured human neuroblastoma (NB) cells by: 1) activating both intrinsic 
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(mitochondrial) and extrinsic (death receptor) pathways of apoptotic death in these cells; 
2) sensitizing them to hydrogen peroxide-induced apoptotic death; and 3) preventing 
growth and proliferation of their neighbouring NB cells in the culture. Importantly, I 
found that LCA does not display any of these deleterious effects in human neurons and, 
therefore, is a selective anti-tumor compound. Furthermore, the demonstrated in chapter 5 
inability of LCA to enter cultured human NB cells suggests that this potent and selective 
anti-tumor compound is unlikely to display undesirable side effects in non-cancerous 
human neurons. My findings described in chapter 5 suggest a mechanism underlying a 
potent and selective anti-tumor effect of LCA in cultured human NB cell lines BE(2)-
m17 and SK-n-MCIXC. In this mechanism, LCA kills these NB cells by: 1) activating 
both intrinsic (mitochondrial) and extrinsic (death receptor) pathways of apoptotic death 
in these cells; 2) sensitizing them to hydrogen peroxide-induced apoptotic death; and 3) 
preventing growth and proliferation of their neighbouring NB cells in the culture. Of 
note, a recent collaborative effort of the laboratories of Dr. Troy Harkness (Department 
of Anatomy and Cell Biology, University of Saskatchewan) and Dr. Vladimir Titorenko 
has revealed that in low concentrations LCA kills cultured MCF7 human breast cancer 
cells and F98 rat glioblastoma cells. Thus, LCA exhibits a universal anti-tumor ability, as 
it has a very broad cytotoxic effect on cancer cells derived from different tissues and 
from different organisms. In the future, one could use an algorithm which I developed for 
cultured human NB cells to define the mechanisms underlying the anti-tumor action of 
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